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Invited Lectures
INV2
INNATE LYMPHOID CELLS AT THE BARRIER AND INFLAMMA-
TION: HALT OR GO?
Cupedo T.
Erasmus University Medical Center, Dept. of Hematology, Rotterdam, The Neth-
erlands
The intestinal epithelium is of vital importance, as it is both a barrier to protect 
us from intestinal microorganisms, and is responsible for uptake of nutrients and 
water. Damage to the intestinal barrier occurs during chronic intestinal inflam-
mation, as well as during chemo- and radiotherapy used to treat cancer. Enhanc-
ing intestinal epithelial repair would reduce disease recurrence in inflammatory 
bowel disease patients and improve the efficiency of anti-cancer treatments. Re-
cently we discovered that intestinal repair is not epithelial cell-intrinsic, but is 
controlled by group 3 innate lymphoid cells (ILC3). 
located close to the stem cell-containing crypts of the small intestine.
Using ILC3-deficient epithelial stem cell-reporter mice, we could show that 
maintenance of intestinal stem cells after acute damage is hampered in the ab-
sence of ILC3s or the ILC3 signature cytokine IL-22, leading to severe tissue 
pathology and loss of regenerative potential. These data unveil a novel func-
tion or ILC3s in limiting tissue damage and bacterial translocation by preserving 
tissue-specific stem cells, allowing restoration of barrier integrity.
INV3
MICROBIOTA IN IBD, FROM INVENTORY TO THERAPEUTIC 
INTERVENTION
Sokol H.
Gastroenterology Dept., Saint Antoine Hospital, APHP and Sorbonne Université, 
Paris, France
The pathogenesis of the inflammatory bowel disease (IBD) is linked to an ac-
tivation of the gastro-intestinal immune system toward the gut microbiota in 
genetically susceptible hosts and under the influence of environment. The mi-
crobial community in the human gastrointestinal tract is fundamental to the 
health and is under the influence of both environmental and genetic factors. 
Loss of the fragile equilibrium within this complex ecosystem, termed dysbi-
osis, is involved in numerous pathologies, including IBD. Patients with IBD 
exhibit an altered gut microbiota composition with notably a decreased abun-
dance of anti-inflammatory bacteria such as Faecalibacterium prausnitzii. We 
also observed alteration in the fungal microbiota composition in these patients. 
The association of several polymorphisms of innate immunity genes involved 
in microbial sensing with IBD is another argument for the involvement of the 
gut microbiota in the IBD pathogenesis. Some genetic factors involved in IBD 
might indeed act through a microbiota effect. We notably demonstrated that this 
is the case for the IBD susceptibility gene CARD9. Gut microbiota alterations 
are thus not only a consequence of intestinal inflammation but a key actor in 
the disease pathogenesis. Fecal microbiota transplantation studies, by showing 
some efficacy in IBD confirm that the gut microbiota can now be considered as 
a potential therapeutic target.
INV4
MICROBIOTA AND GUT INFLAMMATION IN HLA-B27 TRANS-
GENIC RATS: WHAT IS THE RELATIONSHIP?
Colbert R.A., Gill T.
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National 
Institutes of Health, Bethesda, USA
HLA-B27 plays a key role in the pathogenesis of spondyloarthritis (SpA), yet 
the precise mechanism(s) remain incompletely understood. In HLA-B27/hβ2m 
transgenic (HLA-B27 Tg) rats that develop SpA-like disease there is striking 
activation of the IL-23/IL-17 axis with expansion of CD4+ Th17 and Th1 cells, 
as well as Th17 cells that express IFNγ. Disease occurs independently of CD8+ 
T cells and has been linked to aberrant features of HLA-B27, but it is also de-
pendent on the presence of gut microbiota. This has led to the hypothesis that 
this allele may promote SpA by altering gut microbiota. We recently examined 
the effects of HLA-B27/hβ2m expression on gut microbial dysbiosis in different 
rat strains, and found that changes in microbiota are strongly dependent on the 
genetic background and/or environment of the host. 
In contrast, dysregulated cytokines and immune pathways are strikingly similar 
in different rat strains, with increases in TNF, IFNγ and Th17 cytokines such as 
IL-23 and IL-17 implicated in inflammation. Despite differences in the taxonom-
ic classification of dysbiotic microbes, determination of their functional profile 
using PiCRUST software predicted highly similar metabolic functions. 
We then employed a novel ‘inter-omic’ analysis to explore the relationship be-
tween diverse microbes and common host immune dysregulation. To do this 
we correlated the relative frequency of microbes (16S rRNA sequencing) with 
host gene expression levels (RNASeq) in the cecum can colon of HLA-B27 
Tg and wild type (WT) rats on Dark Agouti (DA), Lewis (LEW) and Fischer 
backgrounds. This revealed several organisms whose relative frequency was 
strongly associated with dysregulated cytokines driving Th17 and Th1 pathways 
of inflammation in both the cecum and colon. While some microbes were dif-
ferentially abundant in HLA-B27 Tg vs. WT comparisons on both Lewis and 
Fischer backgrounds (e.g. Clostridium), most were unique to either LEW (e.g. 
Prevotella) or Fischer (e.g. Akkermansia). Interestingly, many microbes that cor-
related strongly with immune dysregulation were not identified by analyzing ef-
fects of HLA-B27 alone in DA, LEW or Fischer strains (e.g. Lachnospiraceae). 
PiCRUST revealed common perturbed metabolic pathways during inflammation 
(e.g. glycan biosynthesis, steroid biosynthesis) despite dramatic differences in 
dysbiotic microbes.
The impact of HLA-B27 on gut microbiota in experimental SpA is best explained 
by an ecological model of dysbiosis rather than alteration of a single or a few 
organisms that then impact disease. Inter-omic analysis reveals the complexity 
of HLA-B27-associated dysbiosis, where perturbation of common metabolic 
pathways by different gut microbiota during inflammation implicate functional 
overlaps that may be key to evoking and perpetuating similar host immune dys-
regulation. This work underscores the importance of microbial communities and 
their functions in experimental SpA pathogenesis.
INV5
EXPLORING GENDER DIFFERENCES IN THE CLINICAL PHE-
NOTYPE AND RESPONSE TO TREATMENT IN AXIAL SPONDY-
LOARTHRITIS
Gensler L.S.
University of California, San Francisco, Dept. of Medicine, Division of Rheuma-
tology, San Francisco, USA
Until the inclusion of patients with non-radiographic disease, Ankylosing Spon-
dylitis (AS) was thought to affect men slightly more commonly than women. Ex-
pansion to axial spondyloarthritis (axSpA) suggests an equigender distribution. 
Women tend to have a lower burden of serologic inflammation, damage and pro-
gression, but similar reported disease activity and yet relatively greater functional 
impairment. Response to biologic treatment may be different across men and 
women. The aim of this presentation is to examine the gender differences in the 
clinical phenotype and response to treatment in axSpA by reviewing the observa-
tional and clinical trial literature and existing cohorts to address these questions. 
INV6
DO WOMEN COME FROM VENUS AND MEN FROM MARS? 
MYTHS AND TRUTHS ABOUT GENDER DIFFERENCES IN AXI-
AL SpA - SO THERE MAY BE SOME TRUTH AFTER ALL: WHAT 
IS THE UNDERLYING BIOLOGY?
Gracey E.1,2, Elewaut D.2, Inman R.D.1
1University of Toronto & Toronto Western Hospital, Toronto, Canada; 2Flanders 
Institute for Biotechnology (VIB) & University of Gent, Belgium
Sex matters, especially in axial spondyloarthritis (axSpA). Gender differences 
have long been observed in patients with AS, yet little is known about the under-
lying biology of the sex/gender gap. This talk aims to close the conceptual gap 
so that researchers and clinicians may address the physical gap between men and 
women with axSpA. 
In discussing the underlying biology of axSpA in males and females, it is impor-
tant to distinguish gender from sex. Gender encompasses social and behavioural 
aspects associated with being male or female, whereas sex is specific for the 
biological effects of being XX or XY. This talk will focus on sex differences in 
axSpA, and more generally in the immune system.
By the end of the talk, SpA Congress attendees will have a basic knowledge 
of normal autosomal (non X/Y) gene expression differences and immunologi-
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cal variation between the sexes. How the immune system controls nociception 
(pain sensing) in males and females will be introduced. Recent studies detailing 
differences in the immune profiles of males and females with axSpA, and how 
such differences may explain variation in disease manifestation and response to 
therapy will be speculated. 
It is hoped that the importance of considering sex as a variable in future SpA 
research will be considered, and that the impact of sex in clinical trials will be 
examined. Indeed, sex is perhaps the easiest variable to consider on the path to 
personalized medicine.
INV7
PAINFUL RISK TO BE FEMALE? WHAT WE KNOW, AND WHY IT 
IS NOT SO TRIVIAL!
Magerl W.
Dept. of Neurophysiology, Center of Biomedicine and Medical Technology 
Mannheim (CBTM), Medical Faculty Mannheim, University Heidelberg, Mann-
heim, Germany
For many painful diseases females exhibit a substantially higher proportion of 
patients than males. These phenomenon cuts across many pain diseases of most 
diverse etiologies, e.g. low back pain, postsurgical pain, neuropathic pain, com-
plex regional pain syndrome, restless legs syndrome a.o. (e.g. Butler et al. 2013, 
Choinière et al. 2014). This is, however, not simply trivially explained by social 
behavioral traits / social role, e.g. the known higher rate of females seeking medi-
cal counseling although this may further inflate disproportionate patient figures. 
To get insight into the potential mechanisms involved in higher likelihood of fe-
males to precipitate pain disease we first have to look into gender differences 
in somatosensory processing. Large scale studies (e.g. by the German Research 
Network on Neuropathic Pain DFNS; have established reference data bases in 
healthy adults that cover all age ranges (18 - >75 years, Rolke et al. 2006, Magerl 
et al. 2010, Pfau et al. 2014). The main finding derived from these data bases is 
higher pain sensitivity in females in general (Magerl et al. 2010). Notably, this is 
not seen in other (non-nociceptive) somatosensory modalities (e.g. cold, warmth 
tactile detection). By contrast, this gender difference is largely absent in children 
(aged 6–16 years) suggesting the segregation of female vs. male pain sensitivity 
with the onset of puberty (Blankenburg et al. 2010). The latter predicts covaria-
tion of female pain sensitivity with the menstrual cycle. However, although this 
has been studied over decades the design of most studies is poor providing little 
conclusive evidence for a role of gender-specific impact of gonadal hormones.
It is now common sense that psychological comorbidities contribute substantially 
to the magnitude of pain perception, either experimental or clinical (c.f. the ex-
tensive U.S. phenotype-genotype association study on pain perception OPERRA; 
Ostrom et al. 2017). Notably, scores in most of these comorbidities are signifi-
cantly higher in female than male subjects/patients. In a recent survey that we 
conducted in 2nd year medical students (n=470) female students exhibited signifi-
cantly stronger expression of personality traits that are linked to emotional dys-
regulation and lesser control, namely they rated higher scores of neuroticism (i.e. 
they feel that they are more easily activated), described themselves as significantly 
more anxious, more depressed, more behaviorally inhibited, more vulnerable, 
more stressed, and more pain-catastrophizing (more specifically as more help-
less and more ruminating towards experimental pain; Mannheim Study on Pain 
Perception and Risk). Many of these traits were significantly positively correlated 
to the magnitude of perceived pain, although correlation coefficients were low. 
In an ongoing study on pain perception in patients with major depressive disor-
der, a disease that also has a higher preponderance in females, we could show 
that exaggerated pain perception is largely explained by patients level of depres-
sion, pain catastrophizing and acute perceived stress. Recent epidemiological 
data show a strong overlapping of polygenetic risk for chronic pain and major 
depressive disorder (McIntosh et al. 2016). Another factor boosting pain sensi-
tivity is shortage and fragmentation of sleep (Lavigne et al. 2010, Schuh-Hofer 
et al. 2013, Sanders et al. 2016). Again, sleep disturbances are substantially more 
frequent and more severe in females (Lavigne et al. 2010, Penzel et al. 2015). 
In aggregate, there is no single physiological predictor explaining the higher pain 
sensitivity of females. However, there is a multiplicity of risk factors that occur 
more frequently and/or that are more severe in females, which in aggregate may 
lead to the higher pain sensitivity of females and most likely also to the higher 
proportion of female patients in most pain diseases.
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INV8
FROM BUGS TO BENCH AND THE BEDSIDE AND BACK
Sieper J.
rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany
Epidemiological and clinical data has provided ample evidence in the past that 
exposure to bacteria, on the background of a mostly genetically determined 
immunological background, plays a crucial role in the pathogenesis of axial 
spondyloarthritis (axSpA). Main candidate bacteria are enteritis-causing bacte-
ria, bacteria of the normal gut flora and Chlamydia trachomatis. Furthermore, 
MRI-investigations of the axial skeleton have confirmed – in addition to earlier 
histological data - that the disease starts with inflammation at the cartilage/bone 
interface and that it starts normally in the sacroiliac joint. Subsequently, many at-
tempts have been undertaken to identify immune responses to bacterial antigens 
and – on the assumption that hiding and persisting of bacterial antigens in the 
bone is unlikely – attempts have been made to identify immunodominant carti-
lage antigens which might crossreact with bacterial antigens, however until now 
without convincing success.
Advances in osteoimmunology have helped to better understand the interaction 
between bony inflammation and new bone formation and have provided new 
bone biomarkers which have been used in clinical trials as markers of new bone 
formation, as predictors of new bone formation and as predictors of treatment 
responses. Such biomarkers are of great clinical relevance because new bone 
formation is a slow process and the currently available imaging methods for scor-
ing new bone formation have a low sensitivity. Applying the MRI method to the 
axial skeleton allowed also to detect bone inflammation earlier and has lead to 
earlier diagnosis in a disease which had a large gap between the occurrence of 
first symptoms and making a diagnosis in the past.
Although until now the immunological pathway(s) leading to inflammation (and 
subsequently new bone formation) has not yet been identified investigation of 
peripheral blood, synovial fluid and – most importantly – of spine tissue tak-
en from patients with axSpA gave evidence that TNF, IL-17 and IL-23 might 
play role in the pathogenesis and might be potential treatment targets. Indeed, 
TNF-inhibition had been proven highly effective – maybe even more effective 
in comparison to other chronic inflammatory diseases – as a treatment of axSpA. 
Subsequently, a similar level of response has been found in clinical trials with 
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IL-17 inhibitors. But other targeted therapies which have been proven to be effec-
tive in other diseases such as rheumatoid arthritis have failed. Most surprisingly, 
also inhibition of IL-23 failed as a treatment of ankylosing spondylitis, despite 
its known link with IL-17 and despite many preclinical data hinting at a poten-
tially important role of IL-23 in the pathogenesis of axSpA. Thus, although we 
have witnessed quite advances in a better understanding of the different aspect 
of the axSpA disease most advances over the last 15-20 years, with benefit for 
the patient, has come from clinical research leading to earlier diagnosis and the 
introduction of new and effective therapies.
INV11
IMMUNE EFFECTOR CELLS IN SpA: WHAT ARE THE PATH-
WAYS?
Bowness P., Ridley A., Chen L., Shi H., Zaarour N., Yager N., Simone D., 
Hammitzsch A., Al-Mossawi M.H.
Oxford, UK
Despite much investigation, the pathogenesis of Ankylosing Spondylitis (AS) 
and related Spondyloarthitides (SpA) remains mysterious. However pro-inflam-
matory leucocytes undoubtedly play a key role and several cytokine pathways 
have been implicated in their generation and effects. 
An important role for the TNF alpha pathway has been confirmed by immuno-
logical, genetic and therapeutic data. Biologic therapies are well established and 
small molecule inhibitors in development.
Both GWAS and experimental data strongly support roles for the IL-23/IL-17 
axis in driving inflammation in SpA/AS. In recent years several groups have 
contributed to a body of work showing that “type 17” immune responses, involv-
ing the key pro-inflammatory cytokines IL-17A and IL-23, play important roles. 
Clinical trials treating patients with secukinumab, a blocking antibody against 
IL-17A, have shown clear efficacy. It is now appreciated that a number of epi-
genetic pathways impact on Th17 responses and could be targets for therapeutic 
intervention. We have used Th17 differentiation/expansion assays using CD4+ T 
cells from patients with SpA/AS to screen epigenetic inhibitors. We have iden-
tified roles for CBP30 (1) and BRPF family members (Chen unpublished) in 
driving Th17 responses, in addition to the key transcription factor ROR-γt (2).
It is now clear that both Th17 CD4 T cells and other type 17 immune cells 
(which can also include CD8+ and gamma delta T cells and innate lymphoid 
cells including NK cells) produce multiple cytokines in addition to IL-17A that 
themselves constitute important target pathways. Thus IL-17F, IL-21, IL-22, 
IL-26, TNF-α, CCL20 and Granulocyte macrophage colony stimulating factor 
(GM-CSF) are all potentially pro-inflammatory cytokines produced by “Th17 
family leukocytes”. CSF2 (the gene for GM-CSF) expression has recently been 
associated with “pathogenic” human Th17 cells. GM-CSF is an important he-
matopoetic growth factor and immune modulator, and is produced by T cells, 
innate lymphoid cells, macrophages and stromal cells. GM-CSF plays a key role 
in neutrophil and monocyte recruitment, dendritic cell and osteoclast differentia-
tion, making it a potent pro-inflammatory cytokine. A major role for GM-CSF 
has been shown in murine arthritis models. Our study of SpA patients (3) has 
shown increased frequencies of GM-CSF-expressing CD4+ and other T cells in 
AS/SpA peripheral blood. This is even more dramatic in synovial fluid, and is 
not confined to CD4 T lymphocytes. GM-CSF-producing cells have a specific 
transcriptional signature. These preclinical data would support clinical trials of 
GM-CSF neutralization in SpA.
In summary a number of different immune effector cells and pathways contribute 
to SpA pathogenesis, many of which constitute potential therapeutic targets.
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INV12
AUTO-IMMUNITY VERSUS AUTO-INFLAMMATION IN EYE 
DISEASE IN SpA
Forrester J.V.1,2,3
1Section of Immunology and Infection, Division of Applied Medicine, School of 
Medicine and Dentistry, Institute of Medical Science, Foresterhill, University of 
Aberdeen, UK; 2Ocular Immunology Program, Centre for Ophthalmology and 
Visual Science, The University of Western Australia, Western Australia; 3Centre 
for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, 
Australia
Uveitis is a frequent extra-articular manifestation of disease in SpA. Uveitis how-
ever has many causes. More than half of cases of uveitis are caused by infection 
while the remaining cases are considered non-infectious or “undifferentiated”. 
Uveitis in SpA is considered non-infectious and, until recently, was presumed to 
be autoimmune in nature. Uveitis in SpA is almost exclusively anterior (acute / 
recurrent) but evidence for autoimmunity in anterior uveitis is essentially lacking 
both in terms of specific antigenic triggers and in development of representa-
tive experimental models. Uveitis, particularly anterior uveitis, is in reality a 
systemic disease manifested in the eye and is a feature of a number of systemic 
diseases, particularly autoinflammatory diseases. Autoinflammatory diseases are 
classically described in relation to specific genetic defects but more recently a 
number of chronic inflammatory polygenic diseases are being viewed as having 
an autoinflammatory basis. This applies particularly to the case of SpA.
Autoinflammatory processes in uveitis are well recognised with regard to activa-
tion of innate immune cells, through activation of pathogen recognition receptors 
such as Mincle and dectin-1 and signalling through pathways such Card-9/Syk, 
with generation of cytokines such as IL-1. Moreover, autoinflammatory diseases 
are exacerbated if not initiated by infection and infections, particularly latent in-
fections, are increasingly recognised as the underlying cause of “non-infectious” 
or “undifferentiated” uveitis. This presentation examines the role of autoimmun-
ity, autoinflammation and infection in uveitis in the context of SpA. In particular 
the role of the microbiome in determining the outcome of intraocular inflamma-
tory disease (aka uveitis) will be discussed. 
INV16
HOW PEPTIDE-LOADING COMPLEX AFFECTS MHC CLASS I 
BIOLOGY
Trowitzsch S.
Institute of Biochemistry, Biocenter, Goethe University Frankfurt, Frankfurt am 
Main, Germany
Identifying and eliminating infected or malignantly transformed cells are fun-
damental tasks of the adaptive immune system. For immune surveillance, the 
cell’s metastable proteome is displayed as short peptides on major histocom-
patibility complex class I (MHC I) molecules to cytotoxic T-lymphocytes. Our 
knowledge about the track from the proteome to the presentation of peptides has 
greatly expanded, leading to a quite comprehensive understanding of the antigen 
processing pathway. I will report on the mechanisms of antigen translocation, 
chaperoning, editing, and final quality control. Based on an integrative approach, 
the contribution of individual proteins as well as the architecture of the MHC I 
peptide-loading complex (PLC) and other MHC I editing complexes, also in the 
context of viral immune evasion, are addressed. The work provides the frame-
work for understanding the quality control of antigen selection and unveils the 
molecular details underlying the onset of an adaptive immune response.
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INV17
HLA-B27 AND MULTI-OMICS: WHERE DOES IT BRING US?
Garchon H.J.1, Jolly A.1, Desjardin C.1, Chaplais E.1, Talpin A.1, Costantino F.1, 
Hue C.1, Jobart-Malfait A.1, Maury B.1, Grassin-Delyle S.1, Bonilla N.2, Leboime 
A.3, Said Nahal R.3, Letourneur F.2, Sébastien J.2, Boland A.4, Deleuze J.F.4, Chi-
occhia G.1, Breban M.1
1INSERM U1173, Simone Veil School of Health Sciences; 2INSERM U1016, 
Cochin Institute; 3Rheumatology Division, Ambroise-Paré Hospital AP-HP; 
4Centre National de Recherche en Génomique Humaine, Evry, France
The association of HLA-B27 with spondyloarthritis (SpA) has been known for 
decades. Its primary role in SpA pathogenesis has been definitively demonstrated 
using the HLA-B27 transgenic rat model. Numerous studies has provided invalua-
ble information on the molecular and cellular alterations determined by HLA-B27. 
Yet the detailed mechanisms through which HLA-B27 alters the cell functions to 
determine the inflammatory process leading to disease have remained elusive. 
To address this gap, we have undertaken a detailed analysis of the gene expression 
programme of dendritic cells in patients compared with controls. These cells are 
thought to play a key role in SpA pathogenesis, as showed by the rat model study. 
More specifically, we derived dendritic cells from blood monocytes in culture and 
stimulated them with LPS to mimic an exposure to an inflammatory stimulus. 
We then analyzed their transcriptome by RNA-seq. In addition, we informed 
these data with the genomic sequence of the HLA-B locus and its flanking region, 
as there is strong evidence of linkage disequilibrium surrounding the HLA-B27 
allele. Finally, we integrated these two genomic layers with the microbiota that 
shows substantial variation in SpA patients.
Importantly, to overcome the major pitfall resulting from the fact that most pa-
tients are B27+ while most controls are B27-negative, making it difficult to dis-
criminate the effects of HLA-B27 and those of the disease process, we analyzed 
three groups of subjects, including B27+ patients, B27+ healthy subjects and 
B27-negative healthy controls. Altogether, our multi-omic approach will hope-
fully provide an integrated view how the HLA-B27 allele influences the behavior 
of dendritic cells in relation to health and disease.
INV18
IS FRUIT FLY RELEVANT TO SpA?
Gaumer S.1, Grandon B.1,2, Rincheval A.1, Jah N.2, Corsi J.M.1, Guénal I.1, 
Breban M.2,3
1Université Paris-Saclay, UVSQ, PSL Research University, EPHE, Laboratoire 
de Génétique et Biologie Cellulaire, Versailles; 2Université Paris-Saclay, UVSQ, 
Unité Infection et Inflammation chronique, UMR1173 Inserm, Versailles; 3Am-
broise-Paré hospital, Rheumatology Dept., AP-HP, Boulogne, France
Introduction/Aim. Spondyloarthritis (SPA) is a group of chronic inflammatory 
disorders of the joint affecting primarily the axial skeleton but also peripheral 
limbs. Extra-articular manifestations are also considered a hallmark of SPA 
(e.g. inflammatory bowel diseases). SPA is highly inheritable, even though the 
environment plays an important role in the development of the disease. The 
most important part of heritability comes from the HLA-B27 allele of the Ma-
jor Histocompatibility Complex (MHC), that is present in 70-90% of patients, 
as compared to 6-8% of the Caucasian population. HLA-B27 functions as a 
classical class I MHC molecule in most instances, in association with the β2-
microglobulin (β2m) invariant light chain, by presenting antigenic peptides to 
CD8+ T cells. However, the mechanism(s) by which HLA-B27 contributes to 
SPA remain(s) poorly understood despite 45 years of research.
Several theories have been proposed, none being yet proven. The “arthritic” pep-
tide theory speculates on the canonical antigen-presenting function of a class I 
MHC molecule, proposing that particular peptides derived from the joint would 
be specifically presented to pathogenic CD8+ T cell, resulting in inflammatory 
disease. The failure to demonstrate the validity of such hypothesis, particularly in 
faithful animal model, fostered the emergence of novel theories implicating non-
canonical characteristics of the HLA-B27 molecule. These include, a tendency 
of HLA-B27 to misfold, which could result in ER stress and unfolded protein 
response (UPR) eventually triggering an inflammatory response. However, the 
folding kinetics of different subtypes does not correlate with their disease associ-
ation. Moreover, no UPR activation in HLA-B27+ cells from SPA patients could 
be observed, suggesting that HLA-B27 misfolding may not be fully relevant to 
pathogenicity. We chose to develop a model, which allows the study of HLA-B27 
activities in the absence of its role on adaptive immunity that may mask some of 
its pathogenic effects. 
Materials and Methods. Fruit fly is a well-studied and highly tractable genetic 
model organism and it is an invaluable system to understand complex molecular 
mechanisms. Indeed, most basic biological and physiological properties as well 
as signaling pathways are conserved between mammals and Drosophila, allowing 
to model genetic aspects of numerous human pathologies. It is being increasingly 
used to gain insight into the molecular and genetic aspects of inflammation. 
To further test the hypothesis that expression of HLA-B27 molecule, in associa-
tion with β2m, triggers cellular disturbance, we produced transgenic Drosophila 
expressing SPA-associated HLA-B27 subtypes in combination with humanβ2m, 
speculating that this simplified animal model could facilitate deciphering of the 
non-canonical cellular and molecular effects of HLA-B27. Using the UAS-Gal4 
inducible system, we tested the effect of different patterns of expression of these 
transgenes and highlighted genetic interaction with essential signaling pathways. 
We then tested whether our results could be extended to HLA-B27 transgenic rat 
model.
Results. Drosophila that are transgenic for SPA-associated B*2705 or B*2704 
alleles, in combination with β2m, display striking phenotypes, including a wing 
crossveinless phenotype and a reduced eye size when the HLA-B27/hβ2m 
transgenes are co-expressed in these tissues. In contrast, neither Drosophila single 
transgenic for HLA-B27 alone, nor transgenic for the SPA-non-associated allele 
HLA-B*0702 with or without hβ2m, developed such phenotypes. Interestingly, 
the wing phenotype appears to result from a genetic interaction with the BMP 
pathway and is associated with misregulation of dad, a BMP signaling target ho-
mologous to mammalian Smad7. Similarly, smad7 is found up-regulated in den-
dritic cells from HLA-B27 transgenic rat, as compared to HLA-B7 expressing 
cells.
Discussion. Interestingly, the BMP pathway is strongly involved in bone renew-
al, hematopoiesis and regulates the immune response in mammals. Moreover, 
the misregulation of the BMP pathway observed in our Drosophila model tends 
to remind of a rare human Mendelian disorder closely reminiscent to SPA, i.e. 
Fibrodysplasia Ossificans Progressiva. 
Conclusions. Altogether, our results highlight how Drosophila can be used as 
a test-tube to study human diseases. The implication of BMP misregulation re-
mains to be scrutinized to identify crucial steps of SPA development.
INV19
GENETIC STUDIES IN ANKYLOSING SPONDYLITIS: PROGRESS 
AND TRANSLATION
Brown M.A.
Institute of Health and Biomedical Innovation, Queensland University of Tech-
nology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, 
Australia
Twin and family studies have shown that both the risk of developing AS is largely 
genetic, and that its clinical manifestations are also under major genetic control. 
The heritability of AS in the UK Biobank and also shown in unbiased popula-
tion level studies to be high (common variant heritability 69.1%, compared with 
20.9% for Crohn’s disease, 15.9% for ulcerative colitis, and 16.3% for rheuma-
toid arthritis). By early 2018 115 non-MHC loci had been identified as being defi-
nitely associated with AS (either at genome-wide levels of significance (p<5x10-8) 
in an AS-specific analysis or in a set-based meta-analysis, with demonstration 
of an association of AS independently at that locus). The MHC associations of 
AS are also complex, with multiple alleles of HLA-B, and of other HLA-genes, 
being associated with increased risk of or protection from the disease. In total 
roughly 30% of the genetic risk of the disease has now been explained by genetic 
studies. An ongoing genome-wide association study involving ~26,000 cases and 
~600,000 healthy controls is nearing completion and is likely to substantially add 
to the number of genetic associations known, as well as defining more precisely 
the variants involved.
The findings from these genetic studies have provided major insights as to the 
causation of the disease and have contributed to major therapeutic developments, 
for example providing the first evidence that the IL-23 pathway was involved 
in the disease and contributing to the trial of compounds targeting that path-
way which are now in widespread clinical usage. Many of the genes discovered 
represent novel potential therapeutic targets, against which drug development 
programs are underway. 
As the molecular mechanisms underpinning the genetic associations at specific 
loci are being determined it is also becoming apparent that different variants at 
the same locus have marked differences in underlying biological effects. Given 
that these variants are often differentially associated with the related diseases 
AS, psoriasis and inflammatory bowel disease, they likely explain in part the 
different phenotypes of these diseases, and their differential response to targeted 
treatments.
Recent discoveries in AS genetics will be discussed with a particular emphasis 
on the significance of these findings to clinical practice in diagnosis and manage-
ment of AS.
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LESSONS FROM EPIGENETICS FOR SpA
Knight J.C.
University of Oxford, Wellcome Centre for Human Genetics, Oxford, UK
Rapid advances in our ability to interrogate the regulation of gene expression 
through epigenetic mechanisms offer new opportunities to understand mecha-
nisms underlying disease pathogenesis, in particular by shedding light on how 
genetic differences associated with disease risk may be acting. 
Currently there is a major challenge to link possession of specific disease as-
sociated genetic markers with functional mechanism, notably noncoding vari-
ants modulating gene expression. Identifying the specific genes and pathways 
modulated by these genetic variants is essential for taking forward such findings 
to understand disease processes and potential therapeutic targets. In my talk I will 
show how epigenetic evidence can be used to inform and interpret genome-wide 
association studies in the setting of SpA with a particular focus on drug target pri-
oritisation. I will outline how understanding chromatin interactions and mapping 
expression quantitative traits in different immune cell types and conditions of 
innate immune activation can be leveraged. I will describe approaches to define 
the epigenetic landscape of ankylosing spondylitis in patients, with application 
to major immune cell populations in peripheral blood.
INV21
OPERATION TRANSFORMATION: THE IMPACT OF GENES AND 
LIFE STYLE IN JOINT DISEASE
O’Shea D.
St Vincents University and St Columcilles Hospitals, University College Dublin, 
Ireland
Obesity is one of the major public health challenges of our day. It kills 1000 peo-
ple per million of the population per year – yet appears on almost no death cer-
tificates. The environment is a major driver of obesity – work, home, school and 
societal. We now know how the body mounts a robust metabolic and behavioural 
defence against weight loss. We know that obesity impacts on every disease and 
makes every disease worse. We know that obesity upregulates proinflammatory 
genes that impact negatively on the course of disease.
In this lecture the drivers of obesity will be reviewed. The nature of the defence 
against weight loss by the immune system will be explored. The use of RNA 
sequencing for exploring the negative effects of obesity on inflammation and 
resolution of inflammation will be reviewed. 
INV22
ROLE OF ECTOPIC BMP SIGNALING IN PATHOGENIC OSSIFI-
CATION AND ANGIOGENESIS
Pacifici M.
Translational Research Program in Pediatric Orthopaedics, The Children’s 
Hospital of Philadelphia, Philadelphia, USA
Introduction. Ectopic formation and accumulation of extraskeletal bone char-
acterize rare pediatric musculoskeletal disorders including Multiple Osteochon-
dromas (MO) and Fibrodysplasia Ossificans Progressiva. MO, also known as 
Hereditary Multiple Exostoses (HME) and the subject of the present study, is 
characterized by benign tumors -called osteochondromas or exostoses- that form 
next to the growth plates of long bones, ribs and other elements in children and 
adolescents. The osteochondromas are initially cartilaginous but with time, un-
dergo endochondral ossification in their proximal region with the recruitment of 
osteoprogenitor and angiogenic cells from the adjacent skeletal element. Because 
of their location and number, the osteochondromas can cause a variety of health 
problems that include skeletal deformities, growth retardation, chronic pain and 
impingement of vessels, muscles and nerves. Surgery is currently used to re-
move the most symptomatic osteochondromas and reduce skeletal problems, but 
many are left in place, causing life-long health problems. There is no treatment 
at the moment to prevent osteochondroma formation. Genetically, MO is linked 
to heterozygous loss-of-function mutations in EXT1 or EXT2 that encode Golgi 
glycosyl-polymerases responsible for the synthesis of heparan sulfate. HS is a 
component of cell surface- and matrix-associated proteoglycans (PGs) such as 
syndecans and perlecan that regulate many essential developmental and physi-
ologic processes. One major mechanism of regulation relies on the ability of HS 
chains to interact with -and restrict the distribution and activities of- key signal-
ing proteins including bone morphogenetic protein (BMP), hedgehog and fibro-
blast growth factor (FGF) family members. However, it was known (i) whether 
the HS deficiency during MO would lead to aberrant distribution and ectopic 
action of signaling proteins in tissues neighboring the growth plates and most 
importantly the perichondrium and (ii) whether these changes were responsible 
for osteochondroma formation and if so, might represent therapeutic targets. In 
studies conducted over the last few years, we set out to test these possibilities in 
animal disease models and in turn, provide a rational for clinical trials on osteo-
chondroma prevention. 
Methods. Conditional postnatal mouse models of MO consisted of floxed Ext1 
mice mated with transgenic Cre and CreER lines targeting different cell popu-
lations within and around the growth plate, including Gdf5Cre and Aggrecan-
CreER. Osteochondroma onset and outgrowth were analyzed and quantified 
by a variety of approaches including micro-computed tomography (microCT), 
histology, histochemistry and in situ hybridization. Cartilaginous portions of 
each osteochondroma were evaluated in serial sections after staining with al-
cian blue or safranin O, followed by 3D reconstruction. Distribution and activity 
of signaling proteins including BMP members and their down-stream effectors 
-phosphorylated SMAD1/5/8 proteins- were determined by immunohistochemi-
cal procedures using commercial antibodies. Similar procedures were used to 
analyze recruitment of angiogenic cells and factors. 
Results. Because osteochondromas start out as cartilaginous outgrowths flanking 
the growth plates, we initially asked whether their formation was preceded by 
presence of ectopic chondrogenic signals within perichondrium, possibly act-
ing as osteochondroma-inducing agents. We focused on BMP signaling because 
of its well established and recognized roles in promoting chondrogenesis. We 
found that conditional ablation of Ext1 alleles did in fact lead to strong ectopic 
activation of canonical BMP signaling in perichondrial cells flanking the growth 
plates in long bones, ribs and cranial base. In controls, the perichondrium had a 
stereotypic histological organization and structure, with the inner portion con-
sisting of skeletal progenitors with a cuboidal shape and an outer portion with 
elongated fibroblastic cells intermixed with blood vessels and other cell types. 
In mutants, ectopic BMP signaling was accompanied by a violation of these ar-
rangements and boundaries, a change in cell morphology particularly within the 
inner portion, and eventually neo-differentiation of cartilage cells. With time, the 
latter became organized in a growth plate-like structure oriented at 90° angle with 
respect to the main skeletal axis, continued to grow outwardly, and eventually 
underwent ossification propelled by osteogenic and angiogenic cells recruited 
from the surroundings. Interestingly, ectopic chondrogenesis and osteochondro-
ma-like formation developed also along the growth plate of control wild type 
long bone explants in which the perichondrium had been locally implanted with 
a bead containing the small molecule HS antagonist Surfen. Biochemical and 
surface plasmon resonance assays showed that Surfen had displayed endogenous 
BMPs bound to HS chains, making them available for biological action. Prox-
imity ligation assays showed that treatment with Surfen or heparitinase led to 
a rapid rearrangement of cell surface BMP receptors, formation of tetrameric 
complexes, and activation of signaling via pSMADs. Given the potency of ec-
topic BMP signaling in inducing osteochondroma formation, we asked whether 
it may represent a therapeutic target. Juvenile floxed Ext1;Aggr-CreER mice 
injected with tamoxifen once were treated with the BMP signaling antagonist 
LDN-193189 (or vehicle) by oral gavage for 6 to 8 weeks. MicroCT and other 
analytical data showed that while numerous osteochondromas had developed in 
control vehicle-receiving mice, osteochondroma formation had been reduced by 
over 60% by drug treatment.
Conclusions. The results of our studies provide strong and novel evidence that 
osteochondromas derive from progenitor cells located within perichondrium and 
that canonical BMP signaling is a major disease- inducing mechanism. Perichon-
drium has long been known to contain endogenous BMPs and other chondro-
genic factors and to concurrently express anti-chondrogenic mechanisms, includ-
ing Noggin and fibroblast growth factor (FGF) and Wnt pathways. Thus, HS is 
normally essential to maintain a balance amongst these contrasting mechanisms 
and allow perichondrium to maintain its phenotype and structure. 
The HS deficiency during MO would alter and tilt these fine-tuning mechanisms 
toward ectopic chondrogenesis. It remains unclear the manner in which the HS 
deficiency elicits subsequent ossification and angiogenic processes that com-
plete the maturation of osteochondromas. Because HS interacts with a very large 
number of growth and signaling factors, its deficiency in MO may directly or 
indirectly elicit those processes as well. Despite these lingering and interesting 
questions, however, our data do provide the first evidence that osteochondromas 
are amenable, and responsive, to drug treatment. The future thus bodes well for 
the design and implementation of a clinical trial to test a drug treatment for the 
prevention or inhibition of osteochondroma formation in patients with MO. 
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IL-17, TNF AND BONE FORMATION, WHAT IS THE EVIDENCE?
Miossec P.
Dept. of Immunology and Rheumatology, Immunogenomics and inflammation 
research unit, University of Lyon, France
IL-17 now IL-17A, was first identified in 1995 as a T cell derived cytokine with 
effects on inflammation and neutrophil activation. Using the example of rheu-
matoid arthritis, it was shown that its inhibition reduced the production of in-
flammatory mediators by explants of inflamed synovitis. This effect results from 
synergistic interactions between IL-17 and proinflammatory cytokines such as 
TNF or IL-1. In addition to its effect on inflammation and related destruction, the 
role of IL-17 was shown in inflammation chronicity through an effect on reduced 
apoptosis of mesenchymal cells and induction of anti-apoptotic molecules. 
At the site of inflammation, increased local production of IL-17 results from lo-
cal interactions between activated T cells with various mesenchymal cells, either 
from bone marrow, skin, muscle or synovium. 
These interactions induce the full differentiation from intra-cellular IL-17 stor-
age to massive local IL-17 production.
On bone matrix formation/destruction balance, the effect of IL-17 alone and with 
TNF can be opposite, depending on the nature of the cell interactions. In destruc-
tive arthritis, such as rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, 
where osteoblasts are in direct contact with osteoclasts, IL-17 particularly in 
combination with TNF leads to massive destruction and defect in repair. Con-
versely, when such interactions are not present, as at the insertion of tendons and 
ligaments, the very same cytokines now induce ectopic bone matrix formation, 
as in the syndesmophytes of ankylosing spondylitis.
Taken together, these results support the early targeting of IL-17 in chronic in-
flammation. Reduced effect of IL-17 inhibition can be expected when inflamma-
tion had a long-term effect on mesenchymal cells. The opposite effects on forma-
tion/destruction balance of IL-17 and TNF justify both the use of their inhibitors 
in conditions associated with bone formation and destruction. Recent clinical 
results are in line with these observations. New tools are now ready to be tested 
in a growing number of diseases.
INV26
IS LOW RADIATION CT OF THE SPINE SUITABLE TO ASSESS 
STRUCTURAL PROGRESSION IN SpA?
van der Heijde D.
Leiden University Medical Center, Dept. of Rheumatology, Leiden, The Nether-
lands
New bone formation is the hallmark of axial SpondyloArthritis (axSpA). Calci-
fication of ligaments leads to syndesmophyte formation, ultimately bridging the 
entire spine. Two-dimensional conventional radiography is the standard method 
for assessment of structural damage in the spine in patients with axSpA. 
However, only the cervical and lumbar spine can be assessed reliably. And even 
only the anterior corners of the vertebrae. Consequently, only limited information 
can be derived from conventional radiographs. 
The modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) is the most 
reliable and sensitive scoring method. However, it takes two years to show pro-
gression in a sufficient number of patients to use it as an outcome in a clinical trial.
Three-dimensional imaging has a clear advantage for assessment of the spine: 
overprojection of other structures do not hamper the assessment. MRI has proven 
a very valuable method for the assessment of inflammation in the spine. Struc-
tural lesions such as fatty lesions and erosions can also be assessed. But new 
bone formation is hard to assess on MRI. In contrast, CT scanning is the most ap-
propriate method to assess bone. The drawback of CT is the high radiation dose. 
However, with the development of new hardware (multislicer scanners) and soft-
ware the radiation dose could be reduced substantially. With a maximum dose of 
4mSv a good quality image of the entire spine can be made (background radia-
tion 2.6mSv/year). It is expected that this may even be reduced in the future. The 
low dose CT (ldCT) provides slices in three planes of the entire spine. Especially, 
the addition of the thoracic spine is promising: this doubles the number of verte-
brae that can be assessed, while it is known that a lot of the inflammation can be 
seen in this part of the spine and early syndesmophytes are frequently observed in 
the thoracic-lumbar junction. Moreover, the entire vertebral rim can be assessed, 
not only the (collapsed) anterior corners on a lateral view. This opens the options 
for a more sensitive method but has also the risk of reduced reliability and speci-
ficity. Therefore, it is important to test the possibilities of the use of ldCT before 
it can be introduced as an outcome measure to replace conventional imaging.
Recently, a new scoring method was developed and validated: the CT Syndesmo-
phyte Score (CTSS) (1). 
The method is evaluating a vertebral unit (known from MRI scoring): the lower 
half of a vertebra, the intervertebral disc space and the upper half of the next ver-
tebra. Only syndesmophytes are assessed and the scores are based on the bridg-
ing of the intervertebral disc height (IVDH): 1 = <50% of the IVDH, 2 = ≥50% 
of the IVDH but no bridging, 3 = Ankylosis/bridging syndesmophyte. This is 
assessed in each quadrant in multiple planes and the highest score per quadrant is 
used for the score. The range of the scoring method is 0 tot 552 (23 VUs, 8 quad-
rants per VU, max score of 3 per quadrant). It was shown that the score showed 
good interreader reliability both for status scores and for change scores over two 
years. Most syndesmophytes were indeed observed in the thoracic spine and also 
most change happened in this part of the spine. Increase in scores was based 
both on the formation of new syndesmophytes and the growth of existing syn-
desmophytes. When comparing the mSASSS with the CTSS in 50 patients with 
a follow-up of two years the CTSS was more sensitive than the mSASSS. For 
example, an increase in score of at least 3 could be found in 6% of the patients 
with the mSASSS and in 30% of the patients with the CTSS (2).
These are the first promising results of using ldCT as an outcome measure. This 
needs further evaluation in a true treatment trial to test the discrimination. Also 
reducing the interval may become an option, which would make trials with a 
structural outcome much more viable.
References
  1. de BRUIN F, de KONING A, van den BERG R et al.: Development of the CT Syn-
desmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the 
SIAS cohort. Ann Rheum Dis 2018; 77: 371-7
  2. de KONING A, de BRUIN F, van den BERG R et al.: Low-dose CT detects more 
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INV27
DO WE NEED TO BOTHER MEASURING BONE PROLIFERA-
TION IN AXIAL SpA? INSIGHTS FROM CLINICAL TRIALS
Baraliakos X.
Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
The introduction of tumour necrosis factor inhibitors (TNFi) about 20 years ago 
has led to the hope of disease modification of ankylosing spondylitis, since bio-
logics showed for the first time a decrease of inflammatory activity on MRI, with 
the latter being theoretically also directly linked to new bone formation. How-
ever, the first open-label extensions of randomized-controlled trials with a treat-
ment duration of 2 years failed to show any positive effect on the radiographic 
progression in AS patients when compared to historical cohorts that had not been 
exposed to biologics. Nevertheless, later data indicated that this lack of influence 
on radiographic progression might have been due to many different reasons that 
were not taken into account in these first analyses, such as the radiographic status 
of patients at baseline, CRP levels or insufficient duration of follow-up. Further-
more, most recent data from MRI studies also indicated that the most important 
link to influence radiographic progression with biologics might not be the sup-
pression of inflammation but the protection of bone to show tissue metaplasia 
to post-inflammatory findings, while early suppression of inflammation might 
be the key to even completely inhibit radiographic progression in AS patients. 
Indeed, most recent cohort data have been able to demonstrate an association 
between TNF-blocker treatment and reduced risk of spinal structural progression 
(e.g. formation of syndesmophytes). 
Furthermore, early escalation of treatment from NSAIDs to biologics and long-
term treatment with biologics have also independently been able to show posi-
tive effects on radiographic progression in patients with AS. Finally, also newer 
biologics such as IL-17A inhibitors have also provided promising results in terms 
of overall low radiographic progression rates as measured by validated scoring 
systems. 
Currently, first head-to-head trials of different biologics are underway to examine 
any possible differences between the available compounds with a primary out-
come of their effect on spinal radiographic progression. 
It remains to be shown whether and how these results will also become clinically 
relevant in terms of decrease or even inhibition of spinal mobility restrictions, in 
order to be able to postulate a ‘real’ disease modifying effect of biologic treat-
ment in axial spondyloarthritis.
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O1
GUT DYSBIOSIS IN ANKYLOSING SPONDYLITIS IS ASSOCI- 
ATED WITH INCREASED FECAL CALPROTECTIN
Klingberg E.1, Magnusson M.2, Strid H.3, Deminger A.1, Carlsten H.1, Öhman L.2, 
Forsblad-d’Elia H.1,4
1Dept. of Rheumatology and Inflammation Research, Sahlgrenska Academy at 
the University of Gothenburg; 2Dept. of Microbiology and Immunology, Sahlg-
renska Academy at the University of Gothenburg; 3Dept. of Internal Medicine, 
Södra Älvsborgs sjukhus, Borås; 4Dept. of Public Health and Clinical Medicine, 
Rheumatology, Umeå University, Sweden
Introduction/Aims. Intestinal dysbiosis may be involved in the pathogenesis of 
ankylosing spondylitis (AS). We aimed to define differences in the gut micro-
biota composition between patients with AS, ulcerative colitis (UC) and healthy 
controls (HC) and determine the relations between gut microbiota, fecal calpro-
tectin (FCal) and disease related variables in AS.
Methods. Fecal microbiota was analyzed in patients with AS(N=150), UC(N=18) 
and HC(N=17) using 16S rRNA sequence technique in a targeted approach. Fe-
cal bacterial abundance and profile was also compared with a healthy reference 
group creating a Dysbiosis Index score (DI 1-5). The AS patients were assessed 
with questionnaires, back-mobility tests, FCal, ESR and CRP.
Results. Principal component analysis showed highly separate clustering of the 
microbiota in stool samples from patients with AS, UC and HC. We found an 
expansion of Proteobacteria and a contraction of Bacteroidetes and Lachno-
spiraceae in AS. Dysbiosis (defined as DI≥3) was found in 88% of AS and an 
elevated DI correlated with increased FCal (rS=0.303; p<0.001). Samples from 
AS patients with FCal<50 (n=57) and >200 mg/kg (n=36) clustered separately in 
multivariate analysis. The patients with a FCal>200 mg/kg had lower abundance 
of bacteria with anti-inflammatory effects such as Faecalibacterium prausnitzii 
and Clostridium and higher abundance of various types of Streptococci. No clear 
association was found between the overall fecal microbiota composition and 
HLAB-27 status, disease activity, function or medication.
Conclusions. The fecal microbiota signature differed greatly between patients 
with AS, UC and HC. An increased FCal, suggestive of intestinal inflammation, 
was associated with aberrations in the microbiota composition and increased 
dysbiosis. 
O2
INFLAMMASOMES ACTIVATION OCCURS IN THE INFLAMED 
TISSUES OF AS PATIENTS AND DRIVES IL-23 EXPRESSION 
AND ILC3 EXPANSION
Ciccia F.1, Guggino G.1, Rizzo A.2, Macaluso F.1, Raimondo S.3, Alessandro R.3, 
Milling S.4, Elewaut D.5
1UOC di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-
Cervello, Palermo; 2Dipartimento Biomedico di Medicina Interna e Specialis-
tica, Section of Rheumatology, University of Palermo, Palermo; 3Dipartimento 
di Biopatologia e Biotecnologie Mediche, Università di Palermo, Palermo, Italy; 
4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glas-
gow, UK; 5Molecular Immunology and Inflammation Unit, University of Ghent, 
Ghent, Belgium
*AR and GG contributed equally to this paper
Background. A growing body of evidences indicate that the aberrant activation 
of innate immune systems, occurring in genetically predisposed patients, drives 
inflammatory processes in Ankylosing Spondylitis (AS) (1). 
Objectives. Aim of this study was to evaluate the activation and the functional 
relevance of inflammasome pathways in patients with AS.
Methods. Intestinal, synovial and bone marrow expression of inflammasome 
pathways, pyroptosis and IL-1b and IL-18 was evaluated in AS patients. Analy-
sis of organic acid extraction was performed as previously described (2). The 
expression of the metabolite-sensing receptors GPR43 and GPR109A involved 
in the regulation of the intestinal inflammasome was also assessed. The role of 
intestinal dysbiosis in modulating inflammasome activation was also studied in 
AS patients and HLA-B27 transgenic rats. Inflammasome activation was evalu-
ated in isolated peripheral AS monocytes. The role of LPS, PGE2 and nicotine 
in inducing monocyte inflammasome activation and the role of inflammasome in 
modulating IL-23 production and ILC3 expansion was also evaluated. 
Results. Activation of inflammasomes was observed in the inflamed gut, syno-
vial and bone marrow samples of AS patients and associated with an increased 
expression of caspase-1, IL-1b and IL-18. In AS, AIM2 expression was observed 
in the context of tuft cells and of adherent ileal bacteria. Inflammasome acti-
vation in AS gut, was associated with the occurrence of dysbiosis and isolated 
bacteria from the gut of AS patients induced inflammasome activation on iso-
lated PBMC from healthy controls. Increased pyroptosis was also observed in 
the gut as demonstrated by the membrane localization of Gasdermin D. Isolated 
intestinal bacteria from AS ileal samples, significantly modulated inflammasome 
activation in isolated monocytes. Reduced Short-chain fatty acids concentrations 
and increased expression of GPR43 and GPR109 were demonstrated in the AS 
ileal samples. Inflammasome activation was also observed in the inflamed gut of 
HLA-B27 TG rats and suppressed by antibiotics treatment. Increased expression 
of NLRP3, NLRC4 and AIM2 was confirmed in AS isolated peripheral mono-
cytes, directly correlated with the ASDAS-CRP, and paralleled by increased 
serum levels of IL-1β. In in vitro studies, LPS and nicotine strongly activated 
NLRP3, NLRC4 and AIM2 pathways in AS monocytes. The CC genotype of 
PTGER4 SNP rs6896969 was associated with a significantly increased activation 
of inflammasome in AS. Inflammasome activation in AS monocytes was required 
for the induction of IL-23p19 expression in an IL-1β-dependent way. Finally, 
inflammasome inhibition blocked IL-23-induced ILC3 expansion.
Conclusions. Inflammasome activation occurs in AS patients and is modulated 
by a plethora of different tissue-specific and circulating stimuli. Inflammasome 
drives IL-23p19 production in a IL-1β-dependent mechanism and modulate 
ILC3 expansion in AS patients possibly representing a future area of therapeutic 
interventions in AS.
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O3
TRANSMEMBRANE TNF SIGNALING THROUGH TNF-RI IN-
DUCES SpA-LIKE INFLAMMATION, WHEREAS SIGNALING 
THROUGH TNF-RII IS CRUCIAL FOR NEW BONE FORMATION
van Tok M.1, Pots D.1, Blijdorp I.1, Armaka M.2, Kollias G.2, van de Sande M.1, 
Baeten D.1, van Duivenvoorde L.1
1Amsterdam Rheumatology and Immunology Center, Dept. of Clinical Immu-
nology and Rheumatology, Academic Medical Center, Amsterdam, The Nether-
lands; 2Division of Immunology, Biomedical Sciences Research Center “Alexan-
der Fleming”, Vari, Greece
Introduction and Aim. TNF can drive strictly distinct inflammatory pathologies 
depending on its expression form. We have shown that transmembrane (tm)TNF 
rather than soluble TNF contributes to key pathological features of spondyloar-
thritis (SpA), including the key hallmark pathological new bone formation. The 
aim is to delineate the cellular and molecular mechanisms by which selective 
tmTNF overexpression leads to SpA-like pathology.
Methods. tmTNFtg mice (TgA86) were crossed with TNF-RI or TNF-RII knock-
out mice and followed clinically for SpA development. Calvarial fibroblasts were 
cultured and differentiated towards osteoblasts.
Results. SpA was observed in all tmTNF+/WT and tmTNF+/WTxTNF-RII-/- mice 
but not in tmTNF+/wtxTNF-RI-/- mice and confirmed by histology. Whereas this 
indicates that TNF-RI is required for tmTNF-induced inflammation, it was strik-
ing that 50% of the tmTNF+/WT versus none of the tmTNF+/WTxTNF-RII-/- mice 
depicted clear histological signs of endochondral new bone formation. To test 
whether TNF-RII is involved in new bone, calvarial fibroblasts from tmTNF+/
WT, tmTNF+/WTxTNF-RI-/-, tmTNF+/WTxTNF-RII-/- and wild type mice were dif-
ferentiated with osteogenic medium with or without IL-17A. tmTNF overex-
pressing fibroblasts enhanced osteogenic differentiation as observed by alkaline 
phosphatase and alizarin red staining and increased mRNA levels of Collagen 
type I and ALP compared to wild type fibroblasts. This enhancement in osteogen-
esis was maintained in tmTNF+/WTxTNF-RI-/--derived fibroblasts but abolished in 
tmTNF+/WTxTNF-RII-/--derived fibroblasts.
Conclusion. The SpA-like phenotype in tmTNFtg mice is crucially dependent on 
TNF-RI to drive inflammation, but TNF-RII signaling is required for new bone 
formation under inflammatory conditions.
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O4
PROGNOSTIC MARKERS IN AXIAL SPONDYLOARTHRITIS 
(PROMISE) – ALPHA 1 ANTI TRYPSIN AND BETA 2 MICRO-
GLOBULIN MAY DIFFERENTIATE ANKYLOSING SPONDYLITIS 
FROM NON RADIOGRAPHIC axSpA, MECHANICAL BACK PAIN 
AND HEALTHY CONTROLS 
Reilly E.1,2, Fisher C.3, McGrogan A.2, Sengupta R.1
1Royal National Hospital for Rheumatic Diseases, Bath; 2Dept. of Pharmacy and 
Pharmacology, University of Bath; 3University College London, UK
Introduction. Over recent years, a clear need for additional biomarkers in ax-
SpA has been identified, for diagnosis, prognostication and treatment response. 
Multiple biomarkers have been explored, but there remains uncertainty as to their 
utility in clinical practice and their inter-relationship. 
Aim. In this cross-sectional study we evaluated a broad panel of serum biomark-
ers, from a large mixed cohort of patients with Ankylosing Spondylitis (AS), non 
radiographic axial spondyloarthritis (nr-axSpA), mechanical back pain (MBP) 
and healthy controls (HC). We aimed to evaluate these biomarkers to describe 
diagnostic subgroups.
Methods. A panel of 46 serum biomarkers were analysed by Myriad RBM using 
multiplexed immunoassays (Fig. 1.) in a cohort of patients from a tertiary refer-
ral centre, consented as part of the Bath Spondyloarthritis Biobank. AS patients 
met mNY criteria, and nr-axSpA patients satisfied ASAS classification. Validated 
patient reported outcomes (including BASDAI, BASFI) and BASMI were com-
pleted. 50 HC blood samples were collected at University College London for 
biomarker analysis. 
Results. 331 patients were included (59.5% AS, 8.2% nr-axSpA, 15.7% MBP, 
15.1% HC). 64.7% were male, mean age 44.2 years (SD 16.6), mean disease 
duration in the AS group of 22.4 years (SD 13.6) with 84% HLA B27 positive. 
Logistic regression identified an increased odds of AS versus control for alpha 
1 antitrypsin (AAT) (OR 44.8 [95%CI 15.9 to 126.3]) and beta 2 microglobulin 
(B2M) (OR 19.8 [95% CI 8.4 to 46.4]). ROC curves for AS patients versus con-
trols for AAT and B2M demonstrated AUC of 0.94 and 0.93 respectively (Figs. 
2 & 3). 
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Fig. 1. Candidate biomarker panel evaluated using multiplexed immunoassays.
Fig. 3. ROC curve for beta 2 microglobulin as AS vs. healthy controls.
Discussion. AAT and B2M have been identified as potential biomarkers dif-
ferentiating distinct diagnostic groups in this preliminary analysis. Further sub 
group analysis is planned, along with evaluation of biomarkers with radiographic 
imaging.
O5
IMPACT OF GUT INVOLVEMENT IN EARLY SPONDYLO- 
ARTHRITIS – THE DESIR COHORT
Wendling D.1, Guillot X.1, Prati C.1, Miceli-Richard C.2, Molto A.2, Lories R.3, 
Dougados M.2
1University Teaching Hospital (CHRU), Besançon; 2Cochin Hospital, Paris, 
France; 3KU Leuven, Belgium
Inflammatory bowel disease (IBD) is a well-known extra articular feature of 
spondyloarthritis (SpA), with a pathophysiological relationship.
Aims. To evaluate in the DESIR cohort the prevalence and incidence of IBD over 
the first 5 years of follow-up, and factors associated. 
Methods. DESIR is a prospective observational cohort of patients with recent 
onset (<3 years) inflammatory back pain, suggestive of axial SpA. All available 
factors in the database were compared between patients with and without past or 
present IBD (with medical confirmation) at baseline and at M60, and incident 
cases of IBD over the 5 years of follow-up, by uni and multivariate analysis.
Results. At baseline, 706 patients were analyzed, 35 had a past history or a con-
comitant IBD: prevalence 4.94% [CI 95%: 3.3-6.5]. IBD was significantly as-
sociated in multivariate analysis with history of uveitis; OR 3.62 [1.95-6.74], 
levels of DKK-1: OR 1.03 [1.02-1.05] and TNF serum level: OR 1.17 [1.08-
1.26]. IBD was not associated with phenotypic presentation (peripheral arthritis, 
enthesitis, dactylitis, uveitis) or baseline serum levels of other cytokines (IL-6, 
IL-17, IL-23). 
At M60, 480 patients were analyzed, 58 with IBD: prevalence 12.1% [9.17-
14.99]. In multivariate analysis, IBD was associated with fulfillment of modified 
New York criteria: OR 4.85 [2.23-10.57], sick leave: OR 1.01 [1.005-1.014], 
BASDAI: OR 1.10 [1.05-1.16], and with smoking: OR 2.79 [1.53-5.07]. No as-
sociation with MRI scores, enthesitis, psoriasis, BMD. 
After a 5-year follow-up period, 23 incident cases of IBD were recorded, giving 
an estimated occurrence rate of 0.95/100 [0.57-1.35] patient-years in this popula-
tion. Incidence of IBD was independently associated (multivariate) with: HLA 
B27: OR 0.36 [0.22-0.59], fulfillment of modified New York criteria at M0: OR 
3.35 [1.85-6.08], family history of IBD: OR 3.31 [1.62-6.77].
Conclusion. In early SpA, IBD occurs with an incidence of around 1/100 patient-
years, and is associated with poor outcome at 5 years, family history of IBD, 
absence of HLA-B27, fulfillment of modified New York criteria.
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Fig. 2. ROC curve for alpha 1 antitrypsin in AS vs. healthy controls.
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O6
GENDER DIFFERENCES IN TNFI TREATMENT ADHERENCE 
AND RESPONSE IN AS PATIENTS: A PROSPECTIVE LONGI- 
TUDINAL COHORT STUDY
Hoekstra S.1, Rusman T.1, Nurmohamed M.T.1, van Denderen J.C.2, Van der 
Horst-Bruinsma I.E.1
1Amsterdam Rheumatology immunology Center, Depts. of Rheumatology; 2VU 
University Medical Center & Reade Amsterdam, The Netherlands
Introduction/Aim. Despite several observations of gender differences in TNF 
inhibitor (TNFi) treatment response and adherence in ankylosing spondylitis 
(AS) patients, limited studies were conducted. Our aim is to assess gender differ-
ences in TNFi treatment adherence and response in a longitudinal cohort study 
over a 10-year follow-up period in AS patients.
Methods. AS patients (fulfilling the modified New York Criteria) treated con-
secutively with TNFi were included in a prospective, observational cohort. Data 
were collected at baseline, screening, 3 and 6 months and thereafter every 6 
months on demographics, lifestyle factors, inflammatory markers (C-reactive 
Protein (CRP)) and disease specific parameters (Bath Ankylosing Spondyli-
tis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activ-
ity Score (ASDAS), Bath Ankylosing Spondylitis Metrology Index (BASMI)). 
TNFi response was defined by BASDAI50% response criteria (50% of the initial 
score or improvement of >2 points) and ASDAS response criteria (improvement 
of >1.1 points). Kaplan-Meier Survival curves and Generalized Estimating Equa-
tions (GEE)-analyses were performed.
Results. In total 359 AS patients (33.4% females) were included with a mean 
follow-up of 5.1 years. Women showed a significant lower follow-up duration 
than men, 4.5 vs. 5.4 years. Patients who were lost to follow-up, were mostly 
still treated. Overall, females showed significantly higher disease activity scores, 
BASDAI (0.57 points) (Fig. 1) and ASDAS (0.27 points), compared to males 
over the entire follow-up period. According to both the BASDAI and the ASDAS 
response criteria, females had an overall significantly lower percentage of re-
sponders compared with males. In the secondary outcomes, females showed only 
a clinically relevant lower BASMI (higher mobility) than males (0.23 points). 
Conclusion. Female AS patients showed a significantly lower follow-up dura-
tion, a lower improvement and a lower clinical response to TNFi according to the 
BASDAI and ASDAS response criteria. 
Fig, 1. Gender differences in AS patients treated with TNFi in mean BASDAI and 
drop-out rate over a 10-year follow-up period.
O7
FATTY LESIONS DETECTED ON MRI SCANS IN PATIENTS WITH 
ANKYLOSING SPONDYLITIS ARE BASED ON THE DEPOSITION 
OF FAT IN THE VERTEBRAL BONE MARROW 
Baraliakos X., Boehm H., Samir A., Schett G., Braun J.
Rheumazentrum Ruhrgebiet, Herne; Clinic for spinal surgery, Bad Berka; Frie-
drich Alexander University Erlangen-Nuremberg; Universitaetsklinikum Erlan-
gen, Erlangen, Germany
Background. Fatty lesions (FL), similar to bone marrow edema (BME) and scle-
rosis (SCL), are characteristic findings in MRI examinations of patients with 
ankylosing spondylitis (AS) and degenerative disc disease (DDD). It has recently 
been shown that FL are associated with syndesmophyte formation in AS. The 
anatomic correlate of FL has not been studied to date. Current assumptions are 
solely based on non-invasive data. 
Objective. To examine the cellular composition of FL in the edges of vertebral 
bodies of patients with AS or DDD by histology. 
Methods. Patients with AS or DDD undergoing planned kyphosis correction sur-
gery by spinal osteotomy (in AS) or surgery to correct spinal stenosis (in DDD) 
were included into this biopsy study. The spinal surgeon (HB) took all biopsies 
mainly in the area close to the vertebral edge in many of which FL had been seen 
by MRI (Fig. 1a for AS and 1b for DDD). Biopsies were decalcified, embedded in 
paraffin, cut and stained by hematoxylin and eosin. The marrow composition was 
analyzed and the cellularity graded (% surface area) by two different investigators 
blinded to patients’ diagnosis. Four different marrow compositions could be dif-
ferentiated: (i) fat, (ii) fibrosis, (iii) inflammation and (iv) hematopoiesis (normal). 
Results. A total of 60 biopsies mostly obtained from the lower thoracic spine and 
the lumbar spine of 21 AS patients (mean age 51.7 years, mean disease duration 
24.6 years) and of the lumbar spine in 18 DDD patients (mean age 60.1 years) 
were available. On the patient level, the histological appearance of MRI-FL was 
different between the groups: fat marrow was present in biopsies of 19 AS (90%) 
but in only 5 DDD (28%) patients. Inflammatory marrow changes, resembling 
mononuclear infiltrates, were found in 8 AS (38.1%) and 14 DDD (77.8%) pa-
tients at areas with concomitant FL and BME on MRI, while marrow fibrosis was 
seen in 6 AS (28.6%) and 4 DDD (22.2%) patients at areas with concomitant FL 
and SCL on MRI. 
In the semiquantitative histopathological analysis, the mean distribution (±stand-
ard deviation) of the various bone marrow tissue types in the biopsies differed 
between the AS vs. DD in a similar way, with 43% (±26.3%) vs. 16% (±30.3%) 
for fatty marrow, 11% (±15.5%) vs. 55% (±42%) for inflammatory marrow and 
9% (±16.1%) vs. 13% (±27.8%) for fibrotic marrow, respectively.
Conclusion. The presence of FL on MRI corresponds to fat deposition in the 
bone marrow of patients with advanced AS. These data show that the MRI change 
termed “fatty lesion” is indeed based on the deposition of fat in the vertebral bone 
marrow in AS. Since vertebral bone marrow is physiologically harboring hemat-
opoiesis, AS seems to lead to a change in the bone marrow microenvironment 
with local disruption of hematopoiesis and replacement by fat. The link between 
fat and new bone formation should be studied in earlier disease stages.
O8
PREVALENCE OF INFLAMMATORY AND CHRONIC CHANGES 
SUGGESTIVE OF AXIAL SPONDYLOARTHRITIS IN MAGNETIC 
RESONANCE IMAGES OF THE AXIAL SKELETON IN INDIVIDU-
ALS < 45 YEARS IN THE GENERAL POPULATION AS PART OF A 
LARGE COMMUNITY STUDY (SHIP)
Baraliakos X., Feldmann D., Ott A., Schmidt C.O., Albers M., Richter A., Braun J. 
Rheumazentrum Ruhrgebiet, Herne, Germany
Background. Magnetic resonance imaging (MRI) is crucial for classification 
and diagnosis of axial spondyloarthritis (axSpA). Characteristic MRI lesions of 
axSpA are bone marrow edema (BME) or structural fatty lesions (FL) of the sac-
roiliac joints (SIJ) and spine. However, the specificity of these lesions has been 
questioned, since patients with chronic back pain but no axSpA may also have a 
positive MRI, as shown in recent cohort studies.
Objective. To investigate the prevalence of BME and FL on MRI of the spine 
and the SIJ in the general population.
Methods. Volunteers <45 years of the population based Study of Health in Po-
merania (SHIP)1,2 underwent MRI examinations of the spine (sagittal orientation, 
T1 and T2 MRI sequences) and the SIJ (coronal orientation, STIR sequences), 
independently of clinical symptoms. Two trained readers blinded for age and 
gender of the examined persons evaluated the prevalence of BME (SIJ and spine) 
and FL (spine) suggestive of axSpA using the ASAS definitions: a lesion in the 
SIJ was considered positive if located periarticularly and in the middle part of the 
joint and A lesion in the spine was considered positive if detected at the edge of 
the vertebral body). Clearly degenerative lesions involving the vertebral endplate 
or being accompanied by abnormalities of the intervertebral disc (protrusion or 
prolapse) were not counted. 
Results. A total of 802 complete MRI sets (spine and SIJ) of 394 male (49.1%) 
and 408 female volunteers (50.9%) was evaluated. The mean age of all patients 
was 37.5±6.2 years. BME in the SIJ suggestive of axSpA were found in 144 
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individuals (18%), with an equal distribution between males (n=74, 18.8%) and 
females (n=70, 17.2%). A similar pattern of BME was found in the spine, again 
with no differences between males and females. However, the location of the 
lesions was different: 9.5% had ≥1 lesion in the cervical, 18.6% in the thoracic 
and 7.4% in the lumbar spine. Overall, 88.6% male and 84.6% female volunteers 
were found to have ≥1 and 54.6% male and 46.1% female volunteers were found 
to have at ≥3 positive spinal lesions in any spinal region. In comparison, the 
prevalence of FL was higher (36.7% volunteers in the cervical, 72.4% in the 
thoracic and 52.7% in the lumbar spine). Overall, 86.5% volunteers were found 
to have ≥1 and 50.2% volunteers were found to have ≥3 positive spinal lesions 
in any spinal segment.
Logistic regression analysis showed that age was the only demographic charac-
teristic that independently contributed to the occurrence of both BME (RR=1.22, 
95%CI 1.03-1.46, p<0.025) or FL ((RR=1.12, 95%CI 1.07-1.19, p<0.001). 
Conclusions. In this large population-based study with healthy volunteers a rela-
tively high prevalence of inflammatory and structural MRI lesions was found. 
Whether these lesions are to be explained by mechanical stress needs to be fur-
ther studied. The high prevalence of BME and FL in the axial skeleton in the 
general population indicates a limited diagnostic value of these MRI findings. 
Thus, those should be interpreted with caution in relation to diagnosis, classifica-
tion and assessment of disease activity.
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O9
VALIDATION OF ASAS MRI LESION DEFINITIONS IN AXIAL 
SPONDYLOARTHRITIS: DATA FROM THE ECHOGRAPHY IN 
SPONDYLOARTHRITIS COHORT (ECHOSPA)
Maksymowych W.P.1,2, Loeuille D.3, Wichuk S.1, Paschke J.2, Judet O.4, Breban 
M.4, D’Agostino M.A.4, Lambert R.G.1
1University of Alberta; 2CaRE Arthritis; 3Ambroise Paré Hospital, Boulogne-
Billancourt; 4CHRU Vandoeuvre les Nancy, France
Introduction/Aims. The ASAS MRI group has generated updated consensus 
MRI lesion definitions in the SIJ and spine (ASAS_MRI_defn). We aimed to as-
sess the distribution, reliability of detection, and construct validity of active and 
structural lesions per these definitions in an early axSpA cohort.
Methods. Consecutive outpatients with age <50 years and symptoms >3 months 
suggestive of SpA were enrolled. MRI scans from 412 of 470 cases were eval-
uated by 2 readers and an adjudicator. ASAS_MRI_defn were recorded in an 
ASAS-consensus derived eCRF according to global assessment (lesion present/
absent) and detailed scoring of individual lesions (SPARCC SIJ inflammation, 
SPARCC SIJ structural). Reliability of detection was analyzed using kappa and 
detailed scoring by ICC. For construct validity we calculated optimal cut-offs for 
bone marrow edema (BME) and erosion that defined active and structural lesion 
typical of axSpA, respectively.
Results. Active and structural lesions typical of axSpA were present in 9.7% 
and 10.8%, respectively, and ASAS positive MRI in 9.3%. Subchondral BME 
(13.6%) and erosion (9.4%) were the most frequent. Active but not structural 
lesions were present in 3.0% while the converse was evident in 4.0%. AxSpA 
was clinically diagnosed at baseline in 88.1% and all categories of active and 
structural lesions were higher in those with axSpA. Substantial κ values (95%CI) 
were evident for detection of these lesions with comparable reliability for active 
and structural lesions: active lesion (0.76 (0.65-0.88)), ASAS positive MRI (0.78 
(0.66-0.89), structural lesion (0.76 (0.65-0.87). Detailed scoring per SIJ quadrant 
that reflect expert opinion as to what constitutes an active or structural lesion 
typical of axSpA are provided in the Table. 
Table. 
Number of SIJ Quadrants Active Lesion Typical of AxSpA
 Sensitivity Specificity
BME Score ≥2 100% 90.27%
BME Score ≥3 100% 95.14%
BME Score ≥4 97.5% 96.76%
 Structural Lesion Typical of AxSpA
 Sensitivity Specificity
Erosion Score ≥2 84.09 99.15
Fat metaplasia ≥2 27.27 98.02
Backfill ≥2 11.36 100
Ankylosis ≥2 4.55 99.72
Conclusions. SPARCC BME score of ≥3 and Erosion Score ≥2 may optimally 
reflect active and structural lesions typical of axSpA, respectively. MRI lesions 
defined by the ASAS-MRI group can be reliably detected.  
O10
INFLAMMATION ON MRI OF SPINE AND SACROILIAC JOINTS 
IS HIGHLY PREDICTIVE OF STRUCTURAL DAMAGE IN AXIAL 
SPONDYLOARTHRITIS: THE 5 YEARS DATA OF THE DESIR 
COHORT
Sepriano A.1, Ramiro S.1, Landewé R.2, Dougados M.3, van der Heijde D.1 
1LUMC, Leiden; 2ARC, Amsterdam, The Netherlands; 3Hospital Cochin, Paris, 
France
Aim. We aimed to test the possible effect of inflammation on structural damage 
both assessed by MRI and at the level of the spine and the SIJ.
Materials and Methods. Patients with axSpA from the DESIR cohort were in-
cluded. MRI of the SIJ (MRI-SIJ) and spine (MRI-spine) were obtained at base-
line, 2 and 5 years and scored by 3 central readers. Inflammation at the MRI-SIJ 
and MRI-spine was assessed according to ASAS definition. Structural damage 
in the SIJ (MRI-SIJ-STR) and spine (MRI-spine-STR) was defined by ≥ 3 fatty 
lesions. The % structural net progression (number of ‘progressors’ minus the 
number of ‘regressors’ divided by the total) was assessed according to CRP and 
BME at baseline. The effect of BME on MRI-SIJ on MRI-SIJ-STR and of BME 
on MRI-spine on MRI-spine-STR was evaluated using two types of GEE models: 
i. effect at baseline on 5 years incorporating measurements from all readers (GEE 
adjusted for reader); ii. effect of BME over 5 years (longitudinal models). 
Results. In total, 151 and 145 pts had complete 5-year MRI-SIJ and MRI-spine 
data available, respectively. 
The net % patients who switched from MRI-SIJ-STR negative to positive ranged 
from 3.8% to 24% according to the presence of objective signs of inflammation 
(figure). Low number of patients didn’t allow for similar analysis in the spine. In 
the multivariable analysis, both the presence of BME at MRI-SIJ (OR=4.2 [95% 
CI: 2.4-7.3]), and BME at MRI-spine (OR=8.9 [95% CI: 2.1-38.7]) at baseline 
were highly predictive of MRI-SIJ and MRI-spine structural progression respec-
tively. Similar associations were found in the longitudinal models (table).
Conclusion. Our results show that local inflammation is strongly associated with 
the development of structural damage over 5 years both in the SIJ and spine in 
early axSpA. 
Figure. Net progression from MRI-SIJ-STR negative to MRI-SIJ-STR positive (≥ 3 
fatty lesions) according to baseline objective inflammatory markers.
Table. Effect of inflammation on MRI (ASAS definition of sacroiliitis and BME 
in the spine) on binary MRI structural outcomes.
 ≥3 fatty lesions ≥3 fatty lesions
 on MRI-SIJ on MRI-Spine
Effect of BMI on: OR (95% CI) OR (95% CI)
 (N=144-197) (N=145-197)
By GEE adjusted for reader 4.2 (2.4; 7.3)* 8.9 (2.1; 38.7)*
By longitudinal GEE adjusted for 5.1 (2.7; 9.6)£ 15.6 (4.8; 50.3)£
reader and repeated measurements
*Adjusted for CRP at baseline; £adjusted for time-varying lagged ASDAS-CRP. 
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O11
DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKI-
ZUMAB IN PATIENTS WITH ACTIVE AS: 12-WEEK RESULTS 
FROM A PHASE 2B STUDY
van der Heijde D.1, Gensler L.S.2, Deodhar A.3, Baraliakos X.4, Poddubnyy D.5, 
Farmer M.K.6, Baeten D.7, Kumke T.8, Oortgiesen M.6, Dougados M.9
1LUMC, Leiden, The Netherlands; 2UCSF, San Francisco; 3OHSU, Portland, 
USA; 4Ruhr-University Bochum, Herne; 5Charité – Universitätsmedizin Berlin, 
German Rheumatism Research Centre, Berlin, Germany; 6UCB Pharma, Raleigh, 
USA; 7UCB Pharma, Brussels, Belgium; 8UCB Pharma, Monheim, Germany; 
9Cochin Hospital, Paris, France
Introduction/Aim. We report 12-week efficacy and safety of bimekizumab, 
a monoclonal antibody that potently and selectively neutralises IL-17A and 
IL-17F, in patients with active AS; the primary objective was ASAS40 dose-
response relationship (Week 12) assessment.
Methods. In this ongoing 48-week study (NCT02963506: double-blind to Week 
12 then dose-blind to Week 48), 303 patients with active AS (BASDAI ≥4; spinal 
pain ≥4 [0–10]), fulfilling modified NY criteria, were randomised 1:1:1:1:1 to 
subcutaneous bimekizumab 16mg, 64mg, 160mg, 320mg or placebo Q4W, for 12 
weeks. Primary endpoint was ASAS40 response rate (Week 12).
Results. 297 (98.0%) patients completed the 12-week double-blind period. The 
majority of patients were male (84.5%) with a mean (SD) age of 42.2 (11.8) years 
and median (range) symptom duration of 13.3 (0.3−48.2) years; baseline charac-
teristics were similar among groups (mean [SD] ASDAS-CRP: 3.9 [0.8]; one prior 
anti-TNF: 11.2%). At Week 12, there was a significant (p<0.001) dose-response 
for ASAS40. A significantly greater percentage of bimekizumab-treated patients 
than placebo achieved ASAS40 (Figure: p<0.05, all doses); also more bimeki-
zumab-treated patients achieved ASAS20 (Figure; p<0.05, 64mg−320mg doses). 
Compared with placebo, bimekizumab provided greater reductions from base-
line for both BASDAI (Figure) and ASDAS-CRP (LS-mean [SE] change from 
baseline: 16mg: −1.0 [0.15]; 64mg: −1.6 [0.15]; 160mg: −1.4 [0.16]; 320mg: 
−1.5 [0.16]; placebo: −0.4 [0.16]; p<0.001, all doses). TEAEs were reported by 
86/243 (35.4%) bimekizumab-treated patients and 22/60 (36.7%) placebo pa-
tients. No unexpected safety findings were observed; the most frequently report-
ed events were nasopharyngitis and headache.
*p<0.05, **p<0.001; calculated from a logistic regression model including fixed effects for treat-
ment, geographic region and prior anti-TNF exposure. A: non-responder imputation, full analysis set; 
B: observed data, full analysis set.
Conclusions. Primary and key secondary objectives were achieved; bimekizum-
ab treatment provided clinically meaningful improvements in disease outcome 
measures. No new safety signals were observed.
O12
HIGH NEED FOR ANTI-TNF THERAPY AFTER WITHDRAWAL 
STRATEGY IN EARLY PERIPHERAL SPONDYLOARTHRITIS
Carron P.1,2, Varkas G.1,2, Renson T.1,2, De Craemer A.1, Elewaut D.1,2, Van den 
Bosch F.1,2
1Dept. of Rheumatology Ghent University Hospital; 2VIB Inflammation Research 
Center, Ghent University, Ghent, Belgium
Introduction. Treatment with TNFi in early stages of peripheral Spondyloarthri-
tis (pSpA) results in higher rates of clinical remission, compared to treatment in 
more longstanding disease (1). When remission is reached, the recently updated 
T2T-recommendations suggest tapering of treatment. In the CRESPA-trial pSpA 
patients were treated with golimumab monotherapy; we demonstrated that – after 
reaching sustained remission – discontinuation of golimumab led to biological-
free remission in 53% of patients; conversely 47% experienced a disease flare. It 
is currently unknown if concomitant administration of DMARDs could lead to 
higher rates of biological-free remission.
Aim. To explore - in pSpA patients in clinical remission - the possibility that co-
medication with methotrexate would allow discontinuation of the TNFi.
Methods. The CRESPA-trial included patients with active pSpA and symptom 
duration <12 weeks; the primary study results have been reported previously. In 
the CRESPA-Extension protocol, patients were included that either did not reach 
remission (but had substantial improvement with golimumab treatment), or that 
experienced recurrence of arthritis, enthesitis or dactylitis within 1 year after 
discontinuation of golimumab. 
These patients received additional open-label golimumab 50 mg SC every 4 
weeks for 2 years. At week 104, patients were offered an additional 12 weeks of 
golimumab treatment, but now in combination with methotrexate 15mg weekly. 
At week 116, patients in clinical remission continued methotrexate, but discon-
tinued golimumab. Patients were prospectively followed to assess the rate of sus-
tained biological-free clinical remission. In case of relapse of arthritis, enthesitis 
or dactylitis under methotrexate monotherapy, golimumab was restarted. 
Results. Currently, twenty-three of the original 60 pSpA patients included in the 
CRESPA-trial, completed the 2-year CRESPA-Extension protocol; of these, 21 
(91%) were in clinical remission at week 104 when methotrexate was added. The 
mean follow-up period after completion of the extension part, was 80±28w. 5 pa-
tients (24%) are still in sustained remission (n=5) under methotrexate monother-
apy whereas in 16 patients (76%), golimumab needed to be re-installed because 
of relapse of disease activity (n=14) or development of adverse events related to 
methotrexate (n=2). Recurrence of disease was characterized by development of 
arthritis in all patients with a median of 4 tender and 3 swollen joints. In 50% 
(n=7) of the cases, concomitant dactylitis was present. 64% (9/14) were hav-
ing concomitant psoriasis which was mild since all had a BSA <5%. The mean 
time for recurrence was 28,6 weeks. Restarting golimumab treatment promptly 
restored clinical remission in all patients within 12 weeks. 
Conclusion. In patients with pSpA in clinical remission after 2 years of goli-
mumab monotherapy, concomitant administration of methotrexate before dis-
continuation of the TNFi, did not significantly raise the percentage of patients 
in biological-free remission. In 76% of patients, golimumab had to be restarted, 
underscoring the overall weak efficacy of methotrexate in pSpA.
Reference
  1. CARRON P, VARKAS G, CYPERS H, van PRAET L, ELEWAUT D, van den 
BOSCH F et al.: Anti-TNF-induced remission in very early peripheral spondyloar-
thritis: the CRESPA study. Ann Rheum Dis. 2017 Aug; 76(8): 1389-1395.
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DUTCH RECOMMENDATIONS FOR PHYSICAL THERAPY IN 
AXIAL SPONDYLOARTHRITIS (axSpA)
van Weely S.F.E.1, van der Giesen F.J.1, van Gaalen F.A.2, van der Horst- 
Bruinsma I.E.3, Ramiro S.2, Weel A.E.A.M.4, Lopuhaä N.5, Vliet Vlieland T.P.M.1
1Orthopaedics, Rehabilitation and Physical Therapy; 2Rheumatology, Leiden 
University Medical Center, Leiden; 3Rheumatology, VU University Medical 
Center, Amsterdam; 4Rheumatology, Maasstad Ziekenhuis, Rotterdam; 5Dutch 
Arthritis Foundation, Amsterdam, The Netherlands
Introduction. According to the ASAS/EULAR recommendations, physical ther-
apy (PT), especially exercise therapy, is an essential element within the manage-
ment of axSpA. In the Netherlands considerable variation in the delivery of PT 
was observed1, suggesting suboptimal care delivery. This practice variation is 
likely to be related to the lack of specific recommendations regarding referral, 
assessment, content, and monitoring of its effectiveness and safety.
Aim. To develop practice recommendations on PT in axSpA.
Material and Methods. A taskforce of 31 experts was responsible for the recom-
mendations. It consisted of patients (2), rheumatologists (7), physical therapists 
(13), policy makers (3), researchers (2) and representatives of patient organisa-
tions (4). The recommendations were based on scientific evidence, expert opin-
ion and patient values and were formulated following a combination of system-
atic literature review and three expert-group meetings. 
Results. In total 12 practice recommendations were formulated on indication (2), 
referral (2), assessment/monitoring (2), treatment (5), reporting (1) and safety 
(2). (Fig. 1) Three recommendations were (partly) based on level 1 evidence 
(Dutch Evidence Based guidelines, EBRO); others were based on lower lev-
els combined with the opinion of experts written in literature. Agreement was 
reached for 11 out of 12 recommendations. Mean levels of agreement were high 
and varied between 8,5-9,1. 
Fig. 1. Short description of the content of the Dutch recommendations for physical 
therapy in axial Spondyloarthritis (axSpA).. 
Conclusions. Using a standardized process of professional guideline develop-
ment, 12 practice recommendations for PT management of patients with axSpA 
were developed. They can guide clinicians and physiotherapists dealing with pa-
tients with axSpA, ultimately leading to a delivery of a better care. Next steps 
are the ratification by relevant professional societies as well as dissemination and 
implementation.
Acknowledgements. This study was Funded by the Dutch Arthritis Foundation.
Reference
  1. van der GIESEN F et al.: Content and supervision of group exercise therapy 
(GET) for axial spondyloarthritis (axSpA) in The Netherlands; a nation wide sur-
vey, Ann Rheum Dis. 2017;76(2): 1479.
702 Clinical and Experimental Rheumatology 2018
Poster Presentations Eleventh International Congress on Spondyloarthritides
Poster Presentations
P1
WHICH IMAGING OUTCOMES FOR axSpA ARE MOST SEN-
SITIVE TO CHANGE? A 5-YEAR ANALYSIS OF THE DESIR 
COHORT
Sepriano A.1, Ramiro S.1, van der Heijde D.1, Dougados M.2, Claudepierre P.3, 
Feydy A.2, Reijnierse M.1, Loeuille D.4, Landewé R.5
1LUMC, Leiden, The Netherlands; 2Hospital Cochin, Paris; 3Hôpital Henri- 
Mondor, Créteil; 4Hospital Brabois, Nancy, France; 5ARC, Amsterdam, The 
Netherlands
Introduction/Aim. Several imaging outcomes have become available to assess 
inflammation and structural damage over time in axSpA. However, no formal 
comparison of their sensitivity to change has been made in the early disease. We 
aimed to compare the sensitivity to change of different MRI and radiographic 
scoring methods in patients with early axSpA.
Methods. Patients from the DESIR cohort were included. Radiographs and MRI 
of the SIJ and spine were obtained at baseline, 1 year, 2 years and 5 years. Each 
film was scored by 2-3 readers in 3 ‘read-waves’. Outcomes measuring inflam-
mation and structural damage both on MRI and radiographs in the spine and SIJ 
were assessed (Table). The analysis of change over time was performed using 
GEE longitudinal models separately for each outcome (‘integrated analysis’). 
To allow comparisons across outcomes, these were standardized (difference be-
tween the individual score and the mean of all scores divided by the standard 
deviation, per reader, wave and time-point) before running the models. 
Table. Standardized rate of change of imaging outcomes over 5 years of follow-up 
in early axSpA patients from the DESIR-cohort who fulfil the ASAS axSpA classifica-
tion criteria.
*Agreement of ≥2 out of 3 readers for binary variables and mean (SD) of 3 readers for continuous 
variables from wave 3; ¥fatty lesions, erosions, sclerosis, partial ankylosis, total ankylosis; †fatty le-
sions, erosions, bone spurs, ankylosis; NA, not applicable.
Results. In total, 345 patients were included. MRI-SIJ inflammation was more 
sensitive to change compared to inflammation on the spine (table). Structural 
damage on the SIJ increased over time, but with a higher change on MRI-SIJ 
(range: 0.015-0.274) compared to X-SIJ (range: 0.043-0.126). Notably, ≥3 Fatty 
lesions on MRI-SIJ was the structural outcome in the SIJ with highest sensitive 
to change (0.274), while ≥3 erosions was the least sensitive (0.015). Spine struc-
tural damage slowly progressed over time but, in contrast to SIJ, radiographic 
outcomes were more sensitive to change than MRI structural outcomes. 
Conclusion. Our data adds to the body of evidence showing that structural dam-
age assessed in pelvic radiographs has low sensitivity to change. MRI-SIJ is a 
promising alternative (especially fatty lesions). In contrast, radiographic out-
comes outperform MRI outcomes in the spine. 
P2
WHICH SCORING METHOD DEPICTS SPINAL RADIOGRAPHIC 
DAMAGE IN (EARLY) AXIAL SPONDYLOARTHRITIS BEST? 
FIVE-YEAR RESULTS FROM THE DESIR COHORT
Ramiro S.1, Claudepierre P.2, Sepriano A.1, van Lunteren M.1, Molto A.3, Feydy A.4, 
d’Agostino M.A.5, Loeuille D.6, Dougados M.3, Reijnierse M.7, van der Heijde D.1
1Rheumatology, LUMC, Leiden, The Netherlands; 2Rheumatology, Université 
Paris Est Créteil, Créteil; 3Rheumatology, Paris Descartes University, Paris; 4Ra-
diology, Paris Descartes University, Paris; 5Rheumatology, Université Versailles-
Saint Quentin en Yvelines Boulogne-Billancourt; 6Rheumatology, University of 
Nancy, Nancy, France; 7Radiology, LUMC, Leiden, The Netherlands
Background. Scores capturing spinal radiographic damage have been proposed 
and compared in r-axSpA. In early phases of the disease, it is still unknown how 
these perform. 
Objectives. To compare the performance of different spinal radiographic damage 
scoring methods in patients with early axSpA.
Methods. Five-year spinal radiographs from the DESIR cohort were scored by 3 
readers (averaged) for the calculation of different radiographic methods (Table)
Following the OMERACT filter, scores were compared with regard to truth, dis-
crimination (sensitivity to change and reliability) and feasibility. Baseline status 
scores, and 2- and 5-year change scores were calculated, as well as the proportion 
of patients with a net change (number of patients with a positive change minus 
number of patients with a negative change divided by all patients) above the 
smallest detectable change (SDC). The proportion of total variance explained by 
the patient (‘true variance’) was calculated for the change scores, as a measure 
of reliability, using ANOVA. 
Results. In total, 699 patients (mean age 34 (SD 9) years, 47% males) were 
included. Mean baseline and 5-year change scores were: SASSS 0.2(0.7) and 
0.4(1.3), mSASSS 0.4(1.5) and 0.5(2.0), RASSS 0.5(1.7) and 0.7(2.5), BASRI-
spine 1.0(1.2) and 0.3(0.6), BASRI-spine-thoracic: 1.1(1.4) and 0.3(0.7), BAS-
RI-total 1.0(1.3) and 0.3(0.6) and BASRI-total-thoracic 1.2(1.4) and 0.4(0.7), 
Table. Two- and 5-year change, above the smallest detectable change, across the dif-
ferent radiographic scoring methods.
 2-year Change > SDC (N=357)
 SDC Positive Negative Net change
  change change N (%)
  N (%) N (%) 
 
SASSS (0-72) 0.75 11 (3) 0 (0) 11 (3)
mSASSS (0-72) 0.88 22 (6) 2 (0.6) 20 (6)
RASSS (0-84) 1.00 17 (5) 0 (0) 17 (5)
BASRI-spine (0-12)  0.59 30 (8) 14 (4) 16 (4)
BASRI-spine- thoracic (0-16) 0.59 35 (10) 16 (4) 19 (5)
BASRI-total (0-16)  0.61 31 (9) 14 (4) 17 (5)
BASRI-total-thoracic (0-20) 0.72 19 (5) 4 (1) 15 (4)
 5-year Change > SDC (N = 265)
 SDC Positive Negative Net change
  change change N (%)
  N (%) N (%) 
SASSS (0-72) 1.17 30 (11) 0 (0) 30 (11)
mSASSS (0-72) 1.10 34 (13) 1 (0.4) 33 (12)
RASSS (0-84) 1.19 44 (17) 0 (0) 44 (17)
BASRI-spine (0-12) 0.74 32 (12) 1 (0.4) 31 (12)
BASRI-spine- thoracic (0-16) 0.89 31 (12) 2 (1) 29 (11)
BASRI-total (0-16) 0.75 33 (12) 1 (0.4) 32(12)
BASRI-total-thoracic (0-20) 0.91 32 (12) 2 (1) 30 (11)
SDC: smallest detectable change; mSASSS: modified Stoke in Ankylosing Spondyli-
tis Spine Score; RASSS: Radiographic Ankylosing Spondylitis Spinal Score; SASSS: 
Stoke Ankylosing Spondylitis Spine Score; BASRI: Bath Ankylosing Spondylitis Ra-
diology Index.
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respectively. SDCs and proportion of 2- and 5-year change, including net change, 
are presented in the Table. The mSASSS and the RASSS performed the best 
in terms of capturing the signal (positive change) despite the noise (negative 
change).
The proportion of variance explained by the patient was highest for the mSASSS 
and RASSS (85% for both 5-year progression scores vs 50-55% for other meth-
ods). The proportion of patient variance in the thoracic segment of the RASSS 
was unsatisfactory (46% for progression). 
Conclusions. The existing scoring methods to assess spinal radiographic damage 
performed well in early phases of axSpA. The mSASSS and RASSS captured 
most change. There was no clear gain in additionally scoring the thoracic spine 
for the RASSS while an increased noise was introduced. The mSASSS remains 
the most sensitive and valid scoring method in axSpA, including early phases of 
the disease.
P3
SPINAL RADIOGRAPHIC PROGRESSION IN EARLY AXIAL SpA: 
5-YEAR DATA FROM THE DESIR COHORT
Ramiro S.1, van der Heijde D.1, Sepriano A.1, van Lunteren M.1, Molto A.2, Feydy 
A.3, d’Agostino M.A.4, Loeuille D.5, Dougados M.2, Reijnierse M.6, Claudepierre 
P.7
1Rheumatology, LUMC, Leiden, The Netherlands; 2Rheumatology, Paris 
Descartes University, Paris; 3Radiology, Paris Descartes University, Paris; 
4Rheumatology, Université Versailles-Saint Quentin en Yvelines Boulogne-
Billancourt; 5Rheumatology, University of Nancy, Nancy, France; 6Radiology, 
LUMC, Leiden, The Netherlands; 7Rheumatology, Université Paris Est Créteil, 
Créteil, France
Background. Spinal radiographic progression has been investigated in patients 
with r-axSpA, but not yet as thoroughly in early axSpA. 
Objectives. To analyse the progression of spinal radiographic damage in patients 
with early axSpA. 
Methods. Five-year spinal radiographs from patients with early axSpA from the 
DESIR cohort were scored by 3 readers (average) according to the mSASSS (0-
72). The development of new syndesmophytes (2 out of 3 readers) was calculated 
as a net change: number of patients with positive change minus number of pa-
tients with negative change divided by total number of patients. Two- and 5-year 
mSASSS progression and development of new syndesmophytes were assessed in 
subgroups defined at baseline according to the ASAS axSpA criteria and its arms, 
mNYC and also to the presence of syndesmophytes. 
Results. In total, 549 patients (mean age 34 (SD 9) years, 46% males, 63% 
ASAS+, baseline mSASSS 0.5(1.5)) were included. Thirty-eight patients (7%) 
had baseline syndesmophytes, 42% of which were ASAS-. Mean mSASSS pro-
gression was 0.2(0.9) at 2 years and 0.4(1.8) at 5 years. 18% of the ASAS+ 
showed a 5-year positive mSASSS change (>0), compared to 30% in ASAS- 
(Figure). 26% of the patients fulfilling the imaging arm had a positive change: 
highest in MRI-mNYC+ (34%), followed by MRI+mNYC+ (27%) and 
lastly MRI+mNYC- (23%). Mean mSASSS progression was highest in the 
mNYC+MRI+ group (1.3(4.0)). Eleven percent of the patients fulfilling only 
the clinical arm had a positive change in mSASSS at 5 years, mean change of 
0.1(0.7). Patients with baseline syndesmophytes (across all subgroups) had the 
highest progression: 2.7(5.0) mSASSS-units. At 5 years, 7% of all patients had a 
net change of any new syndesmophyte; this was 10% for the imaging arm (18% 
for mNYC+MRI+) and 3% for patients fulfilling the clinical arm only, 17% for 
mNYC+ and 42% for patients with baseline syndesmophytes.
Conclusion. Spinal radiographic progression, though limited in early axSpA, can 
be captured already at 2 years of follow-up. Inflammation and damage in the SIJ 
are associated with a higher radiographic progression. The presence of baseline 
syndesmophytes strongly predicts the development of further structural damage 
already early in the disease. 
P4
CORRELATION BETWEEN ULTRASOUND NAIL CHANGES ON 
PSORIATIC DISEASE AND NAIL PSORIASIS SEVERITY INDEX 
COMPARING WITH RHEUMATOID ARTHRITIS AND HEALTHY 
CONTROLS
Carneiro S.1,2, Gynszpan R.1, Moss I.1, Mendonça J.A.2, Fernandes M.1, Arnóbio 
A.2, Ramos-e-Silva M.1
1Federal University of Rio de Janeiro, Rio de Janeiro; 2State University of Rio de 
Janeiro, Rio de Janeiro; 3Pontifical Catholic University of Campinas, Sao Paulo, 
Brazil
Introduction. The nail is intimately linked to enthesis which in turn is associated 
to the synovium forming a distinct organ referred as synovio-entheseal complex 
and nail psoriasis could be a clinical predictor of Psoriatic Arthritis (PsA). The 
objectives were to correlate the ultrasonography (US) changes of the nails by the 
Gray scale (GS) and the Power Doppler (DP) with nail psoriasis and severity in-
dex (NAPSI); to compare the ultrasonographic alterations of the nails of patients 
with psoriatic disease, rheumatoid arthritis and healthy controls.
Material and Methods. Cross-sectional observational study, approved by the 
hospital etic committee. Finger nail and periungual US were performed in 235 
nails (37 nail psoriasis(nPs); 98 health nails of rheumatoid arthritis patients(nRA) 
and 100 nails of health controls(nHC). All the subjects and controls were aged 
between 55 and 75 years. NAPSI score:0-8. The US examination was performed 
by an experienced rheumatologist, with a high resolution equipment, with a 
linear high frequency (18 Mhz) transducer and the following features: Power-
Doppler(PD) maximum frequency of 8 MHz, low filter and pulse repetition 
frequency(PRF)=0.5 KHz. For nail changes, semiquantitative scales were used, 
GS and PD (grade 0-3).
Results. For comparative analysis between nPs, nRA and nHC the Kruskal-
Wallis and Student-Newman-Keuls post-test were used. Patients with psoriasis 
have the highest scores for USGS when compared to healthy and RA patients 
(H=55.4366, p-value Kruskal-Wallis=0.00001). Patients with RA and healthy did 
not present significant difference (H=0.3602, p-valor Kruskal-Wallis=0.8352). 
The correlation between NAPSI and USGS/USPD were not statistically signifi-
cant (rs=0.0814/-0.1542, t=0.4834/-0.9234, p=0.6318/0.3621). 
Conclusions. We observed a significant difference by the gray-scale between 
patients with psoriatic disease (nPs) and controls(nRA+nHC). There was no 
significant difference for PD or between the sonographic findings and NAPSI. 
Limitations of this study are the reduced sample size and the non-availability of 
spectral-Doppler. 
P5
PROGRESSION OF STRUCTURAL DAMAGE ON MRI OF THE 
SPINE AND SACROILIAC JOINTS IN PATIENTS WITH AXIAL 
SPONDYLOARTHRITIS IS LIMITED: THE 5-YEAR RESULTS IN 
THE DESIR COHORT
Madari Q.S.R.1, Ramiro M.S.1, Sepriano A.1,2, Landewé R.3, Dougados M.4, van 
Gaalen F.A.1, van der Heijde D.1
1LUMC, Rheumatology, Leiden, The Netherlands; 2NMS, Rheumatology, Lisbon, 
Portugal; 3ARC, Rheumatology, Amsterdam, The Netherlands; 4Hospital Cochin, 
Rheumatology, Paris, France
Background. Detecting radiographic structural change in axial spondyloarthritis 
(axSpA) patients is difficult. Magnetic resonance imaging (MRI) is an alternative 
for radiographs to assess this. However, longitudinal MRI-assessed structural 
changes are poorly studied. 
Objectives. To evaluate structural changes on MRI of the SIJ(MRI-SIJ) and 
spine (MRI-spine) in early axSpA patients after five years.
Methods. Early (≤3 years) axSpA patients (DESIR cohort) were included. MRI-
SIJ and MRI-spine were obtained at baseline and 5 years and scored by 3 central 
readers blinded for chronology. Sacroiliac and spinal structural damage (MRI-
SIJ-STR resp. MRI-spine-STR) were defined according to 3 binary rules (A1:≥3 
fatty lesions;B1:≥3 erosions;C1:≥5 fatty lesions and/or erosions) and 3 con-
tinuous scores (A2:number of fatty lesions;B2:number of erosions;C2:number 
of fatty lesions/erosions. For binary outcomes, agreement of at least 2 out of 
3 readers and the % of net-progression defined structural change. For continu-
ous outcomes, the mean of the 3 readers and the difference between year 5 and 
baseline was calculated. 
Results. 151 and 145 patients had complete MRI-SIJ and MRI-spine available, 
respectively. The percentages of net-progression at SIJ-level(figure) were 7.9%, 
0.7% and 6.6% for the binary outcomes A1, B1 and C1 respectively. The per-
centage of ‘improvement’ (4.6%) was almost similar to the percentage of ‘wors-
ening’ (5.3%) for definition B1(≥3 erosions); while no ‘improvements’ were 
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seen for definition A1 (≥3 fatty lesions). Comparable differences were seen for 
mean (standard deviation) change of the 3 MRI-SIJ-STR continuous outcomes 
(A2:0.83 (2.20); B2:0.20 (1.39); C2:1.02 (2.60); all p<0.01). Longitudinal MRI-
spine-STR net change was almost absent (A1:0.7%; B1: 0.0%; C1:-0.7%) for 
binary outcomes, and small considering definition A2(0.14 (0.48); p<0.01) and 
C2(0.18 (0.52); p<0.01) but absent for definition B2 (0.03(0.24); p=0.109).
Conclusion. Patients with early axSpA show modest structural progression on 
MRI-SIJ and fatty lesions are more sensitive to change compared to erosions. In 
this early axSpA population, MRI-detected structural progression in the spine is 
very limited.
Figure. Changes in binary MRI-SIJ-STR outcomes assessed in the completers popula-
tion (N=151) MRI-SIJ-STR, structural damage on magnetic resonance imaging of the 
sacroiliac joints.
P6
MAGNETIC RESONANCE IMAGING OF THE CERVICAL SPINE 
IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOS-
ING SPONDYLITIS PRESENTING WITH CHRONIC NECK PAIN 
– A SYSTEMATIC COMPARISON OF CLINICAL ASSESSMENTS
Baraliakos X., Soltani M., Kiltz U., Braun J.
Rheumazentrum Ruhrgebiet, Herne, Germany
Background. Despite the differences in pathogenesis, neck pain associated with 
functional limitation and impaired mobility of the cervical spine is a frequent 
clinical symptom of patients with rheumatoid arthritis (RA) and ankylosing 
spondylitis (AS). 
Objective. To directly compare inflammatory and structural findings obtained by 
magnetic resonance imaging (MRI) in patients with RA and AS who present with 
chronic neck pain, and to correlate MRI findings with clinical measurements.
Methods. A total of 120 patients (60 RA and 60 AS) were consecutively included 
in the study if they had chronic neck pain (duration >3 months). All patients had 
clinical examinations for neck function and mobility and were asked to fill in dis-
ease specific questionnaires. They also had laboratory examinations (CRP, ESR) 
and MRI of the cervical spine (CS) using contrast-enhanced MRI sequences (T1 
pre- and post-Gadolinium, sagittal and axial images). A total of 107 patients (59 RA 
with 295 and 48 AS with 240 vertebral segments) could be finally evaluated. An 
experienced rheumatologist examined all patients blinded to diagnosis and MR im-
ages. In addition, two experienced readers blinded to patients’ diagnosis and clini-
cal assessments evaluated the MRIs by describing the anatomical structures of the 
CS (vertebral body, intervertebral disc, facet joints) and the pattern of inflammatory 
activity in the bone marrow (vertebral edges vs. vertebral endplates). 
Results. The RA group included more females (66.1%) and older patients 
(58.6±11.4 years) in comparison to AS (68.8% males, mean age 47.9±13.1 years), 
while there were no differences in the duration of neck pain. AS patients reported 
higher mean levels of neck pain on a 0-10 numerical rating scale (5.0±3.6) as com-
pared to RA patients (3.0±3,1) (p=0.003), while the Northwick pain questionnaire 
did not reveal any differences. There were numerically more patients with AS 
(n=11, 22.9%) than RA (n=9, 15.3%) (p=0.166) with bone marrow edema (BME) 
at the vertebral edges. The majority of lesions was located in the lower CS. In 
contrast, more patients with RA (n=18, 30.5%) than AS (n=3, 6.3%) had erosive 
osteochondrosis with endplate BME (p=0.002). Atlantoaxial synovitis was found 
in only 1 patient with RA (1.7%), while inflammatory changes around the dens 
axis were found in 2 (3.4%) and atlantodental synovitis in 5 (8.5%) RA patients 
but not in AS patients. In comparison, erosive changes in the dens axis region 
were found in 3 RA (5.1%) vs. 2 AS (4.1%) patients. 
No major differences related to the presence of facet joint osteoarthritis was 
found (78% in RA vs. 65% in AS). The prevalence of facet joint osteoarthri-
tis was the only imaging finding correlating with clinical symptoms: r=0.259 
(p=0.049) for RA and r=0.416 (p=0.003) for AS, respectively. Similarly, only 
facet joint osteoarthritis correlated with restriction of cervical rotation in patients 
with AS (r=0.471, p=0.001).
Conclusion. Both BME and chronic changes of the lower part of the CS but not 
of the atlantoaxial region are seen in patients with RA and AS who present with 
chronic neck pain. The pattern of BME involvement in patients with RA vs. AS 
was different. Facet joint osteoarthritis was the only imaging finding that cor-
related with the magnitude of neck pain, in AS it also correlated with impaired 
cervical rotation. 
P7
ANALYSIS OF THE DIFFERENT VALUE OF MAGNETIC RESO-
NANCE IMAGING CHANGES IN THE SACROILIAC JOINTS FOR 
A DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS AS JUDGED BY 
RHEUMATOLOGISTS AND RADIOLOGISTS
Baraliakos X., Ghadir A., Fruth M., Kiltz U., Braun J. 
Rheumazentrum Ruhrgebiet Herne, Germany
Background. A classification of axial spondyloarthritis (axSpA) by the imaging 
arm of the ASAS criteria relies partly on the detection of a bone marrow edema 
(BME) in the magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) 
suspicious of SpA (1). 
Objective. To evaluate different types of MRI changes possibly relevant for a 
diagnosis of axSpA as judged by radiologists taking the rheumatologist´s diag-
nosis as gold-standard.
Methods. Consecutive patients <45 years were included if they presented in 
a specialized rheumatologic center with chronic low back pain (duration >3 
months). Patients underwent a complete diagnostic workup including MRI of the 
SIJ. All clinical and laboratory information including images but no radiological 
reports was available for experienced rheumatologists to make a diagnosis of 
axSpA or non-axSpA. In parallel, two experienced musculoskeletal radiologists, 
blinded to patients’ demographics and symptoms (except for back pain) evalu-
ated all MR images without knowledge of the rheumatologist´s diagnosis, by 
quantification of BME, fat metaplasia, erosions, sclerosis and ankylosis based on 
the Berlin SIJ score. The radiologists also stated whether the patient is likely to 
have axSpA or not, solely based on MRI findings. 
Results. A total of 100 patients were recruited. The rheumatologist diagnosed 
axSpA in 54 patients (mean age 31.5±8.0 years, 77.8% HLA-B27+, mean symp-
tom duration 36.4±42.0 months), while 46 patients were diagnosed as non-spe-
cific back pain (age 33.6±7.1 years, 17.4% HLA-B27+, mean symptom duration 
25.5±31.6 months). According to the radiologists, 38 patients were identified as 
axSpA, 34 of which were also diagnosed as axSpA by the rheumatologist (overall 
agreement with the clinical diagnosis: 63%), and 4 patients were thought to have 
axSpA by the radiologist but not by the rheumatologist (disagreement with the 
clinical diagnosis: 8.7%). Similarly, the quantification of MRIs showed higher 
scores in patients diagnosed as axSpA by the rheumatologist (Table I). Only few 
patients had sclerosis or ankylosis. 
From the radiologist´s perspective, the calculated odds ratio (OR) for identifica-
tion of axSpA by MRI only was 3.1 (95% CI:1.4-7.1) for the presence of BME, 
3.5 (95% CI:1.4-9.0) for fat metaplasia, 2.8 (95% CI:1.1-7.0) for erosions, 2.0 
(95% CI:0.7-5.5). For the combination of BME and any structural change, the 
OR was 3.7 (95% CI:1.6-8.5).
Conclusions: This study reveals a discrepancy between the rheumatologist’s and 
the radiologist’s identification of axSpA, confirming that a diagnosis of axSpA in 
daily practice should not rely on imaging findings only. Nevertheless, the overall 
specificity of the radiologists was acceptable, although the sensitivity was rela-
tively low. These data suggest also that not only BME but also fat metaplasia and 
erosions are of value to diagnose axSpA, beyond classification. The combination 
of MRI changes seems to enhance the discriminative diagnostic performance. Fi-
nally, it will be important to define clinically relevant cut offs for the MRI scores.
Table I. Mean/median scores ± standard deviation for inflammatory and chronic le-
sions based on the Berlin SIJ score
 Lesion type axSpA non-SpA p-value
Mean±SD Total score 12.3±11.8 4.4 ± 4.8 p<0.001
 BME 3.3 ± 3.8 1.1 ± 1.5 p=0.001
 Fat metaplasia 3.4 ± 5.4 1.0 ± 3.0 p=0.004
 Erosions 3.2 ± 5.8 0.7 ± 2.1 p=0.011
Median Sclerosis or Ankylosis 0 0 --
Reference
  1. LAMBERT R et al.: Ann Rheum Dis 2016
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INFLAMMATORY LESIONS AND STRUCTURAL CHANGES OF 
SACROILIAC JOINTS ON MRI IN EARLY AXIAL SPONDYLO-
ARTHRITIS: 2-YEAR FOLLOW-UP STUDY
Rumiantceva D.G., Dubinina T.V., Demina A.B., Erdes S.
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background. Dynamic monitoring of changes in sacroiliac joints (SIJ) MRI in 
patients with early axSpA will provide a better understanding of the development 
and further progression of the disease in initial stages.
Aim. to describe how inflammation and structural changes of sacroiliac joints 
(SIJ) on MRI in patients with early axSpA evolves over 2-year follow-up.
Materials and Methods. The research included 68 pts with early axSpA (ASAS 
criteria, 2009) from Moscow CORSAR cohort with disease duration <5 years, 
age onset <45 years and at least 2 years follow-up. MRI of SIJ was conducted at 
baseline and after 2 years. Inflammatory lesions and structural changes of SIJ on 
MRI were determined using ASAS/OMERACT recommendations.
Results. 15 (22.0%) pts at baseline were with bone marrow edema (BME) on SIJ 
MRI. After 2 years in 6 (40%) pts BME became in fat metaplasia, in 5 (33.4%) - 
fat metaplasia appeared in addition to BME. In 2 (13.3%) pts BME disappeared, 
and in 2 (13.3%) - BME remained unchanged. 
19 (28.0%) pts at baseline were with structural changes on SIJ MRI as fat meta-
plasia. After 2 years 1 of them (5.2%) had BME in addition to fat metaplasia, and 
18 (94.8%) pts had no changes.
Initially, according to SIJ MRI, there were 24 (35.3%) pts with a combination of 
inflammation and structural changes (BME and fat metaplasia). After 2 years in 1 
(4.1%) patient left signs of fat metaplasia and remained only BME, in 15 (62.5%) 
pts left signs of BME and remained only fat metaplasia. In 8 (33.4%) pts existing 
changes remained without dynamics.
At baseline, 10 (14.7%) patients had no changes on SIJ MRI. After 2 years, 6 
(60%) pts unchanged in SIJ MRI and 4 (40%) - developed fat metaplasia. 
Conclusions. Thus, most pts with early axSpA with fat metaplasia on SIJ MRI at 
baseline remain unchanged after two years. 
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IMPACT OF DOSE TAPERING OF TUMOUR NECROSIS FACTOR 
INHIBITOR ON ACHIEVING INACTIVE DISEASE AS RECOM-
MENDED BY ‘T2T’ STRATEGY IN AXIAL SPONDYLOARTH- 
RITIS: A PROSPECTIVE, NATIONWIDE COHORT STUDY 
Park J.W.1, Shin K.2, Song Y.W.1, Lee E.Y.1
1Division of Rheumatology, Dept. of Internal Medicine, Seoul National Uni-
versity Hospital; 2Division of Rheumatology, Dept. of Internal Medicine, SNU 
Boramae Medical Center, Seoul, Republic of Korea
Objectives. To compare the efficacy of tapering tumour-necrosis factor inhibitor 
(TNFi) with that of standard-dose TNFi treatment in patients with axial spondy-
loarthritis (axSpA). 
Methods. It is a prospective, nationwide cohort study including 776 axSpA pa-
tients receiving TNFi for at least 1 year with a 3-year of observation. Effect of 
dose tapering on longitudinal disease activity was analysed 1) by comparison of 
two patient groups according to their mean dose quotient (DQ) of TNFi during 
the observation (individual level, control group versus tapering group) and 2) by 
comparison of 1-year intervals stratified by relevant DQ (time level). Primary 
outcome was achieving ASDAS inactive disease (ASDAS-CRP <1.3) in a rel-
evant interval. 
Results. In the individual level, baseline and longitudinal ASDAS-CRP were 
comparable between the two groups. Among a total of 1565 intervals, ASDAS 
inactive disease was achieved in 665 (42.3%) ones with no difference according 
to the follow-up time. In the time level, interval with reduced DQ showed compa-
rable odds for achieving inactive disease compared to those with full-dose TNFi 
(adjusted OR=1.09, 95% CI 0.89 to 1.33). However, the probability of achieving 
target was significantly decreased if DQ of interval was lower than 0.5 (adjusted 
OR=0.43 [0.22 to 0.85]). The same analysis performed in the post-matched pop-
ulation (n=126 in both groups) in which ASDAS-CRP measured just prior to the 
first dose reduction (tapering group) and that measured in the relevantly defined 
visit (control group) were matched also showed a consistent result. 
Conclusion. Tapering dose of TNFi, but not by less than 50% of standard-dose, 
showed comparable efficacy in achieving optimal treatment target in axSpA. 
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DIAGNOSTIC VALUE OF MRI IN NON-RADIOGRAPHIC AXIAL 
SPONDYLOARTHRITIS 
Rusman T.1, John M.L.2, van der Weijden M.A.C.1,3, Boden B.J.H.1, van der Bijl 
C.M.A.1, Bruijnen S.T.G.1, van der Laken C.J.1, Nurmohamed M.T.2,3, van der 
Horst-Bruinsma I.E.1
Amsterdam Rheumatology immunology Center, Depts. of 1Rheumatology and 
2Internal Medicine, VU University Medical Center & Reade3, Amsterdam, The 
Netherlands
Introduction/Aim. Few studies showed signs of inflammation at the MRI of the 
sacroiliac joints (SIJ) or spine in only 30% of the non-radiographic axial spondy-
loarthritis (nr-axSpA) patients(1). Aims: 1) to evaluate inflammation at the MRI of 
the SIJ/ spine in TNF naïve nr-axSpA patients 2) consistency in case of absence 
of inflammation after 6 months and 3) evaluate gender differences.
Methods. Consecutive patients with inflammatory back pain who were either 
HLA-B27 positive with ≥1 SpA-feature or HLA-B27 negative with ≥2 SpA-fea-
tures, with high disease activity (BASDAI>4), had an MRI of the SIJ and spine. 
In case of absence of inflammation, the MRI was repeated after six months. MRI 
images were scored according to the Spondyloarthritis Research Consortium of 
Canada (SPARCC spine, range 0-108; SPARCC SIJ, range 0-72) method. 
Results. Included were 70 patients, of whom 37 (53%) females. Half of the 
patients (36/69,52.2%) showed signs of inflammation on the first MRI: 27/69 
patients (39.1%) at the SIJ, 14/46 patients (30.4%) at the spine and 4 patients 
(5.8%) on both sites and one patient missed the baseline MRI. Males had more 
often a positive MRI compared to females 62.5% vs. 43.2%. Patients with a posi-
tive MRI showed a median SPARCC score for SIJ of 8.0 (IQR: 1.8–23.5, higher 
in females) and for spine 6.5 (IQR: 2.8-10.8, higher in males). Only 4/33 patients 
(12.1%) showed a positive MRI after six months. 
Conclusion. Fifty percent of the patients with nr-axSpA and high disease activity 
showed inflammatory lesions at the MRI of the SIJ and/or spine, which occurred 
more often in males compared to females. In most cases (87.9%) a MRI without 
inflammatory lesions remained negative after 6 months, indicating that a second 
MRI after a short period is not valuable.
Reference
  1. BRAUN J et al.: RMD Open 2017; 3(1): e000430
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THE DAMAGE TO THE HIP JOINTS IN ANKYLOSING SPONDY-
LITIS ACCORDING TO X-RAY EXAMINATION
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes Sh.F.
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Introduction. Hip joint (HJ) involvement is one of the most common extra-axial 
manifestations of ankylosing spondylitis (AS).
Objective. To correlate the clinical features of coxitis in AS pts with radiograph-
ic and ultrasonographic findings.
Materials and Methods. 125 consecutive AS pts (mean age 31,7±12,7 y; meet-
ing modified N-Y criteria) with clinical symptoms of coxitis (presence of pain in 
hip joint (HJ) with or without HJ functional limitations (FL)), were examined. 
Mean age at disease onset was 30,8±9,6 y. The following evaluations were made: 
BASDAI, ASDAS-CRP, BASFI, inter-malleolar distance (IMD), radiological HJ 
changes (BASRIhip), ultrasound examination (US) (US symptoms of coxitis - 
the distance between the anterior joint capsule and the femoral neck, capsular-
neck distance CND >7 mm).
Results. For the analysis, all pts were divided into two groups depending on 
BASRI hip. The analysis revealed that in group 1 (BASRI hip 0-1) (n=62) the 
duration of the AS was, Me [25‰, 75‰] 73 [19;90] m and in group 2 (BASRI 
hip II-IV) (n=63) - 124 [21;140] months. The comparative analysis revealed the 
following features of laboratory data of groups 1 and 2: BASDAI 4,6 [2,6; 5,5] 
vs 5,3 [4,2; 6,7] (p=0,06), Age 30 [19;41] and 34 [25;54] (p=0,01), Age of the be-
ginning of the coxitis, years 25 [20;27] vs 27 [21;31] (p=0,01), duration of coxitis 
month 36 [2;54] vs 64 [28; 126] (p=0,005) BASFI 2,9 [2,0; 3,8] vs 3,8 [2,0; 5,4] 
(p=0,01), ASDAS (СRP) 2,8 [2,0; 3,8] vs 3,1 [2,6; 3,8] (p=0,1), ESR mm/h 24 
[5; 30] vs 23 [8; 35] (p=0,1),CRP mg/mL 24 [5; 30] vs 23 [8; 35] (p=0,1), CND 
mm. 7,5 [6,9; 8,1] vs 7,3 [6,7;8,0] (p=0,1).
Conclusion. The results showed that more than half of the patients had a high 
degree of general and laboratory activity, a pronounced restriction of functional 
status. It was also shown that damage to the hip joint revealed during x-ray ex-
amination was more often detected at a greater prescription of coxitis and was 
accompanied by an increase in functional disorders.
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MRI ASSESSMENT OF HIP JOINTS INVOLVEMENT IN ANKY-
LOSING SPONDYLITIS PATIENTS
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes S.F.
V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Introduction. According to the epidemiological study, in Russia in patients with 
ankylosing spondylitis (AS) hip joint damage was clinical detected in 46% of 
cases, but was the cause of endoprosthesis in 7% of cases.
Objective. To compare clinical manifestations with the results of magnetic reso-
nance imaging (MRI) of the hip joints (HJ) in patients with AS.
Material and Methods. 125 consecutive AS pts (mean age 31,7±12,7 y; meet-
ing modified N-Y criteria) with clinical symptoms of coxitis (presence of pain in 
hip joint (HJ) with or without HJ functional limitations (FL)), were examined. 
Mean age at disease onset was 30,8±9,6 y. The following evaluations were made: 
BASDAI, ASDAS-CRP, BASFI, inter-malleolar distance (IMD), MRI in T1 and 
STIR regimens.
Results. Acute inflammatory changes, such as osteitis and / or synovitis, were 
detected in 88% (110) of MRI patients. Most patients (85 %; n=106) had synovi-
tis according to MRI. Osteitis was found in 31%, and the combination of osteitis 
and synovitis - in 28% of patients. It is also worth noting that in 7% of cases, 
there were no inflammatory changes according to MRI, but there were signs of 
fatty degeneration which are usually combined with stage 3-4 on BASRI hip. 
According to the comparative analysis of patients with synovitis and a combina-
tion of synovitis and osteitis, there were no significant differences in the clinical 
picture between the patients. In 17% (18 patients) of MRI cases the changes were 
asymptomatic, i.e. there were no clinical signs of coxitis.
Conclusion. MRI allows to clarify the cause of the pain and limitations of move-
ment in HJ with AS, determine the patient has inflammatory changes, including 
in the absence of radiographic changes in these joints. Further research to clarify 
the relationship of clinical manifestations of coxitis (pain level) from MRI data.
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FACTORS ASSOCIATED WITH CHANGES IN VOLUMETRIC 
BONE MINERAL DENSITY IN PATIENTS WITH ANKYLOSING 
SPONDYLITIS – A FIVE-YEAR PROSPECTIVE STUDY USING 
HRpQCT 
Deminger A.1, Klingberg E.1, Lorentzon M.1, Carlsten H.1, Jacobsson L.T.H.1, 
Forsblad-d’Elia H.1,2
1University of Gothenburg, Gothenburg; 2Umeå University, Umeå, Sweden
Introduction/Aim. Cortical and trabecular volumetric bone mineral density 
(vBMD) can be assessed with high-resolution peripheral quantitative computed 
tomography (HRpQCT). There is no prior prospective study using HRpQCT in 
AS patients. Our aims were to investigate changes over 5 years in peripheral 
vBMD and to assess factors associated with the changes in AS patients. 
Methods. HRpQCT of the ultra-distal radius and tibia were performed in 54 male 
AS patients (NY criteria) at baseline and after 5 years, mean baseline age 48±14 
years. The patients were also assessed with blood samples and questionnaires. 
Univariate and multiple linear regression analyses were performed to find vari-
ables associated with percent changes in vBMD.
Results. At tibia, there were significant decreases in both cortical and trabecular 
vBMD, mean (SD) percent change -1.0 (1.9) and -2.7 (5.0) (p<0.001) respec-
tively. At radius, there was a trend for decreases in trabecular vBMD, mean (SD) 
change -2.0 (5.9) % (p=0.095), whereas no significant change in cortical vBMD 
was observed. In multiple linear regression analyses, an increase in ASDASCRP 
from baseline to follow-up was independently associated with a decrease in corti-
cal vBMD at tibia (B -0.91, 95%CI -1.34 to -0.47) and radius (B -0.57, 95%CI 
-1.08 to -0.048). At tibia, use of TNF-inhibitors was associated with increases in 
cortical vBMD (B 1.09, 95%CI 0.24–1.93), whereas use of corticosteroids was 
associated with decreases in cortical vBMD (B -2.15, 95%CI -3.48 to -0.82). 
Also, at both sites, older age was negative for cortical vBMD and smoking for 
trabecular vBMD. Higher baseline BMI was associated with increases in cortical 
tibia vBMD.
Conclusion. Over five years, these male AS patients decreased in vBMD at tibia. 
An increase in disease activity was found to have a negative effect on the corti-
cal bone at tibia and radius. Use of TNF-inhibitors had a positive effect whereas 
corticosteroids had a negative effect on cortical bone at tibia. 
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THE PHYSIOLOGICAL CHANGES OF THE ENTHESIS IN 
RESPONSE TO AGE, BODY MASS INDEX AND PHYSICAL AC-
TIVITY – AN ULTRASOUND STUDY IN HEALTHY PEOPLE
Ureyen S.1, Solmaz D.1, Stephenson W.1, Eder L.2, Roth J.1, Aydin S.Z.1
1University of Ottawa; 2University of Toronto, Canada
Introduction/Aim. Enthesis are continuously exposed to biomechanical stress 
and entheseal features on ultrasound may not reflect an underlying inflammatory 
spondylarthropathy in all cases. In this study, we aimed to determine the preva-
lence of sonographic entheseal abnormalities in healthy subjects and explore fac-
tors that are contributing to the occurrence and severity of these findings.
Materials and Methods. Eighty healthy subjects who had no joint pain, history 
of rheumatic condition or recent joint trauma were enrolled. Ultrasound scans of 
the insertions of triceps, quadriceps, Achilles tendons and plantar fascia and the 
origins/insertions of patellar tendons were performed by a single sonographer. 
Each enthesis was scored using a semi-quantitative scale (0-3) for sonographic 
features of enthesitis: hypoechogenicity, thickening, Doppler signals, entheso-
phytes, erosions and calcifications. The correlation between the total enthesitis 
score and various demographic and lifestyle factors was evaluated. 
Results. Doppler signals and erosions were detected in 10% and 6.25% of the 
participants, respectively. Thickening was the most frequent lesion within in-
flammatory features that could also be seen in the absence of hypoechogenic-
ity (highest in 70% of the patellar tendon origin). Enthesophytes were common 
at the Achilles tendon insertion, seen in 78.5% of participants. The total scores 
correlated with age (r:0.561, p<0.001) and body mass index (r:0.344, p:0.022). 
Smokers had higher scores (14.0±10.6 vs 9.02±9.6, p:0.010), similar to partici-
pants who were exercising more (13.53±11.1 vs 7.94±8.4, p:0.005). Additionally, 
men had higher scores than women (15.73±11.6 vs 8.06±8.2, p:0.001).
Discussion. There are changes within the enthesis associated with aging and in-
creased mechanical stress, not necessarily reflecting a pathology leading to any 
symptoms. Men and smokers, both of which are risk factors for radiographic 
severity in ankylosing spondylitis, have higher entheseal scores on ultrasound. 
The effect of these factors on the enthesis may be an explanation for the severe 
abnormal response on the spine in ankylosing spondylitis. 
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OPTIMIZING THE MRI IMAGING IN PATIENTS WITH INFLAM-
MATORY BACK PAIN AND SUSPECTED AXIAL SPONDYLO- 
ARTHRITIS
Chan A.1, Mills T.2, Yoong P.2
1Rheumatology Dept., Royal Berkshire NHS Foundation Trust; 2Radiology 
Dept., Royal Berkshire NHS Foundation Trust, Reading, UK
Introduction/Aim. Axial spondyloarthritis (ax-SpA) is divided into non-radio-
graphic ax-SpA (nr-ax-SpA) and radiographic ax-SpA. The ASAS criteria uses 
either MRI or clinical features for the classification of ax-SpA. The aim of this 
study was to determine the percentage of patients presenting with inflammatory 
back pain that meet the ASAS MRI criteria for ax-SpA.
Materials and Methods. 250 patient presenting with inflammatory back pain in 
the musculoskeletal triage service underwent a MRI scan of the spine and sacro-
iliac joints. The MRI sequence used was a modified whole spine & SIJ protocol 
with included sagittal T1 (to include pedicles and facet joints) and STIR cervico-
thoracic, sagittal T1 (to include pedicles and facet joints) and STIR thoracolum-
bar spine and coronal oblique T1 and STIR of the sacroiliac joints. The mean age 
was 41 years (age range 16-58 years), male:female ratio was 1:1.5.
Results. 21% of patients had a positive MRI scan for ax-SpA. 17% had degen-
erative change seen on the MRI scan. In 62% the MRI scan was normal. In the 
patients with a positive MRI scan, 42% had inflammatory change in both the 
spine and sacroiliac joints. 48% had inflammation in the sacroiliac joints only. In 
10% of patients, the MRI scan only showed inflammation of the spine and was 
negative in the sacroiliac joints. In the patients with a positive MRI scan for ax-
SpA, 56% had 1 feature of ax-SpA, 44% had 2 or more features of ax-SpA and 
54% were HLA-B27 positive.
Discussion. The use of MRI whole spine and sacroiliac joints in unselected pa-
tients with inflammatory back pain led to a positive scan in 21% of patients. Hav-
ing additional clinical features or HLA-B27 positivity will increase the detection 
for ax-SpA. An additional 10% of patients were diagnosed with ax-SpA as the 
MRI showed inflammatory change in the spine and not the sacroiliac joints.
Conclusions. MRI imaging and the whole spine and sacroiliac joints combined 
with clinical features and HLA-B27 positivity can increase the detection of ax-
SpA in patients presenting with inflammatory back pain.
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SIMPLE RADIOGRAPHIC FINDINGS OF ACHILLES TENDON IN 
SYMPTOMATIC AND ASYMPTOMATIC POSTERIOR HEEL IN 
ANKYLOSING SPONDYLITIS
Sung I.H., Kim T.H., Lee J.K. 
Hanyang University Medical Center, Seoul, Korea
Aim. Abnormally thickened Achilles tendon (AT) may imply significant patholo-
gies including inflammation or degeneration. Achilles’ enthesitis is generally 
highlighted in posterior heel pain of ankylosing spondylitis (AS). The purpose of 
current study is to assess simple radiographic changes on AT’s shadow not only 
at its insertion but also interstitial portion. 
Materials and Methods. 34 AS patients with unilateral (24) and bilateral (10) 
posterior heel pain were enrolled purposefully to evaluate differences between 
symptomatic and asymptomatic heels. Standing lateral digital radiographs of 
their foot were reviewed. Thickness of AT was measured at near its insertion as 
well interstitial area at ankle level. Retrocalcaneal recess obliteration (RRO) was 
assessed as AT‘s enthesitis and its correlation with abnormally thickened AT (> 
8mm at interstitial area and >5.5 mm at near insertion as previously reported) 
was evaluated. 
Results. In unilateral pain group, symptomatic feet showed 21 (88%) RRO and 
abnormal thickness in 21 (88%) and 14 (58%), respectively at insertion and an-
kle level, and thickness of AT was 7.4±1.7 mm at insertion and 8.2±1.3 mm at 
ankle level. Contrarily, asymptomatic feet showed 3 (12%) RRO, and abnormal 
thickness in 5 (20.8%) and 4 (16.7%), respectively at insertion and ankle, and 
thickness of AT was 5.8±1.6 mm at insertion and 7.0±1.2 mm at ankle level. 
Bilateral group showed 16 (80%) RRO and abnormal thickness in 17 (85%) and 
9 (45%), respectively at insertion and ankle, and thickness of AT was 6.9±1.5 mm 
at insertion and 8.1±1.4 mm at ankle level. There were significant differences in 
thickness of AT and also rate of abnormal thickness between symptomatic and 
asymptomatic feet. (p<0.05).
Conclusion. In simple radiographic alterations on AT of AS, RRO and thickened 
AT near to its insertion are strongly related to current painful posterior heel. In 
addition, thickened interstitial area of AT would be one of sources for posterior 
heel pain in AS which needs further investigation. 
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DIAGNOSTIC ASCERTAINMENT OF AXIAL SPONDYLOAR-
THRITIS IN PATIENTS PRESENTING WITH UNDIAGNOSED 
BACK PAIN: WHAT IS THE IMPACT OF MRI IN RHEUMATO-
LOGICAL PRACTICE?
Maksymowych W.P.1, Carmona R.2, Yeung J.3, Chan J.4, Martin L.5, Aydin S.6, 
Mosher D.5, Masetto A.7, Keeling S.1, Ziouzina O.5, Rohekar S.8, Paschke J.9, 
Carapellucci A.9, Lambert R.G.1
1University of Alberta; 2St. Joseph’s Healthcare Hamilton; 3Richmond BC; 
4Artus Health Clinic, Vancouver; 5University of Calgary; 6Ottawa Hospital, Ot-
tawa; 7Université de Sherbrooke; 8Lawson Health Research Institute ON, Canada; 
9CaRE Arthritis
Introduction/Aims. We aimed to determine whether any particular patient fea-
tures are associated with rheumatologist ordering of MRI and the impact of MRI 
evaluation on diagnostic ascertainment of axial SpA in patients presenting with 
undiagnosed back pain to rheumatologists.
Method. Consecutive patients ≤45 years of age with ≥3 months undiagnosed 
back pain with any one of psoriasis, acute anterior uveitis (AAU), or colitis un-
dergo routine clinical evaluation for axial SpA and MRI evaluation is ordered per 
rheumatologist decision. The rheumatologist determines the presence or absence 
of axial SpA (-10 (definitely not) to +10 (definite)) at 3 consecutive stages: 1. 
After clinical evaluation; 2. After labs (B27, CRP) and radiography; 3. After MRI 
evaluation. Differences in patients between those who did or did not have MRI 
examination were assessed plus the degree of diagnostic reclassification after 
each step.
Stage of Assessment axSpA  Mean (SD) axSpA absent Mean (SD) 
 present n (%) confidence n (%) confidence
1. Clinical only n=91 (70.5) 5.5 (2.4) n=38 (29.5) 3.4 (3.2)
2. Clinical plus labs n=81 (62.8) 5.9 (2.9) n=48 (37.2) 5.1 (3.6) 
    and radiography 
3. Clinical, labs, n=61 (47.3) 7.5 (2.9) n=68 (52.7) 7.5 (2.5) 
   radiography, plus MRI 
Results. 244 patients (51.6% male, age 34.6 years, back pain duration 7.1 years, 
B27+ 37.2%) were referred with AAU (29.9%), psoriasis (21.7%), Crohn’s coli-
tis (32.8%), ulcerative colitis (19.3%). A diagnosis of axSpA was made in 70.5% 
of patients after stage 1, in 62.8% after stage 2, and in 47.3% after MRI review. 
MRI evaluation was ordered significantly more frequently in those with inflam-
matory type back pain (p=0.04), when radiography was mNY- (p=0.005) and 
in those without Crohn’s colitis (p=0.001) but not related to back pain severity, 
NSAID response, or CRP level. 24 (18.6%) were recategorized from SpA to non-
SpA and 4 (3.1%) from non-SpA to SpA. 
Conclusions. In a setting of undiagnosed back pain, use of MRI is primarily 
driven by negative radiography. MRI was primarily helpful in ruling out SpA and 
reducing false positives.
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MRI LESION DEFINITIONS IN AXIAL SPONDYLOARTHRITIS: 
A CONSENSUS REAPPRAISAL FROM THE ASSESSMENTS IN 
SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS)
Maksymowych W.P.1, Lambert R.G.1, Ostergaard M.2, de Hooge M.3, Pedersen 
S.J.2, Bennett A.4, Burgos-Vargas R.5, Eshed I.6, Landewé R.7, Machado P.M.8, 
Marzo-Ortega H.9, Hermann K.G.10, Poddubnyy D.10, Rudwaleit M.10, Sieper J.10, 
van der Heijde D.11, van der Horst-Bruinsma I.12, Weber U.13, Baraliakos X.14
1University of Alberta; 2University of Copenhagen, Denmark; 3Ghent University, 
Ghent, Belgium; 4Imperial College, London, UK; 5Universidad Nacional Auton-
oma de Mexico; 6Sheba Medical Center, Israel; 7Academic Medical Center Am-
sterdam, The Netherlands; 8University College London; 9University of Leeds, 
UK, 10Charité Universitätsmedizin Berlin, Germany; 11Leiden University Medi-
cal Center; 12VU University Medical Center Amsterdam, The Netherlands; 13Uni-
versity of Southern Denmark; 14Rheumazentrum Ruhrgebiet Herne, Germany
Introduction/Aims. To evaluate the literature describing the spectrum of MRI 
lesions in axSpA and to generate a consensus update on standardized definitions.
Methods. The ASAS MRI group reviewed the literature and decided which defi-
nitions would be retained, modified, or newly defined. 
Results. For definitions denoting signs of activity in the SIJ, there are no revi-
sions to the most current ASAS definition of a positive MRI, while capsulitis 
and enthesitis are revised. A new definition, joint space enhancement, replaces 
the term ‘synovitis’ and denotes increased signal on contrast-enhanced images 
in the joint space. For structural change, the revised definition for a fatty lesion 
incorporates morphologic characteristics, and for erosion requires both loss of 
cortical bone and adjacent marrow matrix. A new definition, fat metaplasia in 
the joint space (‘backfill’), denotes the reparative change at the site of erosion 
when signs of activity recede. The new definition for ankylosis stresses the con-
tinuity of bright marrow signal across the joint space. Spinal lesion definitions 
are divided into those occurring in central and lateral sagittal slices. The revised 
definition of vertebral corner inflammatory lesion divides this into a regular (type 
A) and dimorphic (type B) lesion. A new definition for corner erosion requires 
both loss of cortical bone and adjacent marrow matrix. New definitions for new 
bone growth require bright signal on T1W images extending from the vertebral 
corner marrow or endplate.
Conclusions. The ASAS MRI group has generated a consensus-based update on 
MRI lesions in axSpA.
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ABILITY OF MAGNETIC RESONANCE IMAGING TO PREDICT 
REMISSION AND RELAPSE IN PERIPHERAL SPONDYLOAR-
THRITIS
Renson T.1, Carron P.1, Krabbe S.2, Jans L.3, De Craemer A.1, de Hooge M.1, 
Jacques P.1, Østergaard M.2, Elewaut D.1, Van den Bosch F.1
1Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; 2Dept. of 
Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 3Dept. of 
Radiology, Ghent University Hospital, Ghent, Belgium
Introduction. Whole-body magnetic resonance imaging (WB MRI) could offer 
additional information regarding the inflammatory status of joints, entheses and 
soft tissues in peripheral spondyloarthritis (pSpA).
Aim. To determine the value of A) WB MRI in relation to clinical remission in 
pSpA and B) subclinical inflammation, detected by WB MRI, at remission in 
predicting relapse in pSpA.
Methods. 60 early pSpA patients underwent a modified WB MRI at baseline 
and at clinical remission when treatment was withdrawn. The WB MRI was per-
formed by scanning multiple SpA-specific locations. Several sites of pelvis and 
lower limbs were evaluated for bone marrow edema (BME), synovitis and soft 
tissue inflammation (STI) by 3 readers, giving a score of 0-3. For each site a 
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mean of the scores of the 3 readers was calculated. For each patient at each time 
point, we calculated a sum score for synovitis, STI, BME and a total sum score.
Results. Patients reaching remission had lower baseline MRI synovitis (3.0 vs. 
3.6), STI (2.1 vs. 2.2), BME (1.8 vs. 2.9) and total sum scores (7.0 vs. 8,7) then 
the non-remission group. However, these differences lacked statistical signifi-
cance. At remission 22% and 24% patients had residual talocrural and subtalar 
synovitis respectively. There was no statistically significant difference between 
patients who relapsed after treatment withdrawal and those who remained in re-
mission concerning synovitis, BME and STI sum scores at remission.
Conclusions. There was no significant difference in inflammatory burden on 
baseline WB MRI between patients going into remission and those with ongoing 
disease activity. At remission, a substantial part of the participants showed re-
sidual ankle synovitis on MRI. However, residual inflammatory lesions detected 
by MRI did not differ significantly between patients who relapsed after treatment 
withdrawal and those in ongoing remission.
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CLINICAL EVALUATION CORRELATES POORLY WITH ULTRA-
SOUND AND MAGNETIC RESONANCE IMAGING OF JOINTS 
AND ENTHESES IN EARLY PERIPHERAL SPONDYLOARTH-
RITIS
Renson T.1, Carron P.1, Krabbe S.2, Jans L.3, De Craemer A.1, de Hooge M.1, 
Jacques P.1, Østergaard M.2, Elewaut D.1, Van den Bosch F.1
1Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; 2Dept. of 
Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 3Dept. of 
Radiology, Ghent University Hospital, Ghent, Belgium
Introduction. Evaluation of tenderness at the site of an enthesis with a standard 
palpation approach remains the gold standard for detection of enthesitis. Howev-
er, inter/intra-observer variability is high. Imaging could avoid these drawbacks. 
Aim. To compare the performance of ultrasound (US) and magnetic resonance 
imaging (MRI) with clinical examination (CE) of joints and entheses in periph-
eral spondyloarthritis (pSpA).
Methods. 60 early pSpA patients, participating in the CRESPA trial, were evalu-
ated. CE included tender/swollen joint count, dactylitis and enthesitis count. All 
patients underwent Power Doppler (PD)US of entheses and knee, talocrural and 
subtalar joints. Synovitis was scored according to the OMERACT-EULAR-US 
composite PDUS scale, giving a score of 0–3. Entheseal sites were evaluated for 
hypoechogenicity and intraenthesis Doppler signal and were scored 0–3. On MRI 
bone marrow edema, synovitis and soft tissue inflammation were scored (scale 
0-3) by 3 readers at several anatomical sites of pelvis and lower limbs. 
Results. Synovitis detected by US and MRI was most prevalent at knee joints. 
A discrepancy was noted between talocrural synovitis detected by CE, US and 
MRI. Enthesitis was most prevalent at Achilles tendon and plantar fascia. Re-
garding enthesitis, agreement between CE and US ranged from no (kappa -0.082) 
to moderate agreement (kappa 0.562). The highest agreement was observed at 
the Achilles tendon (left 0.511, right 0.350) and plantar fascia (left 0.321, right 
0.507). MRI did not correlate better with CE than US (kappa from -0.077 to 
0.446). Correlation between MRI and US was poor and only in the Achilles ten-
don moderate (range -0.106 to 0.656).
Conclusions. There was a weak agreement between CE and imaging in detect-
ing enthesitis. Overall, US detects less enthesitis compared to CE, while MRI 
detects more.
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CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SACRO-
ILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRI-
TIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDY-
LOARTHRITIS INTERNATIONAL SOCIETY CLASSIFICATION 
COHORT
Maksymowych W.P.1,2, Pedersen S.J.3, Baraliakos X.4, Machado P.5, Weber U.6, 
Sieper J.7, Wichuk S.1, Poddubnyy D.7, Ostergaard M.3, Paschke J.2, Lambert R.G.1
1University of Alberta, Canada; 2CaRE Arthritis; 3University of Copenhagen, 
Denmark; 4Rheumazentrum Ruhrgebiet Herne, Germany; 5University College 
London, UK; 6University of Southern Denmark; 7Charité Universitätsmedizin 
Berlin, Germany
Introduction/Aims. There has been no central reader evaluation of MRI scans 
from the ASAS Classification Cohort (ASAS-CC) to determine the spectrum of 
MRI lesions in the SIJ in this cohort. We aimed to compare the frequencies of 
active and structural lesions on MRI images from the ASAS-CC according to the 
recent ASAS MRI consensus definitions update. 
Methods. Lesions were recorded in an eCRF that comprises global assess-
ment (lesion present/absent) and detailed scoring (SPARCC SIJ inflammation, 
SPARCC SIJ structural). Wording of lesions defining active and structural lesions 
typical of axSpA was the same as in the original ASAS-CC eCRF permitting com-
parisons between central and local readers. MRI images were available from 278 
of the 495 cases who had MRI and were assessed by 7 readers. Comparison of 
active and structural lesion frequencies was assessed descriptively. Detection of 
active lesions typical of axSpA was compared between central and local readers.
Results. The percentage of cases with active lesions typical of axSpA recorded 
by central readers (28.4% by majority read) was lower than the 40% reported 
by local readers (Table I). This was similar to the frequency of structural lesions 
typical of axSpA (28.6% by majority read) (Table II). 11.2% had subchondral 
inflammation but not typical of axSpA, 0.3% had active lesions typical of axSpA 
without subchondral inflammation. Erosion was the most frequently observed 
structural lesion (25.2%) followed by fatty lesion (19.8%). 
Conclusions. In this first central reader analysis of MRI images from the ASAS-
CC we demonstrate similar frequencies of active and structural lesions typical 
of axSpA, erosion as a common lesion, some degree of false positive subchon-
dral inflammation, and a lower frequency of active lesions typical of axSpA than 
noted by local readers. 
Table I. Frequencies of active MRI lesions in the SIJ in the ASAS-CC. 
Variable Mean% (Range) Number (%) 
 of cases*  of cases#
Active lesions typical of axSpA 31.5 (24.5-38.5) 79 (28.4%)
Active lesions typical of axSpA and 22.4 (18.0-27.3) 58 (20.9%) 
   level of confidence ≥3 (scale of 1-4) 
Active lesions typical of axSpA and  30.0 (22.6-37.4) 71 (25.5%)
   meets ASAS definition for positive MRI 
Meets ASAS definition for positive MRI 23.1 (18.3-30.2) 58 (20.9%) 
   and level of confidence ≥3 (scale of 1-4) 
Subchondral inflammation 43.5 (38.5-51.1) 110 (39.6%)
Site of erosion cavity inflammation 8.9 (5.8-12.6) 10 (3.6%)
Capsulitis 4.0 (1.8-7.2) 6 (2.2%)
Joint Fluid 14.1 (6.8-20.5) 11 (4.0%)
Enthesitis 7.5 (1.8-12.2) 6 (2.2%)
(*Individual data from 6 readers; #majority reader (≥4) data).
Table II. Frequencies of structural MRI lesions in the SIJ in the ASAS-CC. 
Variable Mean% (Range) Number (%) 
 of cases*  of cases#
Structural lesions typical of axSpA  31.4 (23.5-39.9) 68 (28.6%)
Structural lesions typical of axSpA and 20.8 (14.0-29.4) 46 (19.3%) 
   level of confidence ≥3 (scale of 1-4)   
Subchondral sclerosis 24.2 (10.1-39.1) 36 (15.1%) 
Erosion 27.9 (23.1-32.8) 60 (25.2%) 
Fatty lesion (any) 23.5 (18.1-29.8) 47 (19.8%) 
Fatty lesion (>1cm)  11.7 (8.0-15.6) 22 (9.2%) 
Bone bud (yes) 2.1 (0.4-3.8) 1 (0.4%) 
Fat metaplasia in joint space (yes) 8.1 (4.2-10.5) 11 (4.6%) 
Ankylosis 1.1 (0.8-3.8) 5 (2.1%) 
(*6 readers; #majority reader (≥4) data).
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THE CONTRIBUTION OF STRUCTURAL MRI LESIONS TO 
DETECTION OF SACROILIITIS IN PATIENTS IN THE ASSESS-
MENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY 
(ASAS) CLASSIFICATION COHORT
Maksymowych W.P.1,2, Ostergaard M.3, Lambert R.G.1, Weber U.4, Pedersen S.J.3, 
Sieper J.5, Poddubnyy D.5, Wichuk S.1, Machado P.6, Paschke J.2, Baraliakos X.7 
1University of Alberta, Canada; 2CaRE Arthritis; 3University of Copenhagen; 
4University of Southern Denmark; 5Charité Universitätsmedizin Berlin, Ger-
many; 6University College London, UK; 7Rheumazentrum Ruhrgebiet Herne, 
Germany 
Introduction/Aims. There has been no data reported on the occurrence of struc-
tural lesions in the ASAS classification cohort (ASAS-CC). We assessed the 
added contribution of structural lesions in the SIJ to the evaluation of sacroiliitis. 
Methods. Lesions were recorded in an eCRF that comprises global assess-
ment (lesion present/absent) and detailed scoring (SPARCC SIJ inflammation, 
SPARCC SIJ structural). Wording of lesions defining active and structural lesions 
typical of axSpA was the same as in the original ASAS-CC eCRF permitting 
comparisons between central and local readers. MRI images were available from 
278 of the 495 cases who had MRI and were assessed by 7 readers. Comparison 
of active and structural lesion frequencies typical of axSpA was assessed descrip-
tively according to individual and majority of central readers data. 
Results. Active or structural lesions typical of axSpA were recorded in about 
40% of patients (Table). Similar data was observed when active sacroiliitis was 
defined using the ASAS definition of a positive MRI. Structural lesions alone, 
without any active lesions typical of axSpA, were recorded in 6.6% of cases. Ac-
tive lesions alone, without any structural lesions typical of axSpA, were recorded 
in 7.8% of cases. Both active and structural lesions typical of axSpA were re-
corded in 23.1% of cases. The frequencies of these categories were only slightly 
lower when majority reader data was analyzed.
Conclusions. Structural lesions typical of axSpA may be observed without any 
active lesions typical of axSpA in 5-10% of cases presenting with undiagnosed 
back pain in the ASAS-CC. This is the same proportion of the cohort for which 
active lesions typical of axSpA are seen without any structural lesions typical of 
axSpA. In view of the concomitant presence of both lesions, contextual interpre-
tation seems optimal.
Table. Contribution of Structural MRI Lesions to Detection of Sacroiliitis in the 
ASAS-CC. 
Variable Mean% (Range)* Number (%) 
  of cases#
Active lesions typical of axSpA 31.5 (24.5-38.5) 79 (28.4%)
Active lesions typical of axSpA but not 7.8 (4.6-11.8) 7 (2.9%) 
   structural lesions typical of axSpA 
Structural lesions typical of axSpA 31.4 (23.5-39.9) 68 (28.6%)
Structural lesions typical of axSpA but not  6.6 (4.2-12.7) 7 (2.9%)
   active lesions typical of axSpA 
Active and structural lesions typical of axSpA 23.1 (16.0-29.0) 51 (21.4%)
Active or structural lesions typical of axSpA 39.2 (28.2-48.7) 99 (41.6%)
  
Active lesions typical of axSpA and meets  30.0 (22.6-37.4) 79 (28.4%)
   ASAS definition for positive MRI 
ASAS positive MRI but not structural lesions  7.2 (3.4-11.3) 7 (2.9%)
   typical of axSpA 
Structural lesions typical of axSpA but not 8.8 (5.0-13.0) 7 (2.9%) 
   ASAS positive MRI 
ASAS positive MRI and structural lesions 22.6 (15.6-28.6) 51 (21.4%) 
   typical of axSpA 
ASAS positive MRI or structural lesions 38.4 (27.7-47.9) 99 (41.6%) 
   typical of axSpA 
(*Individual data from 6 readers; #majority reader (≥4) data).
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FIRST VALIDATION OF CONSENSUS DEFINITIONS FOR MRI 
LESIONS IN THE SACROILIAC JOINT BY THE ASSESSMENTS 
IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) 
MRI GROUP
Maksymowych W.P.1,2, Weber U.3, Pedersen S.J.4, Baraliakos X.5, Machado P.6, 
Sieper J.7, Poddubnyy D.7, Wichuk S.1, Lambert R.G.1, Paschke J.2, Ostergaard 
M.4
1University of Alberta, Canada; 2CaRE Arthritis; 3University of South Denmark; 
4University of Copenhagen, Denmark; 5Rheumazentrum Ruhrgebiet Herne, Ger-
many; 6University College London, UK; 7Charité Universitätsmedizin Berlin, 
Germany
Introduction/Aims. The ASAS MRI group has generated updated consensus 
lesion definitions (ASAS_MRI_defn) for MRI lesions in the SIJ and spine and 
these now require validation in multi-reader exercises. We aimed to assess the 
reliability of detection of active and structural lesions on MRI images of the 
SIJ from the ASAS Classification Cohort (ASAS-CC) in a multireader ASAS 
exercise.
Methods. MRI Lesions were recorded in an eCRF that comprises global assess-
ment (lesion present/absent) and detailed scoring (SPARCC SIJ inflammation, 
SPARCC SIJ structural). Wording of lesions defining active and structural lesions 
typical of axSpA was the same as in the original ASAS-CC eCRF. MRI images 
were available in a variety of formats (DICOM (n=175), JPEG (n=71), DICOM 
film (n=32)) and sequences, axial and semicoronal orientations, and from 278 
of the 495 cases who had MRI. Detailed SPARCC scoring data was based only 
on assessment of images in DICOM format. Detection of lesions by 7 readers 
was assessed as present/absent by global assessment was analyzed using kappa. 
Reliability of detailed scoring was analyzed by intraclass correlation coefficient 
(ICC).
Results. Reliability of detection of active and structural lesions was comparable 
and somewhat better when DICOM images were evaluated (Table). The most 
frequently detected active lesion, subchondral inflammation, was detected to a 
comparable degree of reliability as the most frequently detected structural lesion, 
erosion. 
Fat metaplasia in the joint space (backfill) and ankylosis were also reliably de-
tected despite low frequency of occurrence in this cohort. Mean ICC for de-
tailed scores were BME-0.84, Erosion-0.55, Fatty lesion (any)-0.61, Fatty lesion 
(>1cm depth)-0.55, Sclerosis-0.73, Fat metaplasia in joint space-0.36, Ankylo-
sis-0.97, Bone bud-0.07.
Conclusions. The reliability of the ASAS_MRI_defn was substantial for the most 
frequently detected lesions.
Table. Kappa values for detection of MRI lesions in the SIJ of patients in the ASAS-CC.
 Mean of all reader Mean of all reader 
 pairs (95% CI)* pairs (95% CI)**
Active lesions typical of axSpA 0.73 (0.64-0.81) 0.70 (0.58-0.82)
Active lesions typical of axSpA 0.77 (0.68-0.86) 0.80 (0.69-0.92)
   (confidence ≥3) (1-4 scale) 
ASAS positive MRI 0.74 (0.65-0.82) 0.73 (0.61-0.84)
ASAS positive MRI  0.76 (0.67-0.85) 0.79 (0.67-0.90)
   (confidence ≥3) (1-4 scale) 
Structural lesions typical of axSpA 0.64 (0.53-0.74) 0.71 (0.59-0.83)
Structural lesions typical of axSpA 0.61 (0.49-074) 0.75 (0.62-0.88)
(confidence ≥3) (1-4 scale) 
Subchondral inflammation 0.66 (0.57-0.75) 0.60 (0.49-0.72)
Inflammation in Erosion cavity 0.29 (0.11-0.47) 0.37 (0.15-0.58)
Capsulitis 0.37 (0.12-0.62) 0.55 (0.18-0.90)
Joint fluid 0.35 (0.21-0.50) 0.41 (0.23-0.59)
Enthesitis 0.21 (0.04-0.39) 0.23 (0.03-0.45)
Sclerosis 0.42 (0.30-0.55) 0.48 (0.33-0.63)
Erosion 0.59 (0.47-0.70) 0.61 (0.47-0.75)
Fatty lesion (any) 0.61 (0.50-0.73) 0.61 (0.46-0.76)
Fatty lesion >1cm 0.57 (0.41-0.73) 0.66 (0.47-0.84)
Fat metaplasia in joint space 0.47 (0.27-0.67) 0.50 (0.26-0.74)
Bone bud 0.14 (-0.03-0.31) 0.11 (-0.06- 0.29)
Ankylosis 0.54 (0.22-0.86) 0.58 (0.25-0.89)
*Based on all images (n=278). **Based on DICOM images (n=175).
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WHICH MRI LESIONS IN THE SACROILIAC JOINT ARE ASSO-
CIATED WITH THE DIAGNOSIS OF AXIAL SPONDYLOARTHRI-
TIS AFTER 2 YEARS FOLLOW UP IN THE ECHOGRAPHY IN 
SPONDYLO-ARTHRITIS COHORT (ECHOSPA)?
Maksymowych W.P.1,2, Loeuille D.3, Wichuk S.1, Paschke J.2, Judet O.4, Breban 
M.4, D’Agostino M.A.4, Lambert R.G.1
1University of Alberta, Canada; 2CaRE Arthritis; 3Ambroise Paré Hospital, Bou-
logne-Billancourt; 4CHRU Vandoeuvre les Nancy, France
Introduction/Aims. We aimed to assess the prognostic capacity of specific SIJ 
MRI lesions in patients with axSpA after 2 years follow up in the ECHOSPA 
cohort. 
Methods. Consecutive outpatients with age <50 years and symptoms >3 months 
suggestive of SpA were enrolled. The diagnosis of SpA was ascertained by an 
expert committee, blind to MRI evaluation, after 2 years follow-up. MRI scans 
from 223 cases were available for evaluation by 2 readers and an adjudicator 
who assessed lesions according to updated consensus definitions from the ASAS-
MRI group. Clinical, lab, and imaging variables associated with the diagnosis 
of axSpA at 2 years were first identified by univariate regression. A base model 
of all clinical/lab variables associated with axSpA was included as a group in 
multivariate logistic regression models that tested the independent association 
with MRI lesions.
Results. Mean age of the 223 cases was 39.6 (10.5) years, mean symptom dura-
tion was 2.5 (4.1) years, 49.5% were HLA-B27+ and 63.7% were female. At 2 
years follow up, 165 (74%) were deemed to have axSpA. In group comparisons 
(Table) and univariate regression, both active and structural MRI lesions were 
associated with diagnosis of axSpA at 2 years (p=0.03, p=0.01, respectively). 
Age, B27, and psoriasis were the clinical variables associated with diagnosis of 
axSpA at 2 years and were included with gender in multivariate analyses. Ac-
tive and structural lesions typical of axSpA and SPARCC BME score ≥2 were 
each independently associated with diagnosis of axSpA at 2 years (OR (95%CI)- 
6.8(1.4-34.1) (p=0.02); 17.9(2.2-146.6) (p=0.007); 4.9(1.3-18.4) (p=0.02). With 
all variables simultaneously added to the model, only structural lesions were sig-
nificantly associated. 
Conclusions. Assessment of both active and structural lesions on MRI may help 
determine which patients have axSpA with higher diagnostic certainty over time.
Table. Distribution of MRI lesions at baseline according to diagnosis of axSpA after 
2 years. 
MRI Lesion AxSpA NOT SpA p-value
 n=165 n=58
 (74.0%) (26.0%) 
Active lesion typical for axSpA 26 (16.0%) 2 (3.6%) 0.019
Active lesion typical for axSpA 18 (11.9%) 1(1.8%) 0.027 
   (confidence ≥3, 0-4 scale) 
ASAS MRI positivity 24 (14.6%) 1 (1.7%) 0.006
ASAS MRI positivity 17 (10.8%) 1(1.7%) 0.048 
   (confidence ≥3, 0-4 scale) 
Structural lesion typical for axSpA 32(19.6%) 1 (1.8%) 0.0004
Structural lesions typical for axSpA  27 (17.3%) 0 (0%) 0.0002
   (confidence ≥3, 0-4 scale) 
Active AND structural lesion typical for axSpA 19 (11.7%) 0 (0%) 0.004
Active OR structural lesion typical for axSpA 39 (23.9%) 3 (5.4%) 0.001
Only active lesion typical of axSpA 7 (4.3%) 2 (3.6%) 1.0
Only structural lesion typical of axSpA 13 (8.0%) 1 (1.8%) 0.12
P25
MRI ASSESSMENT OF BONE MARROW EDEMA IN THE SAC-
ROILIAC JOINTS OF PATIENTS WITH SPONDYLOARTHRITIS: 
IS THE SPAIR T2xTECHNIQUE COMPARABLE TO STIR?
Dalto V.F.1, Luppino-Assad R.1, Crema M.D.2, Louzada-Junior P.1, Nogueira-
Barbosa M.H.1
1Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil; 
2Dept. of Radiology, Quantitative Imaging Center, Boston University School of 
Medicine, Boston, USA
Objective. To compare Short tau inversion-recovery (STIR) with another fat 
saturation method in the assessment of sacroiliac joint inflammation. 
Methods. This prospective cross-sectional study comprises 76 patients with con-
firmed diagnosis of spondyloarthritis (SpA). Patients were submitted to sacro-
iliac joints magnetic resonance imaging in a 1.5T scanner, using STIR, Spectral 
Attenuated Inversion Recovery (SPAIR) T2w and Spectral Presaturation with 
Inversion Recovery (SPIR) T1w post-contrast sequences.
Two independent readers (R1 and R2) assessed the images using the Spondyloar-
thritis Research Consortium of Canada (SPARCC) score. We assessed agreement 
of the SPARCC scores for SPAIR T2w and STIR with that for T1 SPIR post-
contrast (reference standard) using the St. Laurent coefficient. We evaluated each 
sequence using the concordance correlation coefficient (CCC). 
Results. We observed a strong agreement between the STIR and SPAIR T2w 
sequences. Lin’s CCC was 0.94 for R1 and 0.84 for R2 for STIR and 0.94 for R1 
and 0.84 for R2 for SPAIR. The interobserver evaluation revealed a good CCC of 
0.79 for SPAIR and 0.78 for STIR.
Conclusion. STIR technique and the SPAIR T2w sequence showed a high agree-
ment in the evaluation of sacroiliac joints subchondral bone marrow edema in 
patients with SpA. SPAIR T2w may be an alternative to the STIR sequence for 
this purpose.
Key points. There are no studies evaluating which fat saturation technique 
should be used.
SPAIR T2w may be an alternative to STIR for sacroiliac joints evaluation.
The study will lead to changes in guidelines for spondyloarthritis.
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VALIDATION OF A WEB-BASED CALIBRATION MODULE FOR 
THE SPARCC MRI SIJ INFLAMMATION SCORE BASED ON 
PRINCIPLES OF ARTIFICIAL INTELLIGENCE
Maksymowych W.P.1,2, Krabbe S.3, Biko D.M.4, Weiss P.4, Maksymowych M.2, 
Cheah J.5, Kröber G.6, Weber U.6, Danebod K.6, Bird P.7, Chiowchanwisawakit 
P.8, Moeller J.3, Francavilla M.4, Stimec J.10, Kogay T.6, Zubler V.11, Batthish M.12, 
Winn N.13, Rumsey D.2, Guglielmi R.14, Pedersen S.J.3, Boutrup H.3, Shafer S.6, 
Jaremko J.2, Malik F.5, Heffernan E.15, Johansson M.P.3, Paschke J.1, Lambert R.G.2
1CaRE Arthritis; 2University of Alberta, Canada; 3University of Copenhagen, 
Denmark; 4Children’s Hospital of Philadelphia; 5Hospital for Special Surgery, 
NY, USA; 6University of Southern Denmark; 7University of New South Wales, 
Australia; 8Mahidol University, Bangkok, Thailand; 10Hospital for Sick Children, 
Toronto, Canada; 11Hospital Balgrist, Zurich, Switzerland; 12McMaster Children’s 
Hospital, Hamilton, Canada; 13RJAH Orthopaedic Hospital, Oswestry, UK; 14Ente 
Ospedaliero Cantonale, Lugano, Switzerland; 15St. Vincent’s University Hospital, 
Dublin, Ireland
Introduction/Aims. The appropriate use of imaging-based scoring instruments 
is usually an ad hoc process based on passive learning from published manu-
scripts and atlases. Our aims were: 1. To develop a web-based calibration module 
for the SPARCC SIJ Inflammation Score based on consensus scores from instru-
ment developers, experiential game psychology, and real-time iterative feedback. 
2. To test the feasibility and attainment of pre-specified performance targets for 
reader reliability.
Methods. The SPARCC method is based on scoring SIJ quadrants. Scans from 
50 cases at baseline and 12 weeks after TNFi therapy are scored blinded-to-
time-point. Continuous visual real-time feedback regarding concordance/dis-
cordance with expert reader scores for each SIJ quadrant is provided by a color-
coding scheme. Reliability (ICC) is assessed progressively in real time as cases 
are scored. Accreditation for SPARCC BME score is achieved with status and 
change score ICC of > 0.8 and >0.7. 26 readers validated the module (7 fellows, 
2 chiropractors, 1 undergraduate, 8 rheumatologists, 8 radiologists), 21 having 
no prior experience. 
Results. The majority of readers achieved accreditation for SPARCC BME score 
on the basis of sufficient reliability with instrument developers for both status 
and change scores, irrespective of prior experience (Table). All readers who com-
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pleted the module a second time, 6 months after the first exposure, achieved 
accreditation for SPARCC BME score. 
Conclusion. Experiential web-based learning is an effective and feasible cali-
bration tool to achieve proficiency targets in the scoring of MRI scans for SIJ 
inflammatory lesions. 
Table.  
 Status Score
 Mean ICC Median ICC N (%) Achieving
 (95%CI)  ICC>0.80*
All readers (N=26) 0.84 (0.81-0.87) 0.84 18(69.2%)
Second read (N=8) 0.89 (0.87-0.91) 0.89 8 (100%)
Naïve readers** (N=10) 0.83 (0.79-0.87) 0.84 8 (80%)
Rheumatologists (N=8) 0.86 (0.79-0.92) 0.85 6 (75%)
Radiologists (N=8) 0.84 (0.77-0.91) 0.82 4 (50%)
 Change Score
 Mean ICC Median ICC N (%) Achieving
 (95% CI)  ICC>0.70*
All readers (N=26) 0.74 (0.69-0.79) 0.76 17(65.4%)
Second read (N=8) 0.84 (0.79-0.90) 0.86 8 (100%)
Naïve readers** (N=10) 0.74 (0.66-0.83) 0.79 7 (70%)
Rheumatologists (N=8) 0.78 (0.69-0.87) 0.79 6 (75%)
Radiologists (N=8) 0.70 (0.59-0.81) 0.72 4 (50%)
*Proficiency targets for reader reliability.**7 rheumatology fellows, 2 chiropractors, 
1 undergraduate.
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CAN SUFFICIENT RELIABILITY OF SCORING SIJ STRUC-
TURAL LESIONS ON MRI BE ACHIEVED USING A WEB-BASED 
CALIBRATION MODULE DEVELOPED ON PRINCIPLES OF AR-
TIFICIAL INTELLIGENCE? 
Maksymowych W.P.1,2, Kröber G.3, Danebod K.3, Weiss P.4, Biko D.M.4, Weber 
U.3, Krabbe S.5, Maksymowych M.P.1, Cheah J.7, Bird P.8, Kogay T.3, Jaremko 
J.1, Zubler V.9, Chauvin N.4, Shafer S.3, Heffernan E.10, Guglielmi R.11, Winn N.12, 
Francavilla M.4, Pedersen S.J.5, Boutrup H.5, Paschke J.2, Lambert R.G.1
1University of Alberta, Canada; 2CaRE Arthritis; 3University of Southern Den-
mark; 4Children’s Hospital of Philadelphia, USA; 5University of Copenhagen, 
Denmark; 7Hospital for Special Surgery, NY, USA; 8University of New South 
Wales, Australia; 9Hospital Balgrist, Zurich, Switzerland; 10St Vincent’s Univer-
sity Hospital, Dublin, Ireland; 11Ente Ospedaliero Cantonale, Lugano, Switzer-
land; 12The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK
Introduction/Aims. The reliable scoring of structural lesions on MRI in the SIJ 
requires considerably more reader training than for inflammatory lesions. Our 
aim was to develop a web-based calibration module for the SPARCC MRI SIJ 
Structural Score based on 1. consensus scores from instrument developers, 2. ex-
periential game psychology, 3. real-time iterative feedback built into a web-based 
interface of an SIJ scoring schematic.
Table. Proficiency targets for reader reliability for status* (≥0.70 for fat metaplasia/
ankylosis and ≥0.50 for erosion/backfill) and change** (≥0.50 for all domains) scores.
 Status Score
 
SPARCC Domains Mean ICC (95%CI) Median ICC N (%) Achieving  
   ICC≥0.70/0.50*
Fat metaplasia 0.88(0.84-0.91) 0.91 20(100%)
Erosion 0.63(0.53-0.73) 0.61 16(80%)
Backfill 0.61(0.45-0.76) 0.71 13(65%)
Ankylosis 0.92(0.88-0.96) 0.95 18(90%)
 Change Score
SPARCC Domains Mean ICC (95% CI) Median ICC N (%) Achieving  
   ICC≥0.50**
Fat metaplasia 0.91(0.89-0.93) 0.91 20(100%)
Erosion 0.49(0.39-0.59) 0.50 10(50%)
Backfill 0.58(0.45-0.70) 0.65 12(60%)
Ankylosis 0.49(0.34-0.63) 0.48 9(45%)
Methods. Scans from 50 cases obtained at baseline and 2 years after TNFi ther-
apy are scored blinded-to-time-point. Continuous visual real-time feedback re-
garding concordance/discordance with expert reader scores for each SIJ quadrant 
is provided by a color-coding scheme on a web-based interface. Reliability (ICC) 
is assessed progressively in real time as cases are scored. Scoring proficiency 
is achieved with pre-specified status ICC of ≥0.7 for fat and ankylosis, ≥0.5 for 
erosion and backfill, and ≥0.5 for change score in all domains. 20 readers scored 
the SPARCC structural module (4 rheumatology fellows, 2 chiropractors, 1 un-
dergraduate, 5 rheumatologists, 8 radiologists). 
Results. The majority of readers achieved scoring proficiency in all 4 domains 
for status scores, irrespective of prior experience (Table). For change scores, the 
majority achieved proficiency for fat metaplasia, erosion, and backfill. Very few 
cases had change in ankylosis. All readers rated the modules as easy and intuitive.
Conclusion. Experiential web-based learning is an effective method to achieve 
proficiency targets in the scoring of even the most challenging SIJ structural 
lesions.
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COMPUTER-AIDED CLASSIFICATION OF INFLAMMATORY 
SACROILIITIS IN MAGNETIC RESONANCE IMAGING
Calil Faleiros M., Jens Rivero Zavala E., Raniery Ferreira Junior J., Luppino-
Assad R., Dalto V.F., Louzada-Junior P., Nogueira-Barbosa M.H., Azevedo- 
Marques P.M.
Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Brazil
Purpose. The reference standard to evaluate active inflammation of sacroiliac 
joints (SIJ) in spondyloarthritis (SpA) is magnetic resonance imaging (MRI). 
However, this evaluation may be challenging to specialists due to clinical vari-
ability. In order to aid the diagnosis of inflammatory sacroiliitis, we aim to de-
velop a computerized semiautomatic classification of SIJ using gray-level and 
texture MRI features. We also aim to assess the performance of the classification 
with features extracted from manually segmented SIJ images and from images 
processed by the warp geometric transformation method. 
Methods. We retrospectively evaluated the SIJ MRI from 51 patients with in-
flammatory sacroiliitis related to SpA. According to ASAS-MRI criteria, 22 pa-
tients presented active SIJ inflammation, and 29 were negative. Segmentation 
was performed in 6 consecutive SPAIR T2 coronal plane MRI for each patient. 
On each image we applied the warp processing method, in order to remove the 
black background of the segmented regions of interest, which could introduce 
noise in the feature extraction and classification processes. 
Results. The highest difference was obtained by the gray-level feature vector, with 
an increase of 0.21 in AUC. On the other hand, the segmented images obtained 
highest performance only with Tamura features, with an increase of 0.30 in AUC. 
However, the best result with highest AUC (0.93) was obtained using all features 
extracted from the warped images, with sensibility of 0.73 (95% confidence inter-
val of 0.50–0.88) and a specificity of 0.9 (95% confidence interval of 0.72–0.97). 
Conclusion. This study on semiautomatic classification of active sacroiliitis 
in SpA achieved promising results for a case-based evaluation, with AUC of 
0.93 using gray-level and texture MRI features extracted from SIJ images. The 
warp image processing method increased the overall classification performance 
compared to segmented images with a black background, except when Tamura 
features were employed. In future studies, we will extract different features from 
the warped images, e.g. Fourier and wavelet transformations, and perform an 
image-based evaluation for each SIJ MRI coronal slice. Further experiments 
will include an observer test to validate the semi-automatic classification as a 
computer-aided diagnosis tool. 
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SACROILIITIS IN PATIENTS WITH PSORIATIC ARTHRITIS AND 
ANKYLOSING SPONDYLITIS – ARE THERE DIFFERENCES?
Luppino-Assad R., de Oliveira R., Nogueira-Barbosa M.H., Louzada-Junior P., 
Dalto V.F., Sampaio-Barros P.D.
Ribeirão Preto Medical School, University of São Paulo, Ribeirao Preto, Brazil
Objectives. The objective of the study was to compare the radiological findings 
in the sacroiliac joint by magnetic resonance imaging in patients with Axial pso-
riatic arthritis (axPsA) and ankylosing spondylitis (AS).
Methods. A retrospective study of the magnetic resonance images (MRI) exams 
of sacroiliac joints was performed in our service between January 2012 and De-
cember 2014, with the identification of cases based on active search in the radiol-
ogy information and imaging systems (PACS).
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Patients aged 18 to 45 years, with clinical suspicion of Spondylarthritis, who un-
derwent MRI for evaluation of sacroiliitis, with clinical history of low back pain 
were selected. Exclusion criteria were examination with incomplete or altered 
protocol, bone and joint infections, pregnancy, metal artifacts and claustrophobia 
implants.
Casuistry - One hundred and twenty-five patients with suspected sacroiliitis were 
initially evaluated.
Of the 125 patients, 86 met the diagnosis of axial spondyloarthritis, by ASAS 
criteria. 10 patients was excluded by fail in the MRI protocol.
After this, we find 76 patients with axial MRI protocol ok.
Of these 76, those with APSax and AS criteria were selected, excluding patients 
with other diseases, including other axial EAs (23 with non-radiographic spondy-
loarthritis, 8 with reactive arthritis, 7 with enteroarthritis), remaining 24 patients 
with AS, and 14 with AxPsA.
Was analyzed the presence and symetric findings of subchondral bone marrow ede-
ma (BME), subchondral bone infiltration (FAT), synovitis, enthesitis and capsulitis. 
Results. 
 
 total BME Fat lesion capsulitis enthesitis
AS 24 15(62,50%) 22(91,66%) 3(12,50%) 1(4,10%)
AxAPS 14 11(78,57%) 12(85,71%) 3(21,42%) 3 ( 2 1 , 4 2 % ) 
Symetric findings 8 3 0.69                       0.3308, 12.94
The results did not show significant differences between the groups, in agree-
ment with the grouping of the diseases as axSpA, and potentially supporting the 
recommendations of treatments of the axPsA with the same treatments of the AS, 
and in general the axSpA.
Conclusions. The authors conclude that despite the reduced sample size and 
the need for more powerful studies, there was no significant difference between 
axPsA and AS, with a high similarity of inflammatory findings in the sacroiliac 
joint between groups.
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RADIOMICS ASSOCIATION OF MRI TEXTURE FEATURES 
WITH SPONDYLOARTHRITIS AND SACROILIITIS
Luppino-Assad R.1, Magalhães Tenórioa A.P.1, Dalto V.F.1, de Oliveira R.1, Louzada-
Junior P.1, Nogueira-Barbosa M.H.1, Azevedo-Marques P.M.1, Calil Faleiros M.2, 
Ferreira-Junior J.R.2, Yoshida H.3
1Ribeirão Preto Medical School, University of São Paulo, Ribeirao Preto; 
2São Carlos School of Engineering, University of São Paulo, Sao Carlos, Brazil; 
3Massachusetts General Hospital, Harvard Medical School, Boston, USA
Purpose. The ASAS Group classification criteria for axial SpA introduced sac-
roiliitis assessed using MRI. Recently, radiomics has emerged as a promising 
approach to improve diagnosis and to provide therapy decision support for pre-
cision medicine. Radiomics consists of the massive extraction of quantitative 
features from medical images and their association with clinical outcomes. The 
main objective of this study is to evaluate the use of radiomics to aid the diagno-
sis and therapy decision of SpA by associating quantitative MRI texture features 
with the outcomes of presence of sacroiliitis, diagnosis of SpA, and subclassifica-
tion in axial or peripheral SpA.
Methods. Retrospective study with 47 patients. From each MRI exam, we se-
lected 6 consecutive images in the coronal plane acquired with fluid sensitive 
technique. Each exam was characterized by the mean and standard deviation of 
each feature for the 6 images, totalizing 230 features.
Results. The univariate analysis showed that the Tamura_D11_SD feature yield-
ed the highest overall performance in distinguishing the diagnostic outcomes with 
AUC equal to 0.97 (association with axial SpA and peripheral SpA, p<0.0001). 
Histogram_Skewness_M feature yielded the highest performance to identify the 
presence of inflammation in the sacroiliac joints with AUC of 0.86 (p<0.0001). 
Tamura_D11_SD feature also yielded the highest associative performance in dif-
ferentiating SpA from other pathologies with AUC of 0.80 (p<0.001).
Discussion. MRI analysis to SpA diagnosis may be a difficult task. To potentially 
improve the diagnosis of these pathologies and their therapy decision, this work 
applied radiomics techniques by extracting 230 quantitative MRI texture features 
and associate them with clinical diagnostic outcomes of SpA. 
Conclusion. Histogram_SM feature presented high association with sacroili-
itis presence and Tamura_D11_SD feature with SpA diagnosis and subtypes. In 
contrast, combining several different quantitative MRI texture features into a 
machine learning model presented highest associative performance for sacroili-
itis and SpA diagnostic outcomes. Further investigation is necessary to improve 
its associative performance and aid the diagnosis and therapy decision of SpA.
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SPONDYLOARTHRITIS IN A POPULATION WITHOUT ACCESS 
TO BIOLOGICS IN 2017 – PADRE HURTADO HOSPITAL EXPERI-
ENCE
Ibáñez S., Valenzuela O., Villar M., Silva F., Poblete M., Mogollones K., Mardones 
C.
Rheumatology Dept., Facultad de Medicina Clínica Alemana, Universidad del 
Desarrollo, Santiago, Chile
Introduction. Chilean patients suffering from spondyloarthritis (SpA) do not 
have guaranteed access to biologics. Our aim was to characterize our patients 
without access to biologics and evaluate the variables associated with greater 
severity of the disease.
Methods. All patients diagnosed with SpA treated at our rheumatology service 
between April and December 2017 were evaluated. Demographic data was ob-
tained. BASDAI, ASDAS, BASFI and HAQ were obtained. Uni and multivariate 
analysis were performed.
Results. 36 patients were evaluated. The mean age was 48.2 years (SD 11.1). 
The median of years since diagnosis was 5 years (IQR 0-10). 44.4% of the pa-
tients were women. 75% of patients met the ASAS criteria for axial SpA, the rest 
for peripheral SpA. 22.2% received disability pension because of their disease. 
69.4% used sulfasalazine, 16.2% methotrexate, 36.1% prednisone, 75% NSAIDs 
and 19.4% tramadol.
The results of the measures of activity, BASFI and HAQ are described in Table I. 
Table I. 
BASDAI (median, IQR) 7.1 (6-8.4)
High activity (BASDAI >4) 86.1%
ASDAS-CRP (mean, SD) 3.6 (0.9)
Activity at least high (>2.1) 95.8%
Very high activity (>3.5) 54.2%
ASDAS-ESR (mean, SD) 3.8 (1)
Activity at least high (>2.1) 96.2%
Very high activity (>3.5) 69.2%
BASFI (mean, SD) 6.8 (2.4)
HAQ (mean, SD) 1.6 (0.7)
After multivariate analysis being a woman was associated with a worse BAS-
DAI, and more years since the diagnosis was associated with worse ASDAS and 
BASDAI. Meeting the ASAS criteria of axial SpA was associated with worse 
BASFI, and the use of tramadol was associated with worse HAQ. 
Discussion. Our patients without access to biologics have a very active disease 
despite having been in medical control for many years, using different DMARDs, 
analgesics and anti-inflammatories. This leads to a high rate of work disability. It 
is imperative that health policies guarantee the worldwide standard treatment for 
SpA for patients in our country.
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DO ETHNICITY, DEGREE OF FAMILY RELATIONSHIP AND THE 
SPONDYLOARTHRITIS SUBTYPE IN AFFECTED RELATIVES 
INFLUENCE THE ASSOCIATION BETWEEN A POSITIVE FAM-
ILY HISTORY FOR SPONDYLOARTHRITIS AND HLA-B27 CAR-
RIERSHIP? RESULTS FROM THE WORLDWIDE ASAS COHORT
van Lunteren M.1, Sepriano A.1,2, Landewé R.3,4, Sieper J.5,6, Rudwaleit M.5,7, van 
der Heijde D.1, van Gaalen F.A.1
1Rheumatology, LUMC, Leiden, The Netherlands; 2Rheumatology, NOVA Medi-
cal School, Lisbon, Portugal; 3Rheumatology, ARC, Amsterdam; 4Rheumatol-
ogy, Zuyderland Hospital, Heerlen, The Netherlands; 5Rheumatology, Charité 
Campus Benjamin Franklin, Berlin; 6German Rheumatism Research Centre, 
Berlin; 7Rheumatology, Klinikum Bielefeld, Bielefeld, Germany
Aim. In two European cohorts only a positive family history (PFH) of ankylosing 
spondylitis (AS) and acute anterior uveitis (AAU) were associated with HLA-
B27 carriership in axial spondyloarthritis (axSpA) suspected patients. As the 
importance of ethnicity or degree of family relationship is unknown, we inves-
tigated the influence of ethnicity, first (FDR)- or second (SDR)-degree relatives 
on the association between a PFH and HLA-B27 carriership in axSpA suspected 
patients.
Methods. Univariable analyses were performed among axSpA suspected pa-
tients in the ASAS cohort at baseline. Each disease (AS, AAU, psoriasis, inflam-
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matory bowel disease (IBD), reactive arthritis (ReA)) in a PFH according to the 
ASAS definition was a determinant in separate models with HLA-B27 carrier-
ship as outcome. Analyses were stratified for self-reported ethnicity, FDR, and 
SDR. Analyses were repeated in multivariable models to investigate independent 
associations.
Results. 594 patients were analysed (mean (SD) age 33.7 (11.7) years; 46% 
male; 52% HLA-B27+; 59% white, 36% Asian, 5% other). A PFH was associ-
ated with HLA-B27 carriership in patients with a white or Asian ethnicity and 
with a PFH in FDR, but not with a PFH in SDR or in other ethnicities (Table I). A 
PFH of AS was positively associated with HLA-B27 carriership in all subgroups. 
A PFH of AAU, ReA, IBD, or psoriasis was never positively associated with 
HLA-B27 carriership. In the multivariate analysis, similar results were found.
Conclusions. In the ASAS cohort, a PFH of AS, but not of AAU, ReA, IBD, or 
psoriasis, was associated with HLA-B27 carriership irrespective of ethnicity or 
degree of family relationship. This cohort and two European cohorts show that 
a PFH of AS and possibly a PFH of AAU can be used to identify patients who 
are more likely to be HLA-B27 positive and therefore have an increased risk of 
axSpA.
Table I. Univariable associations between each subtype of a positive family history 
and HLA-B27 carriership in chronio back pain patients suspected of axSpA included 
in the ASAS cohort (n=594).
Statistically significant results are printed in bold.* Self-reported ethnicities was miss-
ing for 5 patients who are included in this category, and other ethnicities are black, 
East-Indian, Hispanic/Latino, mixed or Turkish). ASAS: Assessment of Spondylo-
Arthritis international Society; CI: confidence interval; HLA-B27: human leucocyte 
antigen B27; n.a.: not applicable; OR: odds ratio.
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IS A POSITIVE FAMILY HISTORY OF SPONDYLOARTHRITIS 
RELEVANT FOR DIAGNOSING AXIAL SPONDYLOARTHRITIS 
ONCE HLA-B27 STATUS IS KNOWN? DATA FROM THE ASAS, 
DESIR, AND SPACE COHORTS
van Lunteren M.1, van der Heijde D.1, Sepriano A.1,2, Landewé R.3,4, Berg I.J.5, 
Dougados M.6, Gossec L.7,8, Jacobsson L.9, Ramonda R.10, Rudwaleit M.11,12, 
Sieper J.11,13, van Gaalen F.A.1
1Rheumatology, LUMC, Leiden, The Netherlands; 2Rheumatology, NOVA Medi-
cal School, Lisbon, Portugal; 3Rheumatology, ARC, Amsterdam; 4Rheumatology, 
Zuyderland Hospital, Heerlen, The Netherlands; 5Rheumatology, Diakonhjem-
met Hospital, Oslo, Norway; 6Rheumatology, Cochin Hospital, Paris; 7Sorbonne 
Université, Paris; 8Rheumatology, Pitié Salpêtrière Hospital, Paris, France; 
9Rheumatology, University of Gothenburg, Gothenburg, Sweden; 10Rheumatol-
ogy, University of Padova, Italy; 11Rheumatology, Charité Campus Benjamin 
Franklin, Berlin; 12Rheumatology, Klinikum Bielefeld; 13German Rheumatism 
Research Centre, Berlin, Germany
Introduction. A positive family history (PFH) of spondyloarthritis (SpA), in 
particular a PFH of ankylosing spondylitis (AS) or acute anterior uveitis (AAU), 
can be used to identify HLA-B27 carriership in chronic back pain patients. It 
is unknown if a PFH contributes to diagnosing axial spondyloarthritis (axSpA) 
once HLA-B27 status is known. 
Methods. In patients suspected of axSpA from the ASAS, DESIR, and SPACE 
cohorts, logistic regression analyses were performed at baseline with HLA-B27 
status and PFH according to the ASAS definition (ASAS-PFH) as determinants 
and clinical axSpA diagnosis as the outcome. Analyses were repeated with a PFH 
of AS or AAU. 
Results. In patients from the ASAS (n=594), DESIR (n=647), and SPACE 
(n=577) cohorts, respectively 23%, 39%, and 38% had an ASAS PFH, 52%, 
58%, and 43% were HLA-B27 positive, and 62%, 47%, and 54% were diag-
nosed with axSpA. In the univariable analysis, HLA-B27 status was significantly 
associated with an axSpA diagnosis in all three cohorts (Table 1). An ASAS-PFH 
and a PFH of AAU were univariately associated with an axSpA diagnosis only in 
the SPACE cohort and a PFH of AS with an axSpA diagnosis only in the ASAS 
cohort. In the multivariable models, HLA-B27 was independently and positively 
associated with an axSpA diagnosis in each cohort but an ASAS-PFH was not 
(Table I). Similarly, a PFH of AS did not have an independent positive associa-
tion with an axSpA diagnosis in any cohort (ASAS cohort: HLA-B27 OR:6.7 
(95%CI:4.6–10.2), ASAS-PFH OR:0.9 (95%CI:0.5-1.7); DESIR cohort: HLA-
B27 OR:2.1 (95%CI:1.5–2.9), ASAS-PFH OR:1.0 (95%CI:0.6–1.4); SPACE 
cohort: HLA-B27 OR:13.4 (95%CI:8.4–21.4), ASAS-PFH OR:0.4 (95%CI 
0.2–0.8)). Similar results were found for PFH of AAU.
Conclusions. When diagnosing axSpA, a PFH is no longer relevant once HLA-
B27 status is known.
Table I. Logistic regression analysis between ASAS PFH, HLA-B27, and clinical 
azSpA diagnosis in the ASAS, DASIR, and SPACE cohort.
Statistically significant associations are printed in bold, ASAS: Assessment of Spondylo-
Arthritis international Society; (ax)SpA: (axial) spondyloarthritis; CI: confidence interval; 
HLA-B27: human leucocyte antigen B27; OR: odds ratio; PFH: positive family history.
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DIAGNOSTIC DELAY IN SPONDYLOARTHRITIS: HOW CAN WE 
DO BETTER?
Resende G.G., Lage R.C., Malheiro O.B., Guimarães D.L., Bomtempo C.A.S., 
Carvalho M.A.P.
Hospital das Clínicas, Universidade Federal de Minas Gerais (HC-UFMG), Belo 
Horizonte, Brazil
Introduction/Aim. Diagnostic delay, the gap between the onset of first musculo-
skeletal symptoms and diagnosis definition, is associated to worse prognostic and 
represents a major challenge to assistance of spondyloarthritis (SpA) patients. 
The aim of this study was to compare it between two different periods in a same 
cohort and evaluate possible associations with SpA features.
Materials and Methods. Two cross-sectional analysis from the same database 
were made. The first included patients admitted to the SpA outpatient clinic up 
to 2002 (group A) and the second one included patients admitted between 2003 
and 2013 (group B).
Results. The mean diagnostic delay was 8.1 (±0.68) years in group A (N=156) 
and 6.9 (±0.76) years in group B (N=99). The subtype of SpA, gender, HLA-B27 
status or presence of radiographic sacroiliitis (mNY criteria) were not associated 
to diagnostic delay. Conversely, the presence of extra-articular manifestations - 
EAM (i.e. uveitis, psoriasis and/or inflammatory bowel disease) (p<0.0001) on 
admission was statistically associated with longer diagnostic delay and the age at 
onset was negatively correlated with it (r=-0.28 p<0.0001).
Discussion. Possibly, the increased awareness amongst health-care profession-
als, the adoption of new classification criteria (ASAS 2009) and the incorporation 
of magnetic resonance imaging - MRI as a diagnostic tool in SpA could explain 
the observed improvement in earlier diagnosing. The association between EAM 
presence and earlier disease onset with longer diagnostic delay, could represent 
a greater difficulty of non-rheumatologists in identify inflammatory-type symp-
toms and an oftener unawareness of the EAM linkage with SpA. As consequence, 
patients may not be referenced to rheumatologist in appropriate time and may 
have an inadequate investigation, delaying the diagnosis. 
Conclusions. We have shown a reduction (mean difference of 1.3 years) in di-
agnostic delay measured in a same SpA outpatient clinic over a decade. Even so, 
there is still a need for further targeted education of health-care professionals to 
address this issue.
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CARDIAC CONDUCTION DISTURBANCES IN PATIENTS WITH 
ANKYLOSING SPONDYLITIS – A SWEDISH LONGITUDINAL 
COHORT STUDY
Bengtsson K.1, Klingberg E.1, Deminger A.1, Jacobsson L.T.H.1, Bergfeldt L.1, 
Forsblad-d’Elia H.1,2
1University of Gothenburg, Gothenburg; 2Umeå University, Umeå, Sweden
Aim. To describe electrocardiographic (ECG) alterations in a cohort of patients 
with AS and if AS related factors at baseline predict the presence of cardiac con-
duction disturbances (CCD) at 5-year follow-up.
Materials and Methods. In total 210 patients (57.6 % men, mean age 50±13 
years) diagnosed with AS at 3 rheumatology clinics from Western Sweden partic-
ipated 2009 in an observational longitudinal cohort study with a planned follow-
up after 5 years. At follow-up 2014, physical examination, ECG, questionnaires, 
laboratory tests and radiographic examinations were repeated in 172 patients 
(54.1% men, mean age 55±13 years). CCD was defined in the presence of AV 
block I (PQ duration ≥220 ms), AV block Ix (PQ duration 200–219 ms), AV block 
II-III, right and left bundle branch block (RBBB and LBBB)), left anterior and 
posterior fascicular block (LAFB and LPFB) and pacemaker. Descriptive statis-
tics and logistic regression analyses were performed in order to find predictors 
at baseline for the presence of CCD at follow-up. Baseline characteristics with 
a p-value <0.2 in univariate analyses (dependent variable present CCD (yes=1, 
no=0)) were included as independent variables in a forward stepwise multiple 
logistic regression analysis. 
Results. In total 23 of the 172 patients (13.4%) had CCD at 5-year follow-up. 
Eight had developed a new CCD out of which 2 had required pacemaker implan-
tation, 3 had a more aggravated CCD, whereas 10 patients had an unchanged and 
2 a less pronounced CCD compared with 2009. Existing CCD at baseline (Odds 
ratio (OR) (95 % CI) 42.4 (8.9–202.2)), a history of anterior uveitis (OR 6.4 
(1.1–36.2)), male sex (OR 4.7 (1.1–20.6)), higher ASDAS-CRP (OR 3.6 (1.6-
7.9)) and increasing age (OR 1.1 (1.0–1.1) per 1 year) were predictors for the 
presence of CCD at follow-up. 
Conclusions. The presence of CCD in AS is dynamic. AS related factors, repre-
sented by baseline ASDAS-CRP and a history of anterior uveitis, predicted their 
presence at 5-year follow-up.
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FACTORS RELATED TO HEALTH RELATED QUALITY OF LIFE 
IN ANKYLOSING SPONDYLITIS, OVERALL AND STRATIFIED 
BY SEX
Law L.1, Beckman Rehnman J.1, Deminger A.2, Klingberg E.2, Jacobsson L.T.H.2, 
Forsblad-d’Elia H.1,2
1Umeå University, Umeå; 2University of Gothenburg, Gothenburg, Sweden
Background. Knowledge about health related quality of life (HRQoL) in Anky-
losing spondylitis (AS) is limited. The aims of this study were to assess HRQoL by 
short form-36 (SF-36) in a cohort of patients with AS compared with controls and 
to examine associations between SF-36 and spinal radiographic changes, physi-
cal function, disease activity and demographic data overall and stratified by sex.
Methods. A cohort of patients with AS were assessed with spinal radiographs 
for mSASSS, BASMI, BASFI, ASDAS-CRP, BASDAI, BASG and SF-36. Each 
patient’s SF-36 results were compared with 5 age- and sex-matched persons 
(n=1055) from the SF-36 Swedish normative population database. Associations 
between SF-36 physical component summary (PCS) and mental component sum-
mary (MCS) scores and disease related and demographic factors were investigat-
ed with univariate and multiple logistic regression analyses with PCS and MCS 
below/above their respective median values as dependent variables.
Results. 210 patients, age (median, IQR) 49.0 (40.0, 61.2) years were included. 
AS patients scored lower (p<0.001) compared to controls in all SF-36 domains 
and component summaries. Both sexes scored significantly lower in PCS com-
pared to MCS. Multiple logistic regression analyses revealed that living without 
a partner (OR 2.38, 95% CI 1.00–5.67), long symptom duration (year in decade 
OR 1.66, 95% CI 1.16–2.37), higher BASFI (OR 1.98, 95% CI 1.46–2.70) and 
ASDAS≥2.1 (OR 3.32, 95% CI 1.45-7.62) were associated with worse PCS, 
while living without a partner (OR 3.04, 95% CI 1.34–6.91), fatigue (VAS global 
fatigue >median (OR 6.36, 95% CI 3.06–13.19) and ASDAS≥2.1 (OR 2.97, 95% 
CI 1.41–6.25) were associated with worse MCS. 
Conclusions. AS patients had significantly lower HRQoL compared with con-
trols. PCS was more affected than MCS in both sexes. Both disease related 
and demographic factors were associated with HRQoL, partly overlapping for 
PCS and MCS. Factors associated with HRQoL showed some differences be-
tween sexes. Modifying factors, such as ASDAS-CRP and fatigue, may improve 
HRQoL.
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OSTEONECTIN IN CARDIOVASCULAR RISK IN AXIAL SPON-
DYLOARTHRITIS: A SEROLOGICAL AND GENETIC STUDY
Genre F.1, Rueda-Gotor J.1, Remuzgo-Martínez S.1, Irure-Ventura J.2, Corrales 
A.1, Portilla V.1, Pulito-Cueto V.1, Blanco R.1, Llorca J.3, Ocejo-Vinyals J.G.2, 
López-Mejías R.1, González-Gay M.Á.1
1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic In-
flammatory Diseases, IDIVAL; 2Immunology Division, Hospital Universitario 
Marqués de Valdecilla; 3Epidemiology and Computational Biology, University 
of Cantabria, and CIBERESP, IDIVAL, Santander, Spain.
Introduction/Aim. Cardiovascular (CV) disease due to atherosclerosis is one 
of the main causes of morbidity in axial spondyloarthritis (axSpA). Osteonec-
tin (ON), mainly implicated in bone homeostasis, was also associated to obe-
sity, insulin resistance and diabetes, constituting thus a potential CV risk factor. 
Thereby, we aimed to evaluate the potential role of ON as a prognostic marker 
of CV disease in axSpA by assessing its association with subclinical atheroscle-
rosis and CV risk factors in a large cohort of patients, both at the serological and 
genetic level. 
Methods. 171 axSpA patients and 84 controls were recruited for this study. Se-
rum ON levels were assessed by multiplex. Markers of subclinical atherosclero-
sis were evaluated by carotid ultrasound. Tag ON polymorphisms (rs1054204, 
rs11950384, rs13182103, rs11745387 and rs4958487) were genotyped by 
TaqMan probes.
Results. Serum ON levels were similar between axSpA and controls. Serum ON 
and CRP at study positively correlated in axSpA (p=0.008). Men, smokers and 
patients with an atherogenic index indicative of dyslipidemia showed higher ON 
levels (p=0.008, 0.01 and 0.001, respectively). ON serum levels and markers of 
subclinical atherosclerosis showed no significant association in axSpA. No dif-
ference in the allelic/genotypic frequencies of ON was observed between axSpA 
and controls. Interestingly, the A alleles of rs13182103 and rs11950384 were 
associated with lower ON serum levels in axSpA (p<0.05). Furthermore, the 
rs13182103 A allele was linked to a later diagnosis of axSpA (p<0.05). 
Conclusion. Serum ON is linked to inflammation and CV risk factors in axSpA. 
Additionally, rs13182103 and rs11950384 A alleles may have a protective effect 
in axSpA, leading to reduced ON serum levels and later diagnosis of the disease. 
These data support an implication of ON in the development and progression of 
atherosclerosis in axSpA.
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IN VIVO PHOSPHORYLATION OF P38 IN MONOCYTES IS 
ENHANCED, AT THE TIME OF DIAGNOSIS, IN PATIENTS WITH 
AXIAL SPONDYLOARTHRITIS (axSpA) 
Kuuliala A.1, Kuuliala K.1, Koivuniemi R.2, Hämäläinen M.3, Moilanen E.3, 
Kautiainen H.4, Repo H.1, Leirisalo-Repo M.2
1Bacteriology and Immunology and 2Rheumatology, Helsinki University Hospital 
and University of Helsinki, Helsinki; 3The Immunopharmacology Research Group, 
University of Tampere School of Medicine, Tampere; 4Folkhälsan Research Cent-
er, Helsinki, Finland
Introduction. Host response to microbes is considered to contribute to pathogen-
esis to axSpA. p38 MAP kinase pathway plays an important role in resistance of 
bacterial replication in HLA-B27 expressing human monocytic U937 cells (1). 
This prompted us to study the phosphorylation of the MAP kinases p38, extracel-
lular signal-regulated kinase (ERK)1/2 and c-Jun-N-terminal kinase (JNK) in 
patients with axSpA.
Patients and Methods. We included 20 patients [19/20 HLA-B27 positive, 
mean time from first period of back pain 5.9 years (range 0.3-16), mean BAS-
DAI 4.4 (SD 1.7)] referred to rheumatology unit for diagnostic workup due to 
back pain. The patients fulfilled ASAS classification criteria. 26 patients [mean 
DAS28 4.0 (SD 1.3)] with early untreated rheumatoid arthritis (RA) fulfilling the 
2010 ACR/EULAR classification criteria served as disease control group, and 18 
adult volunteers as healthy controls. Whole blood phosphospecific flow cytom-
etry was used to reveal phosphorylation of p38, ERK1/2 and JNK in nonstimu-
lated monocytes, and in monocytes stimulated by lipopolysaccharides, E. coli, 
or lipoteichoic acid. Fluorescence intensities of monocyte pERK1/2-PE-CF594, 
pJNK-AlexaFluor647 and pp38-PE-Cy7 were expressed as relative fluorescence 
units. Significance of difference between the subject groups was tested by AN-
COVA, adjusted for high sensitivity CRP levels.
Results. Basal phosphorylation level of p38 in axSpA monocytes was signifi-
cantly higher than that in healthy subjects’ monocytes (p=0.009). The difference 
between RA and healthy subjects was not statistically significant. The respective 
phosphorylation levels of ERK1/2 and JNK did not differ significantly between 
the 3 subject groups. After stimulation, monocyte p38 phosphorylation levels in 
axSpA, RA and healthy subjects were comparable. 
Conclusion. Enhanced monocyte baseline phosphorylation of p38 suggests in 
vivo preactivation of monocytes in patients at the time of diagnosis of axSpA. 
Reference
  1. SAHLBERG AS et al.: Arthritis Rheum 2007; 56: 2652.
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ASSOCIATION OF IgA ANTIBODIES AGAINST CD74 WITH PRO-
DUCTION OF IL17A BUT NOT OF TNFα IN PATIENTS WITH 
ACTIVE AXIAL SPONDYLOARTHRITIS
Baraliakos X., Kniesch K., Baerlecken N., Braun J., Witte T.
Rheumazentrum Ruhrgebiet Herne, Medical University Hannover, Germany
Background. Axial spondyloarthritis (axSpA) is strongly associated with HLA-
B27. Recently, IgA antibodies (Abs) against CD74 (IgA-anti-CD74) and T-cells 
carrying CD-74-specific T-cell receptors were also found to be associated with 
axSpA, especially in patients with ankylosing spondylitis, the radiographic form 
of axSpA. Tumor necrosis alpha (TNF-α) inhibitors and IL-17 antagonists are 
efficacious in patients with active axSpA.
Objective. To investigate whether IgA-anti-CD74 Abs are associated with pro-
inflammatory cytokines in the sera of patients with HLA-B27-positive and -nega-
tive patients with active axSpA. 
Methods. Blood samples of 62 HLA-B27-positive and 58 HLA-B27-negative pa-
tients with axSpA (44% AS) prior to starting a biologic therapy were collected. A 
cytometric bead-array (CBA Flex Set) was used to measure serum levels of inter-
leukin (IL)-17A, IL-6, IL-1α, TNF-α, and interferon (INF)-γ. IgA-anti-CD74 Abs 
were measured by ELISA, using the predefined cut-off of 15 U/ml. Their mean 
concentrations were compared between groups using T-tests. The patients who were 
positive or negative for IgA-anti-CD74 Abs were compared using chi-square test.
Results. IgA-anti-CD74 Abs were detected in 54/120 axSpA patients (45%). 
There were no differences in the baseline demographics and clinical assessments 
in patients with or without IgA-anti-CD74 Abs. The presence of IgA-anti-CD74 
Abs was associated with serum concentrations of IL-17A (p=0.01), irrespective 
of the presence of HLA-B27, CRP and IL-6 (both p<0.05, but not TNF-α (p=0.2). 
Conclusion. In a cross-sectional study, the presence of IgA Abs against CD74 
was associated with serum levels of pro-inflammatory biomarkers such as CRP 
(and IL-6) and IL-17 but not TNFα irrespective of HLAB27 status. Longitudinal 
prospective studies are needed to show that the measurement of IgA anti-CD74 
Abs and/or serum cytokines can help to guide treatment decisions.
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COMPARISON OF RETENTION RATES BETWEEN TUMOR 
NECROSIS FACTOR-α INHIBITORS IN ANKYLOSING SPON-
DYLITIS PATIENTS: DATA FROM THE KOREAN COLLEGE OF 
RHEUMATOLOGY BIOLOGICS REGISTRY
Kim H.A.1, Oh S.2, Park Y.B.3, Shin K.2
1Division of Rheumatology, Ajou University Hospital, Suwon; 2Division of 
Rheumatology, Seoul Metropolitan Government-Seoul National University Bo-
ramae Medical Center, Seoul; 3Division of Rheumatology, Yonsei University 
College of Medicine, Severance Hospital, Seoul, South Korea
Background. Drug persistence of tumor necrosis factor-α inhibitors (TNFi) 
tends to be higher in patients with ankylosing spondylitis (AS) than rheumatoid 
arthritis but there are few studies of Asian AS patients in the literature. 
Objectives. To investigate drug retention rates of various TNFi used in Korean 
AS patients.
Methods. Subjects were AS patients enrolled in the Korean College of Rheuma-
tology Biologics registry (KOBIO, Dec 2012 ~). All approved and commonly 
prescribed TNFi were included in the analysis. Discontinuation was defined as 
switching or stopping the biologic agent. Kaplan-Meier curve and Cox propor-
tional hazard model were used for further analysis. Reason of TNFi discontinua-
tion was also assessed. Univariate and multivariate analyses were used to identify 
possible predictors of discontinuation. 
Results. Data of total of 1005 AS patients were analyzed (median follow-up 
period: 14 months). The mean age of patients was 40.7, and 77.4% were males. 
The mean disease duration was 7.1 years, HLA-B27 were positive in 82.4%, and 
33.2% of patients had lesion(s) of syndesmophytes. Seventy-six percent of pa-
tients were first-time biologic users. Discontinuation of TNFi occurred in 24.2% 
(switching in 9.6%) of patients during follow-up. The drug survival function 
estimate showed that the adjusted hazard ratio (HR) of golimumab (compared 
with etancercept) was 0.441 (95% CI 0.277–0.703, p<0.001). The reason of dis-
continuation was inefficacy (32.6%), adverse events (23.6%), clinical improve-
ment (11.2%), and others (32.6%). A multivariate analysis indicated predictors of 
discontinuation to be shorter disease duration (HR 0.973, p=0.044), and negative 
HLA-B27 (HR 1.623, p=0.0093).
Conclusion. Our study demonstrates that few AS patients switched to other TNFi 
during their course of treatment. The drug retention rate of golimumab was high-
er compared with other agents prescribed in Korean AS patients.
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HIGH SERUM ALLOGRAFT INFLAMMATORY FACTOR 1 IS 
ASSOCIATED WITH POOR RESPONSE TO TNFα INHIBITORS IN 
ANKYLOSING SPONDYLITIS
Lee E.E.1, Lee J.S.1, Park J.W.1, Song J.2, Choi J.Y.1, Song Y.W.1, Lee E.Y.1
1Division of Rheumatology, Dept. of Internal Medicine, Seoul National Univer-
sity College of Medicine, Seoul; 2Dept. of Molecular Medicine and Biophar-
maceutical Sciences, Graduate School of Convergence Science and Technology, 
Seoul National University, Seoul, Korea
Objectives. Anti-tumor necrosis factor-alpha (TNF-α) can improve the symp-
toms and signs of ankylosing spondylitis (AS); however, not all the patients show 
sufficient response to anti-TNF-α treatment. Therefore, the aim of this study was 
to identify candidate serum markers that could be used to predict the clinical 
response to TNF-α inhibitors in AS.
Materials and Methods. Baseline gene expression differences were screened by 
two pathway-focused gene assays of peripheral blood samples from six AS pa-
tients (three responders and three non-responders) before anti-TNF-α treatment, 
and selected candidates were confirmed by qRT-PCR in 18 patients (11 responders 
and 7 non-responders). The concentration of corresponding serum protein was 
compared in 69 responders and 48 non-responders. A poor response to TNF-α 
inhibitors was defined as less than a 50% improvement in the Bath ankylosing 
spondylitis disease activity index (BASDAI50) at week 14 from that at baseline. 
Results. Nine candidate genes were selected and validated by qRT-PCR. Among 
these, the expression of allograft inflammatory factor 1 (AIF1) was 3.52-fold 
higher in non-responders than responders (p=0.032), and the baseline serum 
AIF1 level was significantly higher in BASDAI50 non-responders (32.8 [Inter-
quartile range 20.6–67.3] pg/ml in responders and 54.2 [28.9–91.0] pg/ml in non-
responders, p=0.033). An AIF1 level of 63.5 pg/ml or more was associated with 
a higher risk for BASDAI >5.0 at week 14 after anti-TNF-α treatment (adjusted 
odds ratio 6.953, p=0.002). 
Conclusion. Serum AIF1 level could be used as a novel serum marker for pre-
dicting responses to TNFα inhibitors in AS. 
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OVEREXPRESSION OF MACROPHAGE MIGRATION INHIBI-
TORY FACTOR IN PATIENTS WITH ANKYLOSING SPONDYLI-
TIS AND ITS RELATION TO SEX, INFLAMMATION AND TREAT-
MENT
Kumar A., Do L., Hellman U., Forsblad-d’Elia H.
Dept. of Public Health and Clinical Medicine/Rheumatology, Umeå University, 
Umeå, Sweden
Background. Macrophage migration inhibitory factor (MIF) is a multipotent 
cytokine involved in the regulation of immune and inflammatory responses. The 
present study aimed to investigate the MIF expression in patients with ankylos-
ing spondylitis (AS) compared with controls and to examine associations be-
tween MIF and demographic and inflammation related factors in AS overall and 
stratified by sex.
Methods. MIF in plasma was measured in a cohort of patients with AS from 
Northern Sweden (n= 155) and age- & sex-matched controls (n=151) using Hu-
man MIF Quantikine ELISA Kit (R&D). The patients were assessed with labo-
ratory markers of inflammation, ASDAS-CRP, BASDAI, BASMI and BASFI. 
Comparisons were analyzed by T-test and associations by bivariate Pearson cor-
relations.
Results. The expression of MIF was significantly augmented in the AS patients 
(Mean 65.1 ng/ml±2.0 SEM) compared with the controls (Mean 42.0 ng/ml±2.1 
SEM) (p<0.001), the difference was also found in sex stratified analyses. MIF 
had a weak negative correlation with age in AS (-0.144, p=0.07) but not in con-
trols (-0.037, p=0.66). Stratified by sex, the inverse correlation with age was 
shown in the AS men only (-0.28, p=0.004). When analyzing MIF in different 
age-groups it was revealed that MIF was significantly higher in the men ≤50 
years compared to the women with AS ≤50 years. Moreover, MIF was positively 
correlated with inflammation related variables; swollen joint count, ESR, hsCRP, 
thrombocytes and leukocytes. The expression of MIF was significantly increased 
in AS patients on cDMARDs with or without a biological drug, while NSAIDs, 
glucocorticosteriods or single therapy with a biological drug did not influence 
the MIF levels.
Conclusions. Our results suggest that MIF is overexpressed in AS patients. MIF 
was associated with inflammation and treatment and, in addition, sex seemed to 
have an impact on MIF plasma levels in the AS patients. MIF might be a potential 
biomarker for the development of new treatment-strategies in AS.
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PROGNOSTIC MARKERS IN AXIAL SPONDYLOARTHRITIS 
(PROMISE) – ALPHA 1 ANTITRYPSIN MAY IDENTIFY axSpA 
PATIENTS AT RISK OF UVEITIS
Reilly E.1,2, McGrogan A.2, Sengupta R.1
1Royal National Hospital for Rheumatic Diseases, Bath; 2Dept. of Pharmacy and 
Pharmacology, University of Bath, UK
Introduction. There has been increasing interest in recent years in the identifica-
tion of biomarkers in axSpA to describe diagnostic subgroups and to help identi-
fy patients at increased risk of associated disease manifestations, such as uveitis. 
Aim. In this cross-sectional study, a broad panel of serum biomarkers were eval-
uated, from a large mixed cohort of patients with Ankylosing Spondylitis (AS), 
non radiographic axial spondyloarthritis (nr-axSpA) and mechanical back pain 
(MBP) to identify biomarkers of interest for extra articular manifestations of 
axSpA in these patient groups. 
Methods. A panel of 46 serum biomarkers were analysed by Myriad RBM using 
multiplexed immunoassays by Multi-Analyte Panels (Figure 1), in a cohort of 
patients from a tertiary referral centre, consented through the Bath Spondyloar-
thritis BioBank. AS patients met mNY criteria, and nr-axSpA patients satisfied 
ASAS classification. 
Results. Data for extra articular manifestations (EAM) of SpA was available for 
276 patients. Of these, 162 (58.7%) had a history of at least one EAM. 80.2% of 
these had AS, 10.4% nr-axSpA, 9.3% MBP. For patients with and without EAMs, 
mean age 49.2 vs 44.3years, BASDAI 4.0 vs 4.4, ASDAS 2.6 vs 2.7, male 58.3 
vs 41.7%, family history SpA 61.8 vs 38.2%, HLA B27 positive 64.5 vs 35.5%. 
Uveitis was the commonest EAM (35.1%), enthesitis 19.2%, psoriasis 16.7%, 
inflammatory bowel disease 8.7%, dactylitis 2.9%, reactive arthritis 0.4%; 89/97 
patients with uveitis had AS. Using logistic regression, an odds ratio of 1.51 
(95% CI 1.22, 1.87) was found for alpha 1 antitrypsin in patients with uveitis 
compared to those without (Figure 2). 
Discussion. From this analysis, alpha 1 anti trypsin has been identified as a po-
tential biomarker for patients with uveitis. Further work to validate this finding in 
alternative SpA population is recommended. In addition, longitudinal measure-
ment of alpha 1 antitrypsin in an SpA cohort with active or quiescent inflamma-
tory eye disease may offer further insights.
Fig. 1. Candidate biomarker panel evaluated using multiplexed immunoassays
Fig. 2. Box plot for alpha 1 anti trypsin and the presence or absence of previous uvei-
tis, across diagnostic groups.
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COMPARING DISEASE STATUS, SYMPTOMOLOGY, AND CLIN-
ICAL CHARACTERISTICS OF NON-RADIOGRAPHIC AXIAL 
SPONDYLOARTHRITIS AND ANKYLOSING SPONDYLITIS 
PATIENTS IN THE UNITED STATES 
Deodhar A.1, Hunter T.2, Sandoval D.2, Lobosco S.3, Moon R.3, Miligan G.3
1Oregon Health and Science University, Portland; 2Eli Lilly and Company, Indian-
apolis, USA; 3Adelphi Real World, Bollington, UK
Aim. To better understand the symptoms, clinical characteristics and disease sta-
tus of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they 
compare to ankylosing spondylitis (AS) patients in the United States.
Methods. Data from the 2015 SpA Disease Specific Programme, a cross-section-
al survey of patients and rheumatologists conducted in the United States were 
analyzed. Rheumatologists (n=92) completed forms containing patient demo-
graphics, clinical results and symptomology. Symptoms, disease activity, and 
disease status (defined as improving, stable, unstable, and deteriorating) based 
on rheumatologists’ global assessment of ankylosing spondylitis and non-radio-
graphic axial spondyloarthritis patients were compared. 
Results. Of the 980 axSpA patients included in this study, 498 patients had AS, 
and 482 had nr-axSpA as diagnosed by rheumatologists. A higher proportion of 
AS patients were male (77% vs. 56%), older (Mean Age: 46.1 vs. 42.6), had a 
higher mean BMI and were employed when compared to nr-axSpA patients. Nr-
axSpA patients’ current disease status were less likely to be stable (p=0.0259) 
in comparison to AS patients. Nr-axSpA patients were also less likely to be in 
remission (p=0.0027). AS patients had some axSpA features more common, such 
as sacroiliitis, spinal fusion, and loss of movement, however, nr-axSpA patients 
were more likely to have inflammatory back pain, and enthesitis. QoL absen-
teeism, presenteeism, work productivity, and activity impairment were similar 
between AS and nr-axSpA patients. 
Conclusions. In the US, nr-axSpA and AS patients share many similar clinical 
features with few differences. In spite of these similarities, nr-axSpA patients 
show lower rates of stability and are less likely to be in remission. These findings 
suggest that nr-axSpA is as burdensome as AS.
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CAN SMOKING CAUSE PARADOXICAL FINDINGS IN PATIENTS 
WITH PSORIATIC ARTHRITIS?
Kiliç E.1, Kiliç G.2, Nas K.3, Dağli A.Z.4, Tekeoğlu I.3, Kamanli A.3
1Afyonkarahisar State Hospital, Rheumatology Clinic, Afyonkarahisar; 2Dept. 
of Physical Medicine and Rehabilitation, Afyon Kocatepe University Faculty 
of Medicine, Afyonkarahisar; 3Dept. of Physical Medicine and Rehabilitation, 
Division of Rheumatology and Immunology, Sakarya University Faculty of 
Medicine, Sakarya; 4Bitlis State Hospital, Physical Medicine and Rehabilitation 
Clinic, Bitlis, Turkey
Introduction and Aim. It has been suggested that smoking, one of the environ-
mental risk factors in various rheumatic diseases, may have an important role in 
disease pathogenesis as well as adverse effects on disease progression, quality 
of life and drug response. However, in a recent study a paradoxical relation-
ship between the development of psoriatic arthritis (PsA) and smoking has been 
reported in patients with psoriasis. In current study, we aimed to investigate the 
effects of smoking on disease activity, functional status, quality of life, psycho-
genic measures and fatigue in patients with PsA.
Materials and Methods. Patients with PsA over the age of 18 who met the CAS-
PAR classification criteria were enrolled consequently in this cross-sectional ob-
servational study. The short form 36 (SF-36), Nottingham Health Profile (NHP), 
(PsQoL); health assessment questionnaire (HAQ); hospital anxiety and depres-
sion (HAD) scale; fatigue severity scale (FSS) were used to assess the patients. 
Clinical and laboratory data were recorded. MDA, DAS28-CRP, DAPSA, CDAI, 
SDAI and PASI scores were used to assess disease activity. According to the 
smoking habits, patients grouped as; ever smoker or never smoker. Statistical 
analysis was performed using the SPSS package program. The results were given 
as mean ± SD and %. p<0.05 was considered statistically significant.
Results. A total of 133 PsA patients (33.8% male, 66.2% female) were included 
in the study. The mean disease duration is 10.7 years. 65 (48.9%) of the patients 
had never smoked, and 68 (51.1%) were ever smoked. The mean age of smok-
ers was 43.5±10.5 years, the mean age of the non-smokers was 47.6±11.1 years 
(p=0.031) (Table).
Table. Clinic and demographic features of patients with PsA.
 Never smoker (n= 65) Ever smoker (n=68) p-value
Age, year 47.6±11.1 43.5±10.5 0.031
Male/Female 17/48 28/40 0.067
Disease durations, year 11.4±11.0 9.9±9.2 0.404
BMI 30.4±6.4 27.9±4.8 0.012
Üveitis (n=127) 11(17.7) 3(4.6) 0.018
SDAI 32.6±35.1 23.7±18.7 0.130
CDAI 18.3±12.4 13.3±9.4 0.014
DAS 28 3.6±1.4 3.1±1.2 0.045
DAPSA 33.1±35.0 24.3±19.1 0.131
Tender joint count 5.3±6.1 3.2±4.0 0.022
Swollen joint count 3.2±4.9 1.7±2.9 0.038
VAS-pain 5.1±2.7 4.5±2.7 0.195
Patient global assessment 5.2±2.5 4.6±2.6 0.167
Physician global assessment 4.6±2.2 4.0±2.1 0.150
VAS- fatigue 5.8±2.8 4.8±2.7 0.053
Fatigue severity scale 3.4±1.2 3.4±1.2 0.881
Onset age os psoriatic skin lesion 29.3±15.5 29.6±14.0 0.925
BASDAI 3.7±2.6 3.3±2.4 0.388
BASMI 4.2±6.6 2.1±1.6 0.330
BASFI 4.0±2.8 3.3±2.7 0.220
NHP-pain 62.9±33.5 49.5±33.5 0.028
NHP- physical activity 41.1±25.4 34.8±24.6 0.163
NHP-fatigue 57.5±40.3 44.9±42.0 0.090
NHP-sleep 40.7±32.1 32.0±31.0 0.131
NHP-social isolation 16.8±25.7 11.1±19.2 0.167
NNH-emotional reaction 22.7±28.5 20.6±27.3 0.686
PsAQoL 4.2±4.8 2.6±3.1 0.031
HAD-Depression 6.3±4.3 6.0±3.6 0.757
HAD-Anxiety 7.0±4.7 6.6±3.9 0.635
SF36 Physical component score  37.9±14.1 40.5±17.7 0.471
SF36 Mental component score 47.7±13.7 47.0±16.0 0.834
PASI 4.6±9.1 5.3±5.2 0.676
HAQ 0.5±0.5 0.3±0.5 0.195
MDA 7de5 (+) n=60 1(3.7) 5(15.2) 0.219
Uveitis rates were statistically higher than those of non-smokers (p=0.018). The 
disease activity calculated with CDAI and DAS28 was statistically lower in 
smoker than those non-smokder patients (p<0.05). Disease activity calculated 
with DAPSA and SDAI was also high in non-smokers but not statistically sig-
nificant (p>0.05). NHP-pain and PsAQoL scores of health-related quality of life 
scales were lower in smoker than those of non-smokers (p<0.05). 
Conclusion. As paradox in patients with PsA smokers; low disease activity, de-
creased tender and swollen joints count, and decreased uveitis frequency were 
observed.
Although cigarette smoking is a paradoxical effect in our study, we think that 
it is important to cessation of smoking because of the high risk of comorbidity, 
especially metabolic disease in patients with PsA, in the long term. Further stud-
ies are needed to investigate the effect of smoking on disease activity and other 
clinical manifestations in patients with PsA.
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FATIGUE, HEALTH RELATED QUALITY OF LIFE AND PHYSI-
OLOGIC STATUS IN PATIENTS WITH PSORIATIC ARTHRITIS 
IN REMISSION OR LOW DISEASE ACTIVITY ACCORDING TO 
DIFFERENT OUTCOME MEASURES
Kilic G.1, Kilic E.2, Nas K.3, Kamanli A.3, Tekeoglu I.3
1Dept. Physical Medicine and Rehabilitation, Afyon Kocatepe University Faculty 
of Medicine, Afyonkarahisar; 2Afyonkarahisar State Hospital, Rheumatology 
Clinic, Afyonkarahisar; 3Dept. Physical Medicine and Rehabilitation, Division 
of Rheumatology and Immunology, Sakarya University Faculty of Medicine, 
Sakarya, Turkey
Aim. Psoriatic arthritis (PsA) is a complex systemic disease presented with ar-
ticular and extra-articular manifestations. In PsA, the main goal of treatment is to 
achieve clinical remission or alternatively low disease activity (LDA). PsA has 
adverse effects on health-related quality of life (HRQoL), fatigue and psycho-
logic status. The aim of this study is to examine fatigue, HRQoL and physiologic 
status in patients with PsA in remission or LDA according to different outcome 
measures. 
Materials and Methods. Adult patients with PsA who met the CASPAR cri-
teria were consecutively included in this cross-sectional study. The following 
variables were evaluated: tender joint count (TJC), swelling joint count (SJC), 
VAS-pain, PGA, PhGA, the presence of extra-articular manifestation, PASI, 
Health Assessment Questionnaire (HAQ), physical and mental component sum-
mary score of the SF-36, NHP, PsQoL, Hospital Anxiety and Depression Scale 
(HADS-A and HADS-D), FSS and CRP. In addition, disease activity was meas-
ured by using three different outcome measures including DAS28-CRP, MDA 
and DAPSA.
Table I. Demographic and clinic characteristics of patients.
  Median SD
Age 45.8 11.1
BMI 29.2 5.8
Symptom duration 10.5 10.1
VAS-pain 4.8 2.7
Patient’s global assessment 4.9 2.6
Physician’s global assessment 4.3 2.2
Tender joint count 4.3 5.2
Swelling joint count 2.4 4.1
DAS 28 3.3 1.3
DAPSA 28.2 27.7
BASDAI 3.5 2.5
NHP-pain 56.6 33.9
NHP-physical activity 37.9 24.9
NHP-fatigue 51.3 41.2
NHP-sleep disturbance 36.1 31.6
NHP- social isolation 13.8 22.7
NHP- emotional reaction 21.4 27.7
PsAQoL 3.4 4.1
HADS-Depression 6.1 4.0
HADS-Anxiety 6.7 4.3
SF36 physical component score 39.3 15.9
SF36 mental component score 47.7 14.9
VAS fatigue 5.3 2.8
FSS 3.4 1.2
PASI 5.1 7.1
HAQ  0.4 0.5
Results. A total of 136 patients with PsA (mean age 45.8 years, 46 male/ 90 
female) were analyzed. Only 6(9.7%) patients with PsA achieved MDA. 
30(31.9%) patients had remission, 16(17%) patients had LDA, 39(41.5%) pa-
tients had moderate disease activity (MoDA) and 9 (9.6%) patients had high dis-
ease activity (HDA) status defined as DAS28-CRP. On the other hand, 4(4.3%) 
patients achieved remission, 23(24.7%) patients achieved LDA, 33(35.5%) pa-
tients achieved MoDA and 33(35.5%) patients achieved HAD status according to 
DAPSA. All subscores of NHP except fatigue and sleep disturbance, PsQoL and 
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HAQ scores were significantly lower in patients with PsA who met MDA than 
those who did not achieve MDA (p<0.05). The pain, physical activity and fa-
tigue subscores of NSP and HAQ scores were significantly lower in patients with 
PsA in remission or LDA as defined DAS28-CRP (p<0.05). But, no statistically 
significant difference was observed between patient’s groups with or without in 
DAS28-CRP remission in the term of the sleep disturbance, emotional reaction, 
social isolation subscores of NSP, PsAQoL, SF36-mental component, FSS, PASI, 
HAQ, HADS-Depression and HADS-Anxiety scores (p>0.05). There was no 
statistically significant difference with respect to the fatigue, sleep disturbance, 
emotional reaction, social isolation subscores of NHP, PsAQoL, SF36 mental 
component, FSS, PASI, HAQ, HADS-D and HADS-A scores in patients with 
and without DAPSA remission, although pain and physical activity subscores 
of NSH were significantly lower in DAPSA remission group (p<0.05). %55.2 
of patients in DAS28-CRP remission had high risk for depression and %20.7 for 
anxiety. 75% of patients in DAPSA remission had high risk for depression and 
25% for anxiety.
Conclusions. Due to facts that disease course and clinical manifestation of 
patients with PsA are highly heterogen, it is very difficult determine all aspect 
of disease by using current outcome measures. In patients with PsA despite 
achieving remission or LDA, some levels of fatigue, poor HRQoL and the risk 
of depression and anxiety can persist. These residue symptoms may result in a 
negative effect on patient daily activity, productivity and also an ongoing disease 
burden. 
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FECAL CALPROTECTIN, A USEFUL BIOMARKER OF MICRO-
SCOPIC BOWEL INFLAMMATION IN PATIENTS WITH SPONDY-
LOARTHRITIS
Campos J.F., Resende G.G., Lage J.A., Carvalho, S.C., Barbosa A.J.A., Ferrari 
M.L.A. 
Hospital da Clínicas da UFMG, Dept. of Gastroenterology and Rheumatology, 
Belo Horizonte, Brazil
Introduction. Microscopic bowel inflammation is present in up to 60% of pa-
tients with spondyloarthritis and it may be associated with more severe disease 
and higher risk of developing inflammatory bowel disease. It was conducted 
a study to determine the values of fecal calprotectin that are related to micro-
scopic bowel inflammation in patients with spondyloarthritis, treated or not with 
NSAIDS. 
Materials and Methods. Fecal calprotectin measurement and ileocolonoscopy 
with multiple biopsies were performed in 61 patients with SpA (48 with An-
kylosing Spondylitis and 13 with Psoriatic Arthritis) to assess the presence of 
microscopic and endoscopic signs of bowel inflammation. 
Results. A total of 34 (57%) patients presented with microscopic bowel inflam-
mation and 13 (21%) presented with enanthema and/or ulcer at the colonoscopy. 
Fecal calprotectin levels were significantly higher in patients who presented with 
microscopic inflammation compared to those without inflammatory findings in 
the biopsies (p=0.0002) and only marginally higher in patients with endoscopic 
signs of inflammation (enanthema and ulcers) compared to those without these 
lesions in the ileocolonoscopy (p=0.07). A cutoff of 96 mg/kg of fecal calprotec-
tin was able to predict histological bowel inflammation with 79% sensitivity and 
67% specificity. There was no significant difference in fecal calprotectin levels 
between patients treated or not with NSAIDS.
Conclusions. Patients with spondyloarthritis are at increased risk of develop-
ing inflammatory bowel disease. The higher prevalence of microscopic bowel 
inflammation in these group of patients, treated or not with NSAIDS, may be 
an early sign of this increased risk. The measurement of fecal calprotectin in 
patients with spondyloarthritis, without known gastrointestinal disease, may be 
useful in the stratification of those with higher risk of presenting with micro-
scopic bowel inflammation and could be helpful to the judicious indication of 
colonoscopy. The results of this study support the use of fecal calprotectin as 
a valuable biomarker of early intestinal inflammation in patients with spondy-
loarthritis.
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UNDIFFERENTIATED SPONDYLOARTHRITIS IN BRAZILIAN 
PATIENTS – PREDICTORS OF PERSISTENT DISEASE COM-
PARED TO REMISSION AFTER EIGHT YEARS OF FOLLOW-UP
da Cruz Lage R., Bomtempo C.A.S., Kakehasi A.M., Carvalho M.A.P., Resende G.G.
Unit of Rheumatology, Dept. of Locomotor System, Federal University of Minas 
Gerais, Belo Horizonte, Brazil
Introduction/Aim. In previous published data, we have shown that in predomi-
nately female African Brazilian patients with undifferentiated spondyloarthritis 
(USpA), the progression rate to ankylosing spondylitis (AS) was 25% after eight 
years of follow-up. Buttock pain and low grade radiographic sacroiliitis, but not 
HLA-B27, were statistically associated with progression to AS, as defined by the 
modified New York Criteria (1). In the present analysis we focus on the charac-
teristics associated with persistent disease compared to remission in Brazilian 
patients with USpA during an eight-year follow-up period. 
Materials and Methods. Patients fulfilling the European Spondyloarthritis 
Study Group Classification Criteria were enrolled. Remission was defined as the 
absence of symptoms without medications for at least one year.
Results. Forty patients were seen at baseline, and 36 patients participated in the 
follow-up study. The Assessment of SpA international Society (ASAS) classifica-
tion criteria for axial SpA were fulfilled by 77% of patients and the ASAS criteria 
for peripheral SpA were fulfilled by 59%. Twenty-three (58%) were female, and 
there were 24 (60%) African Brazilians enrolled. HLA-B27 was positive in 18 
(45%) patients. At disease onset, the first presenting symptoms were pure periph-
eral manifestations in 26 (72.2%) patients. After the study period, mixed disease 
(axial + peripheral) predominated occurring in 25 (69.4%) patients. After eight 
years, six (16.7%) of 36 patients entered remission and 30 (83.3%) patients had 
persistent disease, nine (25%) of them were classified as having AS. HLA-B27 
positivity (56.7% vs 0%, p=0.02) and use of oral corticosteroid at baseline (43.3% 
vs 0%, p=0.068, “trend”) were associated to persistent SpA compared to remission. 
Conclusion. Thus, in this predominately female African Brazilian patients with 
USpA, the presence of HLA-B27 was a predictor of persistent disease compared 
to remission, besides it was not associated with the progression to AS.
Reference
  1. da CRUZ LAGE R, de SOUZA BOMTEMPO CA, KAKEHASI AM et al.: Undiffer-
entiated spondyloarthritis in a heterogeneous Brazilian population: an eight-year 
follow-up study. Rheumatol Int 2014; 34(7): 1019-23.
P49
SERUM miR-214 AS A NOVEL NONINVASIVE BIOMARKER FOR 
ANKYLOSING SPONDYLITIS
Jin S.H., Kook H., Jin H.M., Cho Y.N., Lee S.S., Park Y.W., Kim T.J.
Dept. of Rheumatology, Research Institute of Medical Sciences, Chonnam 
National University Medical School and Hospital, Gwangju, South Korea
Introduction. Recently, the discovery of miRNAs (miR) has paved a new way 
for the diagnosis of cancers and other diseases, However, the global serum miR 
pattern in AS patients has rarely been determined. So, the aim of this study was 
to find AS specific miR in the sera of patients with AS.
Materials and Methods. Total RNA was isolated from whole sera in AS pa-
tients, in patients with RA and in healthy controls (HC) using miRNA microarray. 
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Subsequently, differential expression of miRs was validated by Real Time PCR. 
To verify the microarray results, we assayed for candidate circulating miRs using 
qPCR in samples from the patients with AS (n=65), RA (n=25), and healthy con-
trols (n=31). All clinical values were also evaluated at the time of RNA isolation. 
Results. A total of 887 miRNAs were screened. After normalization of the raw 
data, we noted that the expression copy number of serum miR-214 were signifi-
cantly lower than HC and RA. Correlation studies showed that copy numbers 
of miR-214 was significantly associated with ASDAS_CRP (r=0.299, p=0.02). 
However, all others variables were no statistical significance [gender (p=0.286), 
peripheral arthritis (p=0.634), enthesitis (p=0.464), dactylitis (p=0.750), psoria-
sis (p=0.552), inflammatory bowel disease (p=0.369), family history (p=0.235), 
HLA-B27 presence (p=0.473), NSAIDs use for last 3month (p=0.448), use of 
TNF-blocker (p=0.505). 
Conclusion. miR-214 may serve as noninvasive biomarkers for diagnosis of AS. 
In addition, the expression level of miR-214 was associated with the disease ac-
tivity.
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DO N-3 POLYUNSATURATED FATTY ACIDS AFFECT ECM 
REMODELING IN PSORIATIC ARTHRITIS?
Sardar S.1, Kristensen S.2, Siebuhr A.S.1, Christensen J.H.3, Karsdal M.A.1, 
Schmidt E.B.4, Schlemmer A.2, Bay-Jensen A.C.1
1Dept. of Rheumatology, Nordic Bioscience A/S, Copenhagen; 2Dept. of Rheu-
matology, Aalborg University Hospital, Aalborg; 3Dept. of Nephrology, Aalborg 
University Hospital, Aalborg; 4Dept. of Cardiology, Aalborg University Hospital, 
Aalborg, Denmark
 
Introduction. Psoriatic Arthritis (PsA), a chronic immune-mediated inflammato-
ry disease, is characterized by involvement of both axial and peripheral skeleton 
as well as potential skin and nail disease. The inflammatory milieu in PsA leads 
to accelerated tissue remodeling and the release of extracellular matrix (ECM) 
metabolites into circulation. These can be measured in serum as biomarkers of 
tissue remodeling and may give mechanistic insight to effect of different inter-
ventions at the tissue level. This study aimed to investigate if n-3 polyunsaturated 
fatty acids (PUFA) have a beneficial effect on altered tissue remodeling in PsA. 
Materials and Methods. The participating PsA patients were randomized into 
two groups receiving a daily supplement of either 3g PUFA or 3g olive oil (pla-
cebo) for 24 weeks. Tissue metabolites were measured in baseline and 24-weeks 
sera (n=276) by ECM specific ELISAs: C2M (type II collagen degradation), 
C3M (type III collagen degradation), C4M2 (type IV collagen degradation), 
PINP (type I collagen formation), P4NP7S (type IV collagen formation), and 
CRPM (MMP degraded metabolite of CRP). Comparison between groups were 
done by ANCOVA adjusting for age, gender, BMI and disease duration.
Results. Supplementation for 24 weeks led to significant reductions in tender 
joint count, DAS-28 CRP, LEI, SPARCC and PASI in the n-3 PUFA group, but 
these changes were not significantly different compared to the placebo group. 
Furthermore, we found that % changes in ECM biomarkers were positively cor-
related to the clinical outcomes in PUFA treated group. % changes in C2M (rho 
0.242; p=0.048) and P4NP7S (rho 0.246; p=0.031) were correlated to change 
in DAS-28 while PINP (rho 0.266; p=0.031) correlated to change in LEI score. 
Conclusions. Chronic inflammation underlying PsA pathology results in an in-
creased amount of tissue remodeling. n-3 PUFA moderately improves clinical 
outcome in PsA patients possibly by modulating ECM remodeling, as depicted 
by serological biomarkers.
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IMPACT OF TNF INHIBITION ON WORK OUTCOMES, IN AXIAL 
SPONDYLOARTHRITIS
Shim J.1, Jones G.T.1, Pathan E.J.2, Macfarlane G.J.1
1Epidemiology Group, University of Aberdeen, Aberdeen, UK; 2Dept. of Rheu-
matology, Toronto Western Hospital, Toronto, Canada
Introduction/Aim. The ability to participate in work is important from an eco-
nomic standpoint, and for social/psychological health. Although TNF inhibition 
(TNFi) improves disease activity in axial spondyloarthritis (AxSpA), evidence is 
equivocal on whether it improves work outcomes. The aim of the current study 
was to quantify, among patients with AxSpA, the impact of TNFi on work out-
comes.
Materials and Methods. The British Society for Rheumatology Biologics Reg-
ister for Ankylosing Spondylitis (BSRBR-AS) recruits patients with AxSpA, na-
ïve to biologic therapy, across the UK. Work outcomes (Work Productivity and 
Activity Impairment index) 1yr after recruitment were compared between those 
commencing TNFi at the time of recruitment and those not. Propensity score 
matching (incorporating age, gender, BASDAI, BASFI, BAS-G, and smoking) 
was used to adjust for differences between the treatment groups. Results were 
then pooled in a meta-analysis, with data from other studies measuring similar 
outcomes identified from a systematic review.
Results. 465 patients were eligible for this analysis. The 27% commencing TNFi 
were younger (47 vs 54yrs), more likely to be smokers (22% vs 12%) with great-
er disease activity (mean BASDAI 6 vs 4) and poorer function (mean BASFI 6 
vs 4) and, at recruitment, reported poorer work outcomes. After adjustment for 
these differences, patients commencing TNFi demonstrated, at 1yr, significantly 
greater improvements in presenteeism (-14.3%; 95%CI -24.7%,-3.9%) and over-
all activity impairment (-13.1%; -21.9%,-4.3%). Greater improvements were 
detected in absenteeism and work impairment although were not statistically 
significant. In the meta-analysis of four studies, TNFi was associated with sig-
nificantly greater improvements in presenteeism (mean difference -0.23; 95%CI 
0.37,-0.09), work impairment (-0.22; -0.37,-0.08), and overall activity impair-
ment (0.28, 0.43,-0.14).
Discussion/Conclusion. Incorporating new data from the BSRBR-AS, this is 
the first meta-analysis to quantify the effect of TNFi on work outcomes in Ax-
SpA and demonstrates that TNFi yields improvements in work productivity and 
activity impairment. Future work should determine whether this translates into 
improved long-term work disability in this group. 
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PATIENTS AWARENESS OF THE DISEASE TREATMENT, DISEASE 
ACTIVITY AND SPINAL MOBILITY MONITORING BEFORE AND 
AFTER EDUCATIONAL SCHOOLS FOR RHEUMATOLOGISTS 
AND THE PATIENTS WITH ANKYLOSING SPONDYLITIS
Lapshina S.A.1, Dubinina T.V.2, Gaydukova I.Z.3, Sitalo A.V.4, Badokin V.V.5, 
Bochkova A.G.6, Bugrova O.V.7, Godzenko A.A.5, Dubikov A.I.8, Ivanova O.N.9, 
Korotaeva T.V.2, Nesmeyanova O.B.10, Otteva E.N.11, Nikishina I.P.2, Raskina 
T.A.12, Rebrov A.P.13, Rumyantseva O.A.2, Smirnov A.V.2, Erdes Sh.F.2
1Kazan State Medical University, Ministry of Health of Russia, Kazan; 2V.A. Na-
sonova Research Institute of Rheumatology, Moscow; 3Mechnikov North-West-
ern Medical University, Ministry of Health of Russia, Saint Petersburg; 4Mu-
tual Aid Society of Bechterew’s Disease, Moscow; 5Russian Medical Academy 
of Continuing Professional Education, Ministry of Health of Russia, Moscow; 
6Agat Medical Center, Egoryevsk, Moscow Region; 7Orenburg State Medical 
University, Ministry of Health of Russia, Orenburg; 8SANAS Medical Center, 
Vladivostok; 9Voronezh Regional Clinical Hospital One, Voronezh; 10Chely-
abinsk Regional Clinical Hospital, Chelyabinsk; 11Institute for Postgraduate 
Training of Health Professionals, Ministry of Health of the Khabarovsk Territo-
ry, Khabarovsk; 12Kemerovo State Medical Academy, Kemerovo; 13Razumovsky 
Saratov State Medical University, Ministry of Health of Russia, Saratov, Russia
Awareness of patients about the nature of their disease is the key to successful 
treatment of ankylosing spondylitis (AS).
Purposes. To compare the number of patients, informed of the main indexes of 
AS monitoring and in goals of the treatment before and after schools for the pa-
tients, and to get information about frequency of monitoring of AS activity and pa-
tients’ spinal mobility in real practice before and after schools for the physicians.
Methods. In 2017, members of Russian Spondyloarthritis Assessment Group and 
Mutual Aid Society of Bechterew’s Disease performed 11 educational schools for 
patients with AS in different regions of Russia and 12 educational schools for the 
physicians in the same regions. Before and 8±4 month after the school patients, 
participated in the schools, were asked to answer on several questions about AS 
activities and patients’ functional status monitoring and their awareness in it.
Results. 510 patients with AS and 302 physicians participated in schools in 
2017. 320 patients completed the questionnaire twice (in 2017 and 2018). In 
2017 regular monitoring of AS activity had 36.1% of the patients, and 35.1% in 
2018 (p≥0.05).
In 2017, 21.3% of respondents did not know what the ASDAS index is, and in 
2018 only 11.2% of patients were uninformed about ASDAS (p=0.494). In case 
of patients’ worsening ASDAS was calculated in 24.2% of responders in 2017 
and in 49.9% in 2018 (p=0.00). The physician never defined the ASDAS index at 
19.4% of patients in 2017 and 13.3% - in 2018 (p≥0.05).
In 2017 physicians monitored the BASMI 1 and more times per year in 47.2% 
of responders and in 50.9% of AS patients in 2018. In 2017 23.1% of patients 
did not know what the BASMI index is, in 2018 11.9% of respondents were 
uninformed about BASMI.
As a main reason for taking of NSAIDs 72% of respondents noted pain relief, and 
19.6% - decrease of the structural progression of the disease.
100% of patients noted that they constantly receive information from the site of 
the Mutual Aid Society of Bechterew’s Disease.
Conclusions. 4/5 of the patients with ankylosing spondylitis in Russian Federa-
tion were well informed about ankylosing spondylitis from the internet site at 
baseline. Educational schools for the patients and rheumatologists could improve 
quality of AS management and increase number of well- educated patients.
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SERUM GLUCOCORTICOID-INDUCIBLE KINASE-1(SGK-1) 
LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Keskin G.1, Inal A.2, Keskin D.3, Olmez U.1
1Medical School of Ankara University, Ankara, Dept. of Immunology; 2Medical 
School of Baskent University, Istanbul, Dept. of Immunology; 3Medical School 
of Kirikkale University, Dept. of FTR, Kirikkale, Turkey
Introduction/Aim. Ankylosing spondylitis (AS) is an inflammatory autoimmune 
disease. The etiology of AS is not well understood, but evidence supports an 
interplay of genetic, immunologic, and environmental factors. The immune sys-
tem composed of various cells, secreted-mediators and markers that manage and 
regulate the immune responses and inflammation. The inflammation has a criti-
cal role in the pathogenesis of AS. Glucocorticoid-inducible kinase-1(SGK1) is 
genomically upregulated by cell stress. Excessive SGK1 expression and activity 
participates in the pathophysiology of several disorders, such as inflammation, 
autoimmune disease, fibrosis, and tumor growth. In this study, we analyzed the 
possible role of serum SGK-1 levels in the pathogenesis of AS. 
Materials and Methods. 53 patients with AS (25 patients with axial involve-
ment; 9 female, 16 male, mean age; 37.3±4.1 years, mean disease duration 
10.2±2.9 years and 28 patients with peripheral joint involvement; 7 female, 21 
male, mean age; 34.9±3.1 years, mean disease duration; 5.8±2.6 years) and 23 
healthy controls (8 female, 15 male; mean age 33.7±2.6 years) were enrolled in 
this study. Serum SGK-1 levels were determined by ELISA.
Results. The mean serum SGK-1 levels were 74.8±13.5 pg/ml in healthy con-
trols, 285.9±38.1 pg/ml in patients with axial involvement and 428.1±35.9 pg/ml 
in patients with peripheral joint involvement. Serum SGK-1 levels were signifi-
cantly high in patients with AS compared to healthy controls (p<0.001). Serum 
SGK-1 levels were significantly high in patients with peripheral joint involve-
ment compared to in patients with axial involvement (p<0.01). 
Discussion. In this study, serum SGK-1 levels were significantly elevated in pa-
tients with AS.
Conclusions. Our results suggest that serum SGK-1 mediated immunological 
mechanisms play an important role in the pathogenesis of AS. 
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USE OF MRI AND BIOLOGICAL THERAPY IN INCIDENT 
PATIENTS DIAGNOSED AS ANKYLOSING SPONDYLITIS AND 
SPONDYLOARTHRITIS: DANISH NATIONWIDE COHORT STUDY 
2000-2013 
Nygaard A.1, Ljungdalh P.1, Iachina M.2, Schiottz-Christensen B.1
1Medical Research, Spine Centre, Southern Denmark; 2Centre of Clinical Epide-
miology, University Hospital Odense, Denmark
Introduction. Only a few studies have reported incidence of Ankylosing Spon-
dylitis (AS) and Spondyloarthritis (SpA), use of MRI and biological therapy dur-
ing the last decade.
Aim. To describe the incidence of AS and SpA in the Danish population from 
2000-2013 and rates of MRI and biological therapy.
Materials and Methods. All patients with the diagnosis of AS (ICD10:DM45) 
or SpA (ICD10:DM46) with a valid civil registration in Denmark in the time 
period from the January1st 2000 until December 31th 2013 were identified in the 
Danish National Patient Registry. Incident cases were identified and rates of MRI 
and biological therapy were calculated for each year. 
Results. During 2000 until 2013 3620 incident cases were identified (AS: 2116, 
SpA: 1504). AS are overrepresented by males (58–80%) and SpA by females 
(58%).
The incident cases of AS increases from 534 (0.52 rate per 100.000) to 828 cases 
(0.82) from 2005–2009. In 2010–2013 the incidence of AS has decreased to 754 
(0.94).
The incident cases of SpA increases from 220 (0.21) in 2009 to 430 (0.43) in 
2009 with an additional increase in incidence to 854 (1.06) in 2010–2013. 
MRI was used for diagnostic purpose in only 10-15% in 2002, but 95% in 2013.
In 2002 biological therapy was prescribed for only a few number of patients 
followed by an increased number primarily for MB later for SpA, ending at ap-
proximately 25% in 2013. 
Discussion and Conclusion. The incidence of AS stabilizes from 2005 which is 
in line with previous studies exploring the trends of AS incidence. The incidence 
of SpA has increased significantly during the time period 2000 to 2013, which is 
in accordance with introduction of MRI scans for diagnostic use and biological 
therapy for treatment.
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DISEASE ACTIVITY AND CHARACTERISTICS OF SpA-PATIENTS 
FULFILLING ESSG CRITERIA ONLY COMPARED TO SpA- 
PATIENTS FULFILLING ASAS CRITERIA
Hansen I.M.1, Bakland G.2
1Helgelandssykehuset Mo i Rana, Mo i Rana; 2University hospital of Northern 
Norway, Tromsø, Norway
Introduction/Aim. Spondyloarthritis (SpA) is a rheumatic disease with axial 
and peripheral inflammatory arthritis. The disease is associated with psoriasis, 
inflammatory bowel disease and uveitis. Most patients fulfill both ASAS-criteria 
and ESSG- criteria? Do the patients who fulfill only ESSG criteria differ in age, 
disease duration, disease activity, physical function or comorbidities?
Materials and Methods. Patients with spondyloarthritis in the district of Rana, 
Norway, were recruited from hospital registers, family doctors and by advertise-
ment in local newspaper. Clinical data, CRP and HLAB27 were collected; x-ray 
and MRI of SI-joint were performed if the patient had inflammatory backpain. 
273 patients had MRI of SI-joints. 390 patients fulfilling the ESSG-criteria were 
included. Their first-degree relatives were contacted and asked for symptoms 
of synovitis or inflammatory back pain by questionnaire. Symptomatic relatives 
were invited to clinical investigation and were included if they fulfilled the ES-
SG-criteria. 61 patients fulfilled ESSG-criteria only. 8 patients fulfilled ASAS-
criteria only, 329 fulfilled both criteria-set.
Results. Patients fulfilling only ESSG-criteria but not ASAS criteria for SpA do 
not differ from patients fulfilling ASAS-criteria in disease activity as measured 
by CRP or Asdas but they have a lower disease activity by BASDAI, Physical 
function as measured by BASFI is better and there is a trend for a better MHAQ 
but not significantly. They are significantly younger, and there is a trend towards 
shorter disease duration. The proportion of patients with IBD and acute uveitis is 
similar, but the proportion of patients with psoriasis is significantly lower.
Discussion. Patients fulfilling ESSG.criteria only are a minority among SpA-
patients. They are younger and it is possible that they have not developed the 
disease fully yet. Since they have similar disease-activity as patients fulfilling 
ASAS-criteria they should also be considered for treatment with biologicals.
Conclusions. More patients fulfill ESSG-criteria than ASAS-criteria. They have 
similar disease –activity, are younger and have better physical function.
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SERUM FIBROBLAST GROWTH FACTOR-23 LEVELS WERE 
HIGHER IN PATIENTS WITH AXIAL SPONDYLOARTRHRITIS 
AND MAY BE ASSOCIATED WITH DISEASE ACTIVITY
Gercik O.1, Coban E.1, Ozbek Iptec B.2, Avcioglu G.2, Solmaz D.1, Bayindir O.1, 
Kabadayi G.1, Kozaci D.2, Akar S.1
1Dept. Rheumatology, Katip Celebi University, Izmir; 2Dept. Medical Biochem-
istry, Yildirim Beyazit University, Ankara, Turkey
Introduction and Aim. Low levels of sclerostin may be associated with the de-
velopment of syndesmophyte in patients with ankylosing spondylitis (AS). Be-
side sclerostin another osteocyte factor is fibroblast growth factor-23 (FGF-23) 
which may also inhibit osteoblast differentiation and matrix mineralization. 
We aimed to evaluate serum FGF-23 and sclerostin levels in patients with axial 
spondyloarthritis (axSpA) and to compare with healthy control subjects. We also 
assessed relationship between the serum FGF-23, sclerostin levels and disease 
related variables in particular the presence of structural changes.
Materials and Methods. In total 109 axSpA patients according to ASAS clas-
sification criteria and age and sex matched 57 healthy control subjects were in-
cluded. Subjects with renal failure, significant comorbid conditions and under 
anti-TNF treatment were excluded. Serum levels of FGF-23 and sclerostin were 
measured using enzyme-linked immunosorbent assay kits. 
Results. There were 55 patients with non-radiographic axSpA and 54 patients 
with AS. Serum levels of FGF-23 levels were significantly higher in axSpA pa-
tients than healthy subjects. Although there was a trend towards a lower scle-
rostin levels in axSpA patients this difference did not show statistical significance 
(p=0.633). In axSpA patients serum FGF-23 levels were found to be correlated 
with erythrocyte sedimentation rate (ESR) (p=0.006, r=0.265), C-reactive pro-
tein (CRP) (p=0.017, r=0.229) and patients’ height (p=0.027, r=-0.221). There 
was no relationship between FGF-23 and mSASSS score or the presence of syn-
desmophyte. Subgroup analysis revealed that the duration of disease (p=0.005), 
ESR (p=0.007), CRP (p<0.001) and mSASSS (p=0.008) scores were significant-
ly higher in AS patients than nr-axSpA patients. However serum sclerostin levels 
were significantly higher in nr-axSpA patients (1464.4±728.1 vs 1150.8±754.3 
pg/mL and p=0.029). 
Conclusions. Our results suggested that serum FGF-23 is increased in axSpA 
patients. And also disease activity may contribute to an up-regulation in serum 
FGF-23 levels.
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EXPRESSION OF BIOMARKERS IN PSORIATIC ARTHRITIS 
Juneblad K., Rantapää Dahlqvist S., Alenius G.M.
Dept. of Public Health and Clinical Medicine/Rheumatology, University Hospital, 
Umeå, Sweden
Introduction and Aim. The lack of measurable laboratory parameters in Psori-
atic Arthritis (PsA)(1-3) addresses the needs for diagnostic and prognostic tools 
to set early diagnosis and assess disease severity. The aim of this study was to 
analyze if soluble biomarkers could discriminate between disease phenotypes in 
PsA or, between patients with PsA and healthy controls.
Methods and Material. In this cross-sectional study, 274 patients with estab-
lished disease and 30 healthy controls were included. 39 different serological 
biomarkers were investigated in relation to PsA disease activity, disease manifes-
tations and in comparison with controls. In addition to standard statistical meth-
ods, orthogonal partial least squares discriminant analysis (OPLS-DA) was used 
to investigate different phenotypes of PsA.
Results. Psoriatic arthritis activity was significantly associated with CRP 
(pc=0.0008), IL-6 (pc=0.001), IL-16 (pc=0.007) calprotectin (pc=0.014), IL-
12IL-23p40 (pc=0.02) and ICAM-1 (pc=0.045). Different PsA disease pheno-
types were associated with different biomarkers, e.g., axial disease (with or with-
out peripheral disease) was associated with IL-6 (pc=0.044), IL-16 (pc=0.044), 
MIP-1β (pc=0.039) and polyarthritis was associated with IL-6 (pc=0.0006), SAA 
(pc=0.009), CRP (pc=0.012) and IL-8 (pc=0.04)), although it was not possible 
to statistically separate the different phenotypes with OPLS-DA. An associa-
tion was also seen in patients with PsA who, at any time had been prescribed 
bDMARD, (TNFβ (pc=0.0001), TNF-α (pc=0.0003), calprotectin (pc=0.0009), 
CRP (pc=0.016) and lower levels of Tie-2 (pc=0.027)). No significant differences 
were found when PsA patients were compared with healthy controls.
Conclusions. In this study we could confirm the great heterogeneity of PsA, with 
different biomarkers being associated with various phenotypes of the disease. 
None of the biomarkers could, by itself, or in combination, separate PsA from 
controls.
References
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ASSOCIATION BETWEEN HIGH BODY MASS INDEX AND CLIN-
ICAL FEATURES OF AXIAL SPONDYLOARTHRITIS
Yeo J.N., Seo M.R., Ryu H.J., Choi H.J., Baek H.J.
Division of Rheumatology, Dept. of Internal Medicine, Gil Medical Center, 
Gachon University College of Medicine, Incheon, Republic of Korea
Introduction. Obesity is associated with a proinflammatory state and could in-
crease the inflammatory burden of rheumatic disease. The aim of this study was 
to evaluate whether body mass index (BMI) is associated with parameters of 
clinical characteristics, radiologic progression and disease activity in axSpA.
Patients and Methods. Total 87 patients with axSpA were enrolled (male 66 
and female 21). Demographic data, and initial and follow-up data of clinical 
manifestations, treatment and radiologic features were collected. Diseases activ-
ity of axSpA was assessed by erythrocyte sediment rate (ESR), C-reactive protein 
(CRP), and Bath ankylosing spondylitis disease activity index (BASDAI). High 
BMI was defined as ≥25.0 and controls were with BMI <25.0 at the time of 
diagnosis of axSpA. 
Results. The mean BMI in patients with axSpA was 22.4 (IQR 20.6-24.8) and 
22% of all patients had high BMI. There was no statistically significant dif-
ference between high BMI group and controls in demographic data, clinical 
manifestations and radiologic features including positive HLA-B27, ESR, CRP, 
BASDAI, peripheral arthritis, uveitis, IBD, psoriasis, SI grade, mSASSS and 
syndesmophyte at the time of diagnosis. The follow-up duration was 3.2 years 
(IQR 2.3−4.2) in control group and 2.3 years (IQR 2.0-4.3) in high BMI group. 
There was also no statistical significant difference in disease activity, treatment 
and radiologic progression including mean and last CRP, change of SI grade and 
mSASSS, and new syndesmophyte at the time of follow-up.
Conclusions. Our results suggest that high BMI may not affect radiologic pro-
gression, and other disease activity indexes in axSpA. Further large-scale studies 
are required for the identification of clinical significance of BMI in axSpA.
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DISEASE MODIFYING ANTI RHEUMATIC DRUGS IN THE 
TREATMENT OF SAPHO SYNDROME: SYSTEMATIC LITERA-
TURE ANALYSIS
Monet M.1, Prati C.1, Guillot X.1, Sondag M.1, Verhoeven F.1, Aubin F.2, Wendling 
D.1
1University Teaching Hospital (CHRU), Rheumatology; 2University Teaching 
Hospital (CHRU), Dermatology, Besançon, France
Introduction. SAPHO (Synovitis Acne Pustulosis Hyperostosis Osteitis) Syn-
drome is a heterogeneous clinical entity close to spondyloarthritis. The manage-
ment is not codified and there is no validated evaluation tool for SAPHO syndrome. 
Aim. To perform a systematic analysis of the literature in order to evaluate the 
effects of DMARDs in SAPHO syndrome.
Methods. Patients were included when therapeutic effect of treatment (Bispho-
sphonates, synthetic and biologic DMARDs) was evaluable (Pubmed research 
until April 2017). Treatment was considered effective when the patient validated 
the response criteria defined in the study or if at least partial benefit was obtained 
for a minimum of three months. The different treatments were ranked according 
to their effectiveness rate and then grouped by therapeutic class to determine 
an overall response rate. These rates led to the calculation of an efficacy index 
weighted by the number of patients treated in the subgroup (molecule or thera-
peutic class) compared to the total number of patients in our study.
Results. Treatment efficacy was evaluable in 284 of the 292 patients analyzed. 
The group of treatments that most often induces a therapeutic response (in more 
than 75% of cases) includes Ibandronate, Etanercept, Anakinra, Infliximab, Pa-
midronate and Adalimumab. Pamidronate, which represents the largest subpopu-
lation in our study, has the highest weighted index of efficacy. There was no clear 
clinical profile of a good responder to a particular treatment.
Therapeutic class Number of Number of  Efficacy Weighted
 patients responders rate (%) index
Bisphosphonates 139 122 87,77 42,96
Conventional DMARds 68 32 47,06 11,27
Anti TNF alpha 60 51 85 17,96
Other biologics 17 10 58,82 
TOTAL 284 215 75,82 NA
Conclusion. This work made it possible to rank the different DMARDs used in 
the SAPHO syndrome.
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TREATMENT OUTCOME WITH COMBINED METHOTREXATE, 
SULFASALAZINE AND ON-DEMAND NSAIDS IN AXIAL SPON-
DYLOARTHRITIS IN A RESOURCE-LIMITED REAL WORLD 
CLINICAL PRACTICE
Ganapati A.1, Pulukool S.1, Gowri M.2, Antonisamy B.2, Danda D.1
Christian Medical College Hospital, Depts. of 1Clinical Immunology & Rheuma-
tology and 2Biostatistics, Vellore, India
Introduction. ASAS recommendations state, there is no evidence for Methotrex-
ate (MTX)/ Sulfasalazine (SSZ) in axial disease but SSZ may be considered in 
those with peripheral arthritis. In India, most patients cannot afford biological 
agents. 
Aim. Evaluation of response to combined MTX+SSZ & on demand NSAIDs in 
Axial SpA patients with active disease, not affording Anti TNF-alpha agents with 
ASAS20 response as primary outcome.
Materials and Methods. A prospective observational, single centre, cohort 
study on 150 consecutive AxSpA patients fulfilling our study criteria who were 
initiated on combined MTX/SSZ based on physician discretion, was conducted 
from July 2016 to July 2017. The patients were categorised into 2 groups- pure 
axial involvement (group 1) and axial with peripheral involvement (group 2).
Results. In the ‘per-protocol’ study population, ASAS20 response 3 months post 
therapy with MTX/SSZ combination and on-demand NSAIDs was achieved in 
31/59(52.5%) & in 24/35(68.5%) in Groups 1 & 2 respectively (p-0.1). At 6 
months, ASAS20 response was seen in 45/76 (59.2%) & 28/44(63.6%) in groups 
1 & 2 respectively (p-0.6). Combined DMARD therapy, resulted in significant 
reduction in mean NSAID intake (as per ASAS NSAID index) from 29.6 to 14 
over 6 months from baseline (p-0.001); similar in both groups. When using a 
BASDAI score (active disease ≥ 4) driven policy for TNF therapy, a 34% reduc-
tion of AxSpA patients escaping to TNF inhibitors was seen.
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Conclusion. Combined MTX+SSZ is efficacious in managing AxSpA patients 
with active disease as an alternative to Anti TNF-alpha therapy in those who 
cannot afford it, as evidenced by ASAS20 response in 58.5% & 60.8% patients 
(post 3 & 6-month therapy) irrespective of peripheral arthritis, in a per-protocol 
study population. Combined DMARDs were able to bring down the on demand 
NSAID use over 6-month period from baseline and reduced the escalation to 
TNF therapy by 34% in our cohort.
P61
CERTOLIZUMAB PEGOL IN A SPANISH COHORT OF PATIENTS 
WITH PSORIATIC ARTHRITIS - PRELIMINARY RESULTS
Reina D.1, Mateo L.2, Prior Á.3, Laiz A.4, Moreno M.5, Juanola X.6
1Rheumatology, Consorci Sanitari Integral; 2Germans Trias i Pujol, Barcelona; 
3Rheumatology, Germans Trias i Pujol; 4Rheumatology, Hospital de la Santa 
Creu i Sant Pau; 5Rheumatology, Hospital Parc Taulí; 6Rheumatology, Hospital 
Universitari de Bellvitge, Barcelona, Spain
Background. Certolizumab pegol is an anti-TNF drug approved for psoriatic 
arthritis (PsA) in Spain since 2012, so rheumatologists have a long experience 
with its use. However, for the new indication in cutaneous psoriasis (Pso), phase 
III clinical studies are currently underway. 
Objectives. To describe the baseline characteristics and the evolution of a cohort 
of patients with PsA and Pso treated with Certolizumab, and to assess possible 
differences between patients who interrupt or maintain this treatment. 
Methods. Retrospective multicenter study on 34 patients with PsA treated with 
Certolizumab between 2012 and 2017. The main outcome measure was the PGA 
(Physician global assessment) that evaluates cutaneous involvement on a scale of 
5 categories, from “without affectation” up to “severe affectationˮ. 
Results. 34 patients were included, mainly women (73%), with an average dura-
tion of Pso and PsA of 11.9±12.2 and 9.7±6.9 years, respectively. The majority 
had peripheral arthritis (88%), with polyarticular forms (65%). There was axial 
involvement in 26% of the cases, dactylitis and arthritis of distal interphalan-
geal joints (DIP) in 38%, and plaque psoriasis in 59%. 73% had received prior 
biological therapy. The DAS28 showed a downward trend during the follow-up, 
with initial and two years values of 5.2 and 3.2 correspondingly. In relation to the 
main outcome measure, of the 31 initial patients, only 23 could be assessed at 6 
months, 13 at year and 4 at two years. The percentages of patients without affec-
tation were 23%, 43%, 38% and 50% at baseline, 6 months, 1 and 2 years; 55%, 
48%, 54% and 50% had minimal involvement; and the affectation was mild in 
6%, 9% and 8%, for the first 3 follow-up times. The differences between baseline 
PGA and at 6 months of follow-up were significant (p=0.001), while the base-
line-1 year differences were at the limit of statistical significance (p=0.049). Of 
the 34 patients, 6 stopped treatment (18%). The patients who stopped had shorter 
duration of Pso and PsA, higher frequency of obesity, HLAB27, peripheral ar-
thritis, polyarticular forms, arthritis of DIP, Pso in plaques, and treatment with 
MTX and steroids. However, none of the observed differences reached values of 
statistical significance. 
Conclusions. In the studied sample, the treatment with certolizumab pegol has 
shown effectiveness for the Pso and the PsA at 6 months. The 1-year changes 
were at the limit of statistical significance and changes at 2 years could not be 
analyzed due to losses to follow-up. 
No significant differences were observed in the clinical characteristics among the 
patients who continued / interrupted the treatment, although these results may be 
due to the small size of the studied sample. 
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EVALUATION OF THE WORK PRODUCTIVITY IN ANKYLOS-
ING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PsA) PA-
TIENTS BEFORE AND AFTER THE START OF ADALIMUMAB 
THERAPY IN DAILY PRACTICE IN BELGIUM (SpActive STUDY)
De Clerck L.1, Maertens M.2, Remans Ph.3, Stuer A.4, Delmotte N.5, Van den 
Enden M.5, Stubbe M.6
1University Hospital, Antwerpen; 2AZ Damiaan, Oostende; 3Medisch Centrum, 
Genk; 4AZ Delta, Roeselare; 5AbbVie, Wavre; 6OLV Ziekenhuis, Aalst, Belgium
Introduction. The aim of this study was to analyze the employment status and 
work productivity of patients with AS and PsA before and after the start of adali-
mumab and to evaluate the relationship between employment status, work pro-
ductivity, disease activity and clinical evaluation.
Methods. This is a multicenter, observational study of adult patients diagnosed 
with AS and PsA, starting adalimumab treatment in line with Belgian reimburse-
ment criteria. Clinical and HRQoL parameters as well as work productivity (us-
ing WPAI-SHP) are evaluated after 3, 6, 9, 12 and 18 months.
Results. Data from 173 patients were analyzed of which 117 had AS (67,6%) and 
56 had PsA (32,4%). 121 patients (69,9%) completed the study. On average, all 
components of the WPAI questionnaire (absenteeism, presenteeism, total work 
productivity impairment due to the disease and % activity impairment due to 
the disease) improved substantially from baseline to month 18 (and to the last 
observation after baseline). Most of the improvement was already observed after 
3 months. In the AS patients there was a clear correlation between BASDAI 
and HAQ-S improvement between baseline and month 18 and work productiv-
ity parameters. A similar correlation was noted between DAS28 and HAQ-DI 
improvement and work productivity parameters between baseline and month 18 
in the PsA patients. The safety events were in line with the known safety profile 
of adalimumab in AS and PsA patients.
Conclusion. For AS and PsA patients treated with adalimumab there is a marked 
improvement in disease activity and quality of life outcomes. The study demon-
strated a substantial improvement in all four WPAI variables in both AS and PsA 
patients treated with Adalimumab. The clinical and HRQoL outcomes correlate 
clearly with meaningful improvements in work productivity and daily activities.
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CANADIAN OBSERVATIONAL STUDY ASSESSING THE EFFEC-
TIVENESS OF ADALIMUMAB VS. NON-BIOLOGIC DMARDS 
IN ANKYLOSING SPONDYLITIS (COMPLETE-AS): 12-MONTH 
DATA
Bessette L.1, Khraishi M.2, Chow A.3, Pavlova V.4, Silverberg S.5, Stewart J.6, 
Remple V.7
1Laval University, CHUL, Quebec; 2Memorial University of Newfoundland, St. 
John’s; 3University of Toronto, Toronto; 4McMaster University, Hamilton; 5Eto-
bicoke General Hospital, Toronto; 6University of British Columbia, Penticton; 
7AbbVie Corporation, Montreal, Canada
Introduction/Aim. COMPLETE-AS is an ongoing observational study of anti-
TNF-α-naïve adults with active AS requiring change in current AS treatment 
to (1) subsequent NSAID or non-biologic DMARD (nbDMARD group), or (2) 
adalimumab (ADA group). This analysis aimed at comparing the baseline char-
acteristics of patients in the nbDMARD and ADA groups and the 12-month ef-
fectiveness of the two treatment methods.
Methods. Patients were enrolled between July/2011 and Jun/2016. Outcomes 
analyzed were extra-articular manifestations (EAM 1: IBD, psoriasis, uveitis, 
enthesitis; EAM 2: IBD, uveitis, enthesitis), BASDAI, BASFI, and SF-12. Base-
line-adjusted changes in outcomes were compared between-groups using linear 
mixed models.
Results. 609 patients (nnbDMARD=177, nADA=432) were included without signifi-
cant demographic differences between-groups. Patients initiating ADA were 
more likely to be unemployed (38% ADA vs. 27.1% nbDMARD, p=0.009), had 
higher BASDAI (6.4 vs. 5.0, p<0.001) and BASFI (5.5 vs. 3.7, p<0.001) scores, 
and worse QoL (SF-12 PCS: 24.4 vs. 24.7, p=0.002) at baseline. Baseline prev-
alence of EAMs was comparable between-groups (EAM 1: 34.7% vs. 31.6%, 
p=0.454; EAM 2: 25.9% vs. 22.6%, p=0.381). However, IBD was more common 
among ADA patients (9% vs. 4.5%, p=0.062).
After 12 months, EAM prevalence decreased significantly in ADA- (pEAM1=0.004; 
pEAM2=0.033) but not nbDMARD-treated patients. Upon baseline-adjustment, 
ADA patients had numerically lower BASDAI (3.7 vs. 4.3, p=0.171) signifi-
cantly lower BASFI (2.9 vs. 3.6, p=0.031), and comparable SF12-PCS (24.9 vs. 
24.7, p=0.210) and SF12-MCS (19.1 vs. 18.9, p=0.532) at 12 months. 
During follow-up, 7.4% of ADA patients switched biologic and 23.7% in the 
nbDMARD group initiated biologic treatment (p<0.001).
Discussion/Conclusion. AS patients initiating ADA in Canadian routine care 
have greater disease severity and impaired QoL compared with those initiating 
non-biologic treatment. ADA treatment for 12 months resulted in greater reduc-
tion in EAM prevalence and in disease severity scores compared to non-biologic 
agents.
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CANADIAN OBSERVATIONAL STUDY ASSESSING THE EFFEC-
TIVENESS OF ADALIMUMAB VS. NON-BIOLOGIC DMARDS IN 
PSORIATIC ARTHRITIS (COMPLETE-PsA): 12-MONTH DATA
Khraishi M.1, Bessette L.2, Chow A.3, Haraoui B.4, Pavlova V.5, Stewart J.6, Rem-
ple V.7
1Memorial University of Newfoundland, St. John’s; 2Laval University, CHUL, 
Quebec; 3University of Toronto, Toronto; 4Centre Hospitalier de l’Université de 
Montréal, Montreal; 5McMaster University, Hamilton; 6University of British Co-
lumbia, Penticton; 7AbbVie Corporation, Montreal, Canada
Introduction/Aim. COMPLETE-PsA is an ongoing observational study assess-
ing the effectiveness of adalimumab (ADA) and non-biologic DMARDs (nbD-
MARDs) in anti-TNF-α-naïve adults with active PsA failing initial treatment. 
This analysis aimed at comparing the baseline characteristics of nbDMARD- and 
ADA-treated patients, and the 12-month effectiveness of the two treatments.
Methods. Patients were enrolled between Jul/2011 and Jun/2016. Outcomes 
analyzed were: DAS28, SF-12, DLQI, extra-articular manifestations (EAMs; 
enthesitis and dactylitis), psoriasis BSA, modified MDA (achievement of 
4 [mMDA 1] and 5 [mMDA 2] of the following 6 criteria: TJC≤1, SJC≤1, 
BSA≤3%, pain≤15mm, PtGA≤20mm, HAQ≤0.5), modified remission (SJC=0, 
TJC=0, no enthesitis/dactylitis, BSA≤3%, and HAQ≤0.5), DAPSA LDA (≤14) 
and remission (REM;≤4).
Results. 406 patients were included (nnbDMARD=146, nADA=260). Patients initiat-
ing ADA were more likely to be unemployed (47.3% vs 34.9%, p=0.015), had 
higher DAS28 (4.8 vs 4.4, p=0.002) and DLQI (6.1 vs 4.3, p=0.007), and higher 
rates of BSA≥3% (44.6% vs 35.0%, p=0.063) and high DAPSA disease activ-
ity (50.8% vs 32.3%, p=0.015). A higher proportion of nbDMARD patients had 
dactylitis (36.1% vs 25.3%, p=0.023). No differences were observed in baseline 
enthesitis, overall EAMs, or QoL.
At 12 months, baseline-adjusted DAS28 (2.6 vs 3.4, p<0.001) and DLQI (2.2 vs 
2.9, p=0.530), but not SF-12, were lower in ADA patients. Furthermore, ADA 
patients had significantly lower DAPSA score (p=0.025) (LDA/REM: 64.9% vs 
58.6%; REM: 37.7% vs 17.1%), and numerically higher rates of modified remis-
sion (14.7% vs 9.7%, p=0.311), mMDA 1 (15.6% vs 12.6%, p=0.529), mMDA 
2 (17% vs 11.5%, p=0.253), and BSA<3% (89.3% vs 83.9%, p=0.207). EAM 
prevalence was significantly lower in ADA patients (17.4% vs 35.8%, p<0.001).
Discussion/Conclusion. PsA patients initiating ADA in Canadian routine care 
have greater baseline disease severity compared with those initiating nbD-
MARDs. However, 12-month ADA treatment was associated with improved 
disease control and EAMs.
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EXPLORING SUB-OPTIMAL RESPONSE TO TUMOUR NECRO-
SIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS
Yahya F.1,2, Gaffney K.3, Sengupta R.1,4
1Dept. of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, 
UK; 2Dept. of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 3Dept. 
of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation 
Trust, Norwich; 4Dept. of Pharmacology, University of Bath, Bath, UK
Objectives. To define sub-optimal response to tumour necrosis factor inhibitors 
(TNFi), compare long-term drug survival rates and identify predictors of sub-
optimal response in axial spondyloarthritis (axSpA) patients in a United King-
dom (UK) cohort.
Methods. All axSpA patients attending 2 centres who commenced TNFi between 
2002 and 2016 were included. Routinely-recorded patient data was reviewed ret-
rospectively. Patients with paired BASDAI at baseline, 3 and/or 6 months were 
included for analysis. Sub-optimal response was defined as achieving a ≥2-point 
reduction in BASDAI but not BASDAI50, post-treatment BASDAI remaining 
at ≥4, and in the opinion of the treating physician, these patients demonstrated a 
meaningful clinical response.
Results. Four hundred and ninety-nine patients were included: eighty-two 
(16.4%) patients were classified as having a sub-optimal response; 64(78%) 
males, 78 (95.1%) AS and 55/67 (82.1%) HLA-B27 positive. Time to diagnosis 
was 10 (8.6) yrs, age at diagnosis was 37 (11.7) yrs and age at initiating index 
TNFi was 48 (11.1) yrs. Individual index TNFi were Humira® (adalimumab, 
n=41, 50%), Enbrel® (etanercept, n=27, 32.9%), Remicade® (infliximab, n=5, 
6.1%), Simponi® (golimumab, n=3, 3.7%) and Cimzia® (certolizumab pegol, 
n=6, 7.3%). The rate of attrition was greater among sub-optimal responders at 
2 and 5 years (p<0.05), but not at 10 years (p=0.064), compared to responders. 
Older age at initiating TNFi was a predictor of sub-optimal response (OR 1.04, 
95%CI 1.01-1.09, p<0.05).
Discussion. This is the first study to define sub-optimal response and describe the 
characteristics of sub-optimal TNFi responders in axSpA. Older age at initiating 
TNFi is a predictor of sub-optimal response.
Conclusion. A significant proportion of patients continued TNFi despite demon-
strating sub-optimal response. Further research needs to be undertaken in order 
to understand this group.
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EFFICACY OF NEW TREATMENTS ON DACTYLITIS OF PSO-
RIATIC ARTHRITIS: UPDATE OF SYSTEMATIC LITERATURE 
REVIEW
Sondag M., Verhoeven F., Guillot X., Prati C., Wendling D.
Rheumatology, Hospital Jean Minjoz, Besançon, France
Introduction/Aim. Dactylitis is a frequent disabling feature of psoriatic arthri-
tis (PsA). Therapeutic strategy on dactylitis is not really codified. The aim of 
the study was to evaluate efficacy on dactylitis of different treatments currently 
available in PsA.
Methods. We performed a literature review from June 2014 to October 2017 
based on Pubmed, using the search terms “psoriatic arthritis” and “treatment” 
with only clinical trials. 89 articles were identified (English-language reports 
only). Thus, we selected only randomized, double-blind placebo-controlled trials 
in which analysis of dactylitis was exposed: 11 publications were selected for 
full review.
Results. Calculating of effect size was possible and available only in one study: 
secukinumab’s effect size was 4.35 in McInnes study (FUTURE 2). Calculation 
of Odds Ratio (of residual dactylitis between treatment and placebo groups) was 
possible on part of studies with significant results for clazakizumab (200mg dos-
ing) and secukinumab in patients TNF exposed (Table).
Odds Ratio for residual dactylitis in treatment / placebo groups:
Treatment Ustekinumab Clazakinumab Clazakinumab Clazakinumab
 (PSUMMIT 1-2, 200 (Mease  100 (Mease 25 (Mease
 Kavanaugh A&R 2016) A&R 2016) A&R 2016) 
 ARD 2016) (16)   (16) (16)
  (11)    
     
Lower range 0,23 0,06 0,02 0,10
Mean 0,48 0,31 0,14 0,47
Upper range 1,01 1,58 0,93 2,19
Treatment Abatacept Secukinumab Secukinumab Secukinumab
 (Mease ARD (FUTURE, (anti TNF naif) (anti TNF IR) 
 2016) (19)  Mc Innes,  (FUTURE 2, (FUTURE 2,
  Lancet  Kavanaugh JOR Kavanaugh JOR
  2015) (14)   2016) (15)  2016) (15)
Lower range 0,30 0,48 0,01 0,01
Mean 0,65 0,77 0,07 0,13
Upper range 1,40 1,24 0,58 1,15
 
Conclusions. Dactylitis was always used as secondary outcome criteria with het-
erogeneous results. So conclusions need to be cautious. This invalidating clinical 
manifestation need to be evaluated as a primary outcome in the future.
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THE RELATIONSHIP BETWEEN DAILY PHYSICAL ACTIVITY 
AND TUMOR NECROSIS FACTOR INHIBITOR SURVIVAL TIME 
IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Kim T.H.1, Koo B.S.2, Shin J.H.1, Sung I.H.1
1Dept. of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; 
2Dept. of Internal Medicine, Inje University Seoul Paik Hospital, Inje University 
College of Medicine; Seoul, Korea
Background. This study aimed to determine whether daily physical activity is 
associated with tumor necrosis factor (TNF) inhibitor survival time in patients 
with ankylosing spondylitis (AS).
Method. A total of 386 patients in the AS registry who were administered TNF 
inhibitors were retrospectively reviewed. Physical activities were assessed, such 
as intense exercise, moderate physical activity, walking, strength training, and 
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sleep. Clinical information was obtained through electronic medical records. Cox 
proportional hazard ratios (HRs) with confidence intervals (CIs) were estimated 
based on the ratio of TNF inhibitor survival time. In addition, we used a decision 
tree (classification and regression tree method) to visualize a strategy for maxi-
mizing TNF inhibitor survival time.
Result. Of the 386 patients, 33 ceased the initial TNF inhibitor treatment due to 
lack of efficacy and changed to other TNF inhibitors. The activity level of most 
patients was “walking” (298, 81.4%). The physical activity levels were as fol-
lows: 99 (27.0%) patients did not do much intense exercise, 136 (37.3%) did not 
do much moderate physical exercise, and 116 (31.3%) did not do strength train-
ing. In total, 216 (59.7%) patients got sufficient sleep. When assessing the HRs 
of all individual variables for TNF inhibitor survival time, no strength training 
(HR=3.07, CI: 1.07–8.83), female sex (HR=2.7, CI: 1.25–5.8), smoking period 
(HR=0.95, CI: 0.92–0.99), insufficient sleep (HR=0.4, CI: 0.17–0.95), drink-
ing currently (HR=0.38, CI: 0.18–0.83), treatment with etanercept (HR=0.34, 
CI: 0.15–0.77), smoking history (HR=0.32, CI: 0.12–0.88), treatment with 
adalimumab (HR=0.32, CI: 0.12–0.81), and smoking currently (HR=0.18, CI: 
0.05–0.6) were significantly associated with survival time (p<0.05). No variables 
remained significantly associated with survival time after multivariate analysis of 
HRs. In the decision tree, smoking, use of non-steroidal anti-inflammatory drugs, 
use of steroids, the type of TNF inhibitor, period of oral medication only, age, and 
moderate physical activity were predictive of survival time after administration. 
Conclusion. Daily physical activity seems to be associated with the survival time 
of TNF inhibitors. Appropriate physical activity may help to reduce disease ac-
tivity and maintain the survival time of biologics in patients with AS.
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COMPARISON OF CONTINUOUS USE OF NSAIDs AND ON- 
DEMAND MODE IN PATIENTS WITH EARLY AXIAL SPONDY-
LOARTHRITIS
Erdes S., Rumiantceva D.G., Dubinina T.V., Demina A.B.
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background. According to the ASAS-EULAR management recommendations 
NSAIDs are first-line drugs for treatment patients (pts) with axial spondyloarthri-
tis (axSpA). But currently, there is no clear opinion about the effect of NSAIDs 
on radiographic progression in patients with early axSpA. 
Aim: To сompare effect of continuous use of NSAIDs and on-demand mode on 
radiographic progression in sacroiliac joints (SIJ) in pts with early axSpA.
Materials and Methods. The research included 68 pts with early axSpA (ASAS 
criteria, 2009) from Moscow CORSAR cohort with disease duration <5 years, 
age onset <45 years and at least 2 years follow-up. Pts were randomized into 
two treatment groups: pts with continuous use of NSAIDs and on-demand use 
of NSAIDs. The dosages of NSAIDs accounted by the ASAS NSAID index. SIJ 
radiographs performed at baseline and after 2 years follow-up. Radiographic SIJ 
stages were scored according to the modified New York criteria grading system. 
To assess the progression in SIJ, total stage of sacroiliitis was calculated, by 
determining sum score stages of sacroiliitis in the left and right SIJ (from 0 to 8 
points). The mSASSS index is not suitable for assessing radiographic progres-
sion at an early stage of axSpA, because at that stage of the disease, the cervical 
and lumbar spine have practically no damage.
Results. In the continuous NSAIDs treatment group №1, after 2 years of fol-
low-up, median of a total stage of sacroiliitis didn’t change and remained at 4.0 
points, in the “on demand” group №2, this index significantly increased from 3.0 
to 4.0 points.
Table I. Total stage of sacroiliitis at baseline and after 2 years follow up.
 Total stage of sacroiliitis, mediane [IQR] р
 Baseline After 2 years follow-up 
Group №1 (n=35) 4.0 [3.0; 4.0] 4.0 [4.0; 6.0] 0,132
Group №2 (n=33) 3.0 [2.0; 4.0] 4.0 [3.0; 6.0] 0,044
*IQR-interquartile range
Conclusions. Continuously uses of NSAIDs reduces radiographic progression in 
SIJ in pts with early axSpA. 
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HOW TO OPTIMIZE EXERCISE BEHAVIOUR IN AXIAL SPON-
DYLOARTHRITIS - RESULTS OF AN INTERVENTION MAPPING 
STUDY
Hilberdink S.1,2, Van Weely S.F.E.1, Van der Giesen F.J.1, Nijkamp M.3, Lopuhaä 
N.4, Vliet Vlieland T.P.M.1
1Orthopaedics, Rehabilitation and Physiotherapy, LUMC, Leiden; 2PCRR, Gro-
ningen; 3Open University, Heerlen; 4Dutch Arthritis Society, Amsterdam, The 
Netherlands
Introduction. Regular exercise has many health benefits for people with axial 
spondyloarthritis (axSpA). However, most patients do not engage in frequent 
exercise. Therefore, a well-founded intervention is needed.
Aim. To identify effective intervention methods to optimize exercise behaviour 
in axSpA.
Methods. The first three steps of the Intervention Mapping (IM) protocol, which 
is a six-step framework for intervention development, were used to determine 
effective intervention components. This study comprised 1) a needs assessment, 
to examine the discrepancy between current and desired exercise behaviour of 
axSpA patients, 2) a determinant analysis, to identify barriers and facilitators 
(determinants) to overcome this discrepancy, and 3) an intervention method anal-
ysis, to select effective methods that target these determinants. All three steps 
included literature reviews and semi-structured interviews with axSpA patients 
(n=2) and specialised physiotherapists (n=2) to explore the literature search find-
ings qualitatively and to rank the identified determinants and methods in order 
of relevance.
Results. The literature searches resulted in 28 (64), 23 (257) and 15 (209) includ-
ed articles (hits) for IM steps 1, 2 and 3, respectively. IM step 1 revealed that only 
one third of axSpA patients engage in (frequent) mobility, strengthening and/or 
cardiorespiratory exercises, while especially these components appear beneficial 
in axSpA. IM step 2 uncovered 19 relevant determinants of exercise behaviour 
in axSpA. IM step 3 identified 18 effective methods targeting these determinants. 
Guided practice, patient education, motivational interviewing, action planning, 
goal setting, feedback, monitoring, tailoring, health professionals´ training and 
group exercise appeared most relevant.
Conclusions. This study showed that in order to optimize exercise behaviour in 
axSpA, patients should be offered an intervention including education, motiva-
tional interviewing, goal setting and action planning and they should be stimu-
lated to exercise in a group. In addition, therapists should be educated how to tai-
lor, practice and monitor exercise and how to base this on thorough assessment.
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EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH 
AXIAL SPONDYOARTHRITIS TREATED WITH CERTOLIZUM-
AB PEGOL: RESULTS FROM THE 48–WEEK RUN-IN PART OF 
C-OPTIMISE
Landewé R.1, van der Heijde D.2, Dougados M.3, Baraliakos X.4, Van den Bosch 
F.5, Hoepken B.6, Thomas K.6, Gensler L.S.7
1Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuy-
derland MC, Heerlen; 2Dept. of Rheumatology, Leiden University Medical Center, 
Leiden, The Netherlands; 3Rheumatology Dept., Paris-Descartes University and 
Cochin Hospital, Paris, France; 4Ruhr-University Bochum, Herne, Germany; 
5Dept. of Internal Medicine, Ghent University Hospital, Ghent, Belgium; 6UCB 
Pharma, Monheim, Germany; 7University of California, San Francisco, USA
Introduction/Aim. C-OPTIMISE is the first trial to evaluate whether certoli-
zumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-
axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving 
sustained remission after 48 weeks’ (wks’) treatment. Here, we report interim 
efficacy and safety data for both subpopulations from the ongoing trial.
Materials and Methods. Up to wk48, C-OPTIMISE (NCT02505542) was 
open-label (Part A), followed by 48-wk parallel-group, double-blind, placebo-
controlled treatment (full dose and half dose) to wk96 (Part B). Patients with 
adult-onset axSpA of <5 years’ duration, fulfilling ASAS classification criteria, 
were recruited. Part A: patients received CZP 400mg at wks0/2/4, then 200mg 
Q2W); patients achieving sustained remission (ASDAS<1.3 at wk32 and <2.1 
at wk36 [or vice versa], and <1.3 at wk48) were eligible for Part B (secondary 
outcome). Primary outcome (not reported): percentage of patients in Part B not 
experiencing a flare. Missing values were imputed using non-responder imputa-
tion (NRI) and last observation carried forward (LOCF). 
Results. Part A: Of 736 patients (Table I), 43.9% achieved sustained remission 
(r-axSpA/AS: 42.8%; nr-axSpA: 45.3%; NRI). At baseline, 98.5% patients had 
high/very high disease activity (ASDAS≥2.1); at Wk48, 52.7% (r-axSpA/AS: 
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52.6%; nr-axSpA: 52.9%) had inactive disease (ASDAS<1.3; LOCF; Table II). 
The treatment-emergent adverse event (TEAE) rate/100 patient-years’ exposure 
was 224.2; 3.9% patients discontinued CZP due to TEAEs. No new safety signal 
was identified.
Conclusion. The run-in phase of C-OPTIMISE shows that similar and substan-
tial proportions of patients with r-axSpA/AS and nr-axSpA achieved sustained 
remission during 48 wks’ CZP treatment. No new safety signal was identified.
Acknowledgements. The authors acknowledge Costello Medical, UK, for writ-
ing and editorial assistance, which was funded by UCB Pharma.
[a] Patients with prior exposure to >1 anti-TNF were excluded. [b] A central reading of patients’ 
sacroiliac joint x-rays was used to confirm their stratification into nr-axSpA and r-axSpa/AS sub-
populations. [c] Time since diagnosis of disease. [d] MRI or X-ray. [e] Unless stated otherwise. 
[f] NRI. [g] Values below the limit of quantification were set to half of the limit of quantification. 
†n=734. ‡n=327. AS: ankylosing spondylitis; ASAS20/40: ≥20% or ≥40% improvement in Assess-
ment of SpondyloArthritis international Society response criteria; ASAS PR: ASAS Partial Re-
mission; ASDAS: Ankylosing Spondylitis Disease Activity Score; axSpA: axial spondyloarthritis; 
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASDAI 50: ≥50% improvement in 
BASDAI; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spon-
dylitis Metrology Index; BL: baseline; CII: ASDAS Clinically  Important Improvement (RFB ≥1.1); 
CRP: C-reactive protein; CZP: certolizumab pegol; HDA/VHDA: ASDAS High/Very High Disease 
Activity (ASDAS ≥2.1); ID: ASDAS Inactive Disease (ASDAS <1.3); LOCF: last observation car-
ried forward; MI: ASDAS Major Improvement (RFB ≥2.0); MRI: magnetic resonance imaging; nr-
axSpA: non-radiographic axSpA; NRI: non-responder imputation; Q2W: every 2 weeks; r-axSpA: 
radiographic axSpA; RFB: reduction from baseline; Wk: week.
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INTRAVENOUS GOLIMUMAB IN ADULT PATIENTS WITH 
ACTIVE PSORIATIC ARTHRITIS: EFFICACY AND SAFETY 
THROUGH 1 YEAR
Husni M.E.1, Kavanaugh A.2, Harrison D.D.3, Kim L.3 Lo K.H.3, Hsia E.C.3,4
1Cleveland Clinic, Cleveland; 2University of California, San Diego; 3Janssen Re-
search & Development, LLC, Spring House; 4University of Pennsylvania School 
of Medicine, Philadelphia, USA
Intro/Aim. GO-VIBRANT evaluated safety & efficacy of IV golimumab (GLM) 
in adult pts with active PsA over 1yr.
Methods. GO-VIBRANT is a Phase 3, multicenter, randomized, double-blind, 
PBO-controlled trial. Biologic-naïve active PsA pts were randomized (1:1) to 
IV GLM 2mg/kg at 0,4, & q8w or PBO at 0,4,12, & 20wks with crossover to 
GLM(PBO→GLM) at 24, 28, & q8w→Wk52. Efficacy data from Wks24-52 & 
safety data through Wk60 are reported here. 
Results. 480 pts were randomized (PBO:239; GLM:241). At Wk24, great-
er proportions of GLM vs PBO pts achieved ACR20 (77%vs24%), ACR50 
(54% vs 6%), ACR70 (33% vs 3%), & ACR90 (6% vs 0%). Mean improve-
ment from baseline in HAQ-DI score was greater in GLM vs PBO groups 
(−0.63 vs −0.14). At Wk24, greater proportions of GLM vs PBO pts achieved 
PASI75(65% vs 13%), PASI90(43% vs 8%), or PASI100(26% vs 6%). Mean 
change from baseline in total modified vdH-S score in GLM vs PBO groups 
was−0.36 vs +1.95. At Wk52, similar proportions of GLM vs PBO→GLM pts 
achieved ACR20 (76.8% vs 77.0%), ACR50 (58.1% vs 53.6%), ACR70(38.6% 
vs 33.9%), & ACR90(13.7% vs 11.3%). Mean improvements from baseline in 
HAQ-DI score were maintained in GLM&PBO→GLM groups (−0.66 &−0.56). 
After crossover to GLM(Wk24), meaningful improvements in PBO→GLM 
group for ACR&HAQ endpoints were seen as early as Wk28. PASI responders 
at Wk52 for GLM vs PBO→GLM pts were: PASI75(71.9%vs60.6%), PASI90 
(56.1%vs41.9%), or PASI100 (28.6%vs18.7%). Mean change from baseline in 
total modified vdH-S score was maintained for GLM (−0.49). There was no in-
crease in the mean change from baseline at Wk52 in PBO→GLM group (+0.76). 
Through Wk60, 460 pts received ≥1 administration of GLM. Of these,50.9% 
had ≥1 AE & 5.2% had ≥1 SAE. The most common type of AE was infection 
(22.8%). One death (acute hepatitis) & 2 malignancies (gastric cancer, colon 
cancer) were reported in GLM-treated pts. Two GLM-treated pts developed ac-
tive TB. No opportunistic infection, anaphylaxis, or serum sickness reaction was 
reported. Four GLM-treated pts reported infusion reactions; none was serious. 
Conclusions. In pts with active PsA, IV GLM maintained clinically meaningful 
improvements through 1yr.Through Wk60, the safety profile was consistent with 
other anti-TNFs, including subcutaneous GLM.
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WEIGHT-LOSS IMPROVES DISEASE ACTIVITY IN PATIENTS 
WITH PSORIATIC ARTHRITIS AND OBESITY
Klingberg E.1, Bilberg A.2, Björkman S.3, Hedberg M.4, Jacobsson L.1, Forsblad-
d’Elia H.1, Carlsten H.1, Eliasson B.3, Larsson I.3 
1Dept. of Rheumatology and Inflammation Research, Sahlgrenska Academy at 
the University of Gothenburg; 2Institute of Neuroscience and Physiology, Section 
of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy at University 
of Gothenburg; 3Institute of Medicine, Sahlgrenska Academy at University of 
Gothenburg; 4Dept. of Rheumatology, Borås, Sweden 
Introduction/Aim. Psoriatic arthritis (PsA) is highly associated with obesity. 
This study aimed to determine the effects of weight-loss treatment with Very 
Low Energy liquid Diet (VLED) on disease activity in patients with PsA (Caspar 
criteria) and obesity (inclusion criterion: body mass index BMI ≥33 kg/m2).
Methods. VLED, giving a daily energy intake of 640 kcal, was taken during 12 
or16 weeks, depending on BMI. Afterwards an energy restricted diet was succes-
sively reintroduced. The treatment was given within a structured framework for 
support and medical follow-up during twelve months. Treatment with DMARDs 
and/or biologics was held constant from 3 months before baseline until 6 months 
after. The patients were assessed with 66/68 joints count, back-mobility tests, 
psoriasis body surface area (BSA), questionnaires, ESR, CRP and BMI at base-
line, 3 and 6 months. The number of patients reaching Minimal Disease Activity 
(MDA), Psoriatic Arthritis Response Criteria (PsARC) and American College of 
Rheumatology (ACR) response criteria was calculated. 
Results. Totally 41 patients, 63% women, with median age 54 years (IQR 48-
62), completed the study. The median weight-loss was 18.7 kg (IQR 14.6-26.5) 
or 18.6% (IQR 14.7-26.3) of the baseline weight. A majority of the disease ac-
tivity parameters improved significantly. The number of patients with MDA in-
creased from n=12 (29%) to n=22 (54%), (p=0.002). PsARC was reached by 
46.3% (n=19). The ACR 20, 50, 70 responses were 51.2% (n=21), 34.1% (n=14) 
and 7.3% (n=3) respectively.
Conclusions. Weight-loss treatment with VLED had significant positive effects 
on disease activity in joints, spine, entheses and skin in patients with PsA and 
obesity. The study provides proof of the concept that obesity is involved in the 
pathophysiology of PsA.
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A FLARE OF SACROILIITIS UNDER VEDOLIZUMAB THERAPY 
FOR CROHN DISEASE
Sunar İ., Yilmaz G., Yalçin A.P., Ataman Ş.
Ankara University Faculty of Medicine, Division of Rheumatology, Dept. of 
PRM, Ankara, Turkey
Introduction. Vedolizumab is a humanized monoclonal antibody binding to 
α4β7 integrin and blocking the interaction between α4β7 integrin and mucosal 
addressing cell adhesion molecule-1. Vedolizumab is used in moderate to severe 
Crohn disease (CD) as an alternative to TNF inhibitor therapy. While there are 
some case reports on beneficial effects of vedolizumab on both inflammatory 
bowel disease and spondyloarthropathy (SpA), some authors have submitted ex-
acerbations of arthritis or sacroiliitis. Herein, we present a case with CD and SpA 
experiencing a flare of musculoskeletal symptoms under vedolizumab therapy.
Case Presentation. A 35 year-old female patient applied to our rheumatology 
outpatient clinic with complaints of right heel and low back pain. She had been 
diagnosed with CD in 2009 and with SpA in 2010. After treatment failure with 
meselazine, azathioprine, prednisolone, and budenoside she commenced inflixi-
mab. Due to allergic reaction with infliximab, she was prescribed adalimumab 
until she became pregnant. After delivery, on not responding sufficiently to reini-
tialization of adalimumab, she received vedolizumab therapy within an interna-
tional project. Her physical examination revealed tenderness in right Achilles 
tendon insertion and plantar fascia. Sacroiliac compression test was positive at 
the right, and FABER test was bilaterally positive. 
The MASES score was 3. BASDAI score was 7.2, and ASDAS-CRP was 3.1. 
Laboratory analyses were within normal limits (CRP:2.2 mg/l, ESR:7 mm/h, 
HLA B27:(-)). Right ankle ultrasound was unremarkable except for calcaneal 
spur (no effusion and Doppler sign). However, sacroiliac joint MRI reported bi-
lateral early sacroiliitis characterized with irregularity, sclerosis and bone mar-
row edema. We did not stop vedolizumab treatment, rather administered a physi-
cal therapy program comprising interferential current and cold pack and kept her 
in close follow-up. 
Conclusion. Vedolizumab is a novel integrin blocker used for the treatment of 
active inflammatory bowel diseases. Although some improvements with vedoli-
zumab was noted on SpA in the literature, other reports indicate flares of sacro-
iliitis. This may be a paradoxical effect which may also be observed with TNF 
inhibitors (1).
Reference
  1. BANSE C, ARMENGOL-DEBEIR L, VITTECOQ O: Effectiveness of vedolizumab 
for Crohn’s disease with spondyloarthritis in fail with two TNF blocking agents. 
Joint Bone Spine 2017 Jul 11. doi:10.1016/j.jbspin.2017.06.006. 
Fig. 1. STIR coronal MRI of the sacroiliac joint, focal bone marrow edema of the 
left sacral facet.
 
Fig. 2. T1 coronal MRI of the sacroiliac joint, bilateral focal erosive changes and 
minimal sclerosis.
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PREDICTING PERSISTENCE, DISCONTINUATION AND 
SWITCHING PATTERNS OF NEWLY INITIATED TNF INHIBITOR 
THERAPY IN ANKYLOSING SPONDYLITIS PATIENTS 
Hunter T.1, Deodhar A.2, Bolce R.1, Schroeder K.1, Sandoval D.1
1Eli Lilly and Company, Indianapolis; 2Oregon Health and Science University, 
Portland, USA 
Aim. The objective of this study was to analyze treatment patterns in the 2 years 
following the initiation of TNF inhibitors (TNFi) in AS patients.
Methods. Adult patients with ≥2 AS diagnostic codes were included in this ret-
rospective analysis of data from the Truven MarketScan Commercial Claims da-
tabase. Patients who newly initiated a TNFi from 01/01/2009- 12/31/2013 were 
indexed on their first TNFi. Patients were required to have a 1-year pre-index 
clean period of TNFi and continuous enrollment 1-year pre-index and 2-years 
post-index. Demographic, clinical, and treatment patterns were analyzed. Treat-
ment patterns included switching to a new TNFi, discontinuation (≥90-day gap in 
therapy), or persistence (no gaps in therapy ≥90-days) during the 2-year follow-
up period. Logistic regression analyses predicting persistent vs. non-persistent 
and switching vs. discontinuation were conducted.
Results. 1,372 AS patients (846 males/ 526 females) met the inclusion criteria 
for this study. Adalimumab was the first biologic for the majority of patients 
(44.6% males/ 43.3% females), followed by etanercept (40.4% males/ 41.6% 
females), infliximab (10.4% males/ 10.8% females), golimumab (4.6% males/ 
3.8% females), and certolizumab pegol (0.0% males/ 0.4% females). During the 
follow-up period, 32.6% of male patients were persistent on their first TNFi, 
while only 22.8% of female patients were persistent. The majority of male 
(67.4%) and female (77.2%) patients discontinued their first TNFi. Patients pre-
scribed cDMARDs (p=0.0482) were more likely to be persistent, while females 
(p=0.0005) and opioid users (p=0.0002) were less likely to be persistent on their 
first TNFi. Among those that discontinued their first TNFi, 32.8% (n=187) of 
males and 43.6% (n=177) of females switched to a 2nd TNFi., Non-opioid analge-
sic users (p=0.0002), cDMARD users (p=0.0438), and females (p=0.0129) were 
more likely to switch to a 2nd TNFi. 
Conclusion. This study suggests that the majority of AS patients do not remain 
on their index TNF inhibitor 2 years post initiation.
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LEVELS OF ADHERENCE TO BIOLOGIC THERAPY OF SPON-
DYLOARTHRITIS PATIENTS
Madeira N., Cardoso A., Trinca R., Silva C., Santos H., Miguel C., Barcelos F., 
Medeiros D., Campanilho Marques R., Cunha Miranda L.
Instituto Português de Reumatologia, Lisbon, Portugal
Introduction. In clinical practice, knowledge about patients’ levels of adher-
ence to medication is important. Our purpose is to evaluate our Spondyloarthritis 
(SpA) patients’ adherence to biologic therapy. 
Material and Methods. Observational and cross-sectional study which included 
patients with SpA according to 2009 Assessment of SpondyloArthritis interna-
tional Society (ASAS) classification criteria (CC) for axial spondyloarthritis or to 
2011 ASAS CC for peripheral spondyloarthritis (including psoriatic arthritis), on 
biologic therapy, able to complete questionnaires autonomously and who agreed 
to participate. Demographic and clinical data were collected. To assess adher-
ence, the Morisky Medication Adherence Scale (MMAS-8) was used and the 
patients were asked to apply it only to biologic therapy. Based on the MMAS-8, 
3 levels of adherence were considered: 0 to <6 (low); 6 to <8 (medium); 8 (high). 
Statistics: Kruskal-Wallis, Mann-Whitney and Chi-Square tests, p<0.05, SPSS® 
v.23.
Results. 55 patients were included; 54 on anti-TNF, 1 on Ustekinumab. Table I 
reports the variables collected. The mean MMAS-8 score was 6.9±1.1, the me-
dian 7.0 (6.5–8.0), the minimum 3.5 and the maximum 8. The adherence was 
medium in 52.7%, high in 27.3% and low in 20.0% patients. No significant dif-
ferences were found in levels of adherence for gender, current age, disease dura-
tion, time on treatment with the current biologic, BASDAI, BASMI, BASFI, 
ASDAS, HADS-A, HADS-D and FACIT-F (p>0.05).
Table I. Means and medians of demographic and clinical variables.
 Mean±SD Median (IQR)
Current age - years 49.9±12.3 49.1 (40.8-57.7)
Disease duration – years 18.0 ±11.1 14.1 (10.3-21.9)
Time on treatment with the current biologic 4.2±2.6 4.3 (2.0-6.0) 
   therapy - years 
BASDAI 2.9±2.2 2.8 (0.9-4.7)
BASMI 3.4±1.4 3.4 (2.4-4.2)
BASFI 2.5±2.3 2.2 (0.5-3.7)
ASDAS 2.1±0.9 2.2 (1.4-2.8)
HADS-A 5.8±4.1 5.0 (1.0-9.0)
HADS-D 5.2±4.2 4.0 (1.0-9.0)
FACIT-F 37.3±10.1 36.0 (30.0-47.0)
Conclusion. The adherence to biologic was at least medium for 80.0% of pa-
tients. Demographic and clinical variables, including disease activity do not seem 
to influence it.
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SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY 
PROFILE OVER LONG-TERM EXPOSURE (UP TO 4 YEARS) IN 
PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS – UP-
DATED POOLED ANALYSIS OF THREE PHASE 3 TRIALS
Deodhar A.1, Baraliakos X.2, Marzo-Ortega H.3, Sieper J.4, Martin R.5, Porter B.5, 
Shete A.6
1Oregon Health and Science University, Portland, USA; 2Rheumazentrum 
Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany; 3NIHR LBRC, 
Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic & Musculo-
skeletal Medicine, University of Leeds, Leeds, UK; 4Charité University Medi-
cine Berlin, Berlin, Germany; 5Novartis Pharmaceuticals Corporation, East 
Hanover, USA; 6Novartis Pharma AG, Basel, Switzerland
Aim. To report updated longer-term (up to 4 years of treatment) pooled safety 
and tolerability data for secukinumab (SEC) from three phase 3 studies in AS.
Methods. 371, 219, and 226 patients with active AS were randomised in the 
MEASURE 1, 2 and 3 studies, respectively. Study design, efficacy, and safety 
results have been previously reported.1,2 SEC doses included intravenous 10 mg/
kg or subcutaneous (s.c.; 75–300 mg) loading, followed by s.c. maintenance dos-
ing (75, 150, or 300 mg). Analysis included pooled patient (pt)-level data from all 
patients who received any dose (≥1) of SEC up to the date of the last pt attending 
the Week 156 study visit in MEASURE 1, and for all pts up to the Week 156 in 
MEASURE 2 and the Week 104 in MEASURE 3. Exposure adjusted incidence 
rates (EAIR) were calculated for differences in treatment exposure.
Results. 794 patients were included in the analysis (representing 1943.1 patient-
years of SEC exposure). The most frequently reported AE was viral upper res-
piratory tract infection (Table). EAIRs for serious infections, Candida infections, 
inflammatory bowel disease (IBD), uveitis, neutropenia and major adverse car-
diac events (MACE) were low (Table).
Conclusions. SEC was well tolerated during long-term treatment (up to 4 years) 
in patients with AS, with a favourable safety profile consistent with previous 
reports (1, 2).
References
  1. PAVLEKA K et al.: Arthritis Res Ther 2017; 22: 285. 
  2. BAETEN D et al.: N Engl J Med 2015; 373: 2534-48.
Table. Summary of pooled safety: Entire safety period.
1AEs in any SEC group with an EAIR >5 during entire safety perod; 2Rates are for 
system organ class; 3Rates are for high level term; 4Rates are for preferred term (PT) 
(IBD PT data are reported for unspecified IBD); 58 cases of Crohn’s disease, 3 were 
flares in patients with history at baseline; 64 cases of ulcerative colitis, 1 was a flare with 
a history at baseline; 726 cases of uveitis, 14 were flares in patients with a history  at 
baseline; 8Values are based on Novartis MedDRA query, which comprises [1] any MI; 
[2] any CVA; [3] all other CV events that are fatal, out of a listing of 2200+ terms; CI: 
confidence interval; N: number of patients in analysis; n: number of patients with event.
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SECUKINUMAB SUSTAINS IMPROVEMENTS IN SIGNS AND 
SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS 
THROUGH 2 YEARS (FUTURE 4)
Everding A.1, Kivitz A.2, Nash P.3, Tahir H.4, Pellet P.5, Wang Yi.5, Pricop L.6, 
Abrams K.6
1Hamburger Rheuma Forschungszentrum II, Hamburg, Germany; 2Altoona Cen-
tre for Clinical Research, Duncansville, USA; 3University of Queensland, Bris-
bane, Australia; 4Barts Health NHS Trust, London, UK; 5Novartis Pharma AG, 
Basel, Switzerland; 6Novartis Pharmaceuticals Corporation, East Hanover, USA
Aim. To assess long-term efficacy of subcutaneous secukinumab 150mg through 
104 weeks in patients with active psoriatic arthritis (PsA) in the FUTURE 4 study 
(NCT02294227). Additionally, to explore efficacy of increasing 150mg dose to 
300mg. 
Methods. The study design has been described elsewhere.1 Secukinumab 150mg 
was increased to 300mg as early as Week-36 if active signs of disease were ob-
served based on physician’s judgement; secukinumab 300mg was maintained 
thereafter. Clinical responses were analyzed as observed. Pre-escalation and post-
escalation (12-16, 20-24 weeks) ACR and PASI responses were also evaluated. 
Results. Of 341 randomized patients, 272 completed 104 weeks. Both secuki-
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numab 150mg doses were superior to placebo with numerically greater and 
earlier responses observed with secukinumab 150mg loading dose (LD) vs 
secukinumab 150mg no-LD through Week 52 (1). Clinical responses at Week 
52 were sustained through Week 104 (table). Overall, 136 patients were esca-
lated to secukinumab 300mg (median 309 days): 46 in secukinumab LD, 45 in 
secukinumab no-LD, 45 in placebo. Post-escalation, proportion with non/low 
level ACR/PASI response improved with corresponding increase in proportion 
with a moderate/high response level (table). Exposure adjusted incidence rates 
(/100 patient-years) for adverse events of interest for secukinumab 150mg and 
300mg, respectively, were inflammatory bowel disease (0.2, 0.1), malignancies 
(1.3, 1.0) and major adverse cardiac events (0.7, 1.0). Two deaths were reported 
(1/ dose group).
Table.
Data is presented as observed; Pre-escalation is defined as the last assessment done on or before the 
patient administered the 300 mg dose; patients with both pre and all post-dose escalation assessments 
data available are included in analysis PASI reported only in patients with at least 3% body surface 
area affected with psoriasis at baseline.
M is number of patients evaluated; N is number of randomized patients.
*For PASI response, N=55 and N=54 for secukinumab 150 mg and 150 mg no-load, respectively; 
considered non-responders in the dose escalation subset. ACR: American College of Rheumatology; 
PASI: Psoriatic Arthritis Severity Index.
Conclusion. Secukinumab 150mg demonstrated significant and sustained im-
provements in the signs and symptoms of PsA through 104 weeks. Efficacy can 
improve with dose escalation from 150mg to 300mg in patients with lower than 
expected ACR/PASI responses at the time of dose escalation; safety profile was 
consistent with previous reports.
Reference
  1. KIVITZ A, et al.: J Clinical Rheumatol 2018; 24 (Suppl. 3).
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SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS PATIENTS 
WITH OR WITHOUT ENTHESITIS AT BASELINE – POOLED 
ANALYSIS FROM TWO PHASE-III TRIALS OVER 2 YEARS
Wallman J.K.1, Schett G.2, McInnes I.B.3, Quebe-Fehling E.4, Rasouliyan L.5, 
Pricop L.6, Fasth A.E.7, Gaillez C.4 
1Lund University, Lund, Sweden; 2University of Erlangen-Nuremberg, Erlangen, 
Germany; 3University of Glasgow, Glasgow, UK; 4Novartis Pharma AG, Basel, 
Switzerland; 5RTI Health Solutions, Barcelona, Spain; 6Novartis Pharmaceuti-
cals Corporation, East Hanover, USA; 7Novartis Sverige AB, Täby, Sweden
Aim. To report the impact of secukinumab (SEC) treatment on efficacy outcomes 
in active psoriatic arthritis patients with or without baseline (BL) enthesitis by 
post-hoc analysis of pooled data from the FUTURE-2 (NCT01752634) and FU-
TURE-3 (NCT01989468) studies.
Methods. Efficacy outcomes (ACR20/50/70, PASI 90, HAQ-DI, SF-36 PCS, 
and DAS28-CRP) were analysed post-hoc in patients with BL enthesitis (BLE; 
N=466) or without BL enthesitis (No BLE; N=246). Given imbalance in some 
baseline clinical and demographic characteristics, logistic regression/ANCOVA 
was performed as a function of the BL characteristics (enthesitis status, gender, 
DAS28, HAQ-DI, TNFi-status), treatment groups, and the interaction between 
treatment groups and enthesitis status. Binary variables are presented as observed 
and as predicted probabilities and continuous variables as least-square means. 
Results reported for SEC-300 and -150mg.
Results. Overall, 65% of patients had BLE. BL demographics were balanced be-
tween BLE and No BLE groups except for a higher proportion of females, higher 
tender joint count, DAS28-CRP, disability (HAQ-DI), and lower physical func-
tion (SF-36 PCS) in BLE than No BLE patients. At Week 16, improvements in all 
outcomes were similar in both groups treated with SEC-300mg, but were lower 
(except for PASI 90) in SEC-150mg treated BLE patients (Table). Improvements 
in these outcomes followed similar trends at Week 104. Unadjusted and adjusted 
results are presented (Table).
Conclusions. Although patients with BLE had more severe BL characteristics 
than patients with No BLE, SEC showed higher efficacy than placebo at Week 16 
and sustained efficacy through 2 years in both groups. In BLE patients, greater 
magnitudes of improvement were observed with SEC-300mg than 150mg in both 
unadjusted and adjusted analyses.
Table.
aResponse, %
bAt Week 16/104: BLE patients, n=144/132 (SEC 300), 159/145 (SEC 150), 163 (PBO); No BLE, n=95/91 (SEC 300), 
79/70 (SEC 150), 72 (PBO)
cAt Week 16/104: BLE patients, n=66/56 (SEC 300), 82/62 (SEC 150),  63 (PBO); No BLE, n=38/34 (SEC 300), 46/36 
(SEC 150), 30 (PBO) (psoriasis subset)
dAt Week 16/104: BLE patients, n=135/116 (SEC 300), 149/111 (SEC 150), 70 (PBO); No BLE patients,  n= 92/83 
(SEC 300), 77/62 (SEC 150), 70 (PBO)
eAt Week 16/104: BLE patients, n=137/117 (SEC 300), 150/113 (SEC 150), 144 (PBO); No BLE patients,  n=92/82 
(SEC 300), 78/63 (SEC 150), 70 (PBO)
f At Week 16/104: BLE patients, n=135/115 (SEC 300), 149/110 (SEC 150), 142 (PBO); No BLE patients,  n=92/80 
(SEC 300), 77/62 (SEC 150), 70 (PBO)
g Least squares mean of change from BL
hLogistic regression/ANCOVA was performed, adjusting for gender, TNFi-status, and BL DAS28-CRP and HAQ-DL. 
Estimates for the adjusted binary outcomes represent predicted probabilities from the logistic regression model applied 
to the given analysis set based on the estimated coefficients from the following terms in the model: treatment group, 
enthesitis at BL, and the interaction between treatment group  and enthesitis at BL
ANCOVA, analysis of covariance; CRP: C-reactive protein; DAS28: disease activity score in 28 joints; HAQ-DI: Health 
Assessment Questionnaire Disability Index; PASI: Psoriasis Area and Severity Index. 
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REDUCING AVOIDABLE BIOLOGIC DRUG WASTAGE 
THROUGH COLLABORATION BETWEEN PATIENTS AND CARE 
PROVIDERS: THE LEEDS SPONDYLOARTHRITIS SERVICE 
EXPERIENCE
Barr A., Pickles D., Fadl N., Dou J., Vandevelde C., Dubash S., Freeston J.E., 
Marzo-Ortega H.
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and 
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of 
Leeds, UK
Introduction. We manage a cohort of approximately 4,000 patients with inflam-
matory arthritis receiving biologic therapies with an estimated annual cost of 
£15,000,000. One quarter have Spondyloarthritis (SpA). Biologic drug wastage 
is recorded by home-delivery companies on receiving returned ‘unusable’ stock. 
Intravenous biologic wastage occurs when infusions are not attended. A reduc-
tion in actual drug wastage in self-injectable and intravenous biologics has never 
previously been demonstrated. 
Methods. SpA biologic wastage (on the infusions ward or by home-delivery 
companies) was reviewed retrospectively for from January 2016 until May 2017. 
A patient information leaflet (PIL) targeting waste avoidance was developed and 
sent simultaneously to all patients. The same wastage was measured in the fol-
lowing four months. 
Results. In the 16 months prior to the PIL intervention £81,000 of wastage was 
measured. Of this, 80% was infusion ward wastage (n=45 infliximab infusions) 
and 20% was self-injectable biologics. Following the PIL intervention, no wast-
age was measured either on the infusion ward or for self-injectable biologics. 
This resulted in a projected annual saving of £61,000 (80% was avoidable inf-
liximab wastage). The total number of patients taking biologics did not change 
significantly over time. No adverse events associated with the PIL have occurred. 
Etanercept/benepali data are incomplete as the project is ongoing and are there-
fore excluded from the analysis. The post-intervention survey identified that 
90% were approving of and satisfied with the PIL and agreed that reducing drug 
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wastage is a shared responsibility involving stakeholders: patients, clinicians and 
drug companies or providers. 
Conclusion. This is the first quality improvement project that has demonstrated 
an actual reduction in measured biologic drug wastage. It represents a simple, 
reproducible and sustainable intervention which carries high satisfaction through 
a collaborative effort between patients and health care providers and offers po-
tential significant savings in a time of austerity. 
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SIX-MONTH TREATMENT RESULTS FOR USTEKINUMAB (UST) 
AND TNF INHIBITORS (TNFI) IN PSORIATIC ARTHRITIS (PsA) 
IN EUROPE (PsABio-STUDY)
Smolen J.S.1, Bergmans P.2, Bondareva I.3, de Vlam K.4, Gremese E.5, Joven-
Ibáñez B.6, Korotaeva T.V.7, Nurmohamed M.T.8, Sfikakis P.P.9, Siebert S.10, 
Smirnov P.2, Theander E.2, D’Abrosca V.11, Gossec L.12
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tals Leuven, Belgium; 5IRCCS-Fondazione Policlinico Gemelli-Catholic Univer-
sity of Sacred Heart, Rome, Italy; 6University Hospital 12 de Octubre, Madrid, 
Spain; 7Nasonova Rheumatology Research Institute, Moscow, Russia; 8Rheuma-
tology and Immunology Center, VU University Medical Centre & Reade, Am-
sterdam, The Netherlands; 9Athens University, Greece; 10University of Glasgow, 
UK; 11Università della Campania “Luigi Vanvitelli”, Naples, Italy; 12Sorbonne 
Université, Paris, France
Introduction. PsABio (NCT02627768) investigates efficacy, tolerability, and 
persistence of UST and TNFi as 1st, 2nd or 3rd line biologic therapy in PsA in 
routine care in 8 European countries. We present 6-month joint-related outcomes.
Methods. As-observed data for joint-related outcomes were available for 152 
UST and 151 TNFi-treated patients. Baseline and 6-month data were compared 
within the treatment cohorts.
Results. UST was used as 1st bDMARD in 40%, 2nd in 36%, and 3rd in 24% of 
patients; the respective proportions for TNFi were: 64%, 29%, and 7%. Mean 
(SD) baseline DAS28 scores were 4.3 (1.2) and 4.3 (1.2) for UST and TNFi, 
respectively, and improved at 6 months by means of -1.3 (95%CI: -1.6, -1.0) and 
-1.3 (-1.6, -1.1). Significant improvements were seen in both cohorts across all 
treatment lines and subtypes of PsA. DAPSA scores improved significantly from 
baseline mean (SD) values of 34.7 (21.2) and 35.4 (19.1) for UST and TNFi, 
respectively, by means of -18.4 (95%CI: -22.2, -14.5) and -19.5 (-22.5, -16.5), 
with 12% and 16% of patients achieving DAPSA remission and 38% and 37% 
achieving low disease activity. Minimal disease activity was achieved in 29% 
of UST and 30% of TNFi-treated patients. Spinal involvement was significantly 
improved with reductions in BASDAI and ASDAS scores in both cohorts. 
Conclusion. Both UST- and TNFi-treatment in routine care result in statistically 
significant improvements in joint- and spine-related measures at 6 months.
Acknowledgements. Study sponsor: Janssen.
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IMMUNE RESPONSE PROFILING REVEALS SIGNALING NET-
WORKS MEDIATING TNF-BLOCKER FUNCTION AND PRED- 
ICTORS OF THERAPEUTIC RESPONSES IN SPONDYLOAR-
THRITIS PATIENTS
Menegatti S.1, Rouilly V.2, Latis E.1, Yahia H.1, Leloup C.1, Miceli-Richard C.1,3,4, 
Dougados M.3,4, Bianchi E.1,4, Rogge L.1,4
1Institut Pasteur, Immunoregulation Unit, Dept. of Immunology; 2DATACTIX, 
Paris; 3Paris Descartes University, Dept. of Rheumatology-Hôpital Cochin, As-
sistance Publique-Hôpitaux de Paris, EULAR Center of Excellence; 4Unité Mix-
te de Recherche, Institut Pasteur/AP-HP Hôpital Cochin, Paris, France
Anti-TNF therapy has revolutionized treatment of spondyloarthritis. However, 
its impact on the immune system is incompletely understood and predicting ther-
apeutic responses remains a major challenge since TNF-blockers are effective 
only in a subpopulation of patients.
We have used whole-blood, syringe-based assays performing ex-vivo stimula-
tion (TruCulture assays) to define the impact of anti-TNF therapy on immune 
responses to a broad range of microbial stimuli or agonists targeting specific 
immune pathways in spondyloarthritis patients (n=67), and to identify immuno-
logical correlates predicting therapeutic responses.
We found that anti-TNF therapy induces specific changes in immune responses 
of patients to distinct pathogens as well as to stimuli targeting selected immune 
receptors. These changes can be measured in stimulated, but not resting immune 
cells and are detectable already after a single injection of anti-TNF (one-week of 
treatment). Modular transcriptional repertoire analysis of the stimulation cultures 
revealed that the gene modules most affected by anti-TNF therapy are NFkB 
transcription factors and target genes, as well as modules characterizing distinct 
monocyte/macrophage populations. Our findings suggest that TNF-blockers im-
pact monocyte/macrophage polarization and break TNF- and IL-1-dependent 
feed-forward loops of NFkB activation.
We also tested if induced immune responses in patients before initiation of ther-
apy could predict therapeutic responses. Using machine-learning algorithms, we 
found that the expression of several molecules regulating key steps of leucocyte 
migration and invasiveness was significantly higher in patients responding to 
TNF-blockers, while expression of cytotoxic and T/NK-cell genes was higher 
in non-responders. The random forest model that we trained and validated using 
13 selected biomarkers has a predictive power of 83%. We propose that immune 
response profiling of patients before therapy is a powerful new strategy to help 
guiding clinical decisions.
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SWITCHING TO BIOSIMILARS: WHAT HAVE WE LEARNED?
Marona J.1,2, Gomes J.L.1,2, Rodrigues-Manica S.1,2, Lopes C.1,2, Costa T.1,2, 
Mourão A.F.1,2, Silva I.1, Costa M.1, Mateus M.1, Araújo M.P.1, Falcão S.1,2, 
Castelão W.1, Crespo C.L.2, Branco J.C.2,1*, Pimentel-Santos F.M.1,2*
1Hospital de Egas Moniz (CHLO), Rheumatology; 2CEDOC, NOVA Medical 
School (FCM), Lisbon, Portugal
*These authors were equal contributors to this project.
Introduction. Biosimilar drugs intend to be as effective and safe as their origina-
tors and would increase patients’ access to biological therapies. There is emerg-
ing evidence from randomized controlled trials concerning this issue, but data 
from real world clinical practice is still lacking. The decision of switching is not 
always promoted by physicians, as in this case.
Materials and Methods. AxSpA and PsA patients treated in a tertiary referral 
rheumatology center, who were switched from IFX and ETN originators to bio-
similars were included. Disease activity and adverse events 3 months before and 
after switching were assessed (∆ means the difference between 3 months before 
and after the switch). A standardized questionnaire was applied to patients con-
cerning the switching process. Hospital savings were calculated.
Results. Overall, 27 patients (15 males) were included, 4 switching to IFX bio-
similar and 23 to ETN biosimilar. There were no significant changes in efficacy 
for both biosimilars compared to their originators in all disease subgroups [e.g. 
∆BASDAI: 2.1 (IQR:5.4) and 0.6 (IQR:2.2), ∆ASDAS:0.99 (IQR:2.2) and 0.19 
(IQR:1) in axSpA, results presented for IFX and ETN, respectively]. Similar re-
sults were found in terms of VAS (0-10). There were 3 mild to moderate adverse 
events reported with ETN and none with IFX. There were approximately 2300 
euros savings’! Although globally, most patients didn’t change the degree of sat-
isfaction with the switch, they considered it to be made by economic reasons and 
believed they had no other choice.
Conclusion. In this case-study, where a non-medical switch has occurred, dis-
ease activity was largely unaffected and there were no safety major problems. 
Despite the savings and patients’ positive opinion, switching should remain a 
case-by-case clinical decision made primarily by both the physician and the pa-
tient on an individual basis.
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MONOTHERAPY WITH BIOLOGICS VS COMBINED THERAPY 
IN PATIENTS WITH PSORIATIC ARTHRITIS (APSOR) PERIPH-
ERAL
Montero D., Ruiz E., Fernández O., Torre I., Intxaurbe A.R., Pérez C., Blanco 
J.M., Rivera N., Ibarguengoitia O., Guerrero E., Calvo I., Galindez E., García-
Vivar M.L.
Rheumatology Service, Basurto Universitary Hospital, Bilbao, Spain
Background. In Apsor, adding methotrexate to biological treatment (BT) has 
not shown clinical superiority against monotherapy, although it could improve 
survival in the records of some biologics.
Objective. To assess the clinical response and the duration of the BT depending 
on the type of drug and whether it is combined with DMARD or not. Identify 
predictors that advise prolonged maintenance of DMARD.
Methods. Retrospective study of 75 patients with peripheral Apsor in BT seen 
from Dec 2016 to Dec 2017 in our center. We collected clinical, epidemiological 
and activity data of the disease by DAPSA in both groups.
Results. 64 patients. Evolved disease (mean 133 (63) months).
76.6% had received previous FAMES. 34.4% have received one (15.6%) or more 
previous biological tx.
730 Clinical and Experimental Rheumatology 2018
Poster Presentations Eleventh International Congress on Spondyloarthritides
Current tx: 70.3% in monotherapy, 20.7% in combination therapy, median tx 
61.8 (43.7).
67.2% are in remission or low activity according to medical criteria; 93.3% by 
DAPSA (median 3.79 [1.13–8.18].) The referral DAPSA matches the doctor’s as-
sessment. No differences by age, comorbidities, previous tx and activity between 
the monotherapy combination groups.
There was a numerical difference in the duration of the biological tx in favour 
of the combined regimen, but it does not reach statistical significance. The mean 
duration of tx with etanercept was 34.6 months higher than that of tx with adali-
mumab (p=0.004).
Conclusions. In our setting, the use of biological drugs in monotherapy is com-
mon in peripheral Apsor, and most patients are well controlled by DAPSA, both 
in monotherapy and in combined regimen. A prospective study with greater in-
clusion of patients is necessary to see differences in survival, but the high pro-
portion of current tx with etanercept and its longer duration seems significant 
considering the established prescription protocols.
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IS THE CLINICAL AND THERAPEUTIC PROFILE RELATED TO 
SATISFACTORY RESPONSE TO APREMILAST IN PSORIATIC 
ARTHRITIS?
De la Morena I.1, Espinosa M.2, Godoy H.2, Martinez À.3, Santos C.4, Martínez 
A.5, Fernández M.6, Fernández-Llanio N.6, Palma D.7, Moreno M.J.7, Haro A.7, 
Conesa A.8, Calvo J.9
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Méndez, Lorca; 8Hospital General de Castellón, Castellón; 9Hospital General de 
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Aim. To identify the factors that are related with response to Apremilast (APR) 
in Psoriatic Arthritis (PsA).
Materials and Methods. An observational and analytical multicenter retrospec-
tive study. There are included PsA patients treated with APR after two years 
of commercialization. Clinical and demographic data were collected: disease 
duration, previous treatments, cutaneous and joint involvement pattern defined 
as: joint exclusively, non joint and mixed (by several domains combination). It 
was collected: duration of treatment, tolerance, adverse events, and reason for 
APR choice: intolerance or toxicity to csDMARD, preference before bDMARD 
contraindication or caution to bDMARD, csDMARD and bDMARD inefficacy, 
csDMARD and bDMARD intolerance. The effectiveness was considered as a 
dicotomic variable (Yes/No) by clinical criteria. 
Results. There were included 89 patients, 46(51.7%) males, the mean age was 
53.99±12.3 years, and the PsA disease duration was 7.28±6.25 years. The PsA 
pattern was: joint 29(32.6%), non joint, 12(13.5%) and mixed 48(53.9%). The 
reason for APR choice was: intolerance or toxicity to cDMARD 13 patients, 
preference before BT 28, contraindication or caution to BT 22, inefficacy to cD-
MARD or BT 18, intolerance to cDMARD and BT 1, and due to clinical profile 
1. After a mean treatment duration with APR of 8.13(0-23) months a total of 33 
withdrawals were found (17 due to inefficacy and 16 due to intolerance), treat-
ment was maintained on them a mean of 4.3(0-12) months. 56 patients keep with 
APR a mean of 10.4(2-23) months, 22 of them among 1 and 2 years of evolution. 
The treatment was effective in 61(68.5%) patients. Comparisons of the different 
variables analyzed did not show significant differences among the responders 
and non responders patients. 
Conclusions. We have not found a specific profile that relates with a satisfactory 
response to APR. 
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IMPACT OF BIOLOGICS ON IMMUNE CELLS IN AXIAL SPON-
DYLOARTHRITIS
Rosine N.1, Koturan S.1, Yahia H.1, Menegatti S.1, Leloup C.1, Bianchi E.1,3, 
Miceli-Richard C.1,2,3, Rogge L.1,3
1Institut Pasteur, Immunoregulation Unit; 2Paris Descartes University, Dept. of 
Rheumatology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, EULAR 
Center of Excellence; 3Unité Mixte de Recherche, Institut Pasteur/AP-HP Hôpital 
Cochin, Paris, France
Introduction. Biologics (anti TNF and anti IL-17A) are revolutionizing the man-
agement of Axial Spondyloarthritis (AxSpA). However, the impact of these treat-
ments on the immune system and in particular on immune cells is unknown. The 
objective was to identify cells affected by biologics using spectral cytometry and 
an unsupervised analysis.
Patients and Methods. 1 control group and 2 groups of patients with AxSpA 
(according to the ASAS criteria) were recruited: patients treated with anti-TNF 
and anti IL-17A. We have designed 2 panels of 14-color cytometry allowing 
analysis of the main immune cells (T cells, B cells, NK cells and monocytes) 
and analysis of T cell subpopulations (naive, memory, “Th1” -like, “Th2” -like, 
“Th17” -like, “Tfh”-like, T γδ and MAIT). To perform the unsupervised analy-
sis, we used the viSne algorithm.
Results. ViSNE represent in 2D a n-dimensional distribution of m events isolat-
ing unbiased clusters of cells. The comparison of the 2 groups of patients with 
the control group showed a cluster of monocytes specific to the two treatments 
and a cluster of B cells specific to the patients treated with anti-TNF. A second 
analysis showed 2 T-cell signatures (TCR Vα7.2+ CD8+ CD45RAint CD27+ 
CCR6+ CD161+) specific to patients under anti-TNF and (TCR γδ+ CD4- CD8- 
CD45RA- CD161int CD27- CXCR3+) specific to patients under anti IL-17A.
Conclusion. The combination of spectral cytometry associated with an unsuper-
vised analysis allowed us to identify clusters of T cells, B cells and monocytes 
specific to biologics suggesting a modification in phenotype profiles according 
to the treatment.
P86
A CROSS-SECTIONAL EVALUATION OF A BRAZILIAN SPONDY-
LOARTHRITIS SINGLE-CENTER TERTIARY COHORT: CLINI-
CAL AND TREATMENT DATA 
Shimabuco A., de Moraes J.C.B., Sampaio-Barros P., Goldenstein-Schainberg 
C., Gonçalves C.R., Saad C.G.S.
Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo, Brazil
Background. The use of synthetic DMARDS (sDMARDs) in spondyloarthritis 
(SpA) has been increasingly questioned and restricted to peripheral disease, on the 
other hand, the use of immunobiological agents for the treatment of SpA has been 
further improved by anti-TNF and the release of new drugs with other mecha-
nisms such as secukinumab (anti-IL17, SEC) and ustekinumab (anti-IL12 / 23, 
UST). The objective of our study is to describe clinical and treatment data of a 
SpA patients cohort followed at the outpatient clinic of a Brazilian single center.
Methods. 516 SpA patients evaluated from January 2017 to January 2018. Data 
from electronic medical records assessed including diagnosis, disease character-
istics, treatment and disease activity at the last visit.
Results. Among all patients 195 (37.8%) were classified as Ankylosing Spon-
dylitis (AS), 198 (38.3%) psoriasis arthritis (PsA), 66 (12.8%) axial non-radio-
graphic or peripheral SpA, 42 (8.1%) SpA related to inflammatory bowel disease 
and 15 (3.0%) as reactive arthritis patients. From all SpA patients 190 (36.8%) 
have no axial disease, with isolated peripheral arthritis. Regarding treatment, 
321 (62.2%) patients were under sDMARDs as monotherapy or in association 
[156/321 (48.6%) methotrexate (MTX); 125/321 (38.9%) sulfasalazine (SSZ)]; 
298 (57.7%) patients used NSAIDs. Concerning biological therapy 204 (39,5%) 
received biological DMARDs (bDMARDs) [68 infliximab (IFX), 59 adali-
mumab (ADA), 35 etanercept (ETA), 6 golimumab (GOL), 2 certolizumab pegol 
(CTZ), 23 secukinumab (SEC), 10 ustekinumab (UST), 1 rituximab (RTX)]. 
Concerning disease activity, 25/125 (20%) of AS patients had ASDAS ≥2.1 and 
42/198 (21%) of PsA patients had active arthritis in the last visit.
Conclusions. The description of epidemiological and clinical data of this cohort 
reinforces high prevalence of peripheral disease in Brazilian SpA patients. This 
fact could explain the wide use of sDMARDs in these patients. The frequency 
use of bDMARDs is in parallel with literature data including non-antiTNF drugs 
as SEC and UST.
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PERSONALISING CARE: USING INFLIXIMAB DRUG TROUGH 
AND ANTI-DRUG ANTIBODY LEVELS IS A SAFE AND COST 
EFFECTIVE TREATMENT STRATEGY IN SPONDYLOARTHRITIS
Dubash S., Bryer D., Fitton J., Barr A., Vandevelde C., Marzo-Ortega H., Freeston 
J.E.
Leeds Institute for Rheumatic and Musculoskeletal Medicine and Leeds Teach-
ing Hospitals NHS Trust, Leeds, UK
Introduction/Aim. Personalised medicine tailors treatment to the individual. Bi-
ologic drug dosing is standardised and there is paucity of data about the rationale 
and efficacy of dose adjustment. We conducted a service evaluation to measure 
serum infliximab drug trough level (DL) and anti-drug antibody (ADAb) in our 
axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patient cohort re-
ceiving bio-originator infliximab with the aims of: 1) informing clinical decisions 
before possible switch to biosimilar, 2) assessing the impact of this approach to 
our clinical practice within the Leeds SpA Service.
Materials and Methods. Patients provided consent and were counselled on the 
measurement of DLs and ADAbs to infliximab including possible treatment out-
comes. A treatment algorithm was developed to guide the treating physician on 
treatment changes. Clinical and outcome data were recorded as per routine practice.
Results. A total of 53 patients were identified. Based upon the disease activity, 
DL and ADAb, bio-originator infliximab was discontinued in 3 (6%) subjects, the 
infusion interval was extended in 8 (15%) and reduced in 3 (6%). The infliximab 
dose was reduced in 3 (6%) patients with no change in frequency interval. Four 
patients (8%) changed to an alternative biologic, either TNFi or alternative mode 
of action due to persistent high disease activity on infliximab. ADAbs were ab-
sent in 20/28 (71%) patients on concomitant methotrexate (MTX). Very high titre 
ADAbs were identified in 8 (15%) subjects with corresponding very low (n=2) or 
undetectable (n=6) DLs suggesting a likely drug-neutralising effect. A total of 24 
(45%) patients switched to biosimilar (CT-P13).
Estimated cost-savings from drug regime changes based on therapeutic drug 
monitoring by DL and likely drug neutralisation (low DL and high ADAb) were 
an additional £28,689 per annum and biosimilar switching (to CT-P13) saved an 
estimated £41,184 per annum.
Discussion/Conclusion. These data from a small cohort suggest that measur-
ing ADAbs and DLs personalises treatment and is a cost-effective strategy in 
infliximab-treated SpA. This approach unlocks the potential of “personalised 
medicine” which supports individualised treatment and brings significant sav-
ings to the healthcare provider.
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THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEU-
MATIC DRUGS (bDMARDs) IN TARGETING DISEASE REMIS-
SION IN AXIAL SPONDYLOARTHRITIS (axSpA): A SYSTEMATIC 
LITERATURE REVIEW (SLR)
Cruz-Machado A.R.1, Manica S.R.2, Silva J.L.3, Pimentel-Santos F.M.2, Tavares-
Costa J.3, Vieira-Sousa E.1
1Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, 
CHLN and UIR, IMM; 2Rheumatology Dept., Hospital Egas Moniz, Centro Hos-
pitalar de Lisboa Ocidental; 3Rheumatology Dept., Unidade Local de Saúde do 
Alto Minho, Ponte de Lima, Portugal
Introduction. The treat-to-target concept is currently recommended in axSpA 
and remission is the main objective of treatment. Although consensual definitions 
of remission are lacking, ASAS-Partial Remission (ASAS-PR) and ASDAS-In-
active Disease (ASDAS-ID) have gained wide acceptance as clinical remission-
like definitions in current practice. 
Objectives. In this review we assessed the efficacy of different bDMARDs in 
achieving ASAS-PR or/and ASDAS-ID as remission-like outcomes. Data from 
placebo-controlled phases of randomised controlled trials (RCT), conducted in 
radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-AxSpA) patients 
were included.
Methods. A SLR was performed using the MEDLINE database (May 1 
2018). The PICO (P, population; I, intervention; C, comparison; O, outcome) 
concept was used according to: Patients - adults with r-axSpA or nr-axSpA; In-
tervention - any bDMARD; Comparison - placebo and/or any different drug; 
Outcomes: ASAS-PR and ASDAS-ID. 
Results. After screening 152 references, 19 RCTs fulfilled the inclusion cri-
teria – 15 concerning tumor necrosis factor inhibitors (TNFi), 3 secucinumab 
(anti-IL17A) and 1 sarilumab (anti-IL6R). Only 1 RCT used these remission-
like endpoints as primary outcomes, in the remaining, ASAS-PR or ASDAS-ID 
were studied as secondary measures. ASAS-PR was the preferred remission-like 
definition, used in 18 of the trials. Concerning TNFi, all the 15 trials provide 
evidence of efficacy in achieving remission – ASAS-PR and ASDAS-ID vary-
ing between 16–61.9% and 24–40.2%, respectively. Secucinumab was effective 
in achieving ASAS-PR when an initial intravenous loading dose was applied 
(MEASURE 1). Sarilumab was not effective in inducing remission in axSpA.
Conclusions. Clinical trials addressing remission-like concepts as outcomes are 
limited. Considering nowadays aimed treatment targets, these data raise the un-
met need for improved treatment options favoring optimized remissions rates in 
axSpA patients.
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THE GO-DACT PROTOCOL: A RANDOMIZED CONTROLLED 
TRIAL TO COMPARE THE EFFICACY OF GOLIMUMAB IN 
COMBINATION WITH METHOTREXATE (MTX) VERSUS MTX 
MONOTHERAPY, IN IMPROVING DACTYLITIS AND ENTHES-
ITIS, IN MTX NAÏVE PSORIATIC ARTHRITIS PATIENTS
Vieira-Sousa E.1, Canhão H.2, Fonseca J.E.1 on behalf of the GO-DACT research 
team
1Rheumatology Research Unit, Instituto de Medicina Molecular and Rheumatol-
ogy Dept., Hospital de Santa Maria, Lisbon Academic Medical Centre; 2CEDOC, 
NOVA Medical School, Lisbon, Portugal
Introduction. Dactylitis is a hallmark manifestation of psoriatic arthritis (PsA) 
and a key feature for PsA diagnosis. Active dactylitis is associated with a higher 
risk of erosions and can severely impact function. Therapeutic strategies for dac-
tylitis are largely empirical, with absence of properly designed trials assessing 
dactylitis as primary endpoint. 
Methods. GO-DACT is an investigator-initiated multicentric trial, involving 13 
sites. Patients older than 18 years, with PsA diagnosis and active dactylitis (ten-
derness score≥1), refractory to NSAIDs, for 3 months, were included. Patients 
were randomized on a 1:1 ratio, to either MTX in combination with golimumab 
or placebo, for a period of 24 weeks. The primary aim of this trial is to determine 
differences of efficacy between the two treatment arms, in improving dactylitis 
(and enthesitis), as assessed by the dactylitis severity score (DSS) at 24 weeks. 
Key secondary outcomes include: Leeds dactylitis index (LDI), Leeds enthesi-
tis index (LEI), joint counts, psoriasis area and severity index (PASI) and nail 
psoriasis severity index (NAPSI), health assessment questionnaire (HAQ), Der-
matology life quality index (DLQI) and composite indexes for disease activity. 
The effect of treatment arms, on different tissue compartments, will be analysed 
by contrast-enhanced magnetic resonance imaging (MRI), with high resolution 
images for dactylitis, at baseline and 24 weeks. 
Results/Conclusions. The results from GO-DACT are expected to have impli-
cations in clinical practice, bringing robust and valid data for the definition of 
dactylitis treatment stratification and algorithm. GO-DACT will also contribute 
to understand dactylitis pathogenesis through the assessment of treatment effi-
cacy, namely in distinct tissue compartments as defined by MRI. https://www.
clinicaltrials.gov (NCT02065713) 
Acknowledgments. This investigator-initiated trial was supported by a research 
grant from Merck Sharp and Dohme.
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TUMOR NECROSIS FACTOR INHIBITORS PERSISTENCE IN 
PSORIATIC ARTHRITIS PATIENTS
Vieira-Sousa E.1, Eusébio M.2, Ávila-Ribeiro P.1, Khmelinskii N.1, Machado 
A.R.1, Martins-Rocha T.3, Bernardes M.3, Santos-Faria D.4, Leite Silva J.4, San-
tos H.5, Miguel C.5, Carvalho P.6, Costa T.7, Teixeira L.8, Meirinhos T.9, Nero P.10, 
Santos M.J.2,8
1Rheumatology Dept., CAML, Lisbon; 2Portuguese Society of Rheumatology, 
Lisbon; 3Rheumatology Dept., CHSJP, Porto; 4Rheumatology Dept., ULSAM, 
Ponte de Lima; 5IPR; Lisbon; 6Rheumatology Dept., HUC, Coimbra; 7Rheuma-
tology Dept., HEM, Lisbon; 8Rheumatology Dept., HGO, Lisbon; 9Rheumatol-
ogy Dept., CHBV, Aveiro; 10CUF Descobertas, Lisbon, Portugal
Introduction. Tumor necrosis factor inhibitors (TNFi) lead to a dramatic im-
provement in the management of psoriatic arthritis (PsA). Nevertheless, a sig-
nificant proportion of patients do not respond or are intolerant to TNFis. We 
aim to assess TNFis drug retention and main reasons for TNFi discontinuation 
in PsA patients.
Methodology. PsA patients registered at Rheumatic Diseases Portuguese Regis-
try (Reuma.pt), with at least one TNFi prescription were included. Drug retention 
for a 1st, 2nd and 3rd-line TNFi was assessed by Kaplan-Meier survival analysis. 
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Results. 750 PsA patients were identified, with a mean age of 47.6 years; 50.3% 
female. The overall retention of TNFi was 49±40 months when treated with a 1st 
TNFi, decreasing to 36±33 months for the 2nd TNFi, and 23±23 months for the 
3rd TNFi. After being treated with a 1st TNFi, 35.8% discontinued therapy, 53.5% 
due to lack or loss of effectiveness and 24.4 % due to adverse events. The rates 
of discontinuation for the 2nd and 3rd TNFi were of 39% and 54%, respectively, 
with similar proportions for lack/loss of effectiveness and adverse events for the 
2nd (62.3%; 21.6%) and 3rd TNFi (63.0%; 22.2%).
Conclusions. The overall persistence of a 1st TNFi was high in PsA patients reg-
istered at Reuma.pt, decreasing on average 13 months, in those who switched to 
a 2nd TNFi or a 3rd TNFi. Lack or loss of response were the main reason for TNFi 
discontinuation, independently of TNFi position.
Acknowledgement. Financial support for statistics and report writing was pro-
vided by Novartis, S.A.
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REMISSION RATES OF BIOLOGIC-TREATED SPONDYLO- 
ARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS
Ávila-Ribeiro P., Lourenço-Teixeira R., Fonseca J.E., Vieira-Sousa E.
Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, 
UIR, Instituto de Medicina Molecular, Universidade de Lisboa, Centro Académico 
de Medicina de Lisboa, Portugal
Introduction. Biologic disease-modifying drugs (bDMARD) have revolution-
ized the treatment of non-psoriatic spondyloarthritis (SpA) and psoriatic arthritis 
(PsA), allowing clinical remission to become a realistic goal.
Aim. To characterize bDMARD-treated SpA and PsA patients in remission from 
a single-center cohort.
Methods. Register data (Reuma.pt) from Hospital de Santa Maria was extracted 
on August/2017 for patients with SpA and PsA treated with bDMARDs. Remis-
sion was defined as ASDAS <1.3 for SpA and DAS28 <2.6 for PsA. The number 
of patients in remission at the last consultation and at every assessment during the 
previous year was determined. These patients were further characterized regard-
ing disease duration, time to bDMARD, type of bDMARD, previous switches, 
co-medication, persistence in remission and labour situation.
Results. From a cohort of 168 SpA and 117 PsA patients treated with bDMARDs, 
23.8% of SpA and 29.9% of PsA patients were in remission at the last visit. Mean 
age(±SD) was 44.0(±10.1) years for SpA and 52.4(±10.5) years for PsA. Disease 
duration was 18.2(±10.0) years for SpA and 16.2(±8.5) years for PsA. Time from 
diagnosis to first bDMARD was 7.2(±7.5) years for SpA and 6.6(±5.5) years 
for PsA. 6.7% were retired because of their disease, 50.7% were active. 80% of 
patients had never switched a bDMARD,13.3% had switched once, 6.7% had 
switched twice or more.
Persistence on current bDMARD(±SD) was 82(±49) months in SpA and 62(±53) 
months in PsA patients. Persistence on each biologic was roughly proportional 
to the drug’s commercialization time. Persistent (12 month) remission was ob-
served in 12 SpA and 23 PsA patients (respectively, 7.1% and 19.7% of patients 
treated with bDMARDs).
Conclusion. Remission is a feasible target in a small proportion of patients in 
real-life clinical setting. Even patients with longstanding disease can reach sus-
tained remission after starting bDMARDs. Most patients in remission persisted 
in their first bDMARD for several years.
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DISPENSATION OF IMMUNOBIOLOGICALS IN MODEL OF 
ASSISTED THERAPY IN THE SUS REDUCES COSTS WITH 
IMMUNOBIOLOGICAL IN ANKYLOSING SPONDYLITIS
Scomparin-Silverio L.R.1, Saad C.G.S.1, Souza F.H.C.1, Miossi R.1, Ribeiro 
A.C.M.1, Waisberg M.G.1, Bonfiglioli K.R.1, Prado L.L.1, Teich V.2, Bonfá E.1, 
Moraes J.C.B.1
1Faculdade de Medicina da Universidade de São Paulo, Disciplina de Reumato-
logia; 2INSPER - Instituto de Ensino e Pesquisa, São Paulo, Brazil
Introduction. In the 2000s, immunobiologicals were introduced as a treatment 
option in rheumatologic conditions, including Ankylosing Spondylitis (AS). The 
incorporation of these medications by the Public Health System in Brasil (SUS) 
brought clinical advances in the effective control of the inflammatory process 
and the quality of life of patients. With the increase in indications and the volume 
of patients attended, the impact on the SUS budget has increased, requiring a 
rational and efficient dispensation process.
Objectives. To compare the model of assisted therapy with that of direct dispens-
ing of SUS for immunobiological drugs.
Materials and Methods. All the visits were included in the center responsible 
for the model of assisted therapy, with medication provided by the Ministry of 
Health for patients presenting in the year 2015. In each of the consultations were 
recorded: medication, number of bottles, prescribed dose, dose received, cancel-
lations, faults and estimates of bottles that would have been dispensed by the 
direct system. The financial value was calculated according to the acquisition 
value by the Ministry of Health in 2015.
Results and Discussion. A total of 1688 consultations were performed for pa-
tients with AS by the model of assisted therapy. 669 (23.26%) bottles of a total 
volume of 2876 prescribed vials of all medications intended for the treatment 
were no longer used, reducing expenses by € 109.369,57 (23.78%). Based on the 
same savings percentage of the model in question for the whole SUS and accord-
ing to data from DATASUS for AS in 2015, the reduction of immunobiological 
expenses for the treatment would be € 11.503.979,10.
Conclusion. The model of assisted therapy considerably reduces the volume of 
dispensed bottles compared to the model of direct dispensing bringing significant 
reduction of expenses to the SUS.
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DEMYELINATION ASSOCIATED WITH ANTI-TNFα TREATMENT 
IN SPONDYLOARTHRITIS PATIENTS – A SINGLE-CENTER 
EXPERIENCE
Kougkas N.1, Vourakis G.2, Avgoustidis N.1, Mitsias P.D.2,3,4, Sidiropoulos P.1, 
Mastorodemos V.C.2, Bertsias G.1
1Dept. of Rheumatology, University Hospital of Heraklion Crete; 2Dept. of Neu-
rology, University Hospital of Heraklion Crete; 3School of Medicine, University 
of Crete, Greece; 4Dept. of Neurology, Henry Ford Hospital, Detroit, USA
Introduction. Demyelination is a rare, but potentially severe adverse event as-
sociated with anti-TNFα treatment. There are only scarce data regarding the in-
cidence and long-term neurological outcome of this complication in cohorts of 
Spondyloarthritis (SpA) patients.
Objective. To assess the incidence, correlation with disease activity and total 
exposure to anti-TNFα treatment in SpA patients who developed CNS demy-
elination.
Methods. Retrospective, case-control series from a tertiary care hospital. We 
reviewed all medical records of patients with SpA treated with at least one anti-
TNFα agent(s) during 2003–2015 and developed clinical and radiologic features 
consistent with CNS demyelination. Patients were evaluated through multidisci-
plinary approach.
Results. A total of 9 patients (7 women, 2 men) out of 530 (1.69%) developed 
demyelinating disease following anti-TNF therapy. Two patients had peripheral 
SpA associated with psoriasis and 7 axial SpA (5 related to inflammatory bowel 
disease, 1 to psoriasis, 1 ankylosing spondylitis). At the time of the neurologic 
event, patient age was (mean ± SD) 50.3±12.2 years and the duration of treat-
ment with anti-TNF was 31.9±36.9 months (minimum to maximum: 3 to 120 
months). Anti-TNF agents included infliximab (n=3), adalimumab (n=3), etaner-
cept (n=2) and golimumab (n=1). Two patients had previously been treated with 
another anti-TNF agent (1 with adalimumab, 1 with infliximab and adalimumab). 
At the time of demyelination, 3 patients were in remission and 6 in low disease 
activity; mean ± SD DAPSA was 11.3±1.34 and BASDAI was 1.06±1.05. All 
but one patient received pulse intravenous methylprednisolone alone (n=5) or 
in combination with glatiramer (n=3). Anti-TNFα treatment was discontinued in 
all patients; yet, 2 patients continued with secukinumab due to relapse of SpA. 
Regarding neurological outcome, 6 patients evolved into frank multiple sclero-
sis (MS); two patients were diagnosed as transverse myelitis and the remaining 
patient as MS-like disease.
Conclusions. Demyelinating disease is a rare complication of anti-TNFα treat-
ment in SpA, which may occur when the disease is in remission or low disease 
activity. Despite anti-TNF discontinuation, some cases will evolve into definitive 
MS, suggesting possible a priori predisposition.
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PSORIASIS AND INFLAMMATORY BOWEL DISEASE MODELS 
CO-OPERATE WITH BIOMECHANICAL STRESS IN TRIGGER-
ING MILD JOINT INFLAMMATION
Gulino G.R.1, Van Mechelen M.1,2, Lories R.1,2
1Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering 
Center, KU Leuven; 2Division of Rheumatology, UZ Leuven, Leuven, Belgium
Introduction. Spondyloarthritis (SpA) and Psoriatic arthritis (PsA) is a chronic 
inflammatory skeletal disease associated with psoriasis (PsO) and inflammatory 
bowel disease (IBD). Being the attachment sites of tendons and ligaments into 
the bones, entheses are a site of biomechanical stress and are considered as a 
primary disease localization. Increasing evidence supports the hypothesis that 
biomechanical stress, together with inflammatory triggers from distant sites such 
as the skin or the intestine, can contribute to the onset of SpA and PsA.
Objectives. We aim to understand early events leading to SpA and PsA by com-
bining a protocol of forced exercise in mice with simultaneous locally-induced 
cutaneous or intestinal inflammation.
Methods. Eight weeks old C57/Bl6 male mice were treated with imiquimod 
cream (IMQ) on a shaved area of the back skin or with dextran sodium sulphate 
(DSS) dissolved in the drinking water. Control mice were left untreated. After-
wards, half of the mice were subjected to a forced treadmill running protocol to 
increase biomechanical stress. Control mice with or without IMQ or DSS treat-
ment did not run. Severity of cutaneous or intestinal inflammation was assessed 
clinically and by histology, knees and paws were evaluated with microCT and 
histological analysis. 
Results. Assessment of the skin and intestine confirmed the presence of local in-
flammation in the treated mice. Subsequently, systemic inflammation developed 
as demonstrated by the presence of trabecular bone loss and changes in spleen 
size. In the joints, histological assessment revealed mild synovitis and enthesitis 
in the IMQ- or DSS-treated mice, slightly boosted by the forced exercise regimen. 
Conclusions. Local induction of PsO- or IBD-like inflammation also triggers a 
systemic response with inflammation-associated bone loss and discrete signs of 
joint disease. Forced exercise has a negative impact on this joint disease, provid-
ing new support to the hypothesis that biomechanical stress contributes to disease 
manifestations in SpA and PsA.
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THE JAK1 SELECTIVE INHIBITOR FILGOTINIB REGULATES 
BOTH ENTHESIS AND COLON INFLAMMATION IN A MOUSE 
MODEL OF PSORIATIC ARTHRITIS
Robin-Jagerschmidt C., Lavazais S., Marsais F., Ongenaert M., Monjardet A., Cau-
vin A., Saccomani C., Parent I., Merciris D., Chanudet E., Blanqué R., Borgonovi 
M., Lepescheux L., Auberval M., Dupont S., Clément-Lacroix P., Galien R.
Galapagos SASU, Romainville, France
Introduction/Aim. The JAK1-selective inhibitor filgotinib (GLPG0634, GS-
6034) displayed efficacy and safety in phase 2 studies in rheumatoid arthritis 
(RA) patients. Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory 
disease sharing features with RA in addition to syndromes such as psoriasis and 
Inflammatory Bowel Disease. We evaluated the efficacy of filgotinib in an IL-
23-induced mouse model of PsA.
Methods. Overexpression of IL-23 was induced by hydrodynamic delivery of 
mIL23 enhanced Episomal Expression Vector (SBI) to B10.RIII mice. Paw and 
finger inflammation was assessed by clinical scoring and in vivo molecular im-
aging. Enthesis, colon and fingers were collected for transcriptomic analysis. 
Infiltration of inflammatory cells and pSTAT3-positive cells were analyzed in 
Achilles’ enthesis, subcutaneous area, skin and gut.
Results. High levels of IL-23 were maintained during the time-course of the 
study and were correlated with severity of the inflammation in fingers, paw and 
enthesis. Filgotinib significantly improved clinical scores, strongly decreased 
immune cell infiltration in the skin and tended to prevent neutrophil/granulo-
cyte infiltration in paw. Transcriptomic analysis of enthesis, fingers and colon 
showed that filgotinib reversed the effect of IL-23 for a consistent number of 
genes. Filgotinib also significantly counteracted pSTAT3 induction in the sub-
cutaneous area and in the epidermis, further demonstrating target engagement in 
the diseased tissue.
Conclusions. In a mouse model of PsA, filgotinib improved global clinical scores 
and decreased signs of inflammation in hindlimbs. Target engagement both in 
hindlimbs and colon was also demonstrated. These data support the evaluation of 
filgotinib in patients with PsA.
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mTOR BLOCKADE BY RAPAMYCIN DECREASES ARTHRITIS 
AND SPONDYLITIS DEVELOPMENT AND SEVERITY IN HLA-
B27 TRANSGENIC RATS
Chen S.1, van Tok M.1, Pots D.1, Taurog J.2, van de Sande M.1, Baeten D.1, van 
Duivenvoorde L.1
1Academic Medical Center, Dept. of Clinical Immunology and Rheumatology, 
Amsterdam, The Netherlands; 2UT Southwestern Medical Center, Rheumatic 
Diseases Division, Dallas, USA
Introduction/Aim. HLA-B27 misfolding is thought to play an important role in 
the pathogenesis of spondyloarthritis (SpA), possibly through triggering of ER 
stress and the unfolded protein response. One of the mechanisms that regulates 
the unfolded protein response is autophagy. Autophagy is a process that degrades 
proteins, cytoplasmic particles and organelles in lysosomes and is regulated by 
protein kinases, mechanistic target of rapamycin (mTOR) and AMP activated 
protein kinase. The aim is to study whether blockade of mTOR will affect spon-
dyloarthritis development and/or severity in the Mycobacterium tuberculosis (M. 
tub)-induced disease HLA-B27tg rat model.
Methods. HLA-B27/Huβ2m transgenic rats were immunized with heat-inac-
tivated M. tub in IFA and treated with 1.5 mg/kg rapamycin or vehicle intra-
peritoneally. Rats were clinically scored for SpA development and afterwards 
histology and mRNA measurements were performed.
Results. In the prophylactic experiment 72.7% and 18.2% rapamycin treated rats 
developed arthritis and spondylitis compared to respectively 100% (p=0.0225) 
and 92.3% (p<0.0001) control animals. Also severity of SpA was significantly 
decreased in rapamycin treated animals compared to control treated animals; 
mean arthritis severity of diseased rats was respectively 0.45 versus 7.15 on a 
scale from 0-12 (p<0.0001) and mean spondylitis severity was respectively 0.18 
versus 2.07 on a scale from 0-3 (p<0.0001). Clinical findings were confirmed 
by histology with a significant decrease of inflammation, bone- and cartilage 
destruction and new bone formation in peripheral joints of treated rats compared 
to vehicle treated rats and a similar trend was observed in spinal joints. Also in a 
therapeutic setting rapamycin treatment decreased arthritis severity (p=0.0317) 
and spondylitis severity (p=0.0159). Histology for the therapeutic experiment is 
currently being performed as well as mRNA analyses for autophagy genes and 
pro-inflammatory cytokines.
Conclusion. mTOR blockade significantly suppressed SpA in the M. tub-induced 
disease HLA-B27tg rat model of SpA.
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CERTOLIZUMAB PEGOL LIKE MICE EQUIVALENT REDUCES 
INFLAMMATION AND BONE DAMAGE IN TRANSMEMBRANE 
TNF TRANSGENIC MICE
Vieira-Sousa E.1, Silva S.P.1, Vidal B.1, Lopes I.P.1, Canhão H.2, Fonseca J.E.1
1Rheumatology Dept., Hospital de Santa Maria and Rheumatology Research 
Unit, Instituto de Medicina Molecular, Lisbon Academic Medical Centre; 
2CEDOC, EpiDoC Unit, NOVA Medical School, Lisbon, Portugal
Introduction. Transmembrane (tm)TNF (TgA86) mice is a transgenic line that 
spontaneously develops peripheral arthritis and spondylitis, mimicking human 
spondyloarthritis (SpA). The aim of this work is to study TNF blockade in this mice 
SpA-like phenotype, focusing on histological inflammation and bone damage.
Methods. tmTNF (TgA86) mice were treated with certolizumab pegol like prod-
uct mice equivalent (Ab501), 100mg/kg twice weekly intraperitoneal or vehicle, 
for 12 weeks, in a preventive (4 weeks of age) and therapeutic (10 weeks of age) 
settings. A semi-quantitative score for the severity of histologic inflammation and 
bone damage, was applied to paws and spine.
Results. 15 tmTNF (TgA86) mice at 4 weeks of age (preventive group) and 
14 tmTNF (TgA86) mice at 10 weeks of age (therapeutic group) were treated 
with Ab501; and 30 tmTNF (TgA86) mice with vehicle, for 12 weeks. A statisti-
cally significant reduction in inflammatory infiltrate (p≤0.001), lining cells layers 
(v≤0.05), erosions (p≤0.05) and global inflammatory scores (p0.05) of the paws, 
was observed in Ab501 treated group, when compared with vehicle group, both 
in 4 and 10 weeks of age treatment groups. In the spine, statistically significant 
reductions in inflammation (p≤0.001), intervertebral disc destruction (p0.05), 
cartilage damage (p≤0.001), bone erosion (p≤0.05), and ectopic chondrocytes/
chondrophyte scores (p≤0.001) was also depicted in Ab501 treated group in com-
parison with vehicle.
Conclusions. Certolizumab pegol like product mice equivalent reduced histo-
logic inflammatory infiltrate in paws and spine of tmTNF (TgA86) mice. Bone 
damage, as defined by erosions in the paws and spine and ectopic chondrocytes/
chondrophyte formation in the spine, also significantly improved.
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EXPLORING THE ANKYLOSING SPONDYLITIS-ASSOCIATED 
REGULATORY SNPs AT THE RUNX3 LOCUS
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Introduction/Aim. Of the >100 genetic associations with ankylosing spon-
dylitis (AS), the RUNX3 transcription factor (TF), involved in diverse immu-
nological processes, has a very robust (10−15) association (1). Understanding 
the mechanism remains the biggest challenge. We have recently demonstrated 
that the association between AS and the single nucleotide polymorphism (SNP) 
rs4648889 located in a 2kb regulatory locus upstream of the RUNX3 promoter 
can be explained by allele-specific effects on TF recruitment altering gene ex-
pression, specifically in CD8+T-cells (2). In addition, another closely adjacent 
SNP, rs4265380, shows functional effects (TF recruitment, histone marks enrich-
ment, cell count) in CD14+monocytes (3). 
The objectives of this work are: 1) to dissect the functional effects of the different 
RUNX3 SNPs, acting especially in CD8+T-cells and monocytes; 2) to identify 
the different interacting partners (i.e. TFs) binding at the RUNX3 locus in the 
presence of the AS-associated variants. 
Materials and Methods. We used publicly available datasets (including “Road-
map”) to define the RUNX3 epigenetic landscape and in vitro functional studies 
to characterize the effects of specific genetic variants, providing critical func-
tional evidence for their role in AS. 
Results. (1) Roadmap data revealed a robust peak for open chromatin, TF bind-
ing and interaction of RUNX3 with different genomic loci (chromosome 1), in 
GM12878 lymphoblastoid cells; (2) preliminary DNA pull-down affinity capture 
experiments, followed by Mass Spectrometry, identified the whole range of TFs 
(DNA/protein “interactome”) binding to a 50bp probe including rs4648889 at the 
RUNX3 locus, in CD8+T-cells; (3) initial gene/pathway analysis highlighted a dis-
tinct contribution from the Ikaros TF and associated chromatin-remodeling proteins. 
Discussion. We provide strong evidence the 2kb region upstream the RUNX3 gene 
has a plausible functional role in AS, probably by regulating gene transcription. 
Conclusions. These observations are critically important not only in identifying 
specific cell types that play a pathogenic role in AS, but also in defining dysregu-
lated pathways and potential therapeutic drug targets.
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Introduction/Aim. We examined FDR’s of ankylosing spondylitis (AS) patients 
with chronic inflammatory back pain (CIBP), non-inflammatory CBP (NICBP) and 
no CBP for clinical features, HLA-B27 alleles and persistence of IBP over time.
Materials and Methods. 548 FDRs of AS patients were divided into three 
groups, excluding those with a diagnosis of AS at baseline visit and, within each 
group, blood relatives: 1) No CBP (only subjects > 40 years of age who never had 
CBP (n=159)); 2) NICBP (n=79), and 3) CIBP (n=152).
Results. FDRs with CIBP were younger than those with NICBP (45.1 years 
versus 55.6 years, p=0.0002)), and had a higher frequency of heel pain (52.7% 
versus 43.4%, p=0.005). HLA-B27 occurred in 57% of FDR’s with CIBP com-
pared 49.4% of those with NICBP (p=n.s.) and 39.6% of those <40 years with 
no CBP (p=0.005, OR=1.9 (C.I. 1.2, 2.97). Of 23 patients with CIBP at baseline 
seen again 67.04±31.02 months later, 16 (72.7%) still had CIBP, whereas on 
four (33%) of 13 NICBP patients (33%) seen 61.23±31.84 months later were 
still symptomatic. Of the remaining nine, three developed CIBP and six had 
symptoms resolve. Of the 13 without CBP at baseline seen 75.46±29.90 months 
later, 11 remained asymptomatic, two developed CIBP and none developed non 
inflammatory CBP.
Conclusions. These data suggest FDR’s of AS patients with CIBP have a young-
er age at onset, a higher frequency of heel pain, and higher frequency of HLA-
B27 than those who do not develop CBP. The CIBP phenotype remains stable and 
chronic over time in most, suggesting a need for long term treatment approaches 
in this group.
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Introduction and Aim. Increased level of protein phosphatase magnesium-de-
pendent 1A (PPM1A) in the synovium and serum of ankylosing spondylitis (AS) 
has been implicated in the bony ankylosis through the regulation of osteoblast 
(OB) differentiation, yet little is known about potent mechanisms regulating the 
osteoclast (OC) differentiation involving the abnormal bone metabolism. Here, 
we reduced the expression of PPM1A in the macrophages known as OC precur-
sors by generating the conditional gene knockout (PPM1A+/) mice and evalu-
ated the effect of PPM1A on bone phenotype in these mice.
Materials and Methods. Bone phenotypes of wild-type (WT) and PPM1A ± 
mice were evaluated by micro-computed tomography. OC differentiation was 
induced by culturing bone marrow-derived macrophages (BMMs) in the pres-
ence of receptor activator of nuclear factor kappa-B (RANK) ligand and mac-
rophage colony-stimulating factor (M-CSF) and evaluated by counting tartrate-
resistant acid phosphatase (TRAP)-positive multinucleated cells. The mRNA 
expression of PPM1A, RANK and OC-specific genes was examined by reverse 
transcription-polymerase chain reaction. Protein levels of PPM1A and MAPKs 
in BMMs of WT and PPM1A ± mice were determined by Western blotting. The 
surface expression of RANK on BMMs was analyzed by fluorescence-activated 
cell sorting.
Results. Mice with conditional PPM1A knockout display reduced bone density 
and increased OC differentiation as well as expression of OC specific genes (DC-
STAMP, OC-STAMP, CTSK and TRAP) compared with WT littermates. Mecha-
nistically, reduced PPM1A function in OC precursors from seen in PPM1A+/- 
mice increased and mediated OC lineage commitment by up-regulating RANK 
expression dependently of p38 MAPK activation in response to M-CSF. The 
expression of PPM1A mRNA and PPM1A were down regulated in OC precur-
sors when stimulated by lipopolysaccharide. Similarly, in the PBMCs from AS 
patients, the ratio of RANK/PPM1A expression was correlated positively with 
disease activity score.
Conclusion. These results demonstrated that loss of PPM1A function in OC 
precursors in response to inflammatory signals contributes to the OC lineage 
commitment and differentiation via elevation of RANK expression through ac-
tivation of p38 MAPK signaling pathways. Thus, considering the association 
between PPM1A and RANK, ratio of RANK/PPM1A expression in AS patients 
could suggest the dynamic status of bone metabolism.
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IL-23 INDUCTION OF MDL-1+ MYELOID CELLS IS CRITICAL IN 
THE PATHOGENESIS OF PSORIATIC ARTHRITIS
Nguyen C.T.1, Hui D.1, Kang M.1, Gu R.1, Adamopoulos I.E.1,2
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Background/Purpose. Interleukin-23 (IL-23) and its cognate receptor interleu-
kin-23R (IL-23R) play a critical role in the pathogenesis of many autoimmune 
diseases, including EAE, rheumatoid arthritis, psoriasis and psoriatic arthritis. 
Herein we show that IL-23 induces myeloid activation via the engagement of 
MDL-1/CLEC5A receptor a member of C-type lectin superfamily, exclusively 
expressed in myeloid cells. 
Methods. To define the role of MDL-1 in IL-23 signaling and its contribution 
pathogenesis of psoriatic arthritis, we performed in vivo gene transfer of IL-23 in 
WT, IL-23RGFP reporter mice and MDL-1 deficient mice. We investigated the joint 
and skin inflammation in the presence or absence of IL-23R+ MDL-1+ cells and 
assayed inflammation using H&E and immunofluorescence staining, in conjunc-
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tion with various tissue specific biomarkers assayed by qRT-PCR, western blot, 
and ELISA to analyze gene expression, protein, and cytokine levels, respectively.
Results. In vivo gene transfer of IL-23 induced skin inflammation with increased 
number of CD11b+LY6G+, CD11b+LY6C+, CD11b+IL23R+ cells in skin and en-
hanced epidermal MDL-1+ cells. We further demonstrated that IL-23-induced pa-
thology was impaired in IL-23RGFP+/+ (non-functional IL-23R) and MDL-1-/- mice 
with less epidermal hyperplasia and skin (ears and dorsal skin) inflammation, 
compared with wild-type (WT) mice. Expression of skin inflammatory markers 
K16, S100A7-9, CXCL-1, and CXCL-2, phosphorylation of NFκB and AKT as 
well as neutrophil infiltration were also lower than WT counterparts. 
Conclusion. Our data show that MDL-1 is a critical component of IL-23 signal-
ing that dictates synovial and skin inflammation in vivo. Our data suggest that 
activation of myeloid cells via MDL-1 could be effectively targeted for the treat-
ment of spondylarthropathies.
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PROTEOMIC AND TRANSCRIPTOMIC PROFILING OF CELLS 
IN ANKYLOSING SPONDYLITIS PATIENTS IDENTIFIES A NOV-
EL, SYNOVIAL-RESIDENT CD8+ T CELL
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Introduction. Current data suggests that immune events in the gut may impact 
on joint inflammation in ankylosing spondylitis (AS) but what directs cells in the 
gut-joint axis is undefined. For this reason, we examined the expression of traf-
ficking molecules on immune cells using Cytometry by Time-of-flight (CyTOF), 
and the expression of differentially regulated genes using RNA-seq. Our objec-
tives are to utilize proteomic and transcriptomic analysis to 1) assess differential 
expression patterns of trafficking molecules between patients and controls, 2) 
generate joint-specific cellular signatures, and 3) obtain genetic profiles of note-
worthy cell subpopulations. 
Materials and Methods. Male subjects under 40 years of age fulfilling the mNY 
criteria were recruited. The following cells were surface stained using a 36-mark-
er antibody panel: (i) Peripheral blood mononuclear cells (PBMC) from AS pa-
tients, and healthy controls; (ii) Synovial fluid mononuclear cells (SFMC) from 
AS and rheumatoid arthritis (RA) patients. After acquiring on CyTOF2, data 
were analysed using various programs. Additionally, RNA-seq was performed 
on CD8+ T cell subpopulations from the synovial fluid. 
Results. Mature CD8+ T cells were increased in frequency in AS SFMC, with 
significant changes in their phenotype: β7+, CD103+, CD29+ and CD49a+ 
integrin expression was increased in CD8+CD45RO+ cells in AS SFMC vs 
paired AS PBMC (mean 7.51% vs 0.87%, p=0.0035). RNA-seq data analysis of 
CD103+CD49a+ cells in SFMC revealed elevated GZMA, GZMB, PRF1 and 
IL-10 cytokines, in addition to a cytotoxicity regulation profile. 
Conclusion. We identified a novel integrin-expressing mature CD8+ T cell sub-
set (CD49a+CD103+β7+CD29+) that appears to be more prevalent in AS SF 
than RA SF. These cells possess a dual proinflammatory and regulatory profile. 
Further experiments are ongoing to provide evidence of gut-joint trafficking ca-
pabilities and to examine the arthritogenic potential of these cells.
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TYK2 PROMOTES IL-23-INDUCED TYPE 3 IMMUNITY AND 
DISEASE PROGRESSION IN SPONDYLOARTHRITIS
Gracey E.1, Muller M.2, Miao W.3, Westlin W.3, Inman R.D.1
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Introduction. While current therapeutics for ankylosing spondylitis (AS) gener-
ally provide symptomatic control, their ability to prevent disease progression 
remains uncertain. The genetics and animal models of AS support a central role 
for Type 3 (IL-17) immunity driven in part by IL-23. Tyk2, a janus kinase, is a 
genetic risk factor for AS and is crucial for the intracellular signaling of IL-23 via 
STAT3 phosphorylation, making it a potential therapeutic target for AS. 
Methods. In a cohort of AS patients, TYK2 AS risk SNPs (rs12720356, 
rs34536443, rs35164067) were assessed by Taqman assay, TYK2 mRNA expres-
sion was assessed in whole blood by qPCR and at the cellular level in PBMC by 
Primeflow FACS. IL-23 and IL-6 induced pSTAT3 in human CD4+ T cells was 
assessed by FACS, with or without a selective Tyk2 inhibitor (NDI-031407). 
NDI-031407 was tested in the SKG and IL-23 minicircle murine models of spon-
dyloarthritis (SpA) with clinical scoring, histology and immune cell phenotyp-
ing. Pharmacologic (NDI-031407) or genetic (Tyk2-K923E mice) inhibition of 
Tyk2 was assessed in IL-23-stimulated, murine γδ T cells.
Results. TYK2 expression in whole blood or PBMC did not differ in AS patients 
vs controls. TYK2 expression did not stratify by risk SNPs, however the loss of 
function risk SNP, rs12720356, was associated with lower radiographic progres-
sion in the AS cohort. NDI-031407 potently inhibited STAT3 phosphorylation 
induced by IL-23, but not IL-6. In murine SpA models, NDI-031407 reduced 
dermatitis/arthritis and lowered Th17 cell frequency in popliteal lymph nodes. 
Both NDI-031407 and kinase-dead Tyk2-K923E blocked IL-23 induced pSTAT3 
and IL-17A/IL-22 production in γδ T cells in vitro.
Conclusion. AS-associated TYK2 risk variants promote disease through altered 
Tyk2 function. Genetic and pharmacologic inhibition of Tyk2 kinase activity 
blocks Type 3 immune cell activity and protects against experimental SpA.
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Introduction. Deregulation of microRNAs has been poorly studied in spondy-
loarthritis with published studies using diverse methodologies on small numbers 
of samples. Because CD4+ T-lymphocytes and monocytes are important cells in 
SpA pathophysiology, we wanted to assess the miR expression profile in these 
two cell types sorted from axial SpA patients.
Materiels and Methods. Two independent cohorts of 22 and 59 SpA patients 
were compared to 17 and 38 age and sex-matched controls. Both SpA patients 
and controls were recruited in the department of rheumatology at Cochin Hos-
pital in Paris, France. All SpA patients had an active disease (mean BASDAI 
score of 49±19) and were free of any biologic treatment. T-lymphocytes and 
monocytes were isolated from PBMC by direct isolation with magnetic micro-
beads (CD4+ and CD14+). 372 miRs were screened by qPCR on the exploratory 
cohort and only miRs showing a significant differential expression in the first 
cohort were analyzed in the validation cohort. An unpaired T-test was used for 
comparison of miR expression level.
Results. In the exploratory cohort, 51 (CD14+) and 70 miRs (CD4+) were found 
to be differentially expressed between patients and controls. Among these, 15 
miRs (in CD14+), and 12 miRs (in CD4+) were replicated in the second cohort. 
These validated miRNAs were found to play a key role in physiological path-
ways such as NFkB or TGFβ, Wnt signalling and monocyte differentiation, that 
have been involved in the pathophysiology of the disease.
Conclusion. We found a deregulation of miR expression in monocytes and CD4+ 
T-lymphocytes from patients with axial spondyloarthritis, which could contrib-
ute to the pathophysiology of the disease and be of interest from a therapeutic 
perspective.
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DEVELOPMENT OF A 19-PARAMETER FLOW CYTOMETRY 
PANEL TO ANALYZE KILLER IMMUNOGLOBULIN-LIKE RE-
CEPTOR (KIR)-EXPRESSING LYMPHOCYTES IN ANKYLOSING 
SPONDYLITIS
Sharma N., Lee J., Ermann J.
Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Introduction. Killer immunoglobulin-like receptors (KIRs) may play a role in 
the pathogenesis of ankylosing spondylitis (AS). Genetic associations with AS 
have been reported for the KIR3DS1/DL1 locus. KIR3DL1 and KIR3DL2 bind 
to HLA-B27/β2m/peptide complexes and HLA-B27 homodimers, respectively, 
and an expansion of KIR3DL2 positive IL-17A expressing CD4+ T cells has been 
observed in HLA-B27+ AS patients. The impact of KIR expression on other 
adaptive and innate lymphocyte subsets in AS has not been investigated in detail.
Materials and Methods. Human peripheral blood mononuclear cells (PBMCs) 
were prepared by Ficoll density gradient centrifugation. Cells were stimulated 
with PMA/ionomycin for 4 hours in the presence of brefeldin A/monensin fol-
lowed by surface and intracellular staining with fluorescently labeled antibodies 
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and MR-1 tetramers. Cells were analyzed using a 5-laser BD LSRFortessa flow 
cytometer and FlowJo software.
Results. Antibody clones were selected to distinguish 8 major lymphocyte sub-
sets by hierarchical gating: natural killer (NK) cells, mucosal-associated invari-
ant T (MAIT) cells, CD4+ T cells, CD8+ T cells, DN αβ T cells, γδ T cells (fur-
ther subdivided into Vδ1+, Vδ2+, and other γδ T cells). Lineage markers were 
combined with antibodies against KIRs with reported AS association (KIR3DL1, 
KIR3DS1/DL1, KIR3DL2, KIR2DL5) as well as the cytokines IL-17A, GM-
CSF, and IFN-γ. Several antibody-dye combinations were tested to identify a 
staining panel without significant problems due to spectral overlap. Experimental 
protocols were optimized to reduce receptor downregulation upon PMA/ionomy-
cin stimulation. The final panel was applied to specimens from healthy individu-
als demonstrating variable expression of KIR3DL2 and KIR3DS1/DL1 in all 8 
lymphocyte subsets. 
Conclusions. We have developed a 19-parameter flow cytometry panel that relia-
bly distinguishes 8 lymphocyte subsets in PBMCs stimulated with PMA/ionomy-
cin and permits the analysis of multiple KIRs and cytokines in a single sample. 
This panel will be used to study the relationship between KIR and cytokine ex-
pression in HLA-B27- and HLA-B27+ healthy individuals and patients with AS.
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INNATE LYMPHOID CELLS ARE EXPANDED IN THE INFLAMED 
SPONDYLOARTHRITIS JOINT
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Objective. Clinical trials of the anti-IL-17A antibody secukinumab demonstrated 
a crucial role of the IL-17A cytokine in the pathogenesis of spondyloarthritis 
(SpA), however its cellular source in this condition remains controversial. Group 
3 innate lymphoid cells (ILC3s) have been recently identified in a number of dif-
ferent tissues as potent producers of proinflamatory cytokines, including IL-17A 
and IL-22. In this study we set out to characterize the presence and composition 
of ILCs and investigate whether these cells are an important source of IL-17A in 
the synovial tissue of patients with SpA.
Methods. Matched synovial tissue (ST), synovial fluid (SF) and peripheral blood 
(PB) were obtained from SpA patients with actively inflamed knee joints. ILC 
subsets were characterised by flow cytometry. Gene expression analysis at the 
single-cell level was performed directly ex vivo and after stimulation with PMA 
ionomycin. IL-17A ELISPOT assay was used to detect IL-17A-secreting cells.
Results. Analysis revealed that ILCs, and particularly NKp44-positive ILC3s, 
are expanded in inflamed arthritic joints. Single-cell expression analysis demon-
strated that ST ILCs are clearly distinguishable from ST T cells and from their PB 
counterparts. We detected expression of Th17 signature transcripts RORC, AHR 
and IL-23R in a large fraction of ST ILC3s. These cells were capable to induce 
IL-22, but not IL-17A expression in response to in vitro re-stimulation.
Conclusions. We demonstrate in this study that ILC3s are absolutely and rela-
tively enriched in the synovial joint of patients with SpA, however these cells are 
not a significant source of IL-17A cytokine in this pathology.
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MOTORS RATHER THAN REGULATORS OF IL-17A-MEDIATED 
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1Amsterdam Rheumatology and Immunology Center and Dept. of Clinical Immu-
nology and Rheumatology, Academic Medical Center/University of Amsterdam; 
2Dept. of Experimental Immunology, Academic Medical Center/University of 
Amsterdam; 3Dept. of Pathology, Academic Medical Center/University of Am-
sterdam; 4Tytgat Institute for Liver and Intestinal Research, University of Amster-
dam, The Netherlands; 5Hospital Clinic de Barcelona and Institut d’Investigacions 
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Background. Synovial mast cells contain IL-17A, a key driver of chronic tis-
sue inflammation in spondyloarthritis (SpA). Recent in vitro studies showed that 
tissue-derived mast cells can capture, store, and release exogenous IL-17A. The 
present study aimed to investigate if this mechanism promotes rather than regu-
lates chronic tissue inflammation in SpA.
Methods. Potential activation of mast cells by IL-17A was assessed by gene 
expression analysis of the LAD2 mast cell line. The presence of IL-17A-positive 
mast cells was assessed by immunohistochemistry in synovial tissue obtained 
before and after secukinumab treatment, as well as in skin and gut tissues from 
SpA-related conditions.
Results. IL-17A did not induce a pro-inflammatory response in human LAD2 
mast cells according to the canonical IL-17A signaling pathway. Using well vali-
dated anti-IL-17A antibodies, immunohistochemical staining of synovial biop-
sies obtained before and after secukinumab treatment indicated that the percent-
age of IL-17A-positive synovial mast cells increases rather than decreases upon 
anti-IL-17A therapy in SpA. 
IL-17A-positive mast cells were also readily detectable in barrier tissues such as 
skin and intestines, even in non-inflamed conditions. Although both total mast 
cells and IL-17A-positive mast cells were increased in psoriatic skin dermis 
and in submucosa from inflammatory bowel disease gut in comparison to non-
inflamed tissues, the proportion of IL-17A-positive mast cells was strikingly de-
creased in the inflamed IBD gut surface area lamina propria. 
Conclusions. The presence of IL-17A-positive mast cells across different SpA 
target tissues and the inverse correlation between their IL-17A content and inflam-
mation suggest that tissue-resident mast cells could act as sentinel cells preloaded 
with IL-17A, which can be released to amplify inflammatory responses.
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RORγt INHIBITION SELECTIVELY TARGETS PATHOGENIC 
SUBSETS OF HUMAN iNKT AND γδ-T CELLS ENRICHED IN 
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Dysregulated IL-23/IL-17 responses have been linked to inflammatory diseases 
including psoriasis, psoriatic arthritis and other forms of spondyloarthritides 
(SpA). IL-23/IL-17 inflammation is controlled by RORγt, the key Thelper17 
(Th17) cell transcriptional regulator. RORγt is also expressed by subsets of in-
nate-like T cells, including invariant natural killer T (iNKT) and γδ-T cells, but 
how this contributes to disorders such as SpA is still unclear. Here we describe 
a unique population of RORγt+T-betloPLZF- iNKT and γδ-hi T cells present in 
healthy peripheral blood. iNKT and γδ-hi T cells showed profound IL-23 mediat-
ed Th17-like immune responses and were clearly enriched within inflamed joints. 
Moreover, selective depletion of iNKT and γδ-Tcells in synovial fluid mononu-
clear cell samples led to a significant decrease (>70%) in IL-17 responses under-
scoring the pathogenic features of these cells in SpA. Interestingly, unsupervised 
clustering analyses by FlowSOM iterations revealed a marked heterogeneity of 
human blood iNKT and γδ-T cells which seemed skewed in SpA patients. Strik-
ingly, RORγt inhibition blocked γδ17 and iNKT17 cell function while selec-
tively sparing IL-22+ subsets. Overall, these findings highlight a unique diversity 
of human RORγt+ T cells and underscore the potential of RORγt antagonism to 
modulate aberrant type 17 responses.
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SCREENING FOR ANTIBODY REACTIVITY IN EARLY AXIAL 
SPONDYLOARTHRITIS IDENTIFIES NOVEL ANTIGENIC TAR-
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Quaden D.1, Vandormael P.1, Corten K.2, Vandenabeele F.3, Vanhoof J.4, Geusens 
P.1,4,5, Somers V.1
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Dept., Ziekenhuis Oost-Limburg, Genk; 3Hasselt University, REVAL- Rehabili-
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Aim. Diagnosis of axial spondyloarthritis (axSpA) is challenging since clinical 
manifestations often overlap with other disorders and an appropriate serological 
test is still lacking. Although autoantibodies are not considered to be a hallmark 
of axSpA, emerging evidence suggests the involvement of plasma cells and an-
tibodies in the disease. Therefore, we aim to identify novel (auto)antibodies spe-
cific for early axSpA patients. 
Materials and Methods. An axSpA cDNA phage display library was construct-
ed and screened for antibody reactivity with pooled plasma of early axSpA pa-
tients (n=10) with validation in additional pooled plasma of early axSpA patients 
(n=60) and healthy controls (HC, n=30) and in individual plasma samples of 
early axSpA patients (n=79), patients with non-specific chronic low back pain 
(NSCLBP, n=40), rheumatoid arthritis (RA) patients (n=60) and HC (n=94) us-
ing phage-ELISA.
Results. Antibody reactivity against 9 novel peptide targets was increased in 
pooled axSpA plasma. Further validation revealed antibody reactivity against 
at least one of these targets in 53% of early axSpA patients (42/79) compared to 
35% of NSCLBP (14/40, p=0.0803), 38% of RA (23/60, p=0.0894) and 26% of 
HC (24/94, p=0.0003). By combining our 3 best targets, 20% of axSpA patients 
(16/79) were detected with a specificity of respectively 90.4% (9/94, p=0.0531), 
95% (2/40, p=0.0312) and 92% (5/60, p=0.0590) for HC, NSCLBP and RA. 
Discussion. Screening our axSpA cDNA phage display library identified anti-
body responses against 9 novel peptide targets, each one contributing to the de-
tection of a portion of axSpA patients. Antibody reactivity against these targets 
will be further validated in an independent cohort of early axSpA patients.
Conclusion. The increased antibody reactivity against several novel antigenic 
targets in early axSpA patients compared to NSCLBP, RA and HC further sup-
ports the involvement of the humoral immune response in axSpA.
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uardo Liceaga”, Mexico
Introduction. The cause of SpA is unknown, although there is an important rela-
tionship with gut enterobacteria and the HLA-B27 molecule. This later can mis-
fold during its synthesis causing an altered proteostasis with inflammatory conse-
quences. We identified that patients with ankylosing spondylitis (AS) have serum 
antibodies against a 60kDa molecule of Klebsiella pneumoniae. This molecule 
was cloned and characterized as the heat shock protein 60 of K. pneumoniae 
(HSP60Kp). Later, we found high titers of plasma and synovial fluid antibodies 
against the HSP60Kp and the HSP60 of other enterobacteria accompanied by 
an important lymphoproliferative response against HSP60Kp. Human and en-
terobacterial HSP60 have a high homology and, given the key role of molecular 
chaperones in endoplasmic reticulum (ER) stress, we aimed to analyze the rela-
tionship of HSP60 with the consequences of protein misfolding. 
Materials and Methods. We analyzed the expression and location of HSP60 in 
THP-1 monocytes suffering tunicamycin-induced endoplasmic reticulum stress. 
Also, we determined the expression of the ER-stress markers BiP and CHOP. 
Results. We found a tunicamycin dose-dependent increase of the expression of 
HSP60, this expression of HSP60 was associated with the increase of the expres-
sion of CHOP, suggesting a role of the PERK/ATF4 pathway. Furthermore, the 
activation of the ER-stressed monocytes with LPS induced an important induc-
tion of HSP60. Interestingly, we found extracellular detection of HSP60 accumu-
lates in the cell cultures of ER-stress suffering cells. 
Discussion. Heat shock proteins are potent immunomodulatory molecules, so, 
these results could help us to understand how the HLA-B27-induced alterations 
in proteostasis can relate with the inflammatory response.
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Introduction. Both IL-23 and PDE4 inhibition are ineffective in RA but show 
efficacy in PsA related synovitis despite similar cytokine and molecular profiles 
between synovitis in both disease settings. We hypothesised that enthesis resident 
innate immune cells, especially myeloid cells, might be capable of IL-23 produc-
tion that could be modulated by PDE4 pathway blockade.
Materials and Methods. Human entheses (n=6) were digested and myeloid cells 
(CD14+) sorted from both the adjacent bone (EB) and soft tissue (ST) fractions. 
Both CD14+ sorted and CD14- unsorted cells were stimulated with bacterial and 
fungal adjuvants (TLR and CLR agonists) in the presence and absence of a PDE4 
inhibitor and analysed by ELISA and flow cytometry for production of disease 
relevant mediators (IL-23, TNFα, and CCL20). Corresponding peripheral blood 
populations were also stimulated with and without a PDE4 inhibitor and other 
cAMP elevating agents to confirm the role of cAMP in regulating IL-23 associ-
ated inflammation.
Results. A CD45+/CD14+ myeloid cell population could be isolated from the 
normal enthesis in both the ST and EB fractions but with a much higher abun-
dance in EB. This purified population from both ST and EB produced IL-23, 
TNF-α and CCL20 following TLR/CLR receptor stimulation. IL-23 and TNF-α 
production was negligible in the CD14- fraction. Moreover, IL-23 and TNF in-
duction was inhibited by the PDE4 inhibitor rolipram. In blood derived myeloid 
cells, rolipram and other cAMP elevating agents (histamine and 8-br-cAMP), 
also inhibited IL-23 secretion.
Conclusion. These findings demonstrate that the human enthesis harbours an IL-
23 producing myeloid cell population which can be modulated by PDE4 pathway 
manipulation. These findings support the idea of the IL-23/17 pathway genetic 
architecture of SpA in the context of entheseal biology and offer a “reverse trans-
lation” explanation for divergent therapeutic pathways between SpA and RA.
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REGULATION OF CYTOKINE PRODUCTION BY iNKT CELLS 
REQUIRES IRE1a
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Introduction. iNKT cells represent a prototypic example of innate like T cells 
which produces large amount of immunomodulatory cytokines. As such they are 
important in regulation of several forms of inflammatory diseases including SpA 
and inflammatory bowel diseases. It is currently unclear what determines the 
unique features of these cells in producing such large quantities of immunoregu-
latory cytokines. We reasoned that ER stress sensors may be involved such as the 
inositol-requiring enzyme 1a (IRE-1α), a transmembrane protein which gets ac-
tivated upon ER stress. Activated IRE1α results in the splicing of X box binding 
protein 1 (Xbp1) mRNA, which in turn transactivates genes involved in cellular 
homeostasis. Recent studies have shown that IRE1a also regulates the develop-
ment and function of B cells, dendritic cells, and eosinophils. We therefore aimed 
to investigate whether iNKTs require IRE1α to regulate cytokine production fol-
lowing activation both in vitro and in vivo. 
Methods. To assess steady-state IRE1a activity in iNKT cells by flow cytometry, 
we utilized ERA1FP/WT reporter mice as they express VenusFP fused at the sites at 
which IRE1α splices XBP1. QPCR was performed in in vitro expanded iNKT 
cells to examine the role of TCR-dependent signalling in regulating IRE1α activ-
ity within iNKT cells and effector cytokine production. ELISA, flow cytometry 
and QPCR were performed in CD4cre; IRE1αko mice were used to study the role 
of IRE1a in regulating the cytokine production by activated iNKT cells. Intravital 
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microscopy was done on iNKT cells by backcrossing CXCR6-GFP reporter mice 
with CD4 specific IRE1 deficient animals versus controls. 
Results and Discussion. We show that TCR-dependent activation of iNKT cell 
results in splicing of Xbp-1 mRNA, much more than in mainstream T cells. In 
line with this, IRE1α reporter activity at steady state was selectively abundant 
in iNKT cells rather than other T cell subsets. A subsequent analysis in CD4cre; 
IRE1αko mice revealed that TCR-dependent cytokine production by the iNKT 
cells was severely impaired in the absence of IRE1a. In this context, diminished 
cytokine production by IRE1a deficient iNKTs was due to reduced mRNA stabil-
ity for cytokines such as IL-2, IL-4, IL-6, IL-13, 1L-17A TNF-α and IFNγ. As a 
result, lack of IRE1a profoundly affected iNKT cell functions in vivo.
Conclusion. These findings represent a novel mechanism whereby IRE1a func-
tions as a central regulator of cytokine production within iNKT cells, a prototypic 
innate like T cells subset.
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ASSOCIATION OF NEUROPATHIC-LIKE PAIN CHARACTER-
ISTICS WITH CLINICAL AND RADIOGRAPHIC FEATURES IN 
PATIENTS WITH ANKYLOSING SPONDYLITIS
Lee K.A., Kim H.R., Lee S.H.
Division of Rheumatology, Dept. of Internal Medicine, Konkuk University Medi-
cal Center, Seoul, South Korea
Introduction/Aim. Ankylosing spondylitis (AS) is a chronic, progressive, in-
flammatory disorder and causes chronic back pain. It is not unusual for patients 
with AS to have symptoms similar to neuropathic pain. We aimed to investigate 
the neuropathic pain (NeP) component in patients with AS using the painDE-
TECT questionnaire (PD-Q) and to assess the relation between NeP and the dis-
ease characteristics of AS.
Materials and Methods. A single-center prospective study was performed, in-
cluding 105 patients. Patients with AS completed three questionnaires: PD-Q, 
Beck Depression Inventory (BDI), and Euro Quality of life (EQ-5D) question-
naires. Patients were classified into three groups according to the PD-Q scores: 
nociceptive pain (NoP) (score ≤12), mixed pain (MP) (score 13–18), and NeP 
pain (score ≥19). Fifteen patients (14.2%) were classified into the NeP group, 22 
(21.0%) in the MP group, and 68 (64.8%) in the NoP group. The questionnaires 
and clinical and radiographic findings were analyzed.
Results. Patients with NeP and MP scored worse on the Bath ankylosing spon-
dylitis disease activity index (BASDAI); BDI; modified Stoke Ankylosing Spon-
dylitis Spine Score; pain-visual analogue scale (VAS); and EQ-5L index and 
showed an increased prevalence of enthesitis and peripheral arthritis. There were 
no differences in objective inflammatory markers. PD-Q scores were positively 
correlated with pain-VAS, BASDAI, BDI, and inversely correlated with EQ-5D 
index. Age, BASDAI, presence of current enthesitis, and BDI score were inde-
pendently associated with PD-Q scores. 
Conclusion. The findings showed that NeP component in AS was associated 
with age, high disease activity, presence of current enthesitis, and depression. 
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Introduction/Aim. Several referral strategies (RS) have been proposed to pro-
mote early referral of patients with axSpA, but consensus on the ‘best’ RS is 
yet to be achieved. We aimed to evaluate the performance of the RS for SpA of 
a nationwide epidemiological study (EpiReumaPt), as compared to previously 
proposed RS.
Materials and Methods. EpiReumaPt was a three-stage national survey where, 
in the first phase, 10,661 participants were randomly selected and interviewed 
using a face-to-face questionnaire that included screening for rheumatic diseases 
(RD). In the second phase, positive screenings plus 20% negative screenings 
were invited for an assessment by the rheumatologist. Finally, 3 rheumatologists 
revised all the information and defined the final diagnosis. All participants of 
the second phase were included (N=3,877). Each RS (table) was tested against 
the SpA diagnosis using the following metrics: sensitivity, specificity, positive 
predictive value (PPV), and post-test probability given a negative test (1-NPV). 
RS with an imaging or laboratory component were modified (by excluding these 
components) due to limited data. 
Results. From the total 3,877 participants, 92 received a SpA diagnosis, 3,107 
other RD diagnosis and 678 no RD diagnosis. The ASAS RS was the most sensi-
tive (85%) followed by the EpiReumaPt strategy (72%) (Table). The ASAS and 
EpiReumaPt RS had the lowest post-test probabilities of SpA if negative (0.6% 
and 0.7% respectively), thus, yielding a marked decrease in the probability of 
disease [(1.6-0.6)/1.6*100=63%; (1.6-0.7)/1.6*100=56% respectively). On the 
other hand, the likelihood of SpA increased by 38% (2.2-1.6)/1.6*100) and 119% 
(3.5-1.6)/1.6*100) in case of a positive ASAS and EpiReumaPt RS, respectively. 
Conclusion. For the first time, a wide range of SpA RS were tested in a popula-
tion-based setting. The ASAS and EpiReumaPt RS were shown to be the most 
sensitive, suggesting that these strategies are effective screening tools for SpA.
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INTEGRATED LONGITUDINAL ANALYSIS INCREASES PRECI-
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Introduction/Aim. Evaluation of imaging is important in SpA research, but loss 
to follow-up often jeopardizes interpretation. Interpretation may further be chal-
lenged by the fact that often different readers contributed to scores, in multiple 
‘read-waves’. A common approach is to evaluate patients with complete follow-
up (completers analysis), but this approach is not assumption-free and may 
cause non-random data loss. We aimed to investigate if the use of all data in an 
assumption-free manner (‘integrated analysis’) affects the precision of estimates 
for imaging outcomes, compared to the completers analysis.
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Methods. axSpA patients from the DESIR cohort were included (N=416). Ra-
diographs and MRIs of the SIJ and spine were obtained at baseline, 1, 2 and 5 
years. Each film was scored by 2-3 readers in 3 ‘read-waves’. Each outcome was 
analyzed: i. according to a ‘combination algorithm’ (‘2 out of 3’); and ii. per 
reader. The change of each outcome was analyzed by GEE using three approach-
es: i) ‘integrated-analysis’ (including patients with ≥ 1 score from ≥1 reader from 
all waves); ii) completers-only analysis (including only patients with complete 
follow-up, using scores from individual readers from wave 3); iii) aggregated 
completers analysis (similar to ii but using combined-scores). 
Results. An analysis with all data from different readers and ‘read-waves’ (‘in-
tegrated analysis’) was more inclusive with no meaningful loss of precision of 
the change-estimates compared to both completers analyses (Table). In fact, for 
low-incident outcomes (e.g. % mNY), a similar incidence was ‘captured’, with 
more precision, by the ‘integrated analysis’ compared to the completers analysis 
with combined scores (% change/year (95% CI): 1.1 (0.7; 1.5) vs 1.2 (0.5; 1.8), 
respectively). 
Conclusion. An efficient and assumption-free usage of data does not compro-
mise the precision of change estimates in imaging parameters and may yield 
increased statistical power for detecting changes with low incidence. 
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Aim. Axial spondyloarthritis (axSpA) patients still suffer an important diagnos-
tic delay. Previous studies described a high proportion of undetected axSpA in 
patients with anterior uveitis (AAU). We hypothesized that referral of all patients 
with AAU and chronic back pain results in a high prevalence of newly diagnosed 
axSpA patients.
Methods. In 2017 a prospective observational study was started including all 
patients with noninfectious AAU and back pain (≥3 months, started < age of 45 
years) referred from nine Ophthalmology clinics to our Rheumatology depart-
ment. Exclusion criteria were: history of a rheumatic or other known systemic 
disease associated with uveitis. Sociodemographic, clinical, laboratory and ra-
diographic parameters and patient questionnaires were collected. The axSpA 
diagnosis was made by the rheumatologist and classified following the ASAS 
criteria for radiographic or non-radiographic axSpA.
Results. In the first year, 42 patients were referred to the Rheumatology depart-
ment, of whom 32 (age 35 years; 47% female) met all the inclusion criteria. 
Sixty-three percent had a history of more than one AAU and the median back 
pain duration was 11 years. AxSpA was diagnosed in 10 patients (31%, all HLA-
B27 positive), of whom four fulfilled the criteria for radiographic and six for 
non-radiographic axSpA. Another 11 patients (34%, six HLA-B27 positive) were 
suspicious for early axSpA. A high disease activity score (ASDAS≥2.1) was pre-
sent in 57% of the patients with a new diagnosis or suspicion of axSpA. Treat-
ment with non-steroidal anti-inflammatory drugs was started in 20 patients, and 
a tumor necrosis factor inhibitor in one patient. 
Conclusion. The referral of AAU patients with chronic back pain led to a no-
tably high number of new axSpA diagnoses and patients suspicious for begin-
ning axSpA, requiring further follow up. These results stress the importance 
of systematic referral of AAU patients in order to improve early recognition 
of axSpA.
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COMPUTER TOMOGRAPHY DEFINED SACROILIITIS IN 
INFLAMMATORY BOWEL DISEASE – A SERVICE EVALUATION 
OF REPORTING STANDARDS
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Introduction/Aim. A joint rheumatology-radiology service evaluation was un-
dertaken to explore the prevalence and reporting standards of Computer Tomog-
raphy-defined Sacroiliitis (CTSI) in patients with Inflammatory Bowel Disease 
(IBD) imaged for non-musculoskeletal indications.
Materials and Methods. CT abdomen/pelvis of patients with verified IBD 
(Crohn’s disease (CD) or Ulcerative Colitis (UC)) were identified retrospectively 
from the radiology imaging system (RIS) between Jan 2010 and Dec 2017. The 
results were filtered to 18-55 year olds: considered to be the population with the 
highest diagnostic yield for axial spondyloarthritis (axSpA). For patients who 
have undergone multiple scans, the most recent CT scan was used as the index 
scan. CT review was undertaken by 3 radiology trainees (trained and under su-
pervision of a senior musculoskeletal radiologist) in order to identify incidental 
CTSI, highly suggestive of axSpA. 
Results. 301 unique scans of verified IBD patients (mean age 36; female 50.8%) 
were included. The prevalence of CTSI using the highest sensitive criterion of a 
validated CT screening tool was 19.9% (60/301). In 248 CD and 53 UC patients, 
the percentage of CTSI were 20.6% CD (51/248) and 17.0% UC (9/53) respec-
tively. Of 60 positive scans, 15/60 were reported as sacroiliitis but no recom-
mendation was made for onward rheumatological evaluation; 7/15 had no prior 
diagnosis of axSpA. Of the remaining 45 CTSI; 26 were unrecognised despite a 
bone review having apparently been undertaken, 17 did not mention a bone re-
view, 2 were unrecognised despite the SI joints having apparently been reviewed. 
Discussion/Conclusion. 1 in 5 selected IBD patients have sacroiliitis suggestive 
of axSpA but this is not reported in 3 out of 4 scans. Raising the awareness of this 
association and using a validated CT tool may improve reporting quality. Further 
evaluation of this population may differentiate between asymptomatic sacroili-
itis and a potential hidden burden of axSpA among IBD patients undergoing CT 
scanning for non-musculoskeletal indications.
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Introduction/Aim. AS and PsA are chronic inflammatory diseases associated 
with severe pain and joint damage which may impact patient reported outcomes 
(PRO), such as ability to work, depression and quality of life. This analysis 
aimed at assessing PRO differences between anti-TNFα-naïve adults with active 
AS and PsA. 
Methods. Patients eligible for COMPLETE are anti-TNF-α-naïve adults with 
active AS or PsA failing initial treatment. Here, baseline data from patients en-
rolled between Jul/2011-Jun/2017 were included. Disease activity was classified 
as active/severe vs low/moderate based on BASDAI (≥4 vs <4; AS) and DAS28 
(≥5.1 vs <5.1; PsA). PsA patients were further stratified as BSA≥3% vs <3%. 
Differences between-groups in WLQ, SF-12, and BDI were assessed with multi-
variate generalized linear models.
Results. 528 AS and 317 PsA (41% with BSA≥3%) patients were included. Upon 
multivariate adjustment, AS patients showed a trend towards higher scores in SF-
12 Physical Functioning compared to PsA patients with BSA<3% (46.1 vs 38.2, 
p=0.069). PsA patients with BSA≥3% had significantly higher scores in SF-12 Role 
Functioning (47.9 vs 39.1, p=0.031) and showed a trend towards higher scores in 
SF-12 Mental Health (58.6 vs 52.2, p=0.085) compared to those with BSA<3%. 
No differences were observed in the remaining SF-12 subdomains, WLQ, or BDI.
Regarding other PRO determinants, active/severe disease was associated with 
higher BDI and worse scores in all WLQ and SF-12 dimensions, and female gen-
der was associated with higher BDI scores and lower scores in the SF-12 Physi-
cal Functioning, Vitality, Social Functioning and Mental Health subdomains.
Discussion/Conclusion. AS and PsA affect multiple aspects of patients’ lives 
without significant differences. Higher disease severity is associated with depres-
sive symptoms and greater impairment in daily activities and work productivity.
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1Laval University, CHUL, Quebec; 2Memorial University of Newfoundland, St. 
John’s; 3University of Toronto, Toronto; 4Grey Bruce Health Services, Owen 
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treal, Canada
Introduction/Aim. Extra-articular manifestations (EAMs) in rheumatic diseases 
negatively impact health outcomes including quality of life and work capacity. 
Although EAMs may directly affect response to treatment, differences in patient-
reported outcomes (PROs) based on EAM presence could be an important con-
tributory variable. This analysis aimed at assessing the impact of EAMs on PROs 
among patients with active AS or PsA followed in Canadian real-world.
Methods. Patients eligible for the COMPLETE studies are anti-TNF-α-naïve 
adults with active AS or PsA failing initial treatment. Here, baseline data from 
patients enrolled between July/2011-June/2017 were included. 
EAMs were defined as presence of: enthesitis, uveitis, IBD or psoriasis (EA-
MAS1 for AS); enthesitis, uveitis, or IBD (EAMAS2 for AS); enthesitis or dactylitis (EAMPsA for PsA). PROs (SF-12, WLQ, BDI) were compared between patients with vs without EAMs using generalized linear models adjusting for disease state 
(high/very high vs. inactive/low/moderate disease based on the BASDAI and the 
DAS28), disease type, and ever smoking.
Results. 609 AS and 406 PsA patients were included with a mean age of 43.1 and 
51.3 years, respectively. EAMAS1, EAMAS2, and EAMPsA prevalence were 33.9%, 25%, and 45.4%, respectively.
Upon multivariate adjustment, EAMAS1/EAMPsA presence in AS/PsA patients was 
associated with significantly higher BDI (14.0 vs. 12.6, p=0.046) and lower SF-
12 physical function (38.4 vs. 44.8, p=0.047). When evaluating the impact of 
EAMAS2/EAMPsA in AS/PsA patients, no significant differences were observed in PROs; however, BDI was notably higher among patients with EAMs (14.1 vs. 
12.7, p=0.056).
Discussion/Conclusion. In Canadian real-world, a substantial proportion of 
AS and PsA patients requiring a change in treatment report EAMs. Presence 
of EAMs, particularly psoriasis for AS patients, was a significant independent 
predictor of depressive symptoms and reduced quality of life due to worse physi-
cal functioning.
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ASAS CONSENSUS ON SPANISH NOMENCLATURE FOR SPON-
DYLOARTHRITIS
Navarro-Compán V.1, Otón T.2, Loza E.2, Almodóvar R.3, Ariza-Ariza R.4, 
Bautista-Molano W.5, Burgos-Vargas R.6, Collantes-Estévez E.7, de Miguel E.1, 
González-Fernández C.8, Gratacós J.9, Ibáñez S.10, Juanola X.11, Maldonado-
Cocco J.12, Moltó A.13, Mulero J.14, Pacheco-Tena C.15, Ramos-Remus C.16, Sanz-
Sanz J.14, Valle-Oñate R.17, Zarco P.3, Marzo-Ortega H.18
1H. La Paz, IdiPaz, Madrid; 2INMUSC; 3HF. Alcorcón, Madrid; 4H.V. Macarena, 
Sevilla, Spain; 5H. Militar, Bogotá, Colombia; 6H. General, DF, Mexico; 7H.R. 
Sofía, Córdoba; 8H. Gregorio Marañón, Madrid; 9H. Parc-Taulí, Sabadell, Spain; 
10C. Alemana, Santiago, Chile; 11H. Bellvitge, Barcelona, Spain; 12F. Medicina, 
Uni. Buenos Aires, Buenos Aires, Argentina; 13H. Cochin, Paris, France; 14H. 
Puerta Hierro, Madrid, Spain; 15U. Autónoma, Chihuahua; 16Univ. Autonoma 
de GDL, GDL, Mexico; 17Clinica-Salud Reinun, Colombia; 18NIHR LBRC and 
LIRMM, UoL, Leeds, UK
Introduction. In the last three decades, major advances in the spondyloarthritis 
(SpA) field have been achieved leading to new terminology. Whilst this terminol-
ogy is well established in English, there is concern about the disparity of trans-
lated words and acronyms in Spanish, which is used by more than 437 million 
people in 21 countries.
Aim. To develop a consensus to standardize the use of Spanish terms, abbrevia-
tions and acronyms in the field of Spondyloarthritis (SpA).
Methods. An international task force comprising all ASAS Spanish-speaking na-
tive members, the executive committee of GRESSER, two methodologists, two 
linguists from Real Academia Nacional de la Medicina Española (RANM) and 
two patients from CEADE was established. A literature review was performed to 
identify the conflicting terms/abbreviations/acronyms in SpA. This review exam-
ined written sources in Spanish including manuscripts, ICF and ICD, guidelines, 
recommendations and consensus. A nominal group meeting and three-round Del-
phi was followed. The recommendations from the RANM based on the Panhis-
panic dictionary were followed throughout the process. 
Results. Consensus was reached for 46 terms, abbreviations or acronyms related 
to the field of SpA. A Spanish translation was accepted for 6 terms and 6 ab-
breviations to name or classify the disease, and for 6 terms and 4 abbreviations 
related to SpA. It was agreed not to translate into Spanish 15 acronyms. How-
ever, when mentioning these, it was recommended to follow this structure: type 
of acronym in Spanish and acronym and expanded form in English. With regards 
to 7 terms or abbreviations attached to acronyms, it was agreed to translate only 
the expanded form and a translation was also selected for all of them.
Conclusions. Through this standardisation, it is expected to establish a common 
use of the Spanish nomenclature for SpA. The implementation of this consensus 
across the community will be of substantial benefit, avoiding misunderstandings 
and time-consuming processes.
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COMPARISON OF CLINICAL AND IMAGING ARMS OF THE AS-
SESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCI-
ETY (ASAS) CLASSIFICATION CRITERIA AND PARAMETERS 
OF OBJECTIVE INFLAMMATION IN PATIENTS WITH NON-RA-
DIOGRAPHIC AXIAL SPONDYLOARTHRITIS (nr-axSpA)
Landewé R.1, Sieper J.2, Deodhar A.3, Marzo-Ortega H.4, Lambert R.G.5, Li M.6, 
Wang X.6, Anderson J.K.6
1University of Amsterdam, Dept. of Medicine, Amsterdam, The Netherlands; 
2Charité Universitätsmedizin Berlin, Rheumatology, Berlin, Germany; 3Oregon 
Health & Science University, Dept. of Medicine, Portland, USA; 4NIHR LBRC, 
Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, UK; 
5University of Alberta, Dept. of Radiology & Diagnostic Imaging, Edmonton, 
Canada; 6AbbVie, North Chicago, USA
Aim. To characterize clinical phenotypes of nr-axSpA patients enrolled in the 
ABILITY-3 study in terms of ASAS classification criteria and parameters of ob-
jective inflammation at baseline.
Methods. ABILITY-3 enrolled adult nr-axSpA patients fulfilling ASAS classifi-
cation criteria but not modified New York radiologic criteria for ankylosing spon-
dylitis (AS). Minimum-baseline disease activity, objective evidence of inflam-
mation and inadequate response to ≥2 NSAIDs was required. Patients received 
open-label adalimumab 40mg every other week for 28-weeks during period 1. 
Patients achieving sustained remission (weeks 16–28) were randomized into 
double-blind period 2. We analyzed whether enrolled patients fulfilled the imag-
ing arm of ASAS classification criteria, clinical arm, or both arms, and which 
objective parameters of inflammation were present.
Table. Baseline characteristics and parameters of objective evidence of inflammation.
HLA-B27: human leukocyte antigen-B27; hsCRP: high-sensitivity C-reactive protein; MRI: mag-
netic resonance imaging; SI: sacroiliac.
a1 pt had missing HLA-B27 data from the central laboratory.
b4 patients had missing MRI imaging (spine only, n=1; SI joint only: n=2; SI joint and spine: n=1.
cElevated hsCRP = greater than the upper limit of normal for the lab.
Results. 673/1506 screened patients were enrolled. Overall, 98.7% fulfilled the 
ASAS criteria, of which 67.6% fulfilled the imaging arm, 77.4% the clinical arm, 
and 44.0% both arms. Baseline inflammation parameters described in the Table.
Conclusions. Objective measures of inflammation were not present in an important 
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proportion of screened nr-axSpA patients with clinically-active disease; such pa-
tients would not be candidates for biologics. Many patients fulfilled both imaging 
and clinical arms of ASAS criteria. Nearly 60% of patients with MRI-inflammation 
also had elevated hsCRP, suggesting hsCRP assessment as the first step in evaluat-
ing patients for objective inflammation, unless MRI is required for diagnosis. 
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SPINAL MOBILITY MEASURES ALLOW DISCRIMINATION OF 
SUBGROUPS OF DIFFERENT ACTIVITY AND SEVERITY IN 
EARLY AXIAL SPONDYLOARTHRITIS
Marques M.L.1,2, Ramiro S.1,3, van Gaalen F.A.1, Goupille P.4, Dougados M.5, 
van der Heijde D.1
1Rheumatology, LUMC, Leiden, The Netherlands; 2Rheumatology, Coimbra 
University Hospital, Coimbra, Portugal; 3Zuyderland Medical Center, Heerlen, 
The Netherlands; 4Rheumatology, Tours University, Tours, France; 5Rheumatol-
ogy, Paris Descartes University, Hôpital Cochin, Paris, France
Aim. To investigate 1) which spinal mobility measures (SMMs) are most fre-
quently impaired and in which order; 2) which SMMs are most discriminative of 
activity and severity in early axSpA.
Materials and Methods. All SMM measurements of patients from the DESIR 
(5-year data) and SPACE (data from LUMC, 2.6(1.9) years of follow-up) cohorts 
and with a clinical diagnosis of axSpA (level of confidence ≥7/10) were analysed. 
SMMs were considered impaired when falling below pre-defined cut-offs, de-
rived from normal individuals (1). The proportion of patients with each of the 
SMMs impaired was calculated, for both baseline and all observations. The same 
analysis was conducted in subgroups to contrast patient and disease characteristics 
potentially influencing spinal mobility, like treatment with biologics (ever/never), 
disease activity (with/without low disease activity over time, i.e., ASDAS<2.1 in 
≥2/3 of visits) and the presence of baseline syndesmophytes (yes/no). 
Results. We included 328 and 148 patients from the DESIR and SPACE cohorts, 
respectively. Considering patients in whom all SMMs were assessed, in DESIR, 
the most frequently impaired SMM (below 2.5th percentile) was mSchober (42%), 
followed by Lateral Spinal Flexion (LSF;37%), Tragus-to-wall (16%), Cervical 
rotation (16%) and Chest expansion (11%). In SPACE, the order of impairment 
was:LSF (36%), mSchober(14%), Chest expansion(13%), Cervical rotation(11%) 
and Tragus-to-wall(3%). LSF and mSchober captured the majority of patients 
with ≥1SMM impaired (86% and 78% for DESIR and SPACE, respectively). 
LSF and BASMI best discriminated between subgroups of patients, with higher 
impairment in patients ever treated with biologics, with higher disease activity 
and presence of baseline syndesmophytes (Table I, data from DESIR). Similar 
results were obtained in the SPACE cohort.
Table I. Impairment of each of the spinal mobility  measures and of the BASMI score in 
patients with early axSpA from the DESIR cohort, Stratified by subgroups to contrastpa-
tient and disease characteristics potentially influencing spinal mobility§.
Legend: red: spinal mobility measure (SMM) most frequently impaired; orange: 2nd SMM most fre-
quently impaired; yellow: 3rd SMM most frequently impaired; ligh green: 4th SMM most frequently 
impaired; dark green: SMM least frequently impaired.
§Impairment was defined as a value below the 2.5th percentile in normal individuals, and is presented at 
the observation level (n (%) of all 5-year observations).
†BASMI-modified: calculated with cervical rotation in sitting position and 10-cm Schober’s test, using 
the linear method (mean of the five scores: Lateral Spinal Flexion, 10-cm Schober’s test, Cervical rota-
tion, Intermalleolar distance and Tragus-to-wall distance).
Conclusions. LSF and mSchober are the most impaired SMMs, together allow-
ing the identification of the majority of patients with impaired spinal mobility in 
early axSpA. LSF and BASMI discriminate best between subgroups of patients, 
reflecting a worse spinal mobility in patients with more active and severe disease.
Reference
  1. RAMIRO S et al.: Ann Rheum Dis 2015 Jun; 74(6): 1218-24.
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MEASURING SPINAL MOBILITY OVER TIME IN EARLY AXIAL 
SPONDYLOARTHRITIS: CAN WE DO IT RELIABLY?
Marques M.L.1,2, Ramiro S.1,3, van Gaalen F.A.1, Goupille P.4, Dougados M.5, 
van der Heijde D.1
1Rheumatology, LUMC, Leiden, The Netherlands; 2Rheumatology, Coimbra 
University Hospital, Coimbra, Portugal; 3Zuyderland Medical Center, Heerlen, 
The Netherlands; 4Rheumatology, Tours University, Tours; 5Rheumatology, Paris 
Descartes University, Hôpital Cochin, Paris, France
Aim. To investigate the longitudinal use of spinal mobility measures (SMMs) 
and the relation with mobility curves of healthy individuals in patients with early 
axSpA.
Methods. All SMMs of patients from the DESIR (5-year data) and SPACE (data 
from LUMC, 2.6 (1.9) years of follow-up) cohorts and with a clinical diagnosis 
of axSpA (level of confidence ≥7/10) were analysed. All available SMMs were 
plotted for each patient in function of age, and together with the percentile curves 
derived for healthy volunteers, the mobility curves (1). A subgroup analysis was 
performed in patients with low disease activity over time (ASDAS<2.1 in ≥2/3 of 
visits), in order to control for the influence of disease activity on spinal mobility. 
Intra- and inter-observer reliability were analyzed using Intraclass Correlation 
Coefficients (ICC) and the Smallest Detectable Change (SDC) in the SPACE 
cohort.
Results. We included 328 and 148 patients from the DESIR and SPACE cohorts, 
respectively. A high variability in SMMs within the same patient over time was 
observed, even when restricting the analysis to patients with low disease activity. 
Figure 1 shows the results for 10-cm Schober’s test and Lateral Spinal Flexion 
(LSF) in the DESIR cohort. The results were strikingly similar for all the SMMs 
and in both cohorts. The reliability of SMMs was only “fair” to “good” (inter-
reader ICC (2,1): 0.55–0.84; intra-reader ICC (2,1): 0.49–0.72). The obtained 
SDCs reflect that large variations in SMMs are needed to capture a true change 
beyond measurement error (e.g. 1.4 cm for 10-cm Schober’s test; 5.1 cm for LSF).
Figure 1. Measurements of 10-cm Schober’s test and Lateral Spinal Flexion in DESIR co-
hort axSpA patients in function of age: A) 10-cm Schober’s test in all axSpA patients; B) 
10-cm Schober’s test in axSpA patients with low disease activity in at least 2/3 of visits; C) 
Lateral Spinal Flexion in all axSpA patients; D) Lateral Spinal Flexion in axSpA with low dis-
ease activity in at least 2/3 of visits. The dotted lines represent the percentile curves derived 
from the normal individuals (percentiles indicated) and also the help-lines (a’ to d’), derived 
to accommodate impaired values of patients with axSpA. The colored lines represent all the 
real measurements of Schober’s test and Lateral Spinal Flexion, for each patient, over time. 
Conclusion. There is a high variation of SMMs from visit to visit, which impairs 
the use of spinal mobility measures, at the individual level in the follow-up of 
patients with axSpA. It should be tested if reliability can be improved to reduce 
at least part of the variability.
Reference
  1. RAMIRO S et al.: Ann Rheum Dis 2015 Jun; 74(6): 1218-24.
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INFLUENCE OF INFLAMMATION AND STRUCTURAL DAM-
AGE ON GLOBAL FUNCTIONING IN PATIENTS WITH AXIAL 
SPONDYLOARTHRITIS – USING THE ASAS HEALTH INDEX IN 
ROUTINE CARE
Kiltz U., Wiatr T., Baraliakos X., Fedorov K., Braun J.
Rheumazentrum Ruhrgebiet, Herne, Germany 
Aim. To investigate the relationship between spinal mobility and self-report 
global functioning as assessed by the ASAS HI, and to study the influence of 
structural and inflammatory spinal changes on global functioning.
Material and Methods. Patients from the outpatient clinic of our hospital suffer-
ing from axial or peripheral SpA completed self-report questionnaires assessing 
disease activity and functioning. Axial inflammation as detected by MRI was 
assessed by Berlin score, structural damage by mSASSS and spinal mobility by 
BASMI. 
Correlations between the ASAS HI and other health outcomes were analysed by 
Spearman’s test. Logistic regression analyses were performed to investigate the 
association between functioning and other clinical characteristics.
Results. A total of 203 axSpA patients were included. The mean values of clini-
cal assessments were ASAS HI 7.9 (4.0), BASDAI 5.0 (2.2), ASDAS 2.8 (1.1), 
BASMI 3.3 (1.8), pain 6.0 (2.6), and BASFI 5.0 (2.6). Elevated CRP levels 
were found in 37.4% of patients, syndesmophytes in 59.1% and bamboo spine 
in 11.3% of the AS patients. The median (IQR) mSASSS value was 3.8 (IQR 
1.0–22.1) in AS und 0.0 (IQR 0.0–1.4) in nr-axSpA.
The mean Berlin Score was 5.3 (SD 7.1). A significant correlation of the ASAS 
HI was found for BASMI (r=0.5), BASDAI (r=0.7), ASDAS (r=0.5), BASFI 
(r=0.8), BMI (0.3) and Berlin Score (0.3). ASAS HI did not correlate with ra-
diographic damage (mSASSS r=0.2, presence of bamboo spine r=0.2) and CRP 
(r=0.07). Stratifying patients by symptom duration (cut-off 3 years) did not affect 
these results. Logistic regression showed influence of obesity but not of inflam-
mation or structural damage on global functioning.
Conclusion. The influence of obesity on functioning is remarkable in patients 
with SpA. In contrast, the influence of structural damage and spinal inflamma-
tion on functioning was limited in this study, probably due to the relatively low 
mSASSS and MRI scores. 
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OSTEOPOROSIS COMMONLY OCCURS IN AXIAL SPONDYLO-
ARTHROPATHY
Fitzgerald G.E.1, Anachebe T.1, McCarroll K.2, O’ Shea F.1
1Rheumatology Dept., St. James’s Hospital; 2Gerontology Dept., St. James’s 
Hospital, Dublin, Ireland
Background. Osteoporosis, a consequence of inflammatory arthritis, is fre-
quently overlooked in axSpA, a condition with male predominance. Osteoporosis 
prevalence figures are therefore uncertain. To understand the impact of low BMD 
in axSpA, accurate epidemiology is crucial.
Aims. 1. Investigate the prevalence of low BMD in an axSpA cohort
           2. Explore relationships between BMD and axSpA.
Materials and Methods. A detailed assessment was performed on axSpA pa-
tients. Disease severity was assessed using ASDAS-CRP, BASDAI, BASMI and 
BASFI. BMD was assessed using DXA of the spine, hip and radius. The WHO 
criteria were used to classify low BMD.
Results. One hundred and four patients with axSpA were consecutively recruit-
ed: 77.9% (n=81) male, 98.1% (n=102) Caucasian, mean (SD) age 51 (12) years, 
disease duration 26 (13) years. The mean (SD) ASDAS-CRP was 2.3 (1), BAS-
DAI was 3.9 (2.2), BASMI was 4.3 (1.9) and BASFI was 3.8 (2.5). Prior fracture 
was present in 42.3% (n=44) of patients, with 3 fragility fractures. 
Of the cohort, 42.3% (n=44) had osteopenia and 16.3% (n=17) had osteoporosis. 
Low BMD was most prevalent at the spine, with 44% of the cohort affected, 
followed by the femoral neck (30.1%, n=22). Low BMD at the radius was un-
common (<10% of the cohort). Only 6.4% of the cohort had a prior diagnosis of 
osteoporosis and only 39.4% had a previous DXA.
Female gender, higher BASFI, lower BMI and lower urate levels were signifi-
cantly associated with bone loss at spine and hip. ASDAS-CRP and BASDAI 
had no impact on BMD. Longer disease duration was associated with spine BMD 
loss. Non-obese patients were more likely to have low BMD than obese patients 
(62.3% vs 40%, OR 2.5, p=0.04). Biologics use didn’t influence BMD.
Conclusion. Low BMD is common in axSpA, with over 50% affected. Most 
cases of low BMD were undiagnosed prior to this study. Less than half of the 
cohort had a prior DXA, suggesting continued low awareness of the risk of os-
teoporosis in axSpA.
P126
SYNDESMOPHYTES PREVENT ACCURATE DXA ASSESSMENT 
OF THE SPINE IN AXIAL SPONDYLOARTHROPATHY
Fitzgerald G.E.1, Anachebe T.1, McCarroll K.2, O’ Shea F.1
1Rheumatology Dept., St. James’s Hospital; 2Gerontology Dept., St. James’s 
Hospital, Dublin, Ireland
Background. Axial spondyloarthropathy (axSpA) causes syndesmophytes and 
ankylosis of the spine.
Osteoporosis is therefore difficult to diagnose, as traditional dual-energy x-ray 
absorptiometry (DXA) in the antero-posterior (AP) projection of the spine can 
overestimate bone mineral density (BMD) due to syndesmophytes. Lateral DXA 
of the lumbar spine is unaffected by syndesmophyte formation.
Aims. 1. Investigate different projections of DXA of the lumbar spine
           2. Assess effect of syndesmophytes on spine BMD.
Material/Methods. AxSpA patients were assessed with clinical exam, question-
naires and laboratory investigations. The burden of syndesmophytes was scored 
using mSASSS, which ranges from 0-72. DXA was performed of the spine in 
both the AP and lateral projections. 
Results. One hundred patients with axSpA were recruited: 78% (n=78) male, 
mean (SD) age 52 (12) years, disease duration 26 (13) years, median (IQR) 
mSASSS 10 (33). 
Spine BMD was lower by lateral DXA than AP (0.76 vs 1.11 g/cm2, p<0.01). 
Lateral DXA detected more cases of low BMD than AP (21% vs 44%, p<0.01). 
Lateral spine BMD reduced with longer disease (r=-0.3, p=0.02), whereas AP 
spine BMD increased with age (r=0.3, p=0.01). More women had osteoporosis 
at the spine than men when measured by lateral DXA (32% vs 12%, p=0.02), but 
not by AP DXA.
A higher mSASSS, reflecting more syndesmophytes, was associated with a rising 
AP spine BMD (r=0.5, p<0.01), but had no effect on lateral spine BMD. The gap 
between AP and lateral spine BMD, i.e. when AP BMD was higher than lateral 
BMD, increased significantly (p<0.05) with increasing age (r=0.38), disease du-
ration (r=0.37) and mSASSS (r=0.52). mSASSS was the strongest predictor of 
a difference between AP and lateral BMD measurements, suggesting syndesmo-
phyte formation interferes with AP DXA of the spine. 
Conclusion. AP DXA of the spine is affected by a higher burden of syndesmo-
phytes, raising concerns traditional DXA may miss cases of osteoporosis. We 
suggest lateral DXA of the spine may be more accurate in axSpA patients.
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ADD-ON EFFECT OF AEROBIC EXERCISE TO STRETCHING IN 
PATIENTS WITH ANKYLOSING SPONDYLITIS
Kim H.W.1,3, Park J.2, Kim D.2, Park J.H.2, Park M.C.3
1Dept. Internal Medicine, Hospital Medicine Center, Seoul National University 
Bundang Hospital, Seongnam; 2Dept. Rehabilitation Medicine, Gangnam Sever-
ance Hospital, Rehabilitation Institute of Neuromuscular Disease, Yonsei Uni-
versity College of Medicine, Seoul; 3Div. Rheumatology, Dept. Internal Medi-
cine, Yonsei University College of Medicine, Seoul, Korea
Introduction. Unlike stretching exercise, the effect of aerobic exercise in pa-
tients with ankylosing spondylitis (AS) is not well known. We aimed to evaluate 
the additional benefits of aerobic exercise to stretching in patients with AS.
Subjects and Methods. This prospective study recruited 34 patients classified 
as AS according to the 1984 modified New York criteria and randomly assigned 
into aerobic and stretching-exercise group (n=16) and stretching-exercise-only 
group (n=18). All participants performed instructed group-exercise guided by 
a physiatrist and physical therapists and then performed a home exercise for 12 
weeks using an exercise booklet with detailed photos. The outcome measure-
ments, including visual analogue scale (VAS), AS Disease Activity Score (AS-
DAS), Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index 
(BASFI), and AS Quality of Life Questionnaire (ASQoL) were performed before 
instructed group-exercise and after 12 weeks of home exercise. Bath AS Metrol-
ogy Index (BASMI) was examined before and 30 minutes after the instructed 
group-exercise and 12 weeks after a home exercise.
Results. Baseline epidemiologic and baseline outcome parameters showed no 
significant differences between two groups. After exercise, significant improve-
ment in BASMI was observed in both groups. Significant improvement in 
BASDAI was observed only in the combination-exercise group. Otherwise, the 
changes of other outcome measurements at 12 weeks did not show significant 
differences between the groups; ΔVAS (p=0.59), ΔASDAS (p=0.86), ΔBASFI 
(p=0.49), ΔASQoL (p=0.82).
Discussion/Conclusion. The aerobic exercise in patients with AS did not show 
a significant add-on effect to stretching alone in terms of pain, functional level, 
quality of life, and disease perception. Although addition of aerobic exercise 
showed beneficial effect on BASDAI, exercise with an emphasis on stretching 
seems sufficient for management of AS.
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ASSESSMENT OF EARLY MYOCARDIAL DYSFUNCTION USING 
SPECKLE TRACKING ECHOCARDIOGRAPHY IN PATIENTS 
WITH RADIOGRAPHIC AND NONRADIOGRAPHIC AXIAL 
SPONDYLOARTHRITIS
Emren V.1, Gercik O.2, Ozdemir E.1, Solmaz D.2, Gucenmez S.2, Eren N.1, Tokac 
M.1, Kabadayi G.2, Akar S.2
1Cardiology, 2Rheumatology, Izmir Katip Celebi University School of Medicine, 
Izmir, Turkey
Background. Axial spondyloarthritis (axSpA) is a chronic inflammatory disease 
that mainly affects axial skeleton. Although some differences like sex and objec-
tive signs of inflammation were described between these two subgroups, overall 
disease burden was found to be similar in radiographic (r-) and non-radiograph-
ic (nr-) axSpA patients. The association of chronic inflammation with cardiac 
dysfunction was well documented in many inflammatory rheumatic diseases. 
However it was not assessed in the subgroups of axSpA patients. Advanced two-
dimensional (2D) speckle tracking echocardiographic analysis is more sensitive 
and accurate method of early detection of myocardial dysfunction than the con-
ventional 2D transthoracic echocardiography (TTE).
Objectives. To evaluate the left ventricular function by using speckle tracking 
echocardiography in patients with both r- and nr-axSpA.
Methods. In total 64 patients with r-axSpA (70% male) and age– and sex-
matched 27 patients with nr-axSpA (63% male) and 30 healthy control subjects 
(63% male) were included in the analysis. Patients with hypertension, diabetes 
and known cardiac disease were excluded. All patients underwent detailed echo-
cardiographic examination including M-mode, pulsed-wave Doppler imaging, 
pulsed-wave tissue Doppler imaging and 2D speckle tracking.
Results. Age and sex distribution were not different between groups. Some 
demographic and disease related characteristics were shown in the table. BAS-
DAI, BASFI, global assessment of disease activity and ASAS-HI scores were 
found to be similar between r- and nr-axSpA patient groups. Although ejection 
fraction (EF) (p=0.112) and the other echocardiographic variables were similar 
between groups, global longitudinal strain (GLS) (p=0.045) was found to be dif-
ferent among groups (table). Post-hoc analysis showed that GLS was similar 
between nr-axSpA and control groups however GLS was significantly low in 
r-axSpA patients. In univariate analysis GLS was correlated with age (p=0.025), 
EF (p<0.001), peripheral arthritis (p=0.047), and smoking (p=0.019). However 
in regression only peripheral arthritis (p=0.032) and EF (p=0.015) were found to 
be the independent predictors of GLS.
Table. The demographic and disease related characteristics of study groups.
  Radiographic Non-radiographic Control p
 axSpA patients axSpA patients subjects
 (n=64) (n=27) (n=30) 
Age, years (mean ± SD) 40.9 ± 10.2 37.6 ± 9.4 42.3 ± 4.3 0.056
Duration of disease, years (mean ± SD) 14.1 ± 7.8 10.6 ± 8.1 N/A N/A
BASDAI, (mean ± SD) 2.7 ± 2.1 3.0 ± 1.8 N/A N/A
BASFI, (mean ± SD) 2.5 ± 2.3 2.6 ± 2.0 N/A N/A
Ejection fraction, (mean ± SD) 58.9 ± 5.2 60.1 ± 4.7 61.2 ± 4.9 0.112
Global Longitudinal Strain, (mean ± SD)  20.4 ± 3.3 21.3 ± 3.8 22.3 ± 2.5 0.045
Conclusions. The results of the present study showed that left ventricular func-
tion had impaired in r-axSpA patients and speckle tracking echocardiography 
may be a useful tool for early demonstration of left ventricular dysfunction.
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ASAS, BASDAI AND ASDAS REMISSION IN SECUKINUMAB 
TREATED PATIENTS WITH ACTIVE ANKYLOSING SPONDY-
LITIS: 3-YEAR RESULTS FROM A POOLED ANALYSIS OF TWO 
PHASE 3 STUDIES 
Baraliakos X.1, Van den Bosch F.2, Machado P.3, Gensler L.4, Bintu S.5, Porter 
B.6, Gaillez C.7, Deodhar A.8
1Ruhr-University Bochum, Bochum, Germany; 2Ghent University and Ghent 
University Hospital, Ghent, Belgium; 3University College London, London, UK; 
4UCSF School of Medicine, San Francisco; 5RTI Health Solutions, Research Tri-
angle Park, NC; 6Novartis Pharmaceuticals Corporation, East Hanover, USA; 
7Novartis Pharma AG, Basel, Switzerland; 8Oregon Health & Science University, 
Portland, USA
Introduction/Aim. Secukinumab (SEC), a fully human mAb that selectively 
neutralises IL-17A, has demonstrated significant improvement in the signs and 
symptoms of active ankylosing spondylitis (AS) up to 3 years (yrs).1-3 This post-
hoc analysis evaluated the effect of SEC in achieving clinical remission (REM) 
criteria in patients (pts) with AS: 3-yr data pooled from the phase 3 MEASURE 
1 and 2 studies.
Materials and Methods. Study designs have been reported previously.1 REM 
was defined as meeting one or more of these criteria: ASDAS ID (score <1.3), 
ASAS PR (score ≤2 in each of the 4 main ASAS domains) or BASDAI score ≤2 
(non-validated cut-off). Pt-reported outcomes (PROs) in pts with and without 
REM were also explored.
Results. In the overall population, proportion of REM states at Wk 16 were 
higher in SEC versus PBO and further increased through 156 Wks (Table). In 
TNFi-naïve and TNFi-IR pts, proportion of REM states were higher with SEC 
versus PBO at Wk 16 and further improved through Wk 156 (Table). Pts with 
REM response reported greater improvement in PROs compared to pts without 
REM (Figure).
Table. Proportion (%) of patients in remission at Weeks 16 and 156
*P<0.0001, †P<0.001, §P<0.01, ‡P<0.05 vs PBO at Wk16. P-values are from Fisher’s exact 
test. an=144, bn=109, cn=35, dn=143, en=34.
ASAS: Assessment of SpondyloArthritis international Society criteria; ASDAS: ankylos-
ing spondylitis disease activity score; BASDAI: bath ankylosing spondylitis disease activity 
index; N: number of pts included in the analysis; n: number of evaluable pts.
Figure. SF-36 PCS, FACIT-Fatigue, ASQoL, BASFI in patients with and without remission*.
*Remission was defined as meeting one or more of the following criteria: ASDAS ID (score 
<1.3), ASAS PR (score ≤2 in each of the 4 main ASAS domains) or BASDAI score ≤2 (non-
validated cut-off). n. number of patients with measurements at both baseline and the post-
baseline visits. LS mean values are from a mixed-effect model repeated measures wwith 
remission state. ASQoL: ankylosing spondylitis quality of liffe; BASFI: bath ankylosing 
spondylitis functional index; FACIT: functional assessment of chronic illness theraphy; LS: 
least square; PCS: physical component summary; SF-36: medical outcome short form health 
survey.
Conclusion. SEC treated pts maintain ASDAS inactive disease, ASAS PR or 
BASDAI remission up to 3 yrs in this completers’ analysis. Pts who achieved 
remission, reported greater improvement in physical function, health-related 
quality of life, work productivity and less fatigue than pts without remission.
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THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS) 
– LIVING WITH THE CONDITION
Garrido-Cumbrera M.1,2,3, Navarro-Compan V.4, Gálvez-Ruiz D.1,2, Gossec L.5, 
Bundy C.6, Mahapatra R.7, Makri S.8, Plazuelo-Ramos P.3, Delgado Dominguez 
C.J.1,2, Poddubnyy D.9,10
1Universidad de Sevilla, Seville; 2Health & Territory Research, Seville; 3Spanish 
Coordinator of Spondyloarthritis Associations, Madrid; 4Hospital la Paz, Ma-
drid, Spain; 5Sorbonne Universités, Paris, France; 6Cardiff University, Cardiff; 
7Ankylosing Spondylitis International Federation, London, UK; 8Cyprus League 
Against Rheumatism, Nicosia, Cyprus; 9Charité-Universitätsmedizin Berlin, 
Berlin; 10German Rheumatism Research Centre, Berlin, Germany
Aim. The European Map of Axial Spondyloarthritis (EMAS) aims to describe 
how patients diagnosed with axSpA experience the disease from a physical, psy-
chological, and everyday life perspective and how they are managed within the 
healthcare systems.
Methods. EMAS employed a cross-sectional survey adapted from the Span-
ish Atlas of Axial Spondyloarthritis 2017, and containing 120 items on socio-
demographics, diagnosis, comorbidities, psychological distress (General Health 
Questionnaire- GHQ-12), healthcare utilization, pharmacological treatments, 
disease activity (BASDAI), physical activity and limitations, productivity loss, 
and patient perspective. Patients from Austria, Belgium, France, Germany, Italy, 
Netherlands, Norway, Russia, Slovenia, Sweden, Switzerland and UK were in-
cluded. Data from Spain was retrospectively added. A scientific steering com-
mittee, formed by 9 leading axSpA experts was selected to validate the results.
Results. 2,846 axSpA patients participated in the survey: mean age was 44 years, 
61.3% were female, 67.9% were married and 79.2% were HLA-B27 positive. 
Almost half were university educated (48.1%), working (51.5%) and members 
of a patient support group (38.9%). Participants reported a diagnostic delay of 
7.2 years with a disease duration of 16.8 years. Active disease (BASDAI ≥4) was 
detected in 70.9%, while 33.5% had received biological therapy. High GHQ-12 
(≥3) was observed in 57.1%, and patients reported diagnosed anxiety (37.2%) or 
depression (33.3%).
Conclusion. In this sample of non-selected patients, long diagnostic delay and 
high patient burden, including self-reported active disease and psychological dis-
tress, indicate important unmet needs in axSpA. As the first snapshot of issues 
relevant to European axSpA patients and disease management, EMAS results may 
contribute to increasing disease awareness and improving the standard of care.
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ACTIVATION OF NLRP3 INFLAMMASOMES IN PERIPHERAL 
BLOOD MONONUCLEAR CELLS OF PATIENTS WITH ANKY-
LOSING SPONDYLITIS
Kim S.K., Choe J.Y.
Daegu Catholic University School of Medicine, Daegu, South Korea
Objective. NLRP3 inflammasome is a molecular platform triggering activation 
of inflammatory cytokines including interleukin-1β (IL-1β). This study aimed to 
assess the expression of NLRP3 inflammasome complex and pro-inflammatory 
cytokines in patients with ankylosing spondylitis (AS). 
Methods. Peripheral blood mononuclear cells (PBMCs) and serum from 23 male 
patients and gender-matched 30 healthy controls were consecutively collected. 
The mRNA expression for target genes including NLRP3, caspase-1, IL-1β, 
IL-17A, and IL-23 from PBMCs were evaluated by quantitative real-time poly-
merase chain reaction (qRT-PCR). Clinical information related with AS patients 
were collected including Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI), peripheral arthritis, enthesitis, and extraarticular manifestations. Sta-
tistical analyses were performed using Spearman’s correlation coefficient and 
Mann-Whitney t test. 
Results. Higher mRNA expression of NLRP3, caspase-1, IL-1β, IL-17A, and IL-
23 in AS was noted than those in controls (p=0.010, p=0.029, p=0.005, p=0.046, 
and p=0.002, respectively). Patients treated with biological diseases modifying 
antirheumatic drugs (bDMARDs) showed significantly lower caspase-1, IL-1β, 
and IL-17A m RNA levels than those without bDMARDs, but not in IL-23 and 
NLRP3. NLRP3 mRNA levels were significantly associated with IL-23, IL-17A, 
caspase-1, and IL-1β (p<0.05 of all). These gene expression was not associated 
with disease duration and BASDAI score (p>0.05 of all). 
Conclusion. This study suggests that inflammatory response by activation of 
NLRP3 inflammasome might be involved in the pathogenesis of AS. 
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ASSESSING FUNCTIONAL DISABILITY AND GENERAL HEALTH 
SITUATION IN PATIENTS WITH ANKYLOSING SPONYLITIS BY 
ASAS HEALTH INDEX
Can M.
Medipol University, Istanbul, Turkey
Introduction/Aim. Ankylosing Spondylitis can cause physical dysfunction and 
reduce patients health quality and thus can cause disability. Ankylosing Spon-
dylitis Quality of Life (ASQoL) index is widely used to assess patients with 
ankylosing spondylitis. ASAS health index and environmental factors index are 
easy to use and show us the disease from patients perspective. We aimed to assess 
general health status, dysfunctions by using ASAS health index and environment 
factors and other doctor and patient related scales. 
Materials and Methods. 94 patients covered ASAS diagnostic criteria were in-
cluded. ASAS Health index (ASAS-HI), Bath ankylosing spondylitis disease ac-
tivity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), 
patient related health assessment questionnaire (HAQ) and ankylosing spondyli-
tis quality of life (ASQoL) questionnaires were filled by participants. 
Results. 45 of 91 (%50) patients were male, mean age was 35.6 (10.6) and average 
disease duration was 25.7 (40.5) months. %50 of patients BASDAI score was more 
than 4 (0-10) and had active disease. When ASAS health index result was evalu-
ated, 29 patients (%33) had normal function and 32 patients had (%36.4) moderate 
dysfunction and 27 patient (%30.7) had severe dysfunction. When compared with 
BASDAI results disease activity and ASAS health index results showed positive 
relation (p=0.00). ASAS health index results showed positive correlations with 
BASFI, BASDAI, spinal pain, HAQ. (respectively r:0.5, 0.6, 0.5, 0.6).
Discussion. ASAS health index and environmental factor index results showed 
positive correlations with BASFI, BASDAI, spinal pain and HAQ. Although 
ASQoL is only used to assess health quality, ASAS health index and environmen-
tal factor index are used to assess general health status, functional disability de-
grees, pain levels, social participation and emotional and sexual function status. 
Conclusion. ASAS health index is a easy, fast and reliable scale in patients with 
axial spondyloarthritis.
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EMPOWERING ANKYLOSING SPONDYLITIS (AS) PATIENTS 
THROUGH AN ONLINE PERSONAL HEALTH SYSTEM
Eren O.1, Gençtürk M.2, Yüksel M.2
1Rheumatology Clinic VM Medikalpark Hospital, Kocaeli; 2Software Research, 
Development and Consultancy, Ankara, Turkey
Introduction. Patient empowerment integrates multiple concepts that allow a 
patient to self-manage his disease, which are accessing to health information, 
education, bi-directional communication between patients and healthcare pro-
fessionals, self-care support, chronic disease management support and shared 
decision making.
Methods. In order to evaluate whether an online personal health platform improves 
AS patients’ health and enhances their effectiveness in managing their health, an 
online personal health platform is developed for AS patients in Turkey within the 
scope of European Commission supported PALANTE project. Share them with 
healthcare professionals, messaging module which allows patients to ask questions 
to healthcare professionals without getting any appointment, exercise module which 
allows patients to follow the exercise plan specified by physical therapist, videos 
module which allows patients to learn how to do exercises correctly. 
The system has been used by 131 patients and 3 healthcare professionals in Tur-
key. In order to evaluate the success of the system, a questionnaire was sent to the 
patients after they used the system for 6 months. 
Results. Questions are categorized in three groups as communication, education-
al, and informational features. For each group, same set of questions were asked to 
patients.  Using the functionalities enabled me to accomplish my healthcare tasks 
more quickly; Communication 70%, educational 74%, Informational 67%. Using 
the functionalities enhanced my effectiveness in managing my health; Communi-
cation 66%, educational 73%, Informational 66%. I found the … functionalities 
useful for managing my health; Communication 67%, educational 76%, Infor-
mational 73%. I want this service to continue; Communication 86%, educational 
83%, Informational 83%.
Conclusion. As it can be seen from the table, majority of patients reacted posi-
tively and want the services to continue. Patients found educational features, 
which contains videos module that allows patients to do their daily exercises cor-
rectly without consulting physical therapist, as the most useful functionality of 
the system. Consequently, the system improved AS patients’ health and enhanced 
their effectiveness in managing their health.
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PREVALENCE AND CHARACTERIZATION OF PSORIATIC AR-
THRITIS MUTILANS PATIENTS FROM A SINGLE TERTIARY 
CENTER 
Oliveira J.L., Cordeiro R.A., Carrasco S., Gonçalves C.R., Moraes J.C.B., Saad 
C.G.S., Sampaio-Barros P.D., Goldenstein-Schainberg C.
Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da 
Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil
Introduction. Psoriatic arthritis mutilans (PsAM) is the most serious and un-
common form of psoriatic arthritis (PsA) described in about 5% patients. Data 
about PsAM subtype are scarce. Therefore, the aim of our study is to describe 
the clinical characteristics of PsAM patients from a unique tertiary rheumatology 
center in Brazil. 
Materials and Methods. All patients ≥18 years who met CASPAR criteria for 
PsA followed at our rheumatology division between 2002 and 2017 were actively 
searched for PsAM deformity of hands and feet. 
PsAM was considered in the presence of shortened fingers, digital telescoping, 
and anteroposterior radiography showing at least one joint with severe erosive ar-
thritis (for example pencil-in-cup or gross osteolysis of the bones) without osteo-
phytes. Demographic, clinical, laboratory and radiographic data were collected. 
Results. Roughly 8.2% PsA patients had PsAM (17/207), 12 were males and 5 
females with mean age 59.0±9.9 years and mean age at arthritis onset 34±12.6 
years. Most prevalent PsAM comorbid conditions were hypertension in 13 pa-
tients (76%), dyslipidemia in 10 (59%), metabolic syndrome in 9 (53%), osteo-
porosis in 6 (35%), psychiatric disorders in 4 (24%), diabetes in 2 (12%). Inter-
estingly 3 (18%) patients had cancer (colon, breast, multiple myeloma). Axial 
radiographic imaging showed syndesmophytes in 9/16 (56%) patients and sac-
roiliitis in 7/16 (44%). Remarkably 9 of 13 (69%) patients tested for HLA-B27 
were positive. According to therapy, 9/17 PsAM patients (53%) were on biologic 
agents (2 adalimumab, 4 infliximab, 1 etanercept, 2 secukinumab).
Conclusion. We have shown a slightly higher prevalence of PsAM in 8.2% of 
our PsA Brazilian patients. The enhanced positivity of HLA-B27 and radio-
graphic axial involvement in PsAM shown herein for the first time is striking. 
Moreover, use of biologic therapy in more than half PsAM patients reinforces the 
aggressive nature of mutilans involvement.
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HEALTH STATUS IN PATIENTS WITH AXIAL SPONDYLOAR-
THRITIS (axSpA) AS DETERMINED BY THE ASSESSMENT OF 
SPONDYLOARTHRITIS INTERNATIONAL SOCIETY HEALTH 
INDEX (ASAS-HI)
Alva Medina G.1, Pelaez-Ballestas I.1, Burgos Vargas R.1, Avila Valde R.2, Bañue-
los Ramírez D.3, Barbosa Cobos R.E.4, Barrera Guerra R.C.5, Barrera Rodríguez 
A.A.6, Barrera Vargas A.7, Bernard Medina A.G.8, Casasola Vargas J.C.1, Castillo 
Ortíz J.D.9, Chávez López M.A.10, Cruz Alvarez L.J.11, Durán Barragán S.12, Durán 
Ortíz J.S.13, Enríquez Sosa F.E.14, Espinosa Morales R.15, Espinosa Villalpando J.16, 
Flores Alvarado D.E.17, Gámez Nava J.I.18, García Méndez S.19, García Morales 
H.20, García Olivera I.19, González Díaz V.21, González López L.C.22, González 
Pérez D.T.23, Gordillo Huerta M.V.24, Gutiérrez Ureña S.R.21, Hernández Cuevas 
C.B.25, Hernández Paz R.26, Lamuño Encorrada M.27, Macias Palacios M.28, Mara-
diaga Ceceña M.A.29, Marines Castillo A.L.23, Martinez Bonilla G.E.21, Martínez 
Valles M.A.30, Medrano Ramírez G.1, Mendoza Fuentes A.31, Meoño Morales 
E.E.32, Merayo Chalico F.J.7, Miranda Hernandez D.G.33, Miranda Limón J.M.34, 
Mota Mondragón B.A.35, Muñoz López S.36, Muñoz Monroy O.E.35, Navarro Zarza 
J.E.37, Pacheco Tena C.F.38, Palafox Sánchez C.A.39, Pérez Vázquez M.E.40, Pizaña 
Serna A.M.41, Ramírez Assad M.C.42, Ramos Remus C.R.D.43, Reyes Cordero 
G.C.44, Rodríguez García F.45, Saavedra Salinas M.A.46, Sandoval García L.F.47, 
Santana Portillo N.M.48, Silveira Torre L.H.26, Solís Alvarado C.M.49, Vazquez del 
Mercado Espinosa M.50, Veloz Aranda J.A.51, Zazueta Montiel B.E.52
1Hospital General de México ‘Dr. Eduardo Liceaga’, Ciudad de México; 2Central 
Médica Guadiana, Durango; 3Consultorio privado, Puebla; 4Hospital Juarez de 
México, SSA., Ciudad de México; 5Hospital General Regional No. 1, “Vicente 
Guerrero”, Acapulco de Juárez, Guerrero; 6Centro de Especialidades Médicas del 
Sureste, Yucatán; 7Instituto Nacional de Ciencias Médicas y Nutrición “Salvador 
Zubirán”, Ciudad de México; 8Antiguo Hospital Civil de Guadalajara Fray An-
tonio Alcalde, Guadalajara, Jalisco; 9Unidad de investigación en Enfermedades 
Crónico-Degenerativas, Guadalajara, Jalisco; 10Universidad Autónoma de Aguas-
calientes, Aguascalientes; 11Centro médico San Francisco Reynosa Tamaulipas 
Hospital Regional del Río, Tamaulipas; 12Clínica de Investigación en Reuma-
tología y Obesidad, Guadalajara, Jalisco; 13Hospital General de Zona no 1 del 
IMSS, Servicio de Reumatologia, Tepic, Nayarit; 14Hospital Regional Gral. Igna-
cio Zaragoza ISSSTE, Ciudad de México; 15Instituto Nacional de Rehabilitación, 
Ciudad de México; 16Centro Médico Angelus, Reynosa, Tamaulipas; 17Universi-
dad Autónoma de Nuevo León, Hospital Universitario José Eleuterio González, 
Nuevo León, Monterrey; 18UMAE, Hospital de Especialidades Centro Médico 
Nacional de Occidente, Guadalajara, Jalisco; 19Hospital Regional de Alta Espe-
cialidad de Oaxaca, Oaxaca; 20Hospital Amerimed, Quintana Roo; 21Hospital Civil 
de Guadalajara, “Fray Antonio Alcalde”, Oaxaca; 22Hospital General Regional 110 
del IMSS, Guadalajara, Jalisco; 23Centro Hospitalario La Concepcion, Coahuila; 
24Hospital General Querétaro ISSSTE, Querétaro; 25Hospital Regional de Alta Es-
pecialidad del Bajío, León, Guanajuato; 26Hospital Angeles Pedregal, Ciudad de 
México; 27Christus Muguerza Hospital UPAEP, Puebla; 28Hospital Regional de alta 
Especialidad ISSSTE, Veracruz; 29Hospital General de Culiacán S.S. A., Culiacán, 
Sinaloa; 30Hospital San José Celaya, Celaya, Guanajuato; 31Torre medica Venecia, 
Consultorio privado, Toluca; 32Hospital General de Zona No. 1., Tapachula, Chia-
pas; 33Hospital General de Zona No. 29 “Belisario Domínguez”, IMSS, Ciudad de 
México; 34Consultorio privado, Naucalpan, Edo. México; 35Hospital Central Mili-
tar (SEDENA), Ciudad de México; 36Centro Médico Nacional 20 de Noviembre, 
ISSSTE, Ciudad de México; 37Hospital General de Chilpancingo, Chilpancingo, 
Guerrero; 38Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma 
de Chihuahua, Chihuahua, 39Instituto de Investigación en Ciencias Biomédicas, 
Universidad de Guadalajara, Guadalajara, Jalisco; 40Hospital San José, Tec. Mon-
terrey (ITESM), Nuevo León, Monterrey; 41Hospital Dr. Belisario Domínguez. 
ISSSTE, Chiapas; 42Hospital Christus Muguerza Saltillo, Coahuila; 43Universidad 
Autónoma de Guadalajara, Guadalajara, Jalisco; 44Hospital General “Dr. Salvador 
Zubirán”, Chihuahua; 45Hospital Central Sur de Alta Especialidad de Petróleos 
Mexicanos, Ciudad de México; 46Hospital de Especialidades Dr. Antonio Fraga 
Mouret, Centro Médico Nacional La Raza, IMSS, Ciudad de México; 47Hospital 
General del Estado de Sonora “Dr. Ernesto Ramos Bours”, Hermosillo, Sonora; 
48Hospital de Especialidades “Morelos IMSS”, Chihuahua; 49Clínica de Ortopedia 
y Traumatología, Ciudad de México; 50OPD Hospital Civil “Dr. Juan I. Menchaca, 
Guadalajara, Jalisco; 51Hospital Regional ISSSTE, León, Guanajuato; 52Centro 
Médico del Ángel S.C, Mexicalli, Baja California, Mexico
Background. AxSpA, mainly ankylosing spondylitis is a disease that affects 
functioning and ultimately health related quality of life (HRQoL) as consequence 
of inflammation in the initial years and bone proliferation throughout the course 
of the disease.
The ASAS-HI is a new instrument to assess the impact of axSpA based in the In-
ternational Classification of Functioning, Disability and Health, which has been 
validated in Mexican patients. 
Objective. To investigate the status of health of Mexican patients with axSpA 
using the ASAS-HI.
Material and Methods. This is a multicenter cross-sectional study of 323/358 
patients with axSpA (ASAS criteria) referred by 55 rheumatologists private or 
institutional practice across the country through six months. Sociodemographic 
and clinical data were collected at each site and analyzed centrally.
Results. The ASAS imaging arm were fulfilled 87% and the clinical by 82%; 
HLA-B27 was positive in 82.4%; 70% were males; 56% received bDMARDs. 
Mean ages at onset and diagnoses were 26.1 (10.3) and 33.1 (12.1) years. Me-
dian age was 42 (18-72) years. ASAS-HI correlation with BASDAI, BASFI, and 
EQ-5D was significant. ASAS-HI mean score was 6.3 (4.1); the cut off was six, 
values below meant good health; 176 (54.5%) patients had good health and 147 
(45.5%) bad. Univariate analysis disclosed significant differences between the 
two groups in variables that were significant in the regression models (see below) 
and sex, NSAID, sacroiliitis, and ASDAS. The two models that were associated 
ASAS-HI in the multivariate analysis were: 1) education, comorbidities, enthesi-
tis, and physician global assessment; 2) BASDAI, BASFI, and EQ-5D.
Conclusions. ASAS-HI cut off of six identified good health in 54% of patients 
with axSpA, which correlated with BASDAI, BASFI, and EQ-5D. Univariate 
analysis found a number of differences between the two groups, but the multi-
variate analysis found significant association with BASDAI, BASFI, and EQ-5D.
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IS THE DELAY FROM RECOGNITION OF SEVERE ACTIVE 
AXIAL SPONDYLOARTHRITIS TO BIOLOGIC DISEASE MODI-
FYING THERAPY INITIATION IMPROVING?
Williams T.1, Wadeley A.2, Cavill C.1, Freeth M.1, Sengupta R.1
1Royal National Hospital for Rheumatic Diseases, Bath; 2College of Liberal Arts, 
Bath Spa University, Bath, UK
Introduction/Aim. Axial Spondyloarthritis (axSpA) is characterised by chronic 
inflammatory disease affecting spinal and peripheral joints, entheses and extra-
articular manifestations. Since 2000, biological disease-modifying therapy (bD-
MARD) has been available to treat severe active axSpA. In the United Kingdom, 
access to bDMARD is heavily influenced by National Institute for Health and 
Care Excellence (NICE) guidelines, with the first axSpA guideline issued in 
2008. Previous studies have demonstrated substantial delay to bDMARD initia-
tion in severe active axSpA, potentially resulting in worse long-term outcomes. 
Our aim was to establish whether the time from identifying severe active axSpA 
to bDMARD initiation is improving.
Materials and Methods. We performed a retrospective cohort analysis of pa-
tients prescribed bDMARDs for axSpA at the Royal National Hospital for Rheu-
matic Diseases, Bath. Dates of diagnosis, first bDMARD initiation and the first 
recorded BASDAI and back pain VAS scores >4, were included in order to calcu-
late the delay between identifying severe active axSpA and bDMARD treatment. 
The trend in this delay over time was tested by Spearman’s correlation coeffi-
cient. Patients with incomplete data or were diagnosed before the availability of 
bDMARDs in 2000 were excluded from analysis.
Results. 39 patients met the inclusion criteria. The mean delay to initiation of 
the first bDMARD in this cohort was 3.95 years. There was a slight tendency 
towards shorter mean delay in recent years, though this did not reach statistical 
significance (Spearman’s correlation coefficient= 0.18, p=0.27). 
Discussion. Delays in initiating bDMARDs for patients with severe active axS-
pA continue to exist, potentially yielding worse long-term outcomes. It is unclear 
whether these delays are improving despite innovations such as early back pain 
clinics and increased use of imaging. Further work could include prospective 
data collection to establish why such delays occur.
Conclusions. It remains unclear whether the delay from recognition of severe 
active axSpA to bDMARD initiation is improving.
P137
AXIAL SPONDYOARTHRITIS-RELATED QUALITY OF LIFE 
IMPROVES SIGNIFICANTLY FOLLOWING INITIATION OF BIO-
LOGICAL DISEASE-MODIFYING THERAPY
Williams T.1, Wadeley A.2, Cavill C.1, Freeth M.1, Sengupta R.1
1Royal National Hospital for Rheumatic Diseases; 2College of Liberal Arts, Bath 
Spa University, Bath, UK
Introduction/Aim. Axial Spondyloarthritis (axSpA) is characterised by chronic 
inflammatory disease affecting spinal and peripheral joints, entheses and extra-
articular manifestations. Patients with axSpA also suffer worse quality of life 
with increased levels of ill-health, functional impairment and work-related dis-
ability. Our aim was to establish whether initiation of biological disease-modify-
ing therapy (bDMARDs) significantly improved these outcomes.
Materials and Methods. We performed a cross-sectional, retrospective analysis 
of patients prescribed bDMARDs for severe active axSpA at the Royal National 
Hospital for Rheumatic Diseases, Bath. ASQoL measurements immediately prior 
to and the nearest to six months after initiation of the first bDMARD were in-
cluded, with percentage change calculated. The percentage of patients achieving 
20%, 40% and 70% reduction in ASQoL was established (described as ASQoL20/
ASQoL40/ASQoL70). Patients were excluded from analysis where we failed to 
establish both pre- and post-treatment scores or where data was incomplete.
We also looked at changes in BASDAI, BASFI, BASMI, WPAI (overall work 
impairment due to health), FACIT, Jenkins sleep scale and EQ5D for comparison.
Results. 38 patients met the inclusion criteria. Following initiation of the first 
bDMARD, 63.2%, 55.3% and 34.2% achieved ASQoL20, 40 and 70 responses 
respectively. Statistically significant improvements following initiation of the first 
bDMARD were also demonstrated in BASFI (p=0.001, n=21), WPAI percentage 
activity impairment due to health (p=0.000002, n=35), FACIT (p=0.002, n=19), 
EQ5D (p=0.002, n=25) and mean Jenkins sleep scale score (p=0.0002, n=24).
Discussion. Significant improvement in axSpA-related quality of life was 
achieved in the majority of patients treated with their first bDMARD in this co-
hort, reflecting corresponding improvements in function, work-related disability, 
fatigue, sleep, depression and anxiety scores. Future analysis could include iden-
tification of predictors for quality of life improvement with bDMARD treatment.
Conclusion. Treating severe axSpA with bDMARDs significantly improves 
quality of life outcomes for patients.
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WORK PRODUCTIVITY AMONG WORKERS WITH AXIAL 
SPONDYLOARTHRITIS
Lopes C.1,2, Rodrigues-Manica S.1,2, Marona J.1,2, Mateus M.1, Pimentel-Santos 
F.2,1, Branco J.2,1 
1Dept. Rheumatology Hospital de Egas Moniz, CHLO; 2CEDOC, Faculdade de 
Ciências Médicas - NOVA University of Lisbon, Lisbon, Portugal
Background: Axial Spondyloarthritis (axSpA) usually starts in early adulthood 
and the lifetime impact of the disease can be considerable. Absenteeism and pres-
enteeism are still responsible for high costs associated with the disease.
Objectives: Assess absenteeism, presenteeism, work and daily-activities impair-
ment and their related associated factors in patients with axSpA.
Methods: Cross-sectional postal, unicenter, non-interventional study. Patients 
fulfilling the ASAS criteria for axSpA under working age were included. Two 
groups were defined: A) patients under current anti-TNF; B) patients under con-
ventional therapy. Quantitative and qualitative surveys were performed: Work 
Productivity and Activity Impairment Questionnaire in SpA (WPAI); partici-
pants’ experiences of working and their perceptions of how their condition had 
affected their work capacity and workplace relationships were recorded.
The questionnaires were applied through a telephone call, after consent of the 
participant and respecting anonymity.
Results: 60 patients were included. Mean absenteeism, presenteeism, work and 
activities impairment were 6.8%, 32%, 35% and 41%, respectively. The univari-
able analysis showed correlations between absenteeism and phVAS (p=0.027); 
presenteeism and ASDAS-CRP (p=0.002), BASDAI (p=0.03), BASFI (p=0.02), 
patient VAS and phVAS (p=0.01, p=0.006), ESR (p=0.03), CRP (p=0.024); percent 
overall work impairment and ASDAS-CRP (p=0.002), BASDAI (p=0.019), BASFI 
(p=0.026), patient VAS and phVAS (p=0.016, p=0.01), ESR (p=0.03) and CRP 
(p=0.03); percent activity impairment and BASDAI (p=0.006), BASFI (p=0.004), 
pVAS (p=0.0004) and phVAS (p=0.007). BASDAI, BASFI, phVAS, patient VAS 
and CRP accounted for 63% of the variance of presenteeism, with 10 points increase 
in phVAS resulted in an increase of 17% in presenteeism (p=0.046). Over time, 95% 
had already gone to work sick: economic reasons (60%) were the major reasons 
to presenteeism. 63% considered that the disease can limit their projects or career 
progression and 15% stated that had already felt discriminated.
Conclusions: Presenteeism, impairment of work productivity and activity were 
correlated with disease activity and physical functioning, with the increase of 
VAS physician resulting in increase in presenteeism.
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IMPROVEMENT OF CYTOLOGICAL GRADE AND TEAR PRO-
DUCTION IN ANKYLOSING SPONDYLITIS PATIENTS UNDER 
ANTI-TNF THERAPY: A LONG-TERM FOLLOW-UP
Usuba F.S.1, Saad C.G.S.2, Novaes P.1, Santo R.M.1, Moraes J.C.B.2, Bonfá E.2, 
Alves M.R.1
1Ophtalmology Dept., Hospital das Clínicas da Faculdade de Medicina da Uni-
versidade de São Paulo, 2Rheumatology Division, Hospital das Clínicas da Fac-
uldade de Medicina da Universidade de São Paulo, Brazil
Introduction/Aim. Clinical expression and pathophysiology of dry eye disease 
(DED) have recently changed and pro-inflammatory cytokines, such as TNF-α, 
may play a role in the multifactorial mechanism of DED. Few studies evaluated 
the effect of TNF blockage in DED and there are no data regarding this complica-
tion in ankylosing spondylitis (AS). The aim of the study is to analyze the ocular 
surface (OS) in AS patients according to the DED severity grade and conjuncti-
val impression cytology (IC) and the effect of anti-TNF therapy in a subgroup of 
patients with a one-year follow-up.
Methods. Thirty-six AS patients and 39 controls with strict exclusion criteria for 
DED were enrolled at study entry, and 14 were followed prospectively post-anti-
TNF therapy at 3months (3M), and 12 months (12M). AS disease parameters 
were performed for all patients. Ocular evaluation included OS Index Disease 
questionnaire, Schirmer I test, break-up time, vital staining, and conjunctival IC. 
DED severity grade was also applied. 
Results. AS patients presented higher frequency of DED (80.5% vs. 43.6%, 
p=0.01), a worse score of severity [1(0-3) vs. 0(0-1), p=0.001], and a higher 
frequency of altered IC (55.5% vs. 12.8%, p=0.007) when compared to controls. 
The 14 patients under anti-TNF therapy presented an improvement in all clinical 
AS disease activity parameters throughout the one-year treatment (p<0.05). A 
concomitant increase in the Schirmer test was also observed [BL:10(2-35) mm, 
3M:17.5(4-35) mm and 12M:20(4-30) mm, respectively, p=0.04] as well as a 
significant amelioration in the altered IC to a normal IC was noticed (p=0.006). 
Conclusion. DED is a frequent and under-diagnosed ocular disease in AS pa-
tients. The long-term parallel improvement of disease activity and OS parameters 
in AS patients receiving anti-TNF therapy suggests that the OS is an additional 
target of systemic inflammation in AS. 
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EMERGENCE OF SEVERE SPONDYLOARTHROPATHY RELAT-
ED ENTHESEAL PATHOLOGY IN VEDOLIZUMAB TREATED 
INFLAMMATORY BOWEL DISEASE
Dubash S.1, Thiraupathy M.2, Tinazzi I.3, Al Araimi T.4, Pagnoux C.4, Weizman 
A.V.4, Richette P.5, Tran Minh M.L.6, Allez M.6, Singh A.7, Ciccia F.8, Hamlin J.9, 
Tan A.L.10, Marzo-Ortega H.1, McGonagle D.1
1Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of 
Leeds, Leeds; 2East Hertfordshire NHS Trust, Stevenage, UK; 3Sacro Cuore-Don 
Calabria Hospital, Negrar, Italy; 4Mount Sinai Hospital, University of Toronto, 
Toronto, Canada; 5Hôpital Lariboisiere, APHP, University Hospital of Ile-de-
France, Paris; 6APHP, Hôpital Saint Louis, Sorbonne Paris-Cité University, Par-
is, France; 7Royal Free Hospital, London, UK; 8University of Palermo, Palermo, 
Italy; 9Leeds Teaching Hospitals NHS Trust, Leeds; 10Leeds Institute of Rheu-
matic and Musculoskeletal Medicine, Leeds, UK
Introduction/Aim. Vedolizumab (VDZ) therapy for inflammatory bowel disease 
(IBD) has been associated with mild spondyloarthritis (SpA) related features in-
cluding sacroiliitis and synovitis. Following presentation of an index case, we 
collaborated with other centres to determine if severe SpA had occurred after 
IBD therapy with VDZ. Herein, we report a series of cases demonstrating the 
emergence of severe SpA associated enthesitis/osteitis following successful IBD 
treatment with VDZ.
Materials and Methods. We evaluated 11 VDZ treated patients with IBD across 
7 centres that developed severe SpA and/or enthesopathy with the aim of charac-
terising the VDZ associated SpA or entheseal flares.
Imaging features demonstrating particularly severe disease were recorded. 
Results. De novo SpA developed in 9 of 11 patients in total and flare of estab-
lished SpA in 2 patients. Four patients required hospitalisation due to disease 
severity. Available data showed that 1/7 were HLA-B27 positive. The median 
time from VDZ initiation to flare was 12 weeks with IBD activity ameliorated 
in 7/10 (no data 1 case) at flare. Severe SpA enthesitis/osteitis was evident 
on magnetic resonance imaging (MRI) or ultrasound including acute sacroili-
itis (n=5), extensive vertebral osteitis (n=1), peri-facetal oedema (n=1), and 
isolated peripheral enthesitis (n=3). Due to SpA/enthesitis severity, VDZ was 
discontinued in 9/11 cases and changes in therapy were initiated including 
alternative anti-TNF.
Discussion. As we anticipate increasing use of α4β7 inhibition, awareness of 
this paradoxical reaction and specific phenotype amongst rheumatologists and 
gastroenterologists alike, can facilitate combined management decisions for ef-
fective treatment of IBD and SpA or enthesitis. These cases also tell us about the 
disease process and why in the face of quiescent gut disease do patients develop 
a severe SpA/ enthesitis? We believe that α4β7 bound to adhesion molecules 
MADCAM-1/ VCAM-1 for T-cell transportation into mucosal or vascular tissue, 
is not dependent for entheseal or joint tissue and therefore would not hinder adap-
tive T-cell responses at these locations. This proposed model of pathogenesis 
offers an explanation for these severe SpA/enthesitis flares. 
Conclusion. Severe SpA, predominantly HLA-B27 negative, with osteitis/en-
thesitis, may occur under successful VDZ treatment for IBD.
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PATIENT-ACCEPTABLE SYMPTOM STATE IN PSORIATIC 
ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS IN 
REAL CLINICAL PRACTICE
Queiro R.1, Cañete J.D., Montilla C., Abad M.A., Gómez S., Cábez A.
1Rheum. Division. HUCA., Oviedo, Spain; Coordinating centre
Background and Aims. Treatment goals in psoriatic arthritis (PsA) are re-
mission or low disease activity. We know little about whether these objectives 
correlate well with a patient-acceptable symptom state (PASS). To analyse the 
frequency of PASS in routine clinical practice, we used the Psoriatic Arthritis 
Impact of Diseases (PsAID) questionnaire proposed by EULAR. 
Methods. Cross-sectional multicenter study including patients with PsA accord-
ing to CASPAR criteria.
Patients with at least one year of disease evolution and under treatment with 
synthetic (s) and / or biological DMARDs were included. The MDA, VLDA, 
DAPSA remission and clinical (c) DAPSA remission (without CRP) were meas-
ured as treatment targets. A PsAID value <4 was defined as PASS. Factors associ-
ated with PASS were analysed by uni and multivariate models.
Results. This study included 227 patients, 123 men and 104 women, with a mean 
age of 53.2±12.4 years.
The average duration of PsA was 9.6±7.7 years. One hundred and thirty-three 
(58.6%), 26 (11.5%), 52 (30.6%), 65 (36.9%) and 125 (55%) patients were in 
MDA, VLDA, DAPSA remission, cDAPSA remission, and PASS, respectively. 
Mean PsAID was significantly lower in patients reaching any of the treatment 
targets (p<0.0001). Unadjusted associations with PASS (p<0.25) were: age, BMI, 
level of education, work situation, smoking, debut pattern, DIP disease, fam-
ily history of PsA, ischemic heart disease, obesity, CRP, NSAID use, corticoids 
use, structural damage in hands, and syndesmophytes. Involvement of DIP joints 
(OR 0.40, 95%CI: 0.20–0.79, p=0.009), PsA family history (OR 0.25, 95%CI: 
0.09–0.72, p=0.010) and CRP (0.92, 95% CI: 0.85–0.99), p=0.036, decreased the 
odds of PASS in the multivariate model.
Conclusions. More than half of patients treated with systemic therapies under 
routine clinical practice reach a PASS status according to the PsAID. The in-
volvement of DIP joints, higher CRP levels and PsA family history are associated 
with lower odds of achieving that status.
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VITAMIN D DEFICIENCY IS ASSOCIATED WITH GREATER 
PRESENCE OF VERTEBRAL FRACTURES, IN PATIENTS WITH 
AXIAL SPONDYLOARTHRITIS
Romera-Lopez C.1, Fernández-Carballido C.2, Martínez-Vidal M.P.3, Pedraz Pe-
nalva T.2, García Moreno M.A.4
1Reumatología, Hospital Vinalopo, Elche, Alicante; 2Reumatología, Hospital 
General Universitario de Elda (HGUE), Alicante; 3Reumatología, Hospital Gen-
eral Universitario de Alicante, Spain; 4Radiología, Hospital general Universitario 
de Elda, Alicante, Spain
Introduction/Aim. Vitamin D (25(OH)D3) insufficiency has been associated with disease activity in axial spondyloarthritis (axSpA). There are no studies in 
these patients that associate it with vertebral fractures (VF), as in postmenopau-
sal women.
Objective: To evaluate the association between 25(OH)D3 insufficiency and presence of VF in AxSpA, as well as the risk in ten years time (FRAX) and low 
bone mineral density (BMD).
Methods. Cross-sectional study. 25(OH)D3 insufficiency if <30ng/mL. BMD measured with DXA in lumbar spine and femoral neck (FN). Low BMD if T/Zscore 
<-1. Evaluation of VF with semiquantitative method (Genant) in thoracolumbar ra-
diographs. Bivariate and multivariate analysis. Significant p value<0.05.
Results. 206 patients (69.9%male), 86.4% radiographic AxSpA, 51.7±14.1 years 
and 12.9±10.3 years of evolution. Disease activity (ASDAS-PCR 2.2±0.9, AS-
DAS-VSG 2.5±0.9). Total mSASSS 20.5±19.1. 85.7% had 25(OH)D3 insufficien-cy (mean 9.8±9.3ng/mL). 34% had VF. Prevalence low BMD: FN 28.9%, lumbar 
59.7%. These differences were even greater in insufficiency subgroup (Table I).
Differences depending on 25(OH)D3 levels (all p<0.05)
 
 25(OH)D3 insufficiency Normal
Patients 85.65% 14.36%
VF 38.7% 32.48%
Major FRAX 8.7±6.7 7.5±6.4
BASDAI 4.2±2.2 3.1±1.3
BASFI 3.8±2.5 3.0±2.4
ASDAS-CRP 2.21±0.1  1.8±0.1 
ASDAS-ESG 2.72±0.2  2.1±0.2 
Low FN BMD 56.4% 44.6%
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25(OH)D3 insufficiency was inversely associated with low FN BMD (p=0.001), 
as well as with T/Z scores (p=0.002 both). There was no association with lumbar 
BMD. 25(OH)D3 insufficiency was directly associated with the presence of VF, 
thus acting as a protective factor [[OR 0.95 (IC95 0.86-0.98) p=0.029]. 25(OH)
D3 insufficiency was associated with a greater risk of fracture in ten years time 
(major FRAX (p=0.036)).
Conclusions. 25(OH)D3 insufficiency is associated with lower FN BMD and 
greater presence of vertebral fractures, as well as increased disease activity and 
disability, in axial SpA. 25(OH)D3 insufficiency should be taken into account in 
the management of the comorbidities of the axial spondyloarthritis.
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OSTEOPOROSIS AND VERTEBRAL FRACTURES ARE ASSOCI-
ATED WITH DISEASE ACTIVITY AND AXIAL RADIOGRAPHIC 
DAMAGE IN AXIAL SPONDYLOARTHRITIS – 206 SPANISH 
PATIENT’S SERIES
Romera-López C.1, Fernández-Carballido C.2, Martinez-Vidal M.P.3, Pedraz Penalva 
T.2, García Moreno M.A.4
1Reumatología, Hospital Vinalopó, Elche; 2Reumatología, Hospital General Uni-
versitario de Elda; 3Reumatología, Hospital General Universitario de Alicante; 
4Radiología, Hospital general Universitario de Elda, Alicante, Spain
Introduction/Aim. Osteoporosis (OP) and vertebral fractures (VF) are common 
comorbidities of axial Spondyloarthritis (axSpA), included on 2016 ASAS-EU-
LAR recommendations of management of these patients. In our knowledge, this 
is the longest series in European patients. 
Our aim is to evaluate the relationship between activity and radiographic injury, 
bone mineral density (BMD), levels of 25(OH)vitamin D (25(OH)D3), and FV 
in patients with axSpA.
Methods. Cross-sectional study. Activity variables: BASDAI, ASDAS, ESR, 
CRP. Vitamin D insufficiency if <30ng/ml. Dual X-ray absorptiometry (DXA) in 
lumbar spine (LS) and femoral neck (CF). Evaluation of VF with semiquantita-
tive method (Genant) in thoracolumbar radiographs. Bivariate and multivariate 
analysis.
SPSS(v23). Significant p value: <0.05.
Results. 206 patients (62 women). 86.4% radiographic axSpA. Mean values: age 
51.7±14.1; activity (BASDAI 3.6±2.2, ASDAS-PCR 2.2±0.95, ASDAS-VSG 
2.5±0.99, PCR 4.97±8.97/L, ESR 18.2±14mm/h); total mSASSS:20.46±19.14, 
25(OH)D3 19.83±9.25ng/ml. Prevalences: low BMD detected in 28.9%(LS) and 
59.7%(FN), OP in 6.9% and 13.4%, respectively. VF in 34%.
Multivariate analysis confirmed association between disease activity (ASDAS-
VSG) [OR 3.32 (CI 2.35-4.55) p=0.016], 25(OH)D [OR 0.95(IC95 0.86-0.98) 
p=0.029] and low FN BMD (z score).
VF were associated with CRP [OR2.34(IC95(1.10-4.98), p=0.027], lumbar ra-
diographic damage [OR1.06(IC95(1.03-1.10), p=0.001], high lumbar BMD 
[OR296(IC95 5.07-12258)] p=0.006] and low FN BMD [OR 0.11(IC95(0.03-
0.12), p=0.000].
Differences depending on the presence of fracture (all p<0.05)
 Without VF With VF
CRP (mg/L) 5.10 9.51
ESR (mm/h) 15.87 23.12
25OHvitD (ng/mL) 20.80 18.043
cervical mSASSS  8.02 13.11
lumbar mSASSS 8.93 12.36
total mSASSS 17.66 27.13
Lumbar BMD 1.090 1.191
FN BMD 0.912 0.773
Conclusion. In patients with axSpA, low, hip BMD is associated with disease 
activity and vitamin D deficiency.
The presence of VF is associated with CRP and low, CF BMD (p=0.001). Ra-
diographic damage “falsely” increases lumbar BMD, but is associated with the 
presence of fractures.
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VALIDITY OF PROMIS MEASURES IN ANKYLOSING SPONDY-
LITIS PATIENTS
Hwang M.C.1, Ogdie A.R.2, Reveille J.D.1
1McGovern Medical School at The University of Texas Health Science Center 
at Houston, Dept. of Internal Medicine, Houston; 2Hospital of the University of 
Pennsylvania, Dept. of Internal Medicine, Philadelphia, USA
Aim. To evaluate the validity of selected Patient-Reported Outcome Informa-
tion Measurement (PROMIS) measures in Ankylosing Spondylitis (AS) patients 
across self-reported Assessment in Spondyloarthritis International Society core 
set and patient-identified domains.
Materials and Methods. Patients in the Prospective Study of Outcomes in An-
kylosing Spondylitis, a longitudinal, prospective, AS cohort from the Houston, 
Texas study-site from Sept 2017-May 2018 (n=82) completed PROMIS short 
forms (SFs) assessing global health, depression, fatigue, pain and physical func-
tion. PROMIS SFs ranged from 3-12 questions. We assessed internal consistency 
using Cronbach’s alpha. Content validity was assessed by asking patients if the 
PROMIS SF questions related to their disease. We assessed construct validity 
through examination of score distributions, floor effects and through examination 
of the Spearman’s correlation coefficients between PROMIS measures and exist-
ing legacy AS measures (e.g. BASDAI, BASFI, Global Numeric Rating Scale 
(NRS), Pain NRS and CES-D) of similar domains. We hypothesized that there 
would be moderate to strong correlation (e.g., 0.6-1) between the PROMIS meas-
ures and the target legacy measures.
Results. Participants were mostly male (75%), white (84%), with a mean age of 
53 years (Table I). All 82 patients felt the PROMIS SFs addressed AS disease 
aspects. Legacy measures demonstrated a floor effect that was not present in the 
PROMIS SFs (Fig. 1). Strong internal consistency was noted in the PROMIS. 
Table I. AS Patient characteristics (N=82).
Characteristic Value
Age (Mean SD; years) 53.1 ± 14.2
Male Gender (n, %) 62 (75.6%)
Caucasian Race (n, %) 69 (84.1%)
College Education (n, %) 67 (81.7 %)
Current Employment (n, %) 58 (70.7)
Disease Duration (Median, IQR; years) 20.33 (8.4, 28.8)
Biologic Therapy (n, %) 12 (14.6%)
SFs ranging from 0.843–0.973 (Table II). PROMIS Global, Depression, Fatigue, 
Pain, Physical Function correlated moderately-strongly (rho .684-.865) with the 
appropriate legacy measures (Table III). Patients reported time to complete the 
entire PROMIS SFs packet was <10 minutes overall. 
Conclusions. This study demonstrates the content and construct validity of 
PROMIS SFs to assess AS symptoms from a single-center sample of AS patients. 
Further research is needed to assess discrimination (the ability of PROMIS SF to 
distinguish disease activity groups), responsiveness, feasibility/resource burden, 
and translations for AS patients.
(Figure 1 and Tables II and III are on the following page)
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Table II. PROMIS and legacy measure scores in AS patients.
  N Mean Median Std. Deviation Range Minimum Maximum Cronbach’s alpha  
        (95% CI)
Patient Global                
PROMIS Global 82 46.3256 46.3000 8.55506 44.20 23.50 67.70 .843 (.787, .889)
Global NRS 82 25.67 20.00 23.462 100 0 100  
Depression                
PROMIS Emotional Distress -Depression 82 43.9451 38.2000 8.05124 31.10 38.20 69.30 .938 (.916, .957)
Center for Epidemiologic Studies-Depression 80 10.5375 9.0000 8.29205 33.00 0.00 33.00  
Fatigue                
PROMIS Fatigue 82 48.8768 48.6500 10.64216 51.80 26.00 77.80 .970 (.958, .979)
Bath Ankylosing Spondylits Disease Activity Index-Fatigue 82 3.7805 3.0000 2.553 9.00 0.00 9  
Pain                
PROMIS Pain Intensity 82 44.8171 43.5000 9.14456 33.40 30.70 64.10 .925 (.902, .949)
PROMIS Pain Interference 82 51.0341 51.2000 9.73802 36.30 40.70 77.00 .973 (,963, .981)
Pain NRS 82 31.34 25.00 26.516 100 0 100  
Physical Function                
PROMIS Physical Function 78 46.8551 45.2000 9.56299 39.90 26.20 66.10 .911 (.878, .937)
Bath Ankylosing Spondylits Functional Index 82 2.8549 2.2000 2.62279 9.40 0.00 40 
Table III. Correlations between PROMIS and legacy measures in AS patients.
 PROMIS Global PROMIS  CESD PROMIS BASDAI- PROMIS PROMIS Pain PROMIS Bath
 Global NRS Emotional  Fatigue Fatigue Pain Pain NRS Physical Ankylosing
   Distress-D     Intensity Interference  Function Spondylitis  
           Functional  
           Index
PROMIS Global 1.000 -.838** -.494** -.592** -.572** -.706** -.712** -.761** -.688** .760** -.741**
Global NRS -.838** 1.000 .405** .465** .495** .662** .651** .752** .717** -.779** .794**
PROMIS Emotional Distress – -.494** .405** 1.000 .684** .401** .223* .347** .477** .271* -.313** .283*
   Depression 
Center for Epidemiological -.592** .465** .684** 1.000 .429** .441** .442** .504** .381** -.388** .395** 
   Studies-D 
PROMIS Fatigue -.572** .495** .401** .429** 1.000 .574** .376** .474** .333** -.464** .413**
BASDAI- Fatigue -.706** .662** .223* .441** .574** 1.000 .620** .589** .672** -.563** .627**
PROMIS Pain Intensity -.712** .651** .347** .442** .376** .620** 1.000 .753** .861** -.474** .498**
PROMIS Pain Interference  -.761** .752** .477** .504** .474** .589** .753** 1.000 .757** -.688** .680**
PAIN NRS -.688** .717** .271* .381** .333** .672** .861** .757** 1.000 -.558** .586**
PROMIS Physical Function .760** -.779** -.313** -.388** -.464** -.563** -.474** -.688** -.558** 1.000 -.865**
Bath Ankylosing Spondylitis  -.741** .794** .283* .395** .413** .627** .498** .680** .586** -.865** 1.000
   Functional Index 
**Correlation is significant at the 0.01 level (2-tailed), * Correlation is significant at the 0.05 level (2-tailed).
Fig. 1. Distribution of select PROMIS and legacy scores in Ankylosing Spondylitis 
patient sample (n=82). Representative histograms (Physical Function, Global, and Fa-
tigue) show legacy measures floor effects not observed in PROMIS measures. Similar 
results seen on all domains analyzed.
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PATIENTS WITH AXIAL SPONDYLOARTHRITIS RARELY HAVE 
1 OR 2 INFLAMMATORY BACK PAIN PARAMETERS
de Hooge M.1,2, Varkas G.1,2, Elewaut D.1,2, van den Bosch F.1,2
1Dept. of Rheumatology, Ghent University Hospital; 2VIB Inflammation Research 
Centre, Ghent University, Ghent, Belgium
Introduction/Aim. The Berlin Algorithm (BA) is a tool that assists clinicians 
in diagnosing axial spondyloarthritis (axSpA). In the modified BA inflammatory 
back pain (IBP) is excluded as entry criterion.
Although the modified BA is used in clinical practice some argue that this modi-
fication insufficiently emphasises the inflammatory character of axSpA. There-
fore, the study aim was to provide an overview of the IBP parameters present in 
axSpA patients (pts) included in the Be-Giant cohort.
Materials and Methods. Data of an observational multicentre cohort study was 
used. Pts aged ≥18 years with a new axSpA diagnosis and fulfilling the ASAS 
axSpA criteria were included in the Belgian inflammatory arthritis and spondyli-
tis cohort (Be-Giant). All 5 IBP parameters according to the ASAS-criteria were 
collected: 1) Age at onset <40 years, 2) insidious onset, 3) improvement with 
exercise, 4) no improvement with rest and 5) pain at night. IBP is defined when 
≥4 of these parameters are present. All descriptive data was presented as n (%) 
or means (±SD).
Results. All IBP parameters were collected from 228 pts and 49.6% (n=113) was 
male with mean age of 34.7 years (SD 9.7). Individual parameters were present 
in >75% of the pts. The parameter ‘age at onset <40 years’ was present in 95.2%, 
‘insidious onset’ in 89%, ‘improvement with exercise’ in 86%, ‘no improvement 
with rest’ in 81.6% and ‘pain at night’ in 75.9% of the pts. Pts rarely had 1 or 2 
IBP parameters; 2 (0.9%) pts with 1 parameter and 12 (5.3%) pts with 2 param-
eters (Table I).
Conclusion. The majority of early axSpA pts were positive for IBP. A minority 
shows ≤1 IBP parameter. Hence, there is no need to worry that the inflammatory 
character of axSpA is subverted because IBP is not a mandatory feature in clas-
sification of axSpA.
Table I. Total number of ASAS-IBP parameters in patients with axSpA diagnosis and 
classified according to the ASAS criteria in the Be-Giant and SPACE cohort.
 Be-Giant cohort
 n=228
0 IBP parameters 0
1 IBP parameters 2 (0.9%)
2 IBP parameters 12 (5.3%)
3 IBP parameters 31 (13.6%)
4 IBP parameters 59 (25.9%)
5 IBP parameters 124 (54.4%)
axSpA, axial spondyloarthritis; IBP, inflammatory back pain.
IBP parameters: Age onset back pain <40years, insidious onset of back pain, improve-
ment with exercise, no improvement with rest, pain at night.
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RELATIONSHIP BETWEEN THORACIC KYPHOSIS AND SHO-
ULDER MUSCLE STRENGTH AND SHOULDER JOINT MOTION 
IN MALE PATIENTS WITH ANKYLOSING SPONDYLITIS
Mete O.1, Saraç D.C.2, Baglan Yentur S.2, Tore G.2, Sari F.2, Ataş N.3, Göker B.3, 
Oskay D.2
1Ankara Yildirim Beyazit University, Faculty of Health Sciences; 2Gazi Univer-
sity Faculty of Health Sciences; 3Gazi University, Faculty of Medicine, Dept. of 
Internal Medicine, Ankara, Turkey
Introduction. Ankylosing Spondylitis (AS) is a rheumatologic disease that pri-
marily affects the axial skeleton. Spinal inflammation, increased ossification of 
the ligaments and syndesmophytes in the spinal column can cause an increase 
in thoracic kyphosis in the AS patients. Negative effects of thoracic kyphosis on 
shoulder functions have been reported in studies performed in different popula-
tions. The aim of our study is to determine the relationship between thoracic 
kyphosis and shoulder functions in male patients with AS.
Methods. Twenty-three (23) male participants (age:41,18±11, 89 year, body 
mass index:26,25±5,02 kg/m2) diagnosed with AS according to the Modified 
New York criteria were included the study. Thoracic kyphosis angle and shoulder 
motion were evaluated with digital inclinometer. Strength of shoulder muscles 
were evaluated with digital hand-held dynamometer. Pearson correlation test and 
Spearman correlation test were used for statistical analysis.
Results. Thoracic kyphosis angle showed negative correlations with dominant side 
shoulder flexion active range of motion (AROM) (p<0.001;rho:-0.711), abduc-
tion AROM (p:0.007;rho:-0.545), external rotation AROM (p:0.008;rho:-0.536) 
and non-dominant side shoulder flexion AROM (p<0.001;rho:-0.768), abduc-
tion AROM (p:0.008;rho:-0.540), external rotation AROM (p:0.005;rho:-0.563). 
There was no correlation between thoracic kyphosis angle and shoulder abduc-
tion and flexion muscle strength.
Discussion. As a result of our study, it was determined that in patients with male 
AS, thoracic kyphosis angle was correlated with shoulder flexion AROM, abduc-
tion AROM and external rotation AROM. There are muscular and mechanical 
connections between the spinal column, scapula, clavicle and humerus. The posi-
tion changes of these bone structures biomechanically affect each other. We think 
that as the thoracic kyphosis angle increases, the shoulder mobility decreases in 
male patients with AS because of this reason. In light of this knowledge, thera-
peutic approaches to thoracic hyperkyphosis will benefit for the shoulder mobil-
ity in AS patients.
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DIAGNOSTIC PERFORMANCE OF POWER DOPPLER ULTRA-
SOUND OF THE ENTHESES IN PATIENTS WITH UNCERTAIN 
DIAGNOSIS OF SPONDYLOARTHRITIS: THE EchoSpA PRO-
SPECTIVE MULTICENTER FRENCH COHORT 
D’Agostino M.A.1, Aegerter P.2, Loeuille D.3, Judet O.4, Chary-Valckenaere I.3, 
Saraux A.5, Marcelli C.6, Guis S.7, Gaudin P.8, Jousse-Joulin S.5, Amor B.9, de 
Vlam K.10, Falgarone G.11, Said-Nahal R.1, Breban M.1
1Rheumatology, Boulogne-Billancourt; 2Epidemiology, Montigny les Breton-
neaux; 3Rheumatology, Nancy; 4Radiology, Boulogne-Billancourt; 5Rheumatol-
ogy, Brest; 6Rheumatology, Caen; 7Rheumatology, Marseille; 8Rheumatology, 
Grenoble; 9Rheumatology, Paris, France; 10Rheumatology, Leuven, Belgium; 
11Rheumatology, Bobigny, France
Objectives. To evaluate the performance of PDUS-detected enthesitis for the 
diagnosis of SpA in patients with suggestive symptoms.
Methods. Prospective, multicenter French cohort. Outpatients consulting for 
suspected SpA (inflammatory back pain, arthritis or inflammatory arthralgia, 
enthesitis or dactylitis, HLA-B27+ uveitis, familiarity for SpA) were recruited 
and followed up (2yrs). At baseline, patients underwent to standardized physical 
examination, pelvic x-ray, sacroiliac MRI, HLA-B typing, and other tests judged 
useful for diagnosis. A blinded PDUS examination of 14 entheses was also per-
formed. Table I shows demographic, clinical and imaging data.
Table I.
Characteristic All
 (n=470/489)
Sex ratio, men/women 0.6
Age at inclusion in years, mean [sd] 39.6 [10.48]
Symptoms duration at inclusion (any) in years, mean [sd] 2.54 [4.00]
Primary inclusion criterion, no (%) 
IBP 195 (51.3)
Arthritis/arthralgia 102 (26.8)
Enthesitis/dactylitis 33 (8.7)
HLAB27+ AAU 33 (8.7)
Family history of SpA 17 (4.5)
Extra-articular manifestations, no (%) 
Psoriasis 85 (22.4)
IBD 20 (5.3)
Radiological and laboratory findings 
HLA-B27, no. positive/no. performed (% positive)  193/460 (42)
Pelvic x-ray, no. doubtful/no. performed (% doubtful) 132 (35.1)
Pelvic CT-scan, no. positive/no. performed (% positive)  58/234 (25)
Pelvic MRI, no. positive/no. performed (% positive)* 81/451 (21)
PDUS of entheses  470 (100)
Abnormal entheses (any), no (%positive) 334 (87.7)
At least 1 vascularized enthesis, no (%positive) 160 (42)
BASDAI (median [IQR]) 44.50 [28.20, 58.73]
SpA diagnosis (experts opinion at 2 years), no (% positive) 186 (48.9)
SpA diagnosis (LCA at 2 years), no/no included (%) 125/380 (32.9)
Diagnosis of SpA was performed after 2 years, using a latent class analysis (LCA) 
stratified on initial presentation. In the LCA, SpA diagnosis, performed by a group 
of experts using a DELPHI method, considering clinical, laboratory and imaging 
findings (except PDUS) retrieved during follow up, and the baseline PDUS evalu-
ation, were entered as independent variables. 
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Results. 489 patients were included (96% of the target), and 470 followed over 2 
yrs (380 with complete follow up). After 2 years, the experts classified 186 (49%) 
patients as SpA, of which 46 had at least 1 vascularized enthesis (Se=.25) vs 15 
of the 194 non-SpA (Sp=.8). LCA classified 125 patients as SpA, and the diag-
nostic performance of baseline PDUS enthesitis (at least 2 vascularized enthesi-
tis, with minimal inflammation, or 1 highly inflamed enthesitis), was estimated 
through 500 bootstrap replications (stratified by centre) and resulted in: median 
sensitivity=0.57, median specificity=0.87, median RVP=4.39, median RVN=0.5, 
median diagnostic odds-ratio=8.8.
Conclusion. This multicenter study confirms the accuracy of vascularized PDUS 
enthesitis, to ascertain an early diagnosis of SpA in suspected patients.
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INTER-OMIC ANALYSIS REVEALS FUNCTIONAL RELATION-
SHIP BETWEEN DIVERSE GUT MICROBIOTA AND DYSREGU-
LATED HOST IMMUNE RESPONSE IN HLA-B27-MEDIATED 
EXPERIMENTAL SPONDYLOARTHRITIS
Gill T.1, Brooks S.R.2, Asquith M.3, Rosenbaum J.T.3, Colbert, R.A.1
1Pediatric Translational Research Branch, NIAMS/NIH, Bethesda; 2Biodata 
Mining and Discovery Section, NIAMS/NIH, Bethesda; 3Division of Arthritis 
and Rheumatic Diseases, OHSU, Portland, USA
Aim. HLA-B27 has been hypothesized to alter gut microbiota to promote spon-
dyloarthritis (SpA). In HLA-B27 transgenic (HLA-B27 Tg) rats with experimen-
tal SpA, we reported divergent effects of HLA-B27 on gut microbiota despite 
similar immune dysregulation on different host backgrounds. Inter-omic analysis 
was employed to determine the relationship between diverse microbes and com-
mon host immune dysregulation. 
Material and Methods. We correlated the relative frequency of microbes (16S 
rRNA gene sequencing), with host genes expression levels (RNAseq), from ce-
cum and colon of HLA-B27 Tg and wild-type rats on Dark Agouti, Lewis and 
Fischer backgrounds. Microbes with a maximum relative abundance >0.1%, and 
genes with maximum expression value (reads per kilobase million; RPKM) >1 
and coefficient of variation >0.8 were included. Significant correlations (r, FDR 
q<0.1) identified relevant host-microbial relationships. PICRUSt was used to 
predict microbial functions, which were correlated with disease severity (his-
tology scores) to identify inflammation associated metabolic pertubations (FDR 
q<0.1).
Results. Inter-omic analysis determined several microbes whose relative fre-
quency significantly associated with dysregulated cytokines driving Th17 and 
Th1 pathways in both cecum and colon. While some microbes were differentially 
abundant (HLA-B27 Tg vs. wild-type) on both Lewis and Fischer backgrounds 
(Clostridium), most were unique to either LEW (e.g. Prevotella) or Fischer (e.g. 
Akkermansia). Interestingly, many microbes that strongly correlated with im-
mune dysregulation (e.g. Lachnospiraceae) were not identified by analyzing ef-
fects of HLA-B27 alone. PICRUSt revealed perturbed metabolic pathways (e.g. 
glycan biosynthesis, steroid biosynthesis) during inflammation, despite dramatic 
differences in dysbiotic microbes.
Conclusions. Inter-omic anaylsis reveals the complexity of HLA-B27-associated 
microbial dysbiosis. 
Perturbation of common metabolic pathways by divergent gut microbiota dur-
ing inflammation on different genetic backgrounds suggest important functional 
overlaps that maybe key to evoking similar host immune dysregulation, and that 
microbial communities and their function may be more important than individual 
microbes.
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A STUDY OF THE HLA-B*27-ASSOCIATED MICROBIOTA IN 
HEALTHY INDIVIDUALS REVEALS INTESTINAL DYSBIOSIS 
AND AN ALTERED MICROBIOTA-SPECIFIC IMMUNE RES-
PONSE MAY BE PREDISPOSING EVENTS IN THE PATHOPHYSI-
OLOGY OF SPONDYLOARTHRITIS
Asquith M.1, Sternes P.2, Costello M.E.2, Schleisman M.1, Davin S.1, Diamond 
S.1, Karstens L.3, Brown M.A.2, Rosenbaum J.T.1,4,5
1Dept. of Medicine, Oregon Health & Science University, Portland, USA; 2Insti-
tute of Health and Biomedical Innovation, Queensland University of Technology, 
Brisbane, Australia; 3Dept. of Medical Informatics and Clinical Epidemiology, 
OHSU, Portland; 4Casey Eye Institute and Dept. of Ophthalmology, OHSU, Port-
land; 5Legacy Devers Eye Institute, Portland, USA
Introduction. Mechanisms that underpin the substantial contribution of 
HLA*B27 to spondyloarthritis susceptibility remain incompletely understood. In 
this study we tested the hypothesis that HLA-B*27 expression, even in healthy 
individuals, was sufficient to drive intestinal dysbiosis.
Methods. Intestinal biopsies and feces were collected from healthy HLA-B 
typed individuals (n=107) and subject to 16S rRNA gene sequencing. Global 
and taxon-specific IgA responses to the intestinal microbiota were established by 
flow cytometry and IgA-SEQ.
Results. HLA-B*27 +ve individuals exhibited a distinct intestinal microbiota to 
those individuals that were HLA-B*27 -ve. This included significantly increased 
carriage of the genera Roseburia and Oscillospira and decreased carriage of the 
species Dorea formicigenerans and Blautia obeum. These taxa are all members 
of the broader Clostridium XIVa/XIV cluster. HLA-B*27 expression in healthy 
individuals was also associated with a significantly enhanced total frequency of 
IgA-coated bacteria. Interestingly, IgA-SEQ analysis revealed the Dorea genus 
was specifically enriched for IgA coating.
Discussion. Our findings provide evidence that microbial dysbiosis in HLA-
B*27 individuals, and a perturbed microbiota-specific IgA response are not 
merely secondary to SpA disease. Future studies will examine whether over-
represented taxa or those targeted by mucosal IgA responses in this study may 
functionally contribute to SpA pathogenesis.
Acknowledgements. M.A. and J.T.R. are supported by the Rheumatology Re-
search Foundation and the Spondylitis Association of America.
P150
A STUDY OF MICROBIAL TRANSLOCATION IN AN ANIMAL MODEL 
OF SPONDYLOARTHRITIS
Asquith M.1, Schleisman M.1, Davin S.1, Stauffer P.1, Karstens L.2, Rosenbaum J.T.1
1Dept, of Medicine, Oregon Health & Science University, Portland; 2Dept. of 
Medical Informatics and Clinical Epidemiology, OHSU, Portland, USA
Introduction. The mechanism through which enteric microbes contribute to pe-
ripheral inflammation in spondyloarthritis (SpA) remains uncertain. The primary 
objective of this study was to determine whether microbial translocation can be 
observed to extra-intestinal tissues in the HLA-B27/β2m transgenic rat - a fore-
most translational model of SpA. We also compared translocation in HLA-B*27 
transgenic animals with and without arthritis.
Methods. Intestinal (cecal) contents, mesenteric lymph nodes, spleen, serum, 
liver, lung, ankle joint and eye were collected from age matched HLA-B27/β2m 
transgenic rats with or without arthritis and WT controls (n = 20-45/group). DNA 
was extracted under sterile technique and the 16S rRNA V4 region subject to 16S 
rRNA sequencing. Extraction blanks were run throughout sample processing and 
amplification (every 12 samples) to control for environmental contamination. 
Sequencing data was first processed through DADA2 pipeline prior to identify-
ing and removing contaminant sequences with the recently developed Decontam 
(v0.8) algorithm.
Results. Our study revealed a polymicrobial DNA signature in extra-intestinal 
tissues irrespective or rat genotype or disease state. The most abundant microbial 
16S DNAs in joint tissue included Prevotella spp. and Roseburia faecis. Blautia 
obeum DNA was significantly over-represented in arthritic joint tissue. Arthritis 
was also associated with a marked decrease in intestinal colonization by flavone-
producing bacterium Eubacterium oxidoreducens.
Conclusions. We propose translocation of microbes/microbial products from the 
gut to extra-intestinal tissues may be a contributory mechanism to SpA patho-
genesis, although alone is not sufficient to elicit inflammatory disease. Specific 
changes in microbial community DNA profile in the gut or elsewhere may serve 
as useful biomarkers of disease state in either patient populations or disease 
models. This approach may yield useful candidates for further study such as 
Eubacterium oxidoreducens. Future studies will verify our findings using PCR-
independent methods.
Acknowledgement. M.A. and J.T.R are supported by the Rheumatology Re-
search Foundation and the Spondylitis Association of America.
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THE RESPONSE TO TNF-BLOCKERS TREATMENT OF SpA 
PATIENTS IS INFLUENCED BY THE INTERPLAY BETWEEN 
HLA-B27 AND GUT MICROBIOTA COMPOSITION AT BASELINE
Vallier M.1, Dougados M.2,3, Ferreira S.4, Menegatti S.5, Bianchi E.5, Rogge L.5, 
Chamaillard M.1, Miceli-Richard C.2,5
1Université de Lille, CNRS, INSERM, CHRU Lille, Institut Pasteur de Lille, 
U1019 - UMR 8204, Lille; 2Paris Descartes University, Rheumatology Dept., 
Paris; 3Inserm, U1153, Paris, 4Genoscreen, Lille; 5Institut Pasteur, Immunoregu-
lation Unit, Paris, France
Introduction. The response to TNF-blockers in axial spondyloarthritis (AxSpA) 
is at least partially influenced by HLA-B27 through a still poorly understood 
mechanism. Given that HLA-B27 regulates the gut microbiota composition in 
rats, we seek to evaluate the predictive value of the gut microbiota composi-
tion in AxSpA patients at baseline on their subsequent responsiveness to TNF-
blockers.
Methods. 58 patients were recruited according to the following criteria: active 
disease despite NSAIDs intake; no history of inflammatory bowel disease; no 
antibiotics intake within 3 months prior recruitment. Bacterial 16S rRNA gene 
sequencing region was performed on stools samples before and after TNF-block-
er treatment. Diversity metrics and custom LefSe were used to explore the rela-
tionship between the composition of the intestinal microbiota and the efficacy of 
TNF-blockers.
Results. A lower alpha diversity at baseline was unexpectedly associated with 
better treatment response, HLA-B27 genotype and smoking behavior. Mean-
while, beta diversity was associated with smoking behavior and HLA-B27 geno-
type before and after treatment. Beta diversity at baseline was associated with 
the BASDAI index after treatment, and the response to the treatment. These re-
sults indicate a potential regulatory role for the gut microbiota on the underlying 
mechanisms involved in the response to TNF-blockers. Moreover, a LefSe-like 
approach identified 6 bacterial species as potential biomarkers for the treatment 
response, despite the absence of global changes (beta diversity) in the microbiota 
composition following a 3-month TNF-blocker intake.
Conclusions. The baseline composition of the gut microbiota from AxSpA pa-
tients could be associated with treatment efficacy. Further functional studies will 
be conducted to assess which of the aforementioned bacteria could be used as 
predictors of the treatment efficacy and potentially as probiotics promoting treat-
ment efficacy among non-responders patients.
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FUNGI OVERLOOKED: THE MYCOBIOME AS A CAUSE OF 
SPONDYLOARTHRITIS (SpA)
Rosenbaum J.T.1,2,3, Laurence M.4, Asquith M.J.2
1Depts. of Ophthalmology and 2Medicine, Oregon Health & Science University, 
Portland; 3Legacy Devers Eye Institute, Portland, USA; 4Shipshaw Labs, Mon-
treal, QC, Canada
We and others have strongly implicated the bacterial microbiome in the patho-
genesis of SpA. Although bacteria or bacterial products contribute to the patho-
genesis of SpA, the role of bacteria is incompletely understood. In addition, very 
little attention has been focused on the potential contribution of fungi. The hy-
pothesis that the mycobiome contributes to the pathogenesis of SpA is based 
on: 1) Two genetic loci affect susceptibility to spondylitis (CARD9 and IL23R) 
and also regulate the immune response to fungi; 2) Antibodies to Sacchromyces 
cerevisiae antigens (ASCAs) or antibodies against conserved fungal cell wall 
glycans (mannan, beta-glucan, and chitin) are used to diagnose Crohn’s disease, 
and are elevated in SpA and psoriasis; 3) Bacterial cell wall components which 
mimic fungal cell wall components (cord factor (trehalose dimycolate) and cur-
dlan) trigger spondyloarthritis-like disease in rats or SKG mice; 4) Fungicidal 
treatment improves psoriasis, a spondylitis “overlap” syndrome; 5) The prostate 
produces an antifungal protein (PSP94) whose concentration and isoforms affect 
prostate disease risk. Prostatic inflammation is strongly associated with spondyli-
tis. Histology of the human prostate shows yeast-like intracellular structures. Us-
ing primers specific for 18S fungal ribosomal RNA, we have been able to detect 
fungal DNA in the prostate and seminal vesicles of rats. 6) Malassezia contrib-
utes to the pathogenesis of psoriasis and is the only fungal genus universally pre-
sent in psoriatic lesions. Although Malassezia was long thought to be restricted to 
the skin, recent studies report finding Malassezia within mucosal surfaces. These 
observations provide strong but circumstantial evidence that fungi are involved 
in the pathogenesis of SpA, with reservoirs in the prostate, gut, and skin. We are 
actively pursuing experiments to test this hypothesis further.
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SPECIFIC ALTERATIONS IN THE ENTERIC VIROME IN THE 
SUBCLINICAL GUT INFLAMMATION OF AS PATIENTS DRIVE 
INNATE IMMUNE ALTERATIONS
Ciccia F.1, Guggino G.1, Macaluso F.1, Rizzo A.2
1University of Palermo; 2Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, 
Palermo, Italy
Background. Ankylosing Spondylitis is a complex inflammatory disease with 
complex genetic and environmental risk factors. One fundamental environmental 
contributor in AS pathogenesis is thought to be microorganisms that live in the 
intestine. Among these microorganisms, bacteria have gained the greatest atten-
tion in AS because they have been linked to the activation and the expansion of 
intestinal innate immune cells that can re-circulate from the gut to the site of 
extra-intestinal inflammation. Emerging data indicate that the viral component of 
the microbiome, termed the virome, can also profoundly influence host physiol-
ogy and modify host immune responses (Handley et al., 2012; Norman et al., 
2014; Virgin, 2014). In this study, we evaluated whether alterations in intestinal 
virome occur in the gut of AS and may modulate intestinal immune responses.
Methods. Immunohistochemistry and electronic microscopy was used to iden-
tify viral inclusion in AS ileal samples. Latent and lytic EBV infection was 
investigated in AS and normal controls by RT-PCR, in situ hybridization and 
immunohistochemistry/immunofluorescence. To quantify miRNA levels, stem-
loop qPCRs were performed with TaqMan MicroRNA Reverse Transcription kit 
(Thermo Fischer Scientific) and TaqMan Universal Master Mix II (Thermo Fis-
cher Scientific) according to the manufacturer’s protocols. RNU6B was used for 
normalization. Following TaqMan MicroRNA assays, specific primers (Thermo 
Fischer Scientific) were used for detection: ebv-miR-BART2: 197238_mat; ebv-
miR-BART3: 004578_mat; ebv-miR-BHRF1-3 197221_mat; RNU6B: 197238_
mat. The EBV-encoded homologue of IL-10 (viral or vIL-10) and the latent 
BHRF1 transcripts encoding bcl-2 homologue and the EBI-3 protein that forms 
heterodimers with p28 to form interleukin-27 (IL-27) were assessed by RT-PCR 
and immunohistochemistry. The effect of IL-27 on the differentiation of Th17 
cells was assessed in in vitro studies.
Results. Big viral inclusion were observed in the context of Paneth cells of pa-
tients with AS but not in the ileal samples of normal controls. EBV dysregula-
tion was observed exclusively in AS ileal samples but not in healthy controls, as 
revealed by presence of EBV latent (LMP2A, EBV-encoded small RNA (EBER)) 
transcripts, EBER+ cells and immunoreactivity for EBV latent (LMP1, LMP2A) 
and lytic (BFRF1) antigens in B cells and plasma cells, respectively. The pres-
ence of EBV in AS ileal samples was associated with the strong down-regulation 
of HLA class II surface levels on epithelial cells. Analysis of CD4+ and CD8+ 
T-cell localization and granzyme B expression suggests that EBV persistence 
AS ileal samples might be favored by exclusion of CD8+ T cells from B-cell 
follicles and impaired CD8-mediated cytotoxicity. Over-expression of EBV de-
rived miRNA, BART1, BART2 and BART10 were over-expressed in the ileal 
samples of AS patients with more severe gut inflammation and their expression 
was inversely correlated with the expression levels of IL-6, TNF, and IL-12p40. 
EBV-encoded homologue of IL-10 (viral or vIL-10) and the latent BHRF1 tran-
scripts encoding bcl-2 homologue and the EBI-3 protein were up-regulated in 
the inflamed AS ileal samples compared to controls. According to the increased 
expression of EBI-3 protein, increased IL-27 expression was observed in AS ileal 
samples and in in vitro studies IL-27 inhibited the differentiation of podoplanin-
expressing Th17 cells.
Conclusions. We demonstrated alteration of intestinal virome in AS gut charac-
terized by the presence active EBV infection. EBV infection in AS is associated 
with profound virus-mediated alterations of innate immunity such as down-
regulation of IL-12p40, IL-6, TNF-α and increased expression of vIL-10 and 
IL-27.
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IS CALPROTECTIN A USEFUL DIAGNOSTIC TOOL IN DIAG-
NOSING SPONDYLOARTHROPATHIES?
Van Hoovels L.1, Schiemsky T.1, Cauchie M.1, Van Den Bremt S.1, Vander Cruys-
sen B.2, Bossuyt X.3, Stubbe M.2
1Dept. of Laboratory Medicine, Onze-Lieve-Vrouw Hospital, Aalst; 2Dept. of 
Rheumatology, Onze-Lieve-Vrouw Hospital, Aalst; 3Dept. of Laboratory Medi-
cine, University Hospital Leuven, Leuven, Belgium
Introduction. Spondyloarthropathies (SpA) are characterized by clinical and 
radiographic features on which the ‘Assessment of SpondyloArthritis’ (ASAS) 
classification criteria are based. The use of the ASAS criteria in the diagnosis of 
SpA is hampered by a relative low sensitivity of 79.5%. 
In more than 40% of the patients, SpA is associated with clinically (in)overt 
Crohn’s Disease (CD). 
The aim of this study is to investigate, if the currently used diagnostic biomarker 
for CD, fecal calprotectin (FC), has a role in the diagnostic process of SpA.
Patients and Methods. A total of 99 first diagnostic patients with differential di-
agnosis of SpA were included in the study. From these patients, 99 fecal samples 
(n SpA= 52) and 60 serum samples (n SpA= 25) could be retrieved for calprotec-
tin analysis. SpA diagnosis was based on expert opinion. 
Fecal (FC) and serum calprotectin (SC) were quantified in adult patients with 
clinical suspicion of SpA. Patients were asked to discontinue intake of NSAIDs 
2 weeks before sample collection. Patients previously diagnosed with inflam-
matory bowel disease were excluded. Three commercially calprotectin assays 
(Quantum Blue Calprotectin, Bühlmann; QUANTA® Lite Calprotectin Extended 
Range, Inova Diagnostics; LIAISON® Calprotectin, DiaSorin) were performed 
on each sample. 
Results. FC levels were significantly higher in the SpA group versus non SpA 
group, which was not seen for serum calprotectin (SC). Diagnostic performance 
among FC assays did not differ significantly, but there was a significant differ-
ence in diagnostic performance characteristics when using the manufacturer’s 
cut-offs (Table I). 
FC significantly improved diagnostic sensitivity if added to the diagnostic bilan 
of SpA patients, based on radiology and HLA-B27 analysis (Table II). The likeli-
hood for SpA increased, with increasing FC (Fig. 1). 
Conclusion. The dosage of FC significantly improved the diagnostic sensitivity 
for SpA.
Table I. Diagnostic performance of different fecal calprotectin assays in SpA diagnosis.
 Bühlmann DiaSorin Inova
AUC [95 CI] 0.658 [0.556-0.750] 0.684 [0.583-0.774] 0.661 [0.559-0.754]
  p=0.2964* p=0.9056*
Median [95 CI] in SpA (n=52) 59.0 μg/g [39.9 – 82.0] 25.4 μg/g [15.8 – 38.7] 24.6 μg/g [15.2– 32.6]
Median [95 CI] in non-SpA (n=47) 32 μg/g [15.0 – 45.4] 11.5 μg/g [7.9 – 16.6] 13.0 μg/g [10.9 – 15.6]
 p=0.0056§ p=0.0017§ p=0.0057§
Manufacturer’s cut-off  50 μg/g 200 μg/g 50 μg/g 50 μg/g 120 μg/g
Sensitivity for SpA [95 CI] 56% [41-70] 6% [1-16] 29% [17-43] 15% [7-28] 0% [0-7]
Specificity for SpA [95 CI]  68% [53-81] 98% [89-100] 94% [83-99] 96% [86-100] 98% [89-100]
   p<0.0001** p<0.0001** 
Cutoff at 98% specificity for SpA 157 μg/g 62 μg/g 60 μg/g
Sensitivity for SpA [95 CI] 13% [6-26] 21% [11-35] 8% [2-19]
Likelihood ratio for SpA [95 CI] 6.3 [0.8-49.5] 9.9 [1.3-74.1] 3.6 [0.4-31.2]
Odds ratio for SpA [95 CI]  7.2 [0.8-60.5] 12.3 [1.5-99.8] 3.8 [0.4-35.6]
 p=0.1308§§ p=0.018§§ p=0.2372§§
* evaluation performed versus AUC Bühlmann using the method of Delong et al. in MEDCALC® (version 17.1, Ostend, Belgium).
§Mann-Whitney test (independent samples); 
** McNemar test (paired proportions) versus Bühlmann.
§§odds ratios calculated using the method of Altman et al. in MEDCALC®: if the associated p is less than 0.05 it can be concluded that the odds ratio is significantly different from 
1 and that the odds in one group are significantly higher than in the other.
Table II. Diagnostic performance of different diagnostic tests used for SpA diagnosis.
 
 R R + HLA-B27 R+HLA-B27+FC FC HLA-B27+FC R+FC
 n=80 n= 67 n= 67 n=99 n=81 n=80
Sensitivity (%)[95 CI] 36%  67% [52-79] 74% [59-85] 21% [11-35] 71% [57-82] 55% [41-68]
   p=0.2482*   p=0.0026**
Specificity (%)[95 CI] 94% [80-98] 84% [65-94] 84% [65-94] 98% [89-100] 78% [62-88] 88% [73-95]
LR [95 CI] 6.0 [2-24] 4.2 [1.7-10.5] 4.6 [1.8-11.5] 9.9 [1.3-74.1] 3.2 [1.7-6.1] 4.6 [1.8-11.8]
OR [95 CI] 8.8 [1.9-41.3] 10.5 [3.02-36.5-94] 14.8 [4.1-52.8] 6.8 [1.4-32.0] 8.6 [3.1-23.8] 9.0 [2.7-29.6]
With n= number of patients for which the test(s) was/were performed; R= Radiology (RX and/or MRI); HLA= HLA-B27 analysis; FC= fecal calprotectin analysis DiaSorin per-
formed at cutoff of 62 µg/g, corresponding to a 98% specificity for SpA; *McNemar test (paired proportions) versus R + HLA-B27; ** McNemar test (paired proportions) versus R.
Fig. 1. Likelihood ratio for SpA in function 
of fecal calprotectin concentrations (DiaSorin).
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FEATURES OF CHRONIC PAIN SYNDROME IN PATIENTS WITH 
ANKYLOSING SPONDYLITIS
Filatova E.S., Erdes S.
VA Nasonova Research Institute of Rheumatology, Moscow, Russia
Describing their painful sensations, patients with ankylosing spondylitis often 
use the following qualitative characteristics of pain in their complaints: numb-
ness, burning, tingling, pain intensification when exposed to pain stimulus. These 
characteristics are neuropathic pain descriptors resulting from chronic inflamma-
tion leading to changes in the central nervous system.
Objective. To detect dysfunction of the pain component (DPC) in patients with 
ankylosing spondylitis (AS).
Materials and Methods. 150 patients were examined, 127 men and 23 women. 
The average age of 35, and 52±10,55, mean disease duration of 7.19±of 6.31. All 
bol was examined by deny design: Clinic-rheumatology survey (index BASDAI, 
BASFI), the assessment of pain intensity on VAS, clinic-neurological examina-
tion with the use of pros tend DN4 and PainDETECT pain, as well as assessment 
of emotional-attachment disorders (HADS).
Results. 22 patients (14.7%) scored 4 or more points in the DN4 questionnaire, 
however, no somatosensory nervous system lesions were detected in these pa-
tients, therefore, 14.7% of patients had DCP. Comparison of patients with CKD 
group I (22 patients) and absence of DCP group II (128 patients) showed: in 
group I, statistically significant higher back pain intensity in the VAS (6.09±185 
vs 4.55±2,06, p=0.001, respectively); the disease is more active according to the 
BASDAI index (7.05±1.58 vs 4.87±2.16, p=0.001, respectively); expression of 
functional disturbances by the BASFI index (6.46±2.24 vs 4.05±2.81 p=0.001); 
the parameters of the HADS questionnaire in group I corresponded to the pres-
ence of clinically significant anxiety and its absence in group II (10.09±2.86 vs 
6.17±3.35 p=0.0001). However, for the duration of the disease, there were no 
significant differences in the groups (9.41±6.89 vs 6.81±6.13 p=0.07).
Discussion. The study showed that in 22 patients the presence of neuropathic 
pain descriptors in conjunction with anxiety disorders, as a result of which, we 
concluded that along with the nociceptive component of pain, CKD was detected 
in 14.7% of cases.
Conclusion. Thus, in a number of patients with AS, the pain syndrome is mixed, 
which can serve as a rationale for complex therapy including drugs from the 
group of antidepressants (TCAs, SSRIs).
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EFFICIENCY OF LONG TERM EDUCATIONAL PROGRAMS 
FOR PHYSICIANS IN EARLY DIAGNOSIS AND TREATMENT OF 
AXIAL SPONDILOARTHRITIS IN KAZAN
Lapshina S., Myasoutova L.
Kazan State Medical University, Kazan, Russia
In recent years, there have been cardinal changes in terminology, understanding 
of pathogenesis of axial spondylitis (AxsSpA) and ankylosing spondylitis (AS), 
early diagnosis has improved. An important role is played by the level of aware-
ness of primary care physicians in the early diagnosis of AxsSpA and AS.
Aim. To evaluate the effectiveness of educational activities for primary contact 
physicians in AxsSpA (including AS) diagnosis.
Material and Methods. From 2012 to the present time, educational activities 
are conducted for primary care physicians in diagnostics and tactics of manag-
ing patients with AS with discussion of the criteria for inflammatory back pain, 
options for onset and the algorithm for diagnosis and examination of patients 
with AxsSpA for primary contact physicians in Kazan. Since 2014, educational 
modules have been integrated into the system of continuing education of doc-
tors. Assessment of the results of educational schools was carried out according 
to the analysis of reports of outpatient admission to rheumatologist of the City 
Rheumatology Center in Kazan (Clinical Hospital # 7) and the analysis of medi-
cal records of patients sent to a rheumatologist in 2011 (base year) in comparison 
with 2012–2017 in the process of schools.
Results. In the process of conducting schools (2012–2017) the number of pa-
tients with AxsSpA and AS significantly increased for the first time this year. In 
2012–2013, the number of patients almost doubled (575 pts in 2012, 765 in 2013) 
compared to 2011 (378 pts). The second sharp increase in the number of patients 
was observed in 2016 (1178 pts) and in 2017 (1298 pts). The same dynamics was 
observed for AxsSpA patients (including AS) who applied for the first time to 
rheumatologist with a significant increase in patients in 2012–2013 (2012 - 218 
pts, 2015 - 290 pts), 2016 - 506 pts, 2017 year - 711 patients. 
“Peak” increase in the number of patients in 2012–2013 can be explained by 
the beginning of educational activities for doctors; in 2016–2017 - an increase 
in the number of activities (including remote ones), the amount of information, 
increased availability of MRI examinations for patients with AxsSpA.
Primary care physicians were more likely to refer patients with suspected Ax-
sSpA or the number of patients coming from the primary contact physician to 
rheumatologist with the required volume of examination (description of back 
pain, laboratory tests, HLAB27 determination, radiographs and/or MRI) in-
creased significantly from 23.7% in 2012 to 87% in 2017, which allows to verify 
diagnosis without repeated consultations.
Conclusion. Educational programs for primary care physicians (lectures, 
schools, remote programs) have great importance for the timely diagnosis of Ax-
sSpA, reducing the number of consultations before the diagnosis and with the 
subsequent appointment of adequate therapy.
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PRELIMINARY RESULTS OF DEVELOPMENT AND 12 MONTHS 
FOLLOW UP TEST OF THE MOBILE APPLICATION FOR 
PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Rumiantceva D.G., Dubinina T.V., Sitalo A.V., Erdes S.
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background. According to the recommendations for management of axial spon-
dyloarthritis (axSpA) - the treatment to target by measuring disease activity, and 
adjusting therapy accordingly, improves outcomes. 
Authors together with patient organization developed the mobile application (app) 
for Android platforms, which allows patients (pts) to self-control and remote con-
trol of rheumatologist the axSpA disease activity, symptoms and treatment.
Aim. To develop and to test the mobile application «ASpine» for pts with axSpA.
Materials and Methods. The «ASpine» consists of two parts: mobile app for pts 
and website for rheumatologists. For a test of the first version of the mobile app 
included 30 patients (pts) with axSpA (ASAS criteria, 2009) at least 12 months 
(mo) follow up (FUP). In the mobile app, pts fills indexes BASDAI, BASFI, im-
port their laboratory, instrumental tests, note which drugs they take. The doctor 
has an opportunity to observe dynamics of his pts disease activity online. If the 
patient’s condition worsens the doctor receives a notification about the incident 
and decides to correct therapy or call the patient for visit.
Results. Only 5 (16.6%) from 30 pts for 12 mo of FUP required correction of 
therapy. Average BASDAI score at baseline and after 12 mo were 3.2±1.6 vs. 
1.9±1.3 (p<0.05), average BASFI score at baseline after 12 mo were 1.4±1.1 vs. 
1.2±1.0 (p>0.05). An analysis by a doctor of the health status of 30 patients takes 
about 1 minute every day in absence of adverse events. Analysis of one case of 
notification by the patient on average lasts nearly 5–8 minutes. Thus, according 
to this research with a five-day workweek in 12 months, 30 pts were monitored 
by the rheumatologist for about 5 hours, which corresponds to an average of 30 
minutes per month and 1 minute a day.
Conclusions. The mobile app is a new convenient method for pts self-control 
and remote control axSpA disease activity for rheumatologists and effectively 
as our practice shows.
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PAIN BELIEFS AND DISABILITY IN CHRONIC “INFLAMMATORY” 
AND “NON-INFLAMMATORY” LOW BACK PAIN
Yilmaz Z.
Tepecik Training and Research Hospital, Izmir, Turkey
Background. Biopsychosocial factors make important contributions to chronic 
disability from ‘’non-inflammatory’’ low back pain (LBP). Patients beliefs about 
the nature and cause of their pain influence uptake and response to treatment. 
Changes in those beliefs that follow participation in a pain management pro-
gramme are associated with improvements in disability.
Hypothesis: Pain beliefs differ between patients with chronic LBP attributed to 
inflammatory or non-inflammatory medical diagnoses.
Methods. Outpatients with disability attributed to inflammatory LBP were re-
cruited from an ankylosing spondylitis (AS) clinic (n=31, 19 males), those 
with’non-inflammatory’ LBP were recruited through a pain management pro-
gramme (n=65, 25 male). Participants completed a questionnaire booklet ad-
dressing pain beliefs (PBQ), coping strategies(CSQ), pain and disability(SF-36) 
and psychological distress (STAI-SSF, CDI).
Results. Participants with AS were more likely to be male and reported less bod-
ily pain and disability and slightly lower psychological distress than participants 
with ‘non-inflammatory’ LBP. Participants with AS less frequently endorsed 
‘organic’ pain beliefs (p<0.005) and reported les catastrophising (p<0.001). Dif-
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ferences in pain beliefs between the groups persisted after controlling for differ-
ences in gender, pain, disability and distress.
Conclusions. Despite the overtly ‘organic’ medical label of AS, these patients 
endorse fewer organic pain beliefs than do patients with ‘non-inflammatory’LBP. 
Cognitive behavioural interventions may be helpful for some patients with AS, 
but ma need to address different psychological factors to those which mediate 
disability in chronic ‘non-inflammatory’ LBP.
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RAPID ONSET OF EFFICACY IN PATIENTS WITH ACTIVE 
PSORIATIC ARTHRITIS TREATED WITH IXEKIZUMAB: A 
POOLED ANALYSIS OF DATA FROM TWO PHASE III CLINICAL 
TRIALS 
Deodhar A.1, Papp K.2, Shuler C.L.3, Park S.Y.3, Kvien T.4
1Oregon Health & Science University, Portland, USA; 2K. Papp Clinical Research 
and Probity Medical Research Inc., Waterloo, Canada; 3Eli Lilly and Company, 
Indianapolis, USA; 4Diakonhjemmet Hospital, Oslo, Norway
Introduction/Aim. Rapid onset of clinical improvement is an important attribute 
of treatment success for patients with PsA. These analyses evaluate the speed of 
onset of clinical improvement in patients treated with ixekizumab (IXE) com-
pared with placebo (PBO).
Materials and Methods. Patients, either bDMARD-naïve (SPIRIT-P1) or with 
prior lack of efficacy or intolerance to TNF-inhibitor(s) (SPIRIT-P2) were rand-
omized to placebo (PBO, N=224), 80 mg IXE every 4 weeks (IXEQ4W, N=229) 
or every 2 weeks (IXEQ2W, N=226), after a 160 mg starting dose. Continuous 
data were analyzed using mixed-effects model for repeated measures; categorical 
data, using a logistic regression model (missing values imputed by nonresponder 
imputation). 
Results. ACR20 response rates were significantly greater for both IXE doses 
(p<.001) at week 1. ACR50 response rates were significantly greater by week 2 
for IXEQ4W (p=0.013) and week 1 for IXEQ2W (p=0.030). ACR70 response 
rates were significantly greater by week 4 (IXEQ4W, p=0.039) or week 2 (IX-
EQ2W, p=0.002). With the exception of the IXEQ2W ACR70 response rate at 
week 4 (p=0.176), response rates for ACR20, ACR50, and ACR70 remained sta-
tistically significant compared to PBO through the 24-week, double-blind study 
period. In patients with plaque psoriasis (≥3% body surface area) at baseline, 
both IXE dosing regimens achieved significant improvements in psoriasis area 
and severity index total score compared to PBO by week 1. Patients with HAQ-
DI ≥0.35 at baseline demonstrated significantly improved physical function by 
week 1, as measured by HAQ-DI minimal clinically important difference (≥0.35) 
response rates (p<0.001) for IXE both doses.
Conclusion. Patients achieved significantly greater improvements in PsA, skin 
conditions, and physical function with both IXE regimens compared to PBO. 
Statistically significant improvements in multiple clinical measures occurred as 
early as week 1 and remained statistically significant through 24-weeks.
P160
RAPID AND SUSTAINED IMPROVEMENTS IN BOTH SKIN AND 
MUSCULOSKELETAL SYMPTOMS CORRELATES WITH IM-
PROVED QUALITY OF LIFE (QoL) IN PATIENTS WITH ACTIVE 
PSORIATIC ARTHRITIS (PsA)
Kavanaugh A.1, Birt J.2, Lin C-Y.2, Benichou O.2, Hufford M.M.2, Gottlieb A.B.3
1University of California San Diego Health System, San Diego; 2Eli Lilly and 
Company, Indianapolis; 3Dept. of Dermatology, New York Medical College, Met-
ropolitan Hospital, New York, USA; 4Eli Lilly and Company, Brussels, Belgium
Introduction. PsA is commonly associated with psoriasis. Biologic therapies 
have different efficacy and onset of action. 
Aim. To examine patient’s overall QoL if efficacy is achieved early and sus-
tained.
Materials and Methods. Patients, biologic-naïve (SPIRIT-P1) or with an inad-
equate response or intolerant to TNF inhibitors (SPIRIT-P2), were randomized to 
placebo (n=224) or 80 mg (initial dose 160mg) IXE every 4 (n=229) or 2 weeks 
(n=226). Patients had baseline ≥3% body surface area (BSA) and at least one 
visit with a Psoriasis Area and Severity Index (PASI) 75 and American College of 
Rheumatology (ACR) 20 response; all treatment groups were combined. Health-
related QoL (HRQoL) was measured by Short Form-36 Health Survey (SF-36), 
the EuroQoL-5 Dimensions Visual Analog Scale (EQ-5D VAS), and the Work 
Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) ac-
tivity impairment domain. Change in HRQoL at Week 24 was modeled using a 
response surface model with duration of consecutive PASI and ACR responses 
and their interaction as independent variables. Missing data were imputed using 
LOCF and non-responder imputation for continuous and categorical endpoints, 
respectively.
Results. Of the 679 patients, 215 (31.7%) had baseline ≥3% BSA and ≥1 PASI75 
and ACR20 response. Longer consecutive ACR20 responses correlated posi-
tively with greater HRQoL improvements (measured by the EQ-5D VAS). Pa-
tients with a longer consecutive number of ACR20 and PASI75 responses had 
the highest improvements in EQ-5D VAS. This was consistent with 7 of 8 SF-36 
domains, as well as the WPAI-SHP activity impairment domain. 
Conclusions. Early and sustained improvements in the symptoms of PsA cor-
related positively with improved HRQoL. The greatest HRQoL improvements 
were achieved when both skin and musculoskeletal symptoms improved early 
and were sustained.
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HEALTH UTILITY ESTIMATES IN ECONOMIC EVALUATIONS 
IN AXIAL SPONDYLOARTHRITIS – DIFFERENT METHODS, 
DIFFERENT RESULTS
Jones G.T.1, Macfarlane G.J.1, Pathan E.J.2, McNamee P.3, Neilson A.R.3
1Epidemiology Group, University of Aberdeen, Aberdeen, UK; 2Dept. of Rheuma-
tology, Toronto Western Hospital, Toronto, Canada; 3Health Economics Research 
Unit, University of Aberdeen, Aberdeen, UK
Introduction/Aim. A common method for assessing health utility in economic 
evaluations is the EQ-5D questionnaire – five questions each with three possible 
responses (EQ-5D-3L) or five responses (EQ-5D-5L). In axial spondyloarthritis 
(AxSpA), cost-effectiveness analyses have often used indirect measures of health 
utility, estimated from disease activity or function. Several algorithms have been 
proposed to convert one scoring method to another, although their validity is 
unknown. The aim of the current study was to compare directly measured EQ-5D 
health utility values with those estimated from published mapping algorithms.
Materials and Methods. The British Society for Rheumatology Biologics Reg-
ister for Ankylosing Spondylitis (BSRBR-AS) recruits patients with AxSpA, na-
ïve to biologic therapy, across the UK. Annual questionnaires collect information 
on health utility (EQ-5D-5L), disease activity (BASDAI), and function (BASFI). 
Health utility values were:
(1) Derived directly from questionnaire responses (EQ-5D-5L value set for 
England);
(2) Estimated from the ‘crosswalk’ value set, mapping EQ-5D-5L to EQ-5D-3L 
scores; and
(3) Computed using two published algorithms incorporating patient age, gen-
der, BASDAI and BASFI.
Differences in the mean and distribution of utility scores were compared between 
the different methods.
Results. 1987 participants completed 4384 questionnaires (male=71%; mean 
age=51yrs; mean BASDAI=4.4). Mean (5th/95th percentile) utility scores for the 
5L and 3L valuation sets were 0.67 (0.15,0.94) and 0.53 (-0.01,0.88) respec-
tively. Using published algorithms, estimates were 0.63 (0.33,0.89) and 0.56 
(0.20,0.87). The discrepancy between the three estimations, versus the directly 
measured (5L) score, varied with disease activity.
Discussion/Conclusion. Health utility scores calculated directly, differ from 
those obtained by extrapolating data on disease activity and function. Where EQ-
5D can be measured directly, this should be done. Elsewhere, given that small 
differences in health utility can influence the results of cost-effectiveness analy-
ses, consideration should be given to how values are computed. There are impor-
tant implications for both historic and future economic evaluations. 
756 Clinical and Experimental Rheumatology 2018
Poster Presentations Eleventh International Congress on Spondyloarthritides
P162
FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AS A CLINICAL 
MODEL OF NEW BONE FORMATION
Nikishina I., Latypova A., Arsenyeva S., Kaleda M., Alekseev D. 
Nasonova Research Institute of Rheumatology, Moscow, Russian Federation
Introduction. Fibrodysplasia Ossificans Progressiva (FOP) – extremely rare (1: 
2000000) genetic disorder, caused by mutation of ACVR1 gene, a bone mor-
phogenetic protein receptor. FOP is also known as a ‘’second skeleton disease’’ 
attempts to extensive of a new bone formation that leads to severely disabling. 
There are a lot of similarities between rheumatic diseases, especially spondy-
loarthritis (SpA) and FOP in the pathophysiology, clinical manifestation and the 
therapy approach. 
Aim. to present the single-center experience of the FOP patients and to identify 
similar symptoms in FOP and SpA.
Materials. The analysis of the large series of patients with FOP.
Results. All 22 patients (11 male and 11 female) had 3 basic FOP clinical manifes-
tations. In 18 patients molecular-genetic tests were performed and typical muta-
tion (Arginine 206) occurred in 17 cases and one had an extremely rare mutation 
(Glicine 328). 19 (86.4%) patients had common for FOP massive heterotopic ossi-
fications, 3 of them had formed heterotopic ossification through the x-ray negative 
stage to visible changes. Among typical phenotypic stigmas were: great toe mal-
formation in 21(95.5%); thumbs malformation – 4(18.2%); peripheral osteochon-
dromas – 14(63.6%); cervical spine abnormalities – 20(90.9%). Majority of the 
cases presented some similarities to SpA symptoms manifestations: ankylosis of 
the apophysial joints and vertebral bodies mostly in cervical spine; x-ray evidence 
of the sacroiliitis among most patients older than14 years old, recurrent episodes 
of the large joints synoviitis – in 5 patients. 4 patients demonstrated gradually 
formation of great toe ankylosis during the follow-up observation. The involution 
and decreasing of new FOP nodes associated with non-steroidal anti-inflamma-
tory drug (NSAID) and/or glucocorticoids therapy were occurred in all patients. 
Conclusions. Clinical observation of FOP patients provides the important 
information for rheumatologist about insufficiently explored process of new 
bone formation. Appearance of the similarities in FOP and SpA manifestation 
and the therapy approach could identify FOP as a potential rheumatic disease. 
FOP can be considered as a clinical model of innate processes of the new bone 
formation.
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RUSSIAN SPONDYLOARTHRITIS ASSESSMENT GROUPS’ 
DEFINITION AND CRITERIA OF REMISSION IN AXIAL SPON-
DYLOARTHRITIS 
Gaydukova I.Z.1, Lapshina S.A.2, Dubinina T.V.3, Sitalo A.V.4, Badokin V.V.5, 
Bochkova A.G.6, Bugrova O.V.7, Godzenko A.A.5, Dubikov A.I.8, Ivanova O.N.9, 
Korotaeva T.V., Nesmeyanova O.B.10, Otteva E.N.11, Nikishina I.P.2, Raskina 
T.A.12, Rebrov A.P.13, Rumyantseva O.A.2, Smirnov A.V.2, Erdes Sh.F.2
1Mechnikov North-Western Medical University, Ministry of Health of Russia, 
Saint Petersburg; 2Kazan State Medical University, Ministry of Health of Russia, 
Kazan; 3V.A. Nasonova Research Institute of Rheumatology, Moscow; 4Mutual Aid 
Society of Bechterew’s Disease, Moscow; 5Russian Medical Academy of Continu-
ing Professional Education, Ministry of Health of Russia, Moscow; 6Agat Medical 
Center, Egoryevsk, Moscow Region; 7Orenburg State Medical University, Ministry 
of Health of Russia, Orenburg; 8SANAS Medical Center, Vladivostok; 9Voronezh 
Regional Clinical Hospital One, Voronezh; 10Chelyabinsk Regional Clinical Hos-
pital, Chelyabinsk; 11Institute for Postgraduate Training of Health Professionals, 
Ministry of Health of the Khabarovsk Territory, Khabarovsk; 12Kemerovo State 
Medical Academy, Kemerovo; 13Ministry of Health of Russia, Saratov, Russia
Remission is the goal of axial spondyloarthritis (axSpA) treatment, but until now 
the definition of remission is unclear.
Purpose. To develop definition of remission in axSpA and to develop remission 
measurement tools.
Methods. In 2017, members of Russian Spondyloarthritis Assessment Group and 
Mutual Aid Society of Bechterev’s Disease performed 3-tours Delphi exercises 
for development of remission. 80 and more % agreement was enough for accept-
ance of voting point.
Results. Due to voting results clinical-laboratory remission in axSpA is con-
tinued for 6 or more months absence of clinical activity of the disease (absence 
of axial, peripheral and extra-axial manifestations) in the presence of normal 
C-reactive protein (CRP, mg/l) and erythrocyte sedimentation rate (ESR, mm/h) 
(agreement 85.7%).
2. MRT-remission is the absence of active foci of inflammation in the spine and 
sacroiliac joints according to MRI. (agreement 100%).
Due to results of voting process was decided to indicate clinical - laboratory and 
MRI types of remission. Drug-free remission or drug-dependent types of remis-
sion also should be note. Remission with or without structural progression has 
to be marked.
The remission criteria due to opinion of SPA group members are: 
1. The values of the ASDAS index (the Ankylosing Spondylitis Disease Activ-
ity Score) ≤ 1.3 (agreement 80%).
2. The values of the BASDAI index ≤1.0 (100% agreement).
3. The duration of morning stiffness is less than 30 minutes (agreement 83%).
4. Absence of swollen joints (agreement 80%).
5. Absence of enthesitis (agreement 93%).
6. The mean values of nocturnal back pain estimated by the NRS for the last 
week ≤ 1.0 (agreement 83%).
7. Average back pain over the past week ≤1.0 for NRC (agreement 92%).
8. Absence of clinical and instrumental signs of coxites (100% agreement).
9. Absence of active extra-articular manifestations (uveitis, aortitis, carditis, 
etc.) (agreement 92%).
10. Normal levels of CRP and ESR (agreement 92%).
Remission is established only in case when patient fulfills all the criteria.
Conclusions. The developed definition and criteria of remission have to be 
adapted in clinical practice and validated in further studies.
P164
ASSESSMENT OF LUMBAR SPINAL MOBILITY USING INER-
TIAL MEASUREMENT UNITS IN AXIAL SPONDYLOARTHRITIS
Franco L.1, Ward W.2, Sengupta R.2, Cazzola D.1
1University of Bath, Dept. for Health; 2Royal National Hospital for Rheumatic 
Diseases, Bath, UK
Introduction/Aim. Axial Spondyloarthritis (axSpA) is a chronic rheumatic dis-
ease that affects the axial skeleton and is associated with reduction of mobility 
in the patient’s spine. The Bath Ankylosing Spondylitis Metrology Index (BAS-
MI) is a frequently used index to assess spinal mobility in axSpA. However, the 
BASMI has been shown in studies to lack precision, accuracy and sensitivity to 
change. Inertial measurement units (IMU) provide a novel approach to spinal 
measurement of axSpA patients, allowing 3D spinal measurement in real time. 
The aim of this study is to assess the strength of association and predictability 
between lumbar mobility measured via an IMU system and the BASMI. 
Materials and Methods. A cohort of 48 patients diagnosed with axSpA accord-
ing to the ASAS criteria were recruited. Lumbar movements were evaluated using 
2 IMU sensors (ViMove, dorsaVi) located at L4 and T7. BASMI measurements 
were followed immediately with the ViMove low back spinal measurement pro-
tocol. Functionally relevant ViMove parameters were selected to run linear cor-
relations and multivariate regressions with BASMI total and partial scores. 
Results. The BASMI was highly correlated with ViMove overall lumbar mobil-
ity (R2=0.80, p<0.001) and frontal lumbar mobility (R2=0.85, p<0.001); mod-
erately correlated with sagittal lumbar mobility (R2=0.70, p=0.16). The multi-
variate regression analysis showed moderate/high predictability of total BASMI 
score (R2=0.75, p<0.001, sigma=0.5435), and partial BASMI scores (R2=0.78, 
p<0.001, sigma=0.6302) using ViMove parameters.
Discussion. The lumbar mobility measured via IMUs showed comparable 
strength of association and predictability when compared to partial BASMI and 
total BASMI score. This is not an expected result given the higher functional 
affinity between the partial BASMI scores and the selected ViMove parameters. 
Despite this, the ViMove analysis still showed a high correlation and predict-
ability of the total BASMI.
Conclusions. These results open the possibility to further validate IMU technol-
ogy for the assessment of axSpA in clinical setting and suggest improvement in 
the measurement protocol by including the whole spine during assessment.
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THE PREVALENCE OF RHEUMATOLOGICAL DISEASES 
AND PSORIASIS IN THE FIRST-DEGREE RELATIVES OF PsA 
PATIENTS
Nas K.1, Çevik R.2, Dağli A.Z.3, Tekeoglu İ.1, Kamanli A.1, Sağ S.1 
1Dept. of Physical Medicine and Rehabilitation, Division of Rheumatology and 
Immunology, Sakarya University Faculty of Medicine, Sakarya; 2Dept. of Physi-
cal Medicine and Rehabilitation, Division of Rheumatology, Dicle University 
Faculty of Medicine, Diyarbakir; 3Bitlis State Hospital, Physical Medicine and 
Rehabilitation Clinic, Bitlis, Turkey
Introduction/Aim. Psoriatic arthritis is a chronic, inflammatory disease associ-
ated with psoriasis. Both psoriasis and PsA have a strong genetic/hereditary basis 
and cumulation in the family. In the studies based on the family, some alleles 
were shown to increase the tendency to PsA when compared to psoriasis. Hence, 
we aim to define the frequency of psoriasis and other rheumatological diseases in 
the relatives of PsA patients. 
Materials and Methods. Patients fulfilling CASPAR (Classification Criteria 
for Psoriatic Arthritis) criteria for PsA were recruited. Demographic and clini-
cal findings of the patients were recorded. First-degree relatives of PsA patients 
were questioned for psoriasis and rheumatologic diseases and recorded in pa-
tient forms. The most of first-degree relatives of recruited PsA patients were the 
patients with rheumatological disease whom followed up by our rheumatology 
clinic. Form of the disease (psoriasis) at the beginning, either with cutaneous or 
joint findings, were questioned and recorded on the patient’s file.
Results. A total of two hundred sixty-three patients with PsA (170 female and 93 
male patients, mean age: 44.39±12.36 years) were included into our study. In the 
questionnaire of the first-degree relatives of PsA patients; psoriasis in 60 patients 
(%22.8), rheumatoid arthritis (RA) in 6 (%2.3), ankylosing spondylitis (AS) in 
9 (%3.4), psoriatic arthritis (PsA) in 21 (%8), connective tissue disease (SLE, 
Sjögren, SSC) in 3 (%1.1), Crohn’s/ulcerative colitis in 2 (%0.8), Familial Medi-
terranean fever (FMF) in 2 (%0.8) and more than one rheumatological diseases in 
2 (%0.8) patients were detected. In 63,9 % of the PsA patients, skin lesions begin 
earlier than arthritis; joint problems seen earlier than skin lesions in 19.8% and in 
16.3% of the patients appeared Joint problems and skin lesions at the same time.
Conclusions. In the first-degree relatives of PsA patients, the possibility of pso-
riasis and PsA was mostly increased due to genetic inheritance and cumulation 
in the family. Therefore, the prevalence of AS was not significantly increased. 
Further studies are necessary to evaluate whether other inflammatory rheumatic 
diseases including spondyloarthropathies increase or not.
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ASSOCIATION OF WORK INSTABILITY WITH FATIGUE AND 
EMOTIONAL STATUS IN PATIENTS WITH ANKYLOSING SPON-
DYLITIS – COMPARISON WITH HEALTHY CONTROLS 
Ulus Y., Akyo, Y. Bilgici A., Kuru O.
Ondokuz Mayis University, Faculty of Medicine, Dept. of Physical Medicine and 
Rehabilitation, Samsun, Turkey
Introduction/Objective. Ankylosing spondylitis (AS) is usually seen in among 
younger person of working age and carries a significant economic burden. It was 
aimed to explore the relation of work instability with fatigue, depression and 
anxiety in working AS patients comparing with healthy controls. 
Methods. Actively working 61 patients with AS and 40 sex and age matched 
working healthy controls were enrolled. In patients; pain was assessed by Visual 
Analogue Scale, disease activity by the Bath AS Disease Activity Index, func-
tional capacity by the Bath AS Functional Index, and spinal mobility by Bath 
AS Metrology Index. Emotional status, fatigue level, and work instability of all 
participants were evaluated by Beck Depression Inventory, Beck Anxiety Inven-
tory, Multidimensional Assessment of Fatigue, and AS Work Instability Scale, 
respectively. Data were analyzed by SPSS, using Chi-square test, Mann-Whitney 
U test, Kruskal-Wallis test, Spearman correlation analysis, and Multivariate lin-
ear regression analysis. 
Results. Depression, fatigue, and work instability scores were significantly high-
er in patients than controls (p<0.05). Clinical parameters (except spinal mobility) 
showed a significant worsening across the levels of work instability in patients 
(p<0.05) and work instability scores were positively correlated with all clini-
cal parameters except spinal mobility (p<0.001). There was a weak correlation 
between work instability and spinal mobility (p<0.05). Fatigue (p<0.001), pain, 
and functional capacity scores (p<0.05) were found to be influential variables on 
work instability scores.
Conclusion. The results of this study demonstrated that fatigue and depressive 
symptoms had negative effect on work instability beside pain, disease activity, 
and functionality in patients with AS. The recognition and improvement of fa-
tigue and depression may lead to reduced risk of job loss in these patients.
